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Background: Chronic spinal pain is the most prevalent chronic disease with employment 
of multiple modes of interventional techniques including epidural interventions. Multiple 
randomized controlled trials (RCTs), observational studies, systematic reviews, and guidelines have 
been published. The recent review of the utilization patterns and expenditures show that there 
has been a decline in utilization of epidural injections with decrease in inflation adjusted costs 
from 2009 to 2018. The American Society of Interventional Pain Physicians (ASIPP) published 
guidelines for interventional techniques in 2013, and guidelines for facet joint interventions in 
2020. Consequently, these guidelines have been prepared to update previously existing guidelines. 
Objective: To provide evidence-based guidance in performing therapeutic epidural procedures, 
including caudal, interlaminar in lumbar, cervical, and thoracic spinal regions, transforaminal in 
lumbar spine, and percutaneous adhesiolysis in the lumbar spine. 
Methods: The methodology utilized included the development of objective and key questions 
with utilization of trustworthy standards. The literature pertaining to all aspects of epidural 
interventions was viewed with best evidence synthesis of available literature and  recommendations 
were provided. 
Results: In preparation of the guidelines, extensive literature review was performed. In addition 
to review of multiple manuscripts in reference to utilization, expenditures, anatomical and 
pathophysiological considerations, pharmacological and harmful effects of drugs and procedures, 
for evidence synthesis we have included 47 systematic reviews and 43 RCTs covering all epidural 
interventions to meet the objectives.
The evidence recommendations are as follows: 
Disc herniation: Based on relevant, high-quality fluoroscopically guided epidural injections, 
with or without steroids, and results of previous systematic reviews, the evidence is Level I 
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for caudal epidural injections, lumbar interlaminar epidural injections, lumbar transforaminal epidural injections, and cervical 
interlaminar epidural injections with strong recommendation for long-term effectiveness.
The evidence for percutaneous adhesiolysis in managing disc herniation based on one high-quality, placebo-controlled RCT is 
Level II with moderate to strong recommendation for long-term improvement in patients nonresponsive to conservative 
management and fluoroscopically guided epidural injections. 
For thoracic disc herniation, based on one relevant, high-quality RCT of thoracic epidural with fluoroscopic guidance, with or 
without steroids, the evidence is Level II with moderate to strong recommendation for long-term effectiveness.
Spinal stenosis: The evidence based on one high-quality RCT in each category the evidence is Level III to II for fluoroscopically 
guided caudal epidural injections with moderate to strong recommendation and Level II for fluoroscopically guided lumbar 
and cervical interlaminar epidural injections with moderate to strong recommendation for long-term effectiveness.
The evidence for lumbar transforaminal epidural injections is Level IV to III with moderate recommendation with 
fluoroscopically guided lumbar transforaminal epidural injections for long-term improvement. 
The evidence for percutaneous adhesiolysis in lumbar stenosis based on relevant, moderate to high quality RCTs, observational 
studies, and systematic reviews is Level II with moderate to strong recommendation for long-term improvement after 
failure of conservative management and fluoroscopically guided epidural injections. 
Axial discogenic pain: The evidence for axial discogenic pain without facet joint pain or sacroiliac joint pain in the lumbar and 
cervical spine with fluoroscopically guided caudal, lumbar and cervical interlaminar epidural injections, based on one relevant 
high quality RCT in each category is Level II with moderate to strong recommendation for long-term improvement, with 
or without steroids. 
Post-surgery syndrome: The evidence for lumbar and cervical post-surgery syndrome based on one relevant, high-quality RCT 
with fluoroscopic guidance for caudal and cervical interlaminar epidural injections, with or without steroids, is Level II with 
moderate to strong recommendation for long-term improvement. 
For percutaneous adhesiolysis, based on multiple moderate to high-quality RCTs and systematic reviews, the evidence is Level 
I with strong recommendation for long-term improvement after failure of conservative management and fluoroscopically 
guided epidural injections.
Limitations: The limitations of these guidelines include a continued paucity of high-quality studies for some techniques and 
various conditions including spinal stenosis, post-surgery syndrome, and discogenic pain.
Conclusions: These epidural intervention guidelines including percutaneous adhesiolysis were prepared with a comprehensive 
review of the literature with methodologic quality assessment and determination of level of evidence with strength of 
recommendations. 
Key words: Chronic spinal pain, interventional techniques, epidural procedures, caudal epidural, lumbar interlaminar epidural, 
cervical interlaminar epidural, thoracic interlaminar epidural, lumbar transforaminal epidural, percutaneous adhesiolysis
Disclaimer: These guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. 
Due to the changing body of evidence, this document is not intended to be a “standard of care.” There was no external funding 
in the preparation of this manuscript.
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Chronic spinal pain is the most prevalent chronic 
disease across the globe, negatively impacting the 
quality of life (QoL) and function, impacting individu-
als, their families, communities, businesses, and health 
systems, and straining the healthcare system as a lead-
ing cause of disability adjusted life years. Overall, the 
impact of chronic pain, of which spinal pain is the major 
component with low back pain as the leading cause, 
continues to be disproportionate and enormous. 
Chronic persistent spinal pain lasting longer than 
one year is reported in 25% to 60% of patients (1-
38). The prevalence of pain in various spinal regions, 
while variable, is most present in the low back with 
43%, followed by the neck at around 32%, and least 
in the thoracic spine at 13% (29). Further, most painful 
conditions increase with age and because there is an 
increase in multi-morbidity, noncommunicable diseases, 
and reduced physical activity associated with spinal 
pain, the global burden related to pain is expected to 
rise with an increasing global population of 65 years 
and older, which also applies to the United States (US) 
(5-8,13,33-38).
The assessments of the impact of spinal pain in the 
US showed low back pain ranking number 1, neck pain 
ranking number 3, with musculoskeletal disorders rank-
ing number 2, and depression and anxiety ranking num-
ber 4 and 5, among the 30 leading diseases and injuries, 
contributing to years lived with disability in 2010 (2). 
In addition, Dieleman et al (39,40) evaluated the eco-
nomic impact on healthcare in the US and showed an 
estimated spending of $134.5 billion in 2016, a 53.5% 
increase from 2013 or $87.6 billion spent for managing 
spinal pain. The costs of other musculoskeletal disorders 
also increased by 43.5% from $183.5 billion in 2013 to 
$263.3 billion in 2016.
This analysis (40) also showed in 2016, among 154 
conditions, low back and neck pain had the highest 
amount of healthcare spending, of which 57.2% was 
paid by private insurance, 33.7% paid by public insur-
ance, and 9.2% by out-of-pocket payments. In addition, 
the same group analyzing the costs (39,40) also per-
formed an economic attribution analysis of healthcare 
spending attributable to modifiable risk factors in the 
Untied States (US) (41). In this analysis, they included 
behavioral risks, such as smoking and dietary risks; 
metabolic risks, such as high body mass index (BMI) and 
high blood pressure; and environmental risks, such as 
air pollution and occupational carcinogens. This study 
(41) highlighted that 27% of healthcare spending in the 
US in 2016 can be attributed to this broad set of risk fac-
tors, with most spending attributable to high BMI, high 
systolic blood pressure, high fasting plasma glucose, 
dietary risks, and smoking tobacco. 
National health expenditures (42) are projected 
to grow at an average annual rate of 5.4% from 2019 
to 2028 and to represent 19.7% of the gross domestic 
product (GDP) by the end of the period. Among all 
major payers, Medicare is expected to experience the 
fastest spending growth, 7.6% per year, largely because 
of having the highest projected enrollment growth. 
In fact, these projected data show that Medicare and 
Medicaid spending was 37% in 2019 and will grow to 
41.6% in 2028. Similarly, federal and other governmen-
tal spending was 53.2% in 2019, and will increase to 
58% in 2028. 
Additionally, healthcare expenditures have been 
escalating and the financial impact on the US economy 
is growing with a perfect storm created by COVID-19, 
the opioid epidemic, issues related to regulations, and 
lack of reliable, unbiased, evidence-based medicine 
(43-46). The COVID-19 epidemic resulted in severe ac-
cess deficits for patients with undertreatment and a 
lack of treatment for elective care, with severe eco-
nomic consequences for providers because of reduced 
reimbursement and increased costs, as well as a severe 
psychosocial impact, not only on patients, but also on 
healthcare providers (43-53). 
Among multiple modalities of treatments avail-
able, epidural injections are one of the most performed 
procedures in managing spinal pain with or without 
extremity pain. Epidural injections are utilized in man-
aging pain and disability secondary to herniated discs, 
spinal stenosis, discogenic pain, and in post-surgery syn-
drome (7,54-77). Further, in patients with the post-lum-
bar surgery syndrome and spinal stenosis, percutaneous 
adhesiolysis is administered frequently for targeted de-
livery of solutions following the adhesiolysis (7,71-74). 
Adhesiolysis is also utilized occasionally in managing 
recalcitrant disc herniation nonresponsive to epidural 
injections (71). In fact, Best Practices in Pain Manage-
ment, from the Department of Health and Human Ser-
vices (HHS) has reviewed the available evidence in pain 
management and described interventional techniques 
as part of a continuum prior to surgical interventions 
and neuromodulation (78,79). Despite their extensive 
use, discordant conclusions have been brought on by 
multiple challenges related to the conduct of the ran-
domized controlled trials (RCTs) based on approach 
(transforaminal, interlaminar, or caudal), control design 
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(active-controlled versus placebo-controlled), and tech-
nical performance with or without fluoroscopy, alterna-
tive techniques, and outcome assessments ranging from 
absolute difference between 2 groups to minimally 
clinically important difference with assessment of pro-
portion of patients (7,8,54-83).
Discordant conclusions are based on academicians 
not following the fundamental rules in designing sys-
tematic reviews related to inclusion criteria, methodo-
logic quality assessment of the trials or studies, outcome 
assessments, and perceived intellectual bias with con-
flicts of interest. In fact, the Institute of Medicine (IOM) 
(84) has described multiple issues related to the design 
of the systematic review addressing multiple issues as 
an example. Multiple systematic reviews have suffered 
significant bias based on inclusion criteria by converting 
all active controls to placebos, with conclusions based 
on inappropriate analysis, leading to invalid results (66-
69,74,80-83). IOM extensively described the role of bias 
and conflicts of interest and the need to minimize the 
bias and conflicts of interest. IOM defined conflict of 
interest as, “a set of circumstances that creates the pri-
mary interest will be unduly influenced by a secondary 
interest” (84). Often, primary interests are well-known 
and disclosed with financial conflicts (even though it 
is not always the case). However, multiple secondary 
interests such as pursuit of professional advancement, 
future funding opportunities and recognition, personal 
biases, and the desire to do favors for friends and col-
leagues are often not disclosed. Hidden conflicts of 
interest have been identified in those with academic in-
terests, but also by taxpayer paid agencies, which advise 
the policy makers and those preparing reviews for these 
organizations (74,82,84-87). Major conflicts of interest 
and inappropriate assessments have been identified by 
the Cochrane reviews (68,69,88-93). Further, the Insti-
tute for Transitional Medicine and Therapeutics (ITMAT) 
(94) described the confluence (not conflict of interest) 
in which conflicts of interest represent a complex eco-
system that requires the development of a uniform 
approach to minimize bias in clinical research across 
the academic sector. They showed that the conflict of 
interest is pejorative and that disclosure policies have 
focused on financial gains only, whereas in academia, 
the prospect of fame may be even more seductive than 
fortune. Multiple systematic reviews also have confused 
facts (verifiable) with their own opinions (judgment 
based on beliefs and conviction based on personal 
values), ultimately leading to prejudicial statements – 
opinions based on insufficient or unexamined evidence. 
Recently, Manchikanti et al (93) have published a meth-
odologic review and evidence assessment in guideline 
preparation in interventional pain management. 
The study of the methodologic quality of system-
atic reviews published in the highest-ranking journals 
in the field of pain medicine by Riado Minguez et al 
(95), essentially showed a lack of improvement in the 
methodological and reporting quality of systematic re-
views before or after the publication of A Measurement 
Tool to Assess Systematic Reviews (AMSTAR) (96), and 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) checklists (97). In this review 
(95), authors reviewed evidence from multiple journals 
from Anesthesiology and Pain across the globe, but had 
not found any systematic reviews to be included from 
the journal Pain Medicine. Pain Physician published 
a large number of systematic reviews of moderate to 
high-quality. 
In another manuscript, Ross et al (98) assessed the 
methodologic quality of systematic reviews from clini-
cal practice guidelines for the treatment of opioid use 
disorder and concluded that underperforming areas 
and AMSTAR included conflicts of interest, funding, 
and publication bias, whereas in PRISMA, protocol reg-
istration and risk of bias are issues of concern. In fact, 
multiple issues were raised in reference to Cochrane 
reviews and their discrepancies, which were even less 
ominous than errors with interventional pain man-
agement techniques (89-91). Cochrane reviews have 
been internationally regarded as one of the leading 
resources for reliable information on healthcare inter-
ventions. Clark et al (89) reported misrepresentation 
of evidence for vertebroplasty with early interventions 
in severely affected patients. Clark et al (92) in fact 
filed a complaint with the Editor in Chief of Cochrane 
reviews. Clark et al (92) showed that the review did 
not accurately report the evidence for vertebroplasty 
in patients with severe symptoms and early fractures. 
The way the data was presented in the Cochrane re-
view, readers of the review would be unable to discern 
this information. They alluded to multiple issues with 
protocol breaches, misreporting of data in the trials, 
undisclosed conflicts of interest, and faulty risk of bias 
assessment in the Cochrane review. Kirkham et al (91) 
analyzed outcome reporting bias (ORB) in trials and 
concluded that evidence suggests that ORB is a threat 
to the validity of the evidence base and contributes to 
research waste. They have also highlighted up-to-date 
approaches and recommendations for detecting these 
problems and adjusting the results when performing 
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sensitivity analysis in systematic reviews. Shah et al (90), 
in a later publication, assessed ORB in Cochrane system-
atic reviews in a cross-sectional analysis. They described 
that discrepancies in outcome reporting (DOR) between 
protocol and published studies include inclusions of 
new outcomes, omission of prespecific outcomes, 
upgrade and downgrade of secondary and primary 
outcomes, and changes in definitions of prespecified 
outcomes. Thus, DOR can result in ORB when changes 
in outcomes occur after knowledge of the results, which 
essentially has a potential to overestimate treatment ef-
fects and underestimate harms at the level of systematic 
reviews. Their analysis showed that 43%, or 150 of 350, 
Cochrane review protocol pairings contained DOR. Fur-
ther, 35%, or 53 of 150, reviews with DOR contained a 
high risk of ORB, with changes being made after knowl-
edge of results from individual trials. They concluded 
that the presence of DOR and ORB in Cochrane reviews 
is of great concern. Obviously, Cochrane review has 
not identified these issues and has not ascertained to 
resolve these issues, even though they can do so with 
simple measures. 
This discussion leads to various types of bias in 
studies in interventional pain management in multiple 
manuscripts (67,80-82). In fact, Manchikanti et al (81) 
performed a comparative systematic review and meta-
analysis assessing the publication by Chou et al (80), 
which showed significantly different results when the 
analysis was performed appropriately. Their conclu-
sion was also not based on scientific evidence, as both 
local anesthetic and steroids were equally effective. 
Consequently, they concluded that neither one was 
effective. Further, Agency for Healthcare Research and 
Quality (AHRQ) funding has been significantly reduced. 
The same philosophy was applied by Cochrane review 
guidance by Pinto et al (67,68) who utilized a similar 
philosophy with conversion of active control trials with 
a lack of clinical experience or understanding by the 
primary authors and lack of disclosures of conflict of 
interest. These may be added to multiple other deficits 
of the Cochrane reviews. Another issue is based on the 
fact that providing pain relief after a single epidural 
injection, which may last 3 to 13 weeks, the reviewers 
are assessing their effectiveness for a year, and are also 
comparing with long-term surgical procedures without 
any clinical relevance. 
Along the same lines, Manchikanti et al (74) 
analyzed systematic findings of systematic reviews in 
assessing the effectiveness of percutaneous adhesioly-
sis in post-lumbar surgery syndrome. The authors (74) 
found that a single systematic review by Brito-García 
et al (87) of 4 randomized trials on this subject at that 
time, had very low methodologic quality scores on all 
AMSTAR, PRISMA, and Scottish Intercollegiate Guide-
lines Network (SIGN) checklist for systematic reviews. 
The systematic review by Brito-García et al (87) also had 
numerous deficiencies and improper and inappropriate 
information. Contrary to the high-profile reviews by 
Chou et al and others (67,68,80), Lewis et al (99,100) in 
2 manuscripts funded by National Health Services (NHS) 
and Health Technology Assessment Program (HTA) have 
presented positive results for epidural injections. The 
systematic review of health technology assessment (99) 
also utilized an economic model of the clinical effective-
ness and cost-effectiveness of management strategies 
for sciatica, supporting the effectiveness of epidural 
corticosteroid injections, and disc surgery. In the second 
manuscript, Lewis et al (100), utilizing a network meta-
analysis of comparative clinical effectiveness of manage-
ment strategies for sciatica with review of 122 relevant 
studies and 21 treatment strategies showed a statisti-
cally significant improvement with epidural injections. 
In addition, Guo et al (101), in a comparative network 
meta-analysis to compare the efficacy and tolerabil-
ity of treatment for sciatica, showed that the epidural 
steroid with local anesthetic demonstrated superiority 
over the epidural steroid without local anesthetic and 
intramuscular steroid. Further, they found subcutane-
ously injected antitumor necrosis factor-α (anti-TNF-α) 
to be superior to the epidural steroid plus anesthetic at 
reducing pain levels, but the epidural steroids demon-
strated superior reductions in the Oswestry Disability In-
dex (ODI) scores, compared to subcutaneous anti-TNF-α. 
Further, Shanthanna et al (102), in a systematic review 
and meta-analysis of RCTs in the review of addition of 
corticosteroids to local anesthetics for chronic noncan-
cer pain injections, after review of 73 trials, concluded 
that the addition of corticosteroids to local anesthetic 
has only small benefits and a potential for harm. They 
found no meaningful improvement in pain scores or the 
duration of pain relief. They recommended that clinical 
decisions should consider the potential for harm with 
steroids and the therapeutic benefit by the local anes-
thetic alone. 
Consequently, despite the availability of numerous 
systematic reviews (56-77,80-83,102), there have not been 
guidelines systematically developed in assessing clinical 
and cost effectiveness of epidural injections, including 
percutaneous adhesiolysis, in managing spinal pain. The 
American Society of Interventional Pain Physicians (ASIPP) 
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guidelines in managing spinal interventional techniques 
were published in 2013 (7), which included all modali-
ties of treatments in managing spinal pain. Since then, 
multiple other guidelines have been developed relevant 
to interventional pain physicians, including facet joint 
interventions (8), opioid therapy in chronic noncancer 
pain (6), use of biologics in the management of low back 
pain (5), antithrombotic guidelines (103), risk mitigation 
and stratification during COVID-19 for return to interven-
tional pain practice (51), triaging of interventional pain 
procedures during COVID-19 or related elective surgery 
restrictions (52), and a position statement on bone mar-
row concentrate (104). The present guidelines have been 
developed specifically for epidural interventions, includ-
ing percutaneous adhesiolysis. Since the US and the world 
continue to be in the middle of a pandemic, with resur-
gences, the development of guidelines for epidural pro-
cedures is crucial. ASIPP has been at the forefront during 
COVID-19 pandemic and its influence on interventional 
pain management with publications related to guidance 
(51,52), highlighting the value of nonsteroidal injections 
as steroids were considered as a risk factor for COVID-19 
patients (55,58,105-107), value of telemedicine (108,109), 
influence on technological advances and multiple other 
aspects including testing and therapeutics (43-45,110-
115). The impact of chronic pain has been described by 
multiple others, with a continuing downturn of revenues 
and simultaneous increases in expenses (43-53). Conse-
quently, a triad of concurrent epidemics of COVID-19, 
opioid epidemic, and a regulatory burden with declining 
reimbursements has created a perfect storm (43) with 
increasing practice costs, exacerbated by inappropriate 
evidence-based medicine. Furthermore, the addition of 
improper evidence-based assessments continues to add to 
the ongoing storm with inadequate assessments leading 
to inappropriate conclusions.
The development of these guidelines includes an 
overview of the current literature regarding the use 
of epidural injections and percutaneous adhesiolysis 
procedures in managing spinal pain. These guidelines in-
cluded evidence-based and evidence-informed strategies 
utilizing the concepts of efficacy and effectiveness and 
proper evidence synthesis as described in the literature 
(5-8,51,52,104,116-126) to avoid conflicts and confluence 
of interest. 
Consequently, ASIPP has undertaken the develop-
ment of guidelines for epidural interventions, based on 
a rational and systematic approach to the application of 
these interventions in managing spinal pain. This is an 
update of epidural interventions from comprehensive 




The National Uniform Claims Committee (NUCC) 
defines interventional pain management as the discipline 
of medicine devoted to the diagnosis and treatment of 
pain related disorders principally with the application of 
interventional techniques in managing subacute, chronic, 
persistent, and intractable pain, independently or in 
conjunction with other modalities of treatment (https://
www.nucc.org). The Medicare Payment Advisory Commis-
sion (MedPAC) defines interventional pain management 
techniques as minimally invasive procedures including 
percutaneous precision needle placement of drugs in tar-
geted areas or ablation of targeted nerves; surgical tech-
niques such as laser and endoscopic discectomy; and the 
placement of intrathecal infusion pumps and spinal cord 
stimulators for the diagnosis and management of chronic, 
persistent, or intractable pain (http://medpac.gov/). 
Chronic spinal pain is a complex and multifacto-
rial disease process with numerous treatment modali-
ties applied in the management of the problem, and 
the growing social and economic costs continue to 
influence medical decision-making. Intervertebral discs, 
facet joints, sacroiliac joints, ligaments, fascia, muscles, 
and nerve root dura are proven pain generators in the 
spine (5-8,78,79,127-139). Interventional pain physicians 
are familiar with various image-guided interventional 
techniques for the management of spinal pain (5-8).
Many of the causes of spinal pain and other chronic 
pain conditions are considered to be acute recurrent 
problems characterized by periods of quiescence punc-
tuated by flare-ups, or chronic diseases, like diabetes 
or hypertension, requiring long-term treatment with 
ongoing care. The importance of spinal interventional 
techniques in managing chronic spinal pain has been 
established on the basis of advances in imaging, neu-
roanatomic findings, the development of precision 
diagnostic and therapeutic injection techniques, and 
reported nonoperative treatment successes. Many 
guidelines, systematic reviews, Cochrane Reviews, 
and other articles pertaining to interventional pain 
management (IPM) have been published (5-8,54-83). 
Some of these guidelines, however, are ambiguous 
and not based on appropriate evidence synthesis, with 
the inclusion of extensive confluences of interest (66-
69,74,80-93,95,97,98,105,140-150). Consequently, these 
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approaches may not be applicable in managing chronic 
spinal pain utilizing contemporary IPM. 
2.2 Objectives
The objective of these guidelines is to provide a 
rationale and systematic approach to the application 
of epidural interventions in managing spinal pain. The 
guidelines are based upon the available evidence con-
cerning the effectiveness and safety in the treatment of 
spinal pain. The literature shows the value of evidence-
based guidelines and the need for appropriate updat-
ing of the guidelines to practice with current concepts 
(5-8,93,116-126).
These guidelines include the description and appli-
cation of epidural interventions in managing spinal pain 
due to disc, spinal stenosis and post-surgery syndrome. 
2.3 Application
While these guidelines may be applied by any 
specialty, they are specifically intended for use by in-
terventional pain physicians. These guidelines do not 
constitute inflexible treatment recommendations. It is 
expected that a clinician will establish a plan of care on 
a case-by-case basis, considering an individual patient’s 
medical condition, personal needs, and preferences, 
and the physician’s experience. Based on an individual 
patient’s needs, treatment different from that outlined 
here could be warranted. Consequently, these guide-
lines do not represent a “standard of care.” It is a well-
known fact that all treatments are not supported by 
existing evidence and grading. However, there may be 
strong clinical support for some interventions.
The goal of these guidelines is to provide patients, 
practitioners, regulators, and payers, information that 
may be used to determine whether the available evidence 
supports the notion of a “standard” for interventional 
techniques. “Standard” refers to what is applicable to the 
majority of patients, with a preference for patient conve-
nience and ease of administration without compromising 
treatment efficacy or morbidity (5-8). It is essential to rec-
ognize the difference between “standard” and “standard 
of care,” as utilized as a legal definition (151).
2.4 Key Questions
These guidelines focus on the following key ques-
tions regarding disc-related and stenotic spinal pain: 
1.  What is the impact of chronic spinal pain on health-
care resources? 
2.  What are the statistics regarding the trends in utiliza-
tion of treatment modalities in managing spinal pain? 
3.  What is the evidence for the structural basis of spinal 
pain? 
4. What is the pathophysiologic basis of epidural in-
terventions in spinal pain?
5.  What are the noninterventional diagnostic meth-
ods in disc related pathology, spinal stenosis, and 
post-surgery syndrome? 
6.  Are the available therapeutic epidural injections 
and adhesiolysis in managing chronic spinal pain 
effective? 
7.  What is the evidence for cost-effectiveness of epi-
dural interventions including adhesiolysis in man-
aging spinal pain? 
8.  What are the adverse consequences, harms, 
and related precautions in providing epidural 
interventions? 
9. What are the implications of antithrombotic and 
anticoagulant therapy and epidural interventions? 
10. What are the guidelines for epidural injections and 
adhesiolysis in managing chronic spinal pain? 
2.5 Adherence to Trustworthy Standards 
In preparation of guidelines for epidural interven-
tions (epidurals and adhesiolysis), the standards from 
the IOM and the National Guideline Clearinghouse 
Extent Adherence to Trustworthy Standards (NEATS) 
were followed (94,118-125). The NEATS instrument 
was developed and tested as a tool to be used by the 
trained staff at the AHRQ National Guideline Clear-
inghouse to provide assessment focused on adherence 
(119). 
2.5.1 Disclosure of Guideline Funding Source 
Comprehensive evidence-based guidelines for 
epidural interventions in managing chronic spinal pain 
were commissioned, prepared, edited, and endorsed by 
ASIPP without external funding.
2.5.2 Disclosure and Management of Financial 
Conflicts of Interests 
Potential conflicts of interest for all panel members 
within the last 5 years were evaluated prior to the final-
izing of these guidelines. Conflicts of interests extended 
beyond financial relationships, including personal expe-
rience, practice patterns, academic interests, and promo-
tions. The panel members with potential conflicts were 
recused from discussion or preparation of the guidelines 
in which they had conflicts of interest, and these mem-
bers agreed not to discuss any aspect of a given guideline 
with the related industry before data publication.
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2.5.3 Composition of Guideline Development 
Group 
A panel of experts in managing spinal pain and 
interventional techniques from various medical fields, 
convened by ASIPP, reviewed the evidence and for-
mulated recommendations for epidural procedures, 
including adhesiolysis. Overall, the panel provided a 
broad representation of academic and nonacademic 
clinical practitioners with interest and expertise in 
interventional techniques as applicable to epidural 
procedures. 
2.6 Evidence Review 
The evidence-based guidelines for epidural inter-
ventions were developed utilizing consensus among the 
panel members after they had reviewed all published 
literature concerning the use and safety of epidural 
procedures, including adhesiolysis, in patients with 
chronic spinal pain. The recommendations have been 
developed using principles of best evidence synthesis 
developed by the Cochrane Review, incorporating mul-
tiple guidelines modified by ASIPP (152).
2.6.1 Grading or Rating the Quality or Strength of 
Evidence 
The grading of evidence is based on RCTs, obser-
vational studies, and other clinical reports. In addition, 
systematic reviews and meta-analyses were utilized. The 
grading of evidence based on ASIPP guidelines is shown in 
Table 1 (152), whereas Table 2 shows GRADE recommenda-
tion grading (125). This grading system specifies levels of 
scientific evidence and offers an approach to grading the 
quality of evidence and secondarily the strength of recom-
mendations. AHRQ has recommended a similar approach 
to the strength of a recommendation (121,125,152).
2.6.2 Assessment and Recommendations of 
Benefits and Harms 
These guidelines describe the potential benefits 
and harms for the interventions and explicitly link the 
information to specific recommendations.
2.6.3 Evidence Summary of Recommendations 
Guideline-supporting documents summarize the 
relevant supporting evidence and link this information 
to the recommendations.
2.6.4 Rating or Grading the Strength of 
Recommendations 
IOM standards demand that for each recommenda-
tion, a rating of the strength of the recommendation 
related to benefits and harms, available evidence, and 
the confidence in the underlying evidence should be 
provided. To meet the appropriate standards, the rating 
schemes recommended by NEATS were utilized as shown 
in Table 3 (119).
Table 1. Qualitative modified approach to grading of  evidence 
of  therapeutic effectiveness studies.
Level I Strong Evidence obtained from multiple relevant high-quality randomized controlled trials 
Level II Moderate
Evidence obtained from at least one 
relevant high-quality randomized 
controlled trial or multiple relevant 
moderate or low-quality randomized 
controlled trials
Level III Fair
Evidence obtained from at least one 
relevant moderate or low-quality 
randomized trial 
or
Evidence obtained from at least one 
relevant high-quality non-randomized 
trial or observational study with multiple 
moderate or low-quality observational 
studies
Level IV Limited
Evidence obtained from multiple 
moderate or low-quality relevant 
observational studies 
Level V Consensus based
Opinion or consensus of large group of 
clinicians and/or scientists
Modified from: Manchikanti L, et al. A modified approach to grading 
of evidence. Pain Physician 2014; 17:E319-E325 (152).
Table 2. Recommendation grade.
A
- At least one meta analysis, systematic review, or RCT rated as 
1 + + and directly applicable to the target population or
- A systematic review of RCTs or a body of evidence 
consisting principally of studies rated as 1 + directly 
applicable to the target population and demonstrating overall 
consistency of results
B
A body of evidence including studies rated as 2 + + directly 
applicable to the target population and demonstrating overall 
consistency of results or 
- Extrapolated evidence from studies rated as 1 + + or 1 +
C
- A body of evidence including studies rated as 2 + directly 
applicable to the target population and demonstrating overall 
consistency of results or
- Extrapolated evidence from studies rated as 2 + +
D - Evidence level 3 or 4 or- Extrapolated evidence from studies rated as 2 +
Source: Harbour R, Miller J. A new system for grading recommenda-
tions in evidence based guidelines. BMJ 2001; 323:334-336 (125).
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2.6.5 Specificity of Recommendations 
Evidence and best practices were utilized in forming 
recommendations for epidural injections and adhesiolysis. 
2.7 Methodologic Quality and Risk of Bias 
Assessment  
Key recommendations included transparency and 
reproducibility of judgements, separating risk of bias 
from other constructs such as applicability and preci-
sion, and evaluation of the risk of bias per outcomes. 
2.7.1 Randomized Controlled Trials 
Multiple instruments have been developed over the 
years to assess the methodological quality, along with 
bias, in RCTs (153,154). The criteria developed by the Co-
chrane review editorial board has been used extensively 
and has been modified over the years. Appendix Table 
1 shows Cochrane review criteria (154) and Appendix 
Table 2 shows criteria developed by interventional pain 
physicians with a specific item checklist for assessment 
of RCTs of interventional pain management techniques 
(153). A third criteria used is based on SIGN (74,155,156) 
as shown in Appendix Table 3.
While Cochrane criteria is universally accepted and 
was implemented in several trials, this was not specific 
for interventional techniques. In contrast, Intervention-
al Pain Management techniques - Quality Appraisal of 
Reliability and Risk of Bias Assessment (IPM-QRB) was 
specifically developed for interventional techniques, 
specifically in patients suffering with chronic spinal 
pain. This checklist includes various types of criteria, 
including trial design and guidance report, along with 
setting, physician, imaging, chronicity of pain, previous 
treatments, and multiple other appropriate criteria. It 
has been shown to be more robust than the Cochrane 
review criteria and was considered as providing better 
information than the Cochrane review criteria when 
compared head-to-head with both Cochrane review cri-
teria and IPM-QRB. Both criteria have been extensively 
utilized in IPM evidence synthesis. 
The literature pertaining to SIGN (74,125,155,156) is 
not extensive, even though it has been reported in some 
studies related to interventional techniques (74,155).
2.7.1.1 Scoring IPM-QRB Criteria
Based on IPM-QRB criteria for randomized trials, 
the studies meeting the inclusion criteria but scoring 
less than 16 were considered as low-quality and were 
excluded; studies scoring from 16 to 31 were considered 
as moderate quality; and studies scoring from 32 to 48 
were considered as high-quality.
2.7.1.2 Scoring Cochrane Review Criteria
Utilizing Cochrane review criteria, studies meeting 
the inclusion criteria with at least 9 of 13 criteria were 
considered high-quality; 5 to 8 were considered moder-
ate quality. Those meeting criteria of less than 5 were 
considered as low-quality and were excluded. 
2.7.1.3 Scoring SIGN
Methodologic quality assessment of systematic 
reviews was also conducted utilizing SIGN (74,155,156). 
The quality assessment was based on 3 options, i.e., 
those which were designated as ++ (indicated all or 
most of all standards are met), + (indicated some of the 
standards are met), and – (indicated all or most of all 
standards are not met).
2.7.2 Nonrandomized Studies
Similar to the checklist for RCTs, Manchikanti et 
Table 3. Guide for strength of  recommendations.
Rating for Strength of  recommendatrion
Strong
There is high confidence that the recommendation reflects best practice. This is based on: a) strong evidence for a true net effect 
(e.g., benefits exceed harms); b) consistend results, with no minor exceptions; c) minor or no concerns about study quality; and/or 
d) the extent the panelists’ agreement. Other compelling considerations (discussed in the guideline’s literature review and analyses) 
may also warrant a strong recommendation.
Moderate
There is moderate confidence that the recommendations reflects best practice. This is based on: a) good evidence for a true net 
effect (e.g. benefits exceed harms); b) consistent results, with minor and/or few exceptions; c) minor and/or few concerns about 
study quality; and/or d) the extent of panelists’ agreement. Other compelling considerations (discussed in the guideline’s literature 
review and analyses) may also warrant a moderate recommendation.
Weak
There is some confidence that the recommendation offers the best current guidance for practice. This is based on: a) limited 
evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, but with important exceptions; c) concerns about 
study quality; and/or d) the extent of panelists’ agreement. Other considerations (discussed in the guideline’s literature review and 
analyses) may also warrant a weak recommendation.
Source: National Guideline Clearinghouse Extent Adherence to Trustworthy Standards (NEATS) instrument (119).
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al (157) developed a comprehensive instrument that 
is helpful in assessing the methodological quality of 
nonrandomized trials and is specific to interventional 
techniques (Appendix Table 4).
IPM checklist with Interventional Pain Management 
Techniques – Quality Appraisal of Reliability and Risk of 
Bias Assessment for Nonrandomized Studies (IPM-QRB-
NR) has been evaluated in multiple assessments. With 
the rapid development of RCTs, observational studies 
are not as frequently used. Further, methodologic qual-
ity assessment for these is not utilized. 
SIGN also has developed an instrument to assess 
the methodologic quality and risk of bias assessment 
in observational studies as shown in Appendix Table 
3 (74,125,155,156). In contrast to RCTs, observational 
studies have not been methodologically assessed as 
frequently. Further instruments for assessment are also 
limited.
2.7.2.1 Scoring For IPM-QRBNR 
Based on IPM-QRBNR criteria, studies meeting the 
inclusion criteria but scoring less than 16 were consid-
ered low-quality and were excluded, studies scoring 
from 16 to 31 were considered moderate quality; and 
studies scoring from 32 to 48 were considered high-
quality and were included. 
2.7.3 Quality Assessment of Systematic Reviews
Risk of bias and methodological and reporting 
quality assessment may be performed utilizing 3 tools: 
AMSTAR, PRISMA, and SIGN.
In the past, we have performed such assessments 
utilizing all 3 tools; however, it is not only very cumber-
some, but also did not provide any meaningful informa-
tion. A low-quality meta-analysis may be high-quality 
methodologically. To avoid such time issues, we have 
categorized all the systematic reviews into 3:
1. Low-quality: This category with either a systematic 
review or meta-analysis, with conversion of stud-
ies or moving them into a different category, such 
as placebo to active control, against the intent of 
the authors of the original manuscripts, without 
consent, and without STRONG scientific basis, even 
though they may be of high, moderate or low 
methodologic quality based on PRISMA, AMSTAR, 
or SIGN.
2. Moderate quality: This category included the ma-
jority of the systematic reviews, methodologically 
sound, which followed the appropriate principles 
without violation of practices, with either a sys-
tematic review or meta-analysis with conventional 
dual-arm analysis only. 
3. High-quality: In this category, the systematic re-
views, methodologically sound, with the inclusion 
of appropriate, high-quality principles, with con-
ventional dual-arm meta-analysis and single-arm 
meta-analysis without violation of standards and 
keeping the intent of the original manuscripts. 
2.8 External Review 
Guidelines have been subjected to external peer 
review as per the policies of the publishing journal, Pain 
Physician.
2.9 Updating Guidelines 
The epidural interventions for chronic spinal pain 
guidelines will be updated within 5 years or less, based on 
significant changes in scientific evidence, public policy, or 
adverse events occurring 
before January 2026. 
3.0 IMpact of 
chronIc spInal 
paIn on health 
care
Key Question 1: 
What is the impact of 
chronic spinal pain on 
healthcare resources? 
The impact of 
chronic pain continues 
to be enormous (1-
30,39-43,46-50). Figure 
1 shows musculoskeletal 
Fig. 1. Prevalence of  musculoskeletal pain and years lived with disability.
Source: Hoy D, March L, Brooks P, et al. The global burden of low back pain: Estimates from the Global 
Burden of Disease 2010 study. Ann Rheum Dis 2014; 73:968-974 (21).
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pain and years lived 
with disability. Even 
prior to the CO-
VID-19 pandemic, 
the annual US ex-
penditures alone, 
including direct 
medical costs and 
lost wages due to 
chronic pain have 
been estimated 
to be higher than 
those for cancer, 
heart disease, and 
diabetes combined 
(2-7,39-42,104,158-
174). As described 
by Dieleman et al 
(40), low back and 
neck pain consti-
tute the number 
one category of 
expense in medical 
expenditures in the US. In spite of extensive expendi-
tures and multiple measures undertaken to control 
the expenditures (5-8,39-43,103,104,175-178), with 
multiplying treatment options, disability continues to 
escalate (1-8,39,40,103,104,170-174). As shown in Fig. 
2, Dieleman et al (40) illustrated the expenses related 
to musculoskeletal conditions, including back and neck 
pain, as determined in 2016 based on spending on 
healthcare in the US.
The prevalence of pain in various spinal regions, is 
variable, with the highest prevalence in the low back 
at 43%, followed by the neck at 32%, with the lowest 
in the thoracic spine at 13% (29). The overall preva-
lence of low back pain and neck pain over a period of 
one-year ranged from 22% to 65% with an estimated 
lifetime occurrence of 84% for low back and neck pain 
from 20% to 40% with a lifetime prevalence of 67% 
(3,28-35,103,104,174,179-185). Furthermore, chronic 
persistent spinal pain may last longer than one-year in 
as many as 60% of the patients, even after conservative 
treatment or surgical interventions (1-35,174,179-185).
The prevalence of chronic low back pain is about 
23%, with disabling pain in 11% to 12% of the popula-
tion (183). A systematic review of the clinical course of 
nonspecific low back pain found that recovery was seen 
in only 33% of the patients after the first 3 months, 
whereas after one year after onset, 65% still reported 
pain (185). The 2016 US National Pain Strategy (NPS) 
(181) placed a focus on those with high impact chronic 
pain defined as that, “associated with substantial re-
striction of participation in work, social, and self-care 
activities for 6 months or more.” However, multiple 
studies have used different algorithms to identify those 
with high impact chronic pain and to demonstrate 
significantly higher healthcare costs, lower QoL, depres-
sion, and increased absenteeism (180,181,185). 
A survey from the CDC (181), in 2016, estimated 
that 20.4% of US adults, or 50 million, had chronic pain 
and 8% of US adults, or 19.6 million, had high impact 
chronic pain, and with higher prevalence associated 
with advanced age. Age-adjusted prevalences of both 
chronic pain and high-impact chronic pain were signifi-
cantly higher among women, adults who had worked 
previously, but were not currently employed, adults 
living in or near poverty, and rural residents. Further, 
the data also showed that non-Hispanic White adults 
had a significantly higher age-adjusted prevalence of 
chronic pain than did all other racial and ethnic groups. 
No significant difference in high impact chronic pain 
prevalence by race or ethnicity were observed. Among 
adults aged less than 65 years, prevalences were higher 
after adjusting for age, for chronic pain, and high 
impact chronic pain among those with Medicaid and 
other public healthcare coverage or other insurance 
Fig. 2. Estimated health care spending by aggregated age group, type of  payer, and aggregated health 
category in 2016.
Source: Dieleman JL, Cao J, Chapin A, et al. US health care spending by payer and health condition, 1996-2016. 
JAMA 2020; 323:863-884 (40). 
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than among adults with private insurance or those who 
were uninsured. Additionally, among adults aged 65 or 
greater years, those with both Medicare and Medicaid 
had higher age-adjusted prevalences of chronic pain 
and high impact chronic pain than did adults with all 
other types of coverage, reflecting their disability sta-
tus, finances, and education.
In fact, a significant proportion of rising morbid-
ity and mortality in midlife among white non-Hispanic 
Americans in the 21st century was attributed to opioid 
poisonings related to chronic pain and subsequently 
drug abuse (182) as shown in Figs. 3 and 4. 
Freburger et al (35), in assessment of the rising 
prevalence of chronic low back pain from 1992 to 2006 
showed that the prevalence of chronic, impairing low 
back pain rose significantly over the 14-year interval, 
from 3.9% in 1992 to 10.2% in 2006. They reported 
increases for all adult age strata, in men and women, 
and in white and black races. However, symptom, se-
verity and general health were similar for both years, 
with some increase in individuals seeking care from a 
healthcare provider in the past year, increasing from 
73.1% to 84%, while the mean number of visits in all 
providers were similar. They concluded that the preva-
lence of chronic, impairing low back pain has risen sig-
nificantly in North Carolina, with continuing high levels 
of disability and care utilization. They also concluded 
that a substantial portion of the rise in low back pain 
care costs over the past 2 decades may be related to the 
rising prevalence. These studies have not been repeated 
since then. However, based on the other studies of dis-
ability and healthcare costs, the prevalence, as well as 
disability, may be increasing (2,21,22,36-42,167-173).
Further, Blyth et al (38), in assessing the global bur-
den of musculoskeletal pain, summarized the current 
understanding of the global burden of musculoskeletal 
related conditions, applying evidence-based principles 
generated the prevalence and identified key gaps in the 
understanding of musculoskeletal pain, with proposals 
to address these gaps. They identified key long-term 
drivers of contemporary burden of disease estimates, in-
cluding age, structure of populations, and their longev-
ity. They identified the escalating growth of treatments, 
along with harms associated with treatment, including 
medication-based interventions, notably long-term 
opioids, nonsteroidal, and steroidal immunosuppressive 
therapies, and surgical interventions. However, these 
Fig. 3. All-cause mortality, ages 45–54 for US White 
non-Hispanics (USW), US Hispanics (USH), and six 
comparison countries: France (FRA), Germany (GER), 
the United Kingdom (UK), Canada (CAN), Australia 
(AUS), and Sweden (SWE).
Source: Case A, Deaton A. Rising morbidity and mortality in 
midlife among white non-Hispanic Americans in the 21st century. 
Proc Natl Acad Sci USA 2015; 112:15078-15083 (182).
Fig. 4. Mortality by cause, white non-Hispanics ages 45–54.
Case A, Deaton A. Rising morbidity and mortality in midlife 
among white non-Hispanic Americans in the 21st century. Proc 
Natl Acad Sci USA 2015; 112:15078-15083 (182).
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were not included in their estimated burden. Given 
the importance of musculoskeletal pain with regard 
to functional status in older age group, these findings 
have profound implications for future disability burden 
and treatments provided to reduce it (20).
A systematic review of the prevalence of muscu-
loskeletal symptoms in the construction industry (37), 
including back and neck pain, one-year prevalence of 
low back pain was 51.1% whereas for neck pain it was 
24.4 %, and 19.8% for upper back pain. Thus, some 
prominent authors have indicated that guidelines must 
be different for developing countries and developed 
countries in reference to invasive and noninvasive treat-
ments (37,172,174). Chou et al (174) and Acaroğlu et al 
(37), synthesized recommendations on the use of com-
mon elective surgical and interventional procedures 
for individuals with recommendation of epidural injec-
tions, as well as augmentation procedures with forma-
tion of clinical care pathways on patient presentation in 
low- and middle-income communities, contrary to their 
descriptions of earlier presentations of opposition to 
these interventions in the US (80,174). In these guide-
lines, they theorized that epidural steroid injections and 
vertebral augmentation procedures are less expensive 
than most surgeries with fewer harms. 
Healthcare expenditures have been escalating over 
the years with estimates of the US healthcare spend-
ing reaching $3.814 trillion in 2019 (42). Furthermore, 
healthcare expenditures are expected to continue to 
grow at a rate of 5.4% from 2019 to 2028 (42). Overall, in 
2019, cost of healthcare was $11,597 per person, the cost 
per person in 2028 will rise to $17,611. In 2016, low back 
and neck pain had the highest amount of healthcare 
spending with an estimated $134.5 billion with 33.7% 
of that spent by public insurance. Other musculoskeletal 
disorders accounted for the second highest amount of 
healthcare spending of $129.8 billion, totaling $264.3 
billion (40,41). It appears that expenditures have in-
creased disproportionately with low back and neck pain 
with the highest healthcare spending, whereas diabetes 
and ischemic heart disease ranked lower in spending in 
2016, a reversal from 2013. However, the calculations of 
healthcare spending drastically changed in 2020 due to 
COVID-19. The COVID-19 pandemic not only increased 
overall healthcare expenditures, but also affected the en-
tire healthcare system with significant increases of costs 
and reduced access to healthcare (43-53,115). 
With increasing prevalence and disability as de-
scribed above, it is obvious that healthcare expenditures 
have been escalating and that the financial impact on 
the US economy is growing. Additionally, the calculus 
of healthcare has drastically altered in 2020 and beyond 
due to COVID-19 catapulted the country into one of the 
deepest recessions in history, leading to poor health 
and increase in cardiovascular disease, mental health 
problems, cognitive dysfunction, and early death that 
has affected chronic pain patients in numerous ways. 
The pandemic also resulted in severe economic conse-
quences for providers with reduced reimbursement and 
increased costs, as well as severe psychosocial impact on 
healthcare providers (43-53,115). Also, COVID-19 may 
adversely affect the increasing prevalence of chronic 
pain, health, anxiety, and behavioral changes (186). In 
fact, the data shows that 81% of physicians surveyed 
in July and August of 2020 said that revenue was still 
lower than pre-pandemic levels. This study also showed 
increased levels of expenses due to safety practices re-
quire use of more personal protective equipment (PPE). 
Federal financial relief early in the pandemic was some-
what helpful and widely appreciated. However, the 
core revenue issues these programs were intended to 
address remain, both in terms of decreased revenue and 
increased costs. At the same time, practices have been 
hit with reduced reimbursement (https://www.cms.gov/
medicare/medicare-fee-for-service-payment/physician-
feesched). Furthermore, elective surgeries continue to 
be reduced by approximately 20% or so and physician 
burnout among interventional pain physicians is over-
whelming as has been reported (44). 
Annual healthcare costs for patients with high 
impact chronic pain (overall and spine-related) ($14,661 
SE: $814; and $5,979 SE: $471, respectively) were signifi-
cantly higher than in patients with low impact chronic 
pain ($6,371 SE: $557; and $2,300 SE: $328) (183). Pa-
tients with high impact chronic spinal pain who use opi-
oids are at prevalent at much higher rates than those 
with low impact chronic pain (48.4% versus 12.4%). 
4.0 the trends In utIlIzatIon of healthcare 
ModalItIes In ManagIng dIsc-related and 
spInal stenosIs paIn
Key Question 2: What are the statistics regard-
ing the trends in utilization of treatment modalities 
in managing spinal pain? 
Overwhelming healthcare costs are a major burden 
on the economy of the US leading to the implemen-
tation of various healthcare reform measures, regula-
tions, and to the imposition of guidelines which have 
often been based on public policy priorities to reduce 
healthcare costs. These governmental actions have of-
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ten resulted from feigned evidence-based medicine and 
comparative effectiveness research muddled with con-
flicts and controversies (5-7,19,22,26,39-46,103,104,166-
169,187-264). There has been escalating growth of 
various modalities for the treatment of spinal pain, 
including physical therapy, drug therapy, interventional 
techniques, and surgical interventions.
4.1 Surgery 
Ever since the description of the first discectomy to 
treat disc herniation in 1932 by Mixter, a neurosurgeon, 
and Barr, an orthopedic surgeon (255), the surgical 
interventions to treat spinal pain have taken off with 
evolution of multiple techniques with rapid increase 
of surgical interventions, raising questions of the ef-
fectiveness of surgical treatments (256). Goldthwait and 
Osgood in 1905 (257), and subsequently in 1929, Dandy 
(258), an American neurosurgeon, surgically treated 2 
patients who complained of back and leg pain. How-
ever, in the 1980s, Weber (259) and Hakelius (219) dem-
onstrated significant improvement with nonoperative 
treatment alone. Thus, the debate about surgical versus 
nonoperative interventions ensued. Consequently, the 
Spine Patient Outcomes Research Trial (SPORT) was 
created to prospectively collect the data (260). In a 
systematic review by Oster et al (221) of outcomes fol-
lowing 10 year mark of SPORT for intervertebral disc 
herniation, patients that were likely to cross over to the 
surgery group had lower incomes, worse baseline symp-
toms, more baseline disability on the ODI, and were 
more likely to rate their symptoms as getting worse. In 
contrast, patients that crossed over to the nonopera-
tive group were older, had higher incomes, were more 
likely to have upper lumbar disc herniation, less likely 
to have a positive straight leg raise test, had less pain, 
better physical function, less disability on ODI, and were 
more likely to rate their symptoms as getting better 
(260). They also identified multiple other factors with 
subgroup analysis, which included level of disc hernia-
tion, duration of symptoms, presence of retrolisthesis, 
patient functional status, effects of previous treatments 
with epidural steroid injections and opioid medication, 
outcomes after incidental durotomy, and reoperation 
rates and associated risks with reoperation. In this as-
sessment, patients who had not received an injection 
preferred surgery, whereas those who have received 
injections had a higher rate of crossover to nonsurgical 
treatment, even though this was confounded by the 
increased desire to avoid surgery (263). The authors 
concluded that 4 years and 8 years as treated analysis 
showed statistically greater improvements in those 
patients who were treated surgically. However, the 
analysis of the RCT cohort failed to show a significant 
difference based on the intent to principle due to sig-
nificant patient crossover, which was around 50% (221).
National trends in surgical interventions have been 
increasing rapidly (202,216,218,220,264,265). Best et al 
(264) assessed the national surgical trends for interver-
tebral disc disorders and spinal stenosis between 1994 
and 2006. The number of procedures increased from 6.1 
to 34.2 for intervertebral disc disorders, and from 0.38 
to 3.46 for spinal stenosis per 100,000 population. Yo-
shihara and Yoneoka (202), in an assessment of national 
surgical trends of lumbar degenerative disc disease in the 
U.S. from 2000 to 2009, showed a 2.4-fold population-
adjusted increase. Bae et al (227) showed that from 2004 
to 2009 there was an increase of spinal fusions for lumbar 
spinal stenosis from 21.5 % to 31.2%, even though the 
rate of decompressions decreased from 58.5 % to 49.2%.
Lopez et al (189), in a publication on trends in Medi-
care utilization and reimbursement for anterior cervical 
discectomy and fusion, showed an annual increase in 
procedure volume of 24.2% from 2012 to 2017. Fur-
thermore, hospital reimbursements for cervical spine 
fusion surgeries without complications or comorbidities 
experienced nominal and inflation-adjusted increases 
of 9.5% and 0.7% respectively from $12,030 in 2012 to 
$13,168 in 2017. Similarly, surgeon reimbursements for 
single level and multilevel anterior cervical discectomy 
and fusion each nominally decreased from $958 and 
$1,173 in 2012 to $950 and $1,138 in 2017. 
Reoperation rates for disc herniation and spinal 
stenosis have been shown to vary from 10 to 23% 
(227). Overall, 40% of postoperative patients develop 
postsurgery syndrome or failed back surgery syndrome, 
requiring further treatment (221,228,265-268). Unfor-
tunately, the numbers of pre- and post-operative pa-
tients with disabilities requiring surgical interventions 
including complex fusions, those patients being treated 
for failed back surgery syndrome, and patients with 
refractory chronic low back pain continue to increase 
(71-74,221-246,265-268).
Overall results of surgical interventions have been 
lackluster, consequently, post-surgery syndrome, or pain 
after operative procedures of the spine is observed in 
a significant proportion of patients (221,228-235,265-
268). Fritsch et al (267) reported that epidural fibrosis, 
recurrent disc herniation, instability, and facet joints 
were responsible for recurring symptomatology. 
Ideally, clinicians should first exhaust all treatment 
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modalities in the low to moderate risk tier with patients 
enduring chronic lower back pain before pursuing a sur-
gical intervention. A recent retrospective chart by Kim et 
al (269) of more than 75 million individuals found that 
guideline nonadherence in patients with newly diagnosed 
low back pain (or lower extremity pain) contributed to a 
substantial amount of economic burden in the US. Inter-
estingly, 38.7% of patients that underwent surgery did 
not receive conservative management (neither physical 
therapy or epidural steroid injections) accounting for $265 
million dollars’ worth of healthcare expenses in the first 12 
months after diagnosis (269). This gap in proper care utili-
zation indicates the need for a more informed perspective 
regarding high-risk surgical solutions in order to achieve a 
favorable outcome more effectively.
Multiple investigators have attempted to assess the 
role of epidural injections in the prevention of surgery 
for spinal pain in the form of systematic review and 
meta-analysis of RCTs and retrospective observational 
series (188,270-278) showing significant, but variable 
success rate of epidural injections in avoiding surgery 
ranging as high as 75% response rate. Despite the 
demonstrated success rate of surgical interventions, the 
struggle continues in managing patients after surgery 
(279,280). One of the examples is back pain in surgically 
treated degenerative lumbar spondylolisthesis (279). 
Guidelines developed for the use of surgical interven-
tions for the treatment of chronic refractory back pain 
in degenerative spondylolisthesis have established a 
poor quality level of evidence and the need for further 
evidence with studies evaluating primary outcome of 
back pain in patients with degenerative lumbar spondy-
lolisthesis (281). Bond et al (279) showed improvement 
in numeric rating scale (NRS) of back pain on average of 
2.97 (SD 2.5 points at one year and clinically significant 
improvement in back pain was observed in 75% of the 
patients). Even then, 25% of the patients continue to 
suffer even with minimal criteria used at 30% or so im-
provement, rather than 50% improvement. It was also 
shown that rates of imaging in failed back surgery syn-
drome patients continue to increase, even in patients 
with spinal cord stimulation (280), driving healthcare 
costs and indicating lack of response to surgery and also 
to spinal cord stimulation. 
In this context, building on a stepwise strategy 
stemming from a modest approach such as physical and 
pharmacological therapy to interventional pain proce-
dures before considering surgery. This strategy allows 
an additional opportunity to make adjustments to the 
course of action before escalating care and avoid po-
tentially unnecessary or cost-prohibitive treatment. It is 
worth noting that constant advancements in new lines of 
treatment (chemonucleolysis, intradiscal therapies) and 
regenerative medicine (nerve growth factor, stem cells, 
plasma therapy) can bridge the gap between conserva-
tive and surgical intervention (269). While the results 
from this novel approach provides encouraging improve-
ments in lower back pain, the limited number of RCTs 
warrants further study (270). Ultimately, the judicious 
application of interventional tools in a multidisciplinary 
healthcare setting has the potential to improve pain 
outcomes in patients diagnosed with chronic spinal pain.
4.2 Interventional Techniques
The use of interventional techniques for the treat-
ment of spinal pain and musculoskeletal disorders in-
creased until 2009, at which point utilization began to 
decrease (193-200). Recent analysis of growth of utiliza-
tion of interventional techniques in managing chronic 
pain in the Medicare population (193) showed an overall 
decline in utilization of interventional techniques from 
2009 to 2018 of 6.7%, with an annual decline of 0.8% 
per 100,000 fee-for-service (FFS), despite an increase of 
0.7% per year of population growth (3.2% of those 65 
years or older), and a 3% annual increase in Medicare 
participation from 2009 to 2018. Further, analysis of 
utilization patterns of epidural procedures (194) showed 
epidural procedures have declined at a rate of 20.7% per 
100,000 Medicare enrollees from 2009 to 2018, with an 
annual decline of 2.5 %. This analysis (194) also showed 
a decline in all categories, with an annual decrease of 
4.7% for lumbar interlaminar and caudal epidural injec-
tions, 4.7% decline for cervical/thoracic transforaminal 
epidural injections, 1.1% decline for lumbar/sacral 
transforaminal injections, and 0.4 % decline for cervical/
thoracic interlaminar epidural injections. Overall declines 
were higher for lumbar interlaminar epidural injections 
of 34.9%, compared to lumbar/sacral transforaminal epi-
dural injections of 9.4% (Fig. 5).
The utilization data also shows patterns which con-
tinue to fluctuate. As shown in Fig. 6, epidural injections 
constituted 58% of all procedures in 2000, declining to 
39% of overall utilization of interventional techniques 
in 2018. This graphic display also shows changing pat-
terns of other procedures with increasing facet joint 
interventions, even though they have plateaued or 
declined in recent years (193,194). Figure 7 shows that 
the pattern of utilization of the type of the procedures 
also has significantly changed. As an example, in the 
year 2000, lumbar interlaminar epidural injections con-
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Fig. 6. Distribution of  procedural characteristics (rates) by type of  procedures from 2000 to 2018 (193,194).
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(All)
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58%
Fig. 5. Frequency of  utilization of  epidural injections (annual change in the rate) by procedures from 2000 to 2018, in Medicare 
recipients (194).


































stituted 73.7% of all epidural procedures, declining to 
34.5% in 2018. Similarly, lumbar transforaminal epidural 
injections constituting 14.6% in 2000, increased to their 
proportion of utilization to 53%. Cervical interlaminar 
procedures were 9% in 2000, increasing to 10.1% in 
2018 without any significant growth.
Manchikanti et al (282,283) published an analysis of 
utilization trends and Medicare expenditures of spinal in-
terventional techniques until 2008. The data showed that 
spinal interventional techniques increased 186.8%, at an 
annual rate of increase of 14.1% per 100,000 FFS Medicare 
beneficiaries (283). They showed overall per patient costs 
were $1,054.33 in 2000, which increased to $1,104.57 in 
2008. The total approved amounts in FFS population were 
$362,347,025 in 2000 compared to $1,231,180,420 in 2008, 
a 240% increase for all spinal interventional techniques.
The study of expenditures of epidural procedures in 
chronic spinal pain in FFS Medicare population from 2009 
to 2018 (195) showed a decrease in total expenditures 
after adjusting to inflation. Inflation adjusted cost per 
procedure per patient also decreased. However, prior to 
the inflation, total expenditures increased by 14.6% or 
an annual increase of 1.5% from $723,981,594 in 2009 
to $829,987,636 in 2018. Inflation adjusted costs were 
$847,058,465 in 2009 compared to $829,987,636 in 2018, 
a reduction of overall 2%. Inflation adjusted cost per pa-
tient decreased from $988.93 in 2009 to $819.27 in 2018 
with a decrease of 17.2% or an annual decline of 2.1%. In 
addition, inflation adjusted costs per procedure decreased 
from $399.77 to $377.94, with a 5.5% overall reduction or 
0.6% annual reduction. The proportion of Medicare pa-
tients per 100,000 receiving epidural procedures decreased 
9.1% or 1.1% annually. This evaluation also showed over-
all costs of transforaminal epidurals increased to 27.6% or 
2% annually, whereas for lumbar interlaminar and caudal 
epidural injections cost was reduced 2.7% or 0.3% annu-
ally prior to inflation adjustment. The proportion of pa-
tients receiving lumbar transforaminal epidural injections 
reduced 6.5% or at an annual rate of 0.7% compared to 
lumbar interlaminar and caudal epidural injections, which 
decreased a total of 33.5% or an annual decline of 4.4% 
(Fig. 8). Table 4 shows total allowed charges, which also 
shows specific charges for each type of epidural injection. 
Table 5 shows characteristics of Medicare beneficiaries and 
utilization pattern of epidural interventions, whereas Fig. 
9 shows epidural procedures and their utilization patterns 
with number of patients visits and services, all of them 
showing a decline, specifically services and visits showing 
Fig. 7. Frequency of  utilization of  epidural injections by procedures from 2000 to 2018, in Medicare recipients (194).
Reproduced with permission from authors and Pain Physician journal.
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a more significant decline than the number of patients re-
ceiving epidural procedures. This assessment included only 
epidural procedures and has not included percutaneous 
adhesiolysis. 
Cost expenditures analysis for facet joint inter-
ventions showed increases even after inflation adjust-
ment compared to declines for epidural procedures 
(284). 
4.3 Opioids in Spinal 
Pain 
The opioid epidemic 
has once again taken a 
central role, adding to new 
pandemic of COVID-19 with 
tightened restrictions and 
worries about increasing CO-
VID risk in opioid-receiving 
patients, with declining 
prescriptions for opioids, 
and finally, recently reported 
increases of opioid deaths in 
2019 and 2020 (46,253). This 
trend is followed by exten-
sive increases of opioid drug 
overdoses, with a subsequent 
increase of 18.2% death rate 
in year ending from June 
2019 to May 2020, due to 
COVID-19 pandemic (43-53,79,114,115,253,254,285-302).
Over the years, multiple reviews have been per-
formed in reference to opioid use, overuse, abuse, and 
a multitude of adverse consequences including opioid-
related deaths (5-8,46,103,104,168,213-215,247-254,285-
289,303-318). The US drug overdose data of drug-related 
deaths from 2018 shows an arrest of the escalation and 
a dip in the curve towards reductions. However, recent 
Fig. 8. Frequency of  utilizations of  epidural injections in the FFS Medicare population per 100,000 participants from 2009-
2018 (195).
Reproduced with permission from authors and Pain Physician journal.
Fig. 9. Epidural procedures rate per 100,000 FFS Medicare population by services, episodes, and 
patients from 2009-2018 (195).
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reports by Health Alert Network of CDC Health Advisory (46) 
showed a significant increase in fatal drug overdoses across 
the US driven by synthetic opioids before and during the 
COVID-19 pandemic. This report showed based on the recent 
provisional data that approximately 81,230 drug overdose 
deaths occurred in the US in the 12 months ending in May 
Table 5. Characteristics of  Medicare beneficiaries and utilization pattern of  epidural interventional 2009-2018.
F2009 F2010 F2011 F2012 F2013 F2014 F2015 F2016 F2017 F2018 Change Rate
U.S. 
Population 307,006 308,746 311,583 313,874 316,129 318,892 320,897 323,127 326,625 327,167 6.6% 0.7%
≥ 65 years 39,570 40,268 41,370 43,144 44,704 46,179 47,734 49,244 51,055 52,347 32.3% 3.2%
Medicare 
beneficiaries’ 45,801 46,914 48,300 50,300 51,900 53,500 54,900 56,500 58,000 59,600 30.1% 3.0%
≥ 65 years 38,177 38,991 40,000 41,900 43,100 44,600 46,000 47,500 49,200 50,800 33.1% 3.2%
% ≥ 65 
years 83.4% 83.1% 82.8% 83.1% 83.0% 83.4% 83.6% 84.1% 84.7% 85.2% 2.3% 0.2%
< 65 years 7,624 7,923 8,300 8,500 8,800 8,900 9,000 9,000 8,900 8,800 15.4% 1.6%
Epidural 
Services F2009 F2010 F2011 F2012 F2013 F2014 F2015 F2016 F2017 F2018 Change Rate
Services 
(Allowed) 2,118,840 2,205,160 2,290,740 2,311,880 2,251,720 2,268,300 2,288,520 2,335,000 2,197,300 2,196,100 3.6% 0.4%
Rate 4,626 4,700 4,743 4,596 4,339 4,240 4,169 4,133 3,788 3,685 -20.4% -2.5%
Episodes 1,727,640 1,793,240 1,866,800 1,894,380 1,849,100 1,836,400 1,851,940 1,895,620 1,785,900 1,798,100 4.1% 0.4%
Rate 3,772 3,822 3,865 3,766 3,563 3,433 3,373 3,355 3,079 3,017 -20.0% -2.5%
Visits 1,681,200 1,748,660 1,823,380 1,853,120 1,831,420 1,822,260 1,842,720 1,887,260 1,778,580 1,791,200 6.5% 0.7%
Rate 3,671 3,727 3,775 3,684 3,529 3,406 3,357 3,340 3,067 3,005 -18.1% -2.2%
Patients 856,540 891,640 936,500 967,080 959,520 971,280 993,960 1,027,120 1,001,700 1,013,080 18.3% 1.9%
Rate 1,870 1,901 1,939 1,923 1,849 1,815 1,810 1,818 1,727 1,700 -9.1% -1.1%
Age groups (Patients) 
≥ 65 Years 686,060 711,020 737,080 756,680 747,640 760,140 783,140 820,060 809,940 832,000 21.3% 2.2%
% 80.1% 79.7% 78.7% 78.2% 77.9% 78.3% 78.8% 79.8% 80.9% 82.1% 2.5% 0.3%
Rate 1,498 1,516 1,526 1,504 1,441 1,421 1,426 1,451 1,396 1,396 -6.8% -0.8%
<65 Years 170,480 180,620 199,420 210,400 211,880 211,140 210,820 207,060 191,760 181,080 6.2% 0.7%
Rate 372 385 413 418 408 395 384 366 331 304 -18.49% -2.2%
Episodes by age
≥ 65 1,365,840 1,413,080 1,452,280 1,466,500 1,421,500 1,421,960 1,446,800 1,501,960 1,433,840 1,466,960 7.4% 0.8%
Rate 2,982 3,012 3,007 2,916 2,739 2,658 2,635 2,658 2,472 2,461 -17.59% -2.1%
< 65 361,800 380,160 414,520 427,880 427,600 414,440 405,140 393,660 352,060 331,140 -8.5% -1.0%
Rate 790 810 858 851 824 775 738 697 607 556 -29.79% -3.8%
Episodes by PLCR
HOPD 577,100 591,640 618,400 611,780 586,380 584,120 581,020 587,380 538,880 538,200 -6.7% -0.8%
Rate 1,260 1,261 1,280 1,216 1,130 1,092 1,058 1,040 929 903 -28.39% -3.6%
ASC 460,740 469,840 501,920 522,560 498,040 502,180 511,920 542,800 508,100 510,360 10.8% 1.1%
Rate 1,006 1,001 1,039 1,039 960 939 932 961 876 856 -14.99% -1.8%
Office 689,800 731,760 746,480 760,040 764,680 750,100 759,000 765,440 738,920 749,540 8.7% 0.9%
Rate 1,506 1,560 1,546 1,511 1,473 1,402 1,383 1,355 1,274 1,258 -16.59% -2.0%
Rate
Rate: per 100,000 Medicare beneficiaries
Change: Of change from 2009 to 2018, GM – Geometric average.   PCPY – Percentage of Change from Previous Year
Source: Manchikanti L, et al. Declining utilization and inflation-adjusted expenditures for epidural procedures in chronic spinal pain in the Medicare popula-
tion. Pain Physician 2021; 24:1-15 (195).
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Fig. 10. Twelve-month provisionala drug overdose death 
counts for all drugsb, synthetic opioidsc, cocained, and 
psychostimulantse, for 50 states, the District of  Columbia, 
and New York City: 12-months ending in June 2019 to 
12-months ending in May 2020f.
a Provisional drug overdose death counts are based on death 
records received and processed by NCHS. Provisional drug 
overdose death data are often incomplete, and the degree of 
completeness varies by jurisdiction and 12-month ending 
period. 
b Deaths were classified using the International Classification 
of Diseases, Tenth Revision (ICD–10). The drug classes are 
all nested within all drug overdose deaths, but multiple drug 
classes may be involved in a single drug overdose death.
c Drug overdose deaths, as defined, that involve synthetic opi-
oids other than methadone (T40.4).
d Drug overdose deaths, as defined, that involve cocaine 
(T40.5).
e Drug overdose deaths, as defined, that involved psychostimu-
lants with abuse potential (T43.6).
f Included time periods will have some amount of overlap. 
2020, as shown in Fig. 10 (286). Thus, a worsening of the 
drug overdose epidemic in the US has not only shown a re-
surgence, but also is the largest number of drug overdoses 
for a 12-month period ever recorded (46,293). This report 
is preceded by news of declining 4.1% from 2007 to 2018 
(285). However, since then, the number of overdose deaths 
increased 18.2% from the 12 months ending in June 2019 
to the 12 months ending in May 2020 (Fig. 10) (286). Fur-
ther, increases of the drug overdose deaths ranged more 
than 20% in 25 states and the District of Columbia, 10% 
to 19% in 11 states and New York City, and 0% to 9% in 
10 states. However, overdose deaths decreased only in 4 
states (Appendix Fig. 1).
The CDC report also delved into various issues re-
lated to COVID-19. The increases in overdose mortality 
began in 2019, even before COVID-19 and continued 
into 2020, exacerbated by the COVID-19 national emer-
gency in the US in March. The acceleration of overdose 
deaths due to COVID-19 pandemic was clearly demon-
strated (46,49,287-291). Due to the effect of COVID-19, 
estimates indicate that the largest monthly increases in 
drug overdose deaths occurred in 12 months ending in 
May 2020 with 81,230 deaths. Further, the one-month 
increases were shown to be 2,146 and 3,388 deaths 
respectively for the 12-month period as shown in Fig. 
10. These are the largest monthly increases documented 
since provisional 12-month estimates began to be calcu-
lated in January 2015 (286). 
As described earlier in our manuscripts and also 
supported by overwhelming literature, the primary 
driver of the increases in overdose deaths continues to 
be synthetic opioids as shown in Figs. 11 and 12 (285-
287,293,294,296,298,303-317). The 12-month count 
of synthetic opioid deaths increased 38.4% from 12 
months ending in June 2019 compared with the 12 
months ending in May 2020 (Fig. 10). Of the 38 jurisdic-
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tions, the reports were available for 37, which showed 
an increase in synthetic opioid overdose deaths (286). 
In these reports, 18 jurisdictions reported increases 
greater than 50%, 11 reported increase of 25% to 45%, 
7 reported increases of 10% to 24%, only one reported 
an increase of less than 10%, as shown in Appendix Fig. 
2 (46). Once again, it also has been confirmed by these 
jurisdictional reports and state and local health depart-
ment reports that an increase in synthetic involved 
opioid deaths is primarily linked to illicit manufactured 
fentanyl (287,293,294,296). Fentanyl deaths have been 
concentrated in the 28 states east of the Mississippi river, 
where the heroin market has primarily been dominated 
by white powder heroin (296,297). In contrast, states 
west of the Mississippi river have seen the largest in-
creases in synthetic opioid deaths occurring in 10 west-
ern states with a 98% increase. This is consistent with 
large increases in illicitly manufactured fentanyl avail-
ability in western states (288) and increases in fentanyl 
positivity in clinical toxicology drugs tested in the west 
after the COVID-19 pandemic (289). However, synthetic 
opioid overdose deaths have increased substantially in 
multiple other regions including 12 southern states and 
the District of Columbia (35.4%), 6 midwestern states 
(32.1%), and 8 northeastern states and New York City 
(21.1%), as shown in Appendix Fig. 2. 
Apart from heroin and synthetic fentanyl, overdose 
deaths involving cocaine increased by 26.5% during 
this period as shown in Fig. 10 (46). In addition, data 
have shown that recent increases in overdose deaths 
involving cocaine are primarily related to overdose 
Fig. 11. Number of  opioid overdose deaths by category, 1999 to 2019.
Source(s): For 1999-2018: National Institute on Drug Abuse. Overdose death rates. May 7, 2020 https://www.drugabuse.gov/relatedtopics/
trends-statistics/ overdose-death-rates (253,285).
For 2019: Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2020 (286) 
https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
Fig. 12. Quantification of  opioid deaths.
Source(s): NIDA. Overdose Death Rates. National Institute on 
Drug Abuse website. https://www.drugabuse. gov/related-topics/
trends-statistics/overdose-death-rates (285).




deaths and involved both cocaine and synthetic opioids 
(primarily illicitly manufactured fentanyl) (290), but also 
illicitly manufactured heroin (295).
Similar to synthetic opioids and cocaine, overdose 
deaths involving psychostimulants, such as metham-
phetamine have been increasing with and without 
synthetic opioid co-use and at a rate faster than 
overdose deaths involving cocaine (290). Thus, provi-
sional 12-month counts of overdose deaths involving 
psychostimulants in the US increased by 34.8% from 
the 12 months ending in June 2019 compared to the 
12 months ending in May 2020. This leads to striking 
statistics that the number of deaths involving psycho-
stimulants now exceeds the number of cocaine involved 
deaths as shown in Fig. 10 and 11. As CDC data shows, 
these increases are consistent with the increased avail-
ability of methamphetamine in the illicit drug supply 
and increases in the methamphetamine related treat-
ment admissions (46,288,292). 
Based on the CDC report, they have distanced from 
calling the opioid epidemic and opioid deaths and 
called it driven by synthetic opioids, confirming the ap-
propriate name, illicit drug epidemic or synthetic opioid 
epidemic. The previous reports also showed a decline of 
overdose death rates of 14.5% for prescription opioids 
from 2017 to 2018. Furthermore, the provisions data 
from 2018 to 2019 showed a 4.2% decrease of prescrip-
tion opioid deaths with total deaths of 14,347 in 2019. 
However, the CDC report has not shown prescription 
related opioid deaths in the present report (46). Con-
sequently, prescription opioid deaths seem to be de-
clining below the levels of cocaine, heroin, and maybe 
even methamphetamine. The lower numbers may 
be achieved if methadone deaths are separated from 
prescription opioids, as methadone may be obtained by 
multiple means with only a small proportion from pre-
scription opioids for management of chronic pain (Fig. 
11 and Table 6). During COVID-19, opioid prescriptions 
and morphine milligram equivalent (MME) doses also 
have significantly decreased and are expected to de-
crease further. Prescription opioid related deaths with 
inclusion of methadone were 14,375 in 2019, whereas, 
Table 6. National drug overdose (od) deaths, 2000-2018




Deaths 17,415 38,329 41,340 41,502 43,982 47,055 52,404 63,632 70,237 67,367 71,364 71,987
Any Opioid1 
(T40.0-T40.4, T40.6) 8,407 21,088 22,784 23,164 25,050 28,647 33,091 42,249 47,600 46,802 50,343 50,806
Prescription Opioids2 
(T40.2-T40.3) 3,785 14,583 15,140 14,240 14,145 14,838 15,281 17,087 17,029 14,975 14,252 14,375
Prescription 
Opioids AND Other 
Synthetic Narcotics




3,618 13,644 14,251 13,379 13,130 13,349 13,018 13,032 11,585 9,558 NA NA
Other Synthetic 
Narcotics (fentanyl)3 
(T40.4), other than 
methadone
782 3,007 2,666 2,628 3,105 5,544 9,580 19,413 28,466 31,335 36,733 37,147
Heroin4 (T40.1) 1,842 3,036 4,397 5,925 8,257 10,574 12,989 15,469 15,482 14,996 14,157 14,282
Cocaine5 (T40.5) 3,544 4,183 4,681 4,404 4,944 5,415 6,784 10,375 13,942 14,666 16,071 16,207
Psychostimulants 
With Abuse Potential 
(methamphetamine)6 
(T43.6)
578 1,854 2,266 2,635 3,627 4,298 5,716 7,542 10,333 12,676 16,356 16,528
Benzodiazepines7 
(T42.4) 1,298 6,497 6,872 6,524 6,973 7,945 8,791 10,684 11,537 10,724 NA NA
R – Reported; P – Predicted values 
Source for 2000 to 2018:  https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates
For 2019: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm (data based on 12/6/2020)
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excluding methadone these deaths were 12,084 with 
2,787 deaths attributed to methadone. Methadone is 
obtained from multitude of sources with prescription 
methadone contributing to a small proportion of the 
deaths or a minority of deaths. It is also worrisome that 
stricter regulations, lack of access to prescription opi-
oids during COVID-19 epidemic may be fueling the illicit 
drug market. Thus, previous postulations that if we can 
control overdose deaths related to heroin and synthetic 
opioids, the opioid epidemic will be resolved, may be 
fine-tuned to state if we control illicit drug epidemic 
and maintain access to appropriate opioid prescriptions. 
In reviewing the prescription trends in the US, mul-
tiple reports over the years have captivated the country 
with most attention paid to the opioid epidemic, which 
changed this year in the face of COVID-19 pandemic. 
Patients with chronic pain and addiction have been 
affected by disruptions to life and healthcare during 
COVID. Prescription opioid trends in the US published 
by IQVIA Institute (313) in December 2020, showed 
that prescription opioid use in the US continues to 
decline rapidly, with only 100 billion MME expected to 
be dispensed in 2020. This is a 60% decline from 246 
billion MME dispensed at the peak of opioid prescrib-
ing in 2011 as shown in Fig. 13 and Appendix Fig. 3. 
Reports also highlighted that between 2019 and 2020, 
there is an expected 17.1% decline in MME, including 
the effects of disruptions from the COVID-19 pandemic, 
marking the ninth consecutive year of declines and the 
third year of double-digit change. Prescription opioid 
use was approximately 16 pills or 134 MME per adult 
Americans in 1992, and rose to a peak of 55 pills or 790 
MME in 2011. This use has since declined by 54% to 29 
pills and 366 MME per capita in 2019, though popula-
tion growth has been 5.4% since 2011. 
In 2020, the projected decline in MME per capita 
is 17.1%, meaning prescription opioid use will reach 
mid 2000 levels. This represents a 20 years cycle, marked 
by 11 years of gains and 9 years of reductions. Conse-
quently, by the end of 2020, MME per capita is expected 
to drop to 298, nearing the levels seen in 2000, which 
was 270 MME per capita (Fig. 13) (313). 
Even though overall prescriptions have seen a 
significant reduction, Medicare Part D prescriptions 
have increased by 2% since 2011, rising from 53 million 
prescriptions to 54 million in 2019. The Medicare Part D 
share of prescriptions has increased from 21% to 35% 
over the same timeframe, as the over 65 population 
has increased by 31% and seniors often require more 
procedures and also suffer with multiple degenerative 
conditions resulting in larger number of opioid pre-
scriptions. Even then, compared to 2019, prescriptions 
have declined 17% from 66 million in 2014; however, 
prescriptions for commercial patients declined by 51%, 
even though commercial prescriptions still comprised 
the largest share of prescription opioids, with 48% of 
the volume in 2019 down from 58% in 2011.
Overall, these decreases in volume and dosage 
along with redistribution among the populations have 
been driven by changes in clinical usage, regulatory 
Fig. 13. Prescription opioid use in morphine milligram equivalents (MME) per capita, 1992-2020*.
Source: IQVIA Xponent, Mar 2020; IQVIA Prescription Audit; IQVIA Institute, Nov 2020
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and reimbursement policies, and progressively more 
restrictive legislation enacted since 2012, and finally 
the guidelines from the CDC. Multitude of these leg-
islations including National All Schedules Prescription 
Electronic Reporting (NASPER) Act have resulted in 
prescription drug monitoring programs in all states 
which facilitates decrease in inappropriate prescriptions 
(286,296,303,314-328). 
Manchikanti et al (303) described various issues relat-
ed to the opioid epidemic and pointed out the tragic fail-
ures of the current systems to control opioid misuse. Thus, 
multiple factors propagated the epidemic, starting with 
the fifth vital sign pain movement together with a conflu-
ence of interest and a failure of oversight from the opioid 
industry, which was largely responsible for the epidemic. 
Multiple confluences of interests were reported, including 
promotion of opioids based on inadequate evidence with 
advocacy from Portenoy and Foley (329). Further fuel was 
added with the establishment of pain as the fifth vital 
sign, which was embraced by multiple organizations and 
it was essentially forced on hospitals and other healthcare 
professionals in assessing pain relief and quality improve-
ment (6,303). Further contributing issues were the medical 
boards themselves. Most of the guidelines although alleg-
edly written for appropriate opioid use, were essentially 
promoting excessive use and abuse patterns, as they were 
developed by the opioid industry with confluence of in-
terest. Further, multiple failures in the oversight of opioid 
manufacturing, distribution, diversion and import, in ad-
dition to medical necessity and appropriate monitoring of 
opioid prescriptions fueled the epidemic (303).
It is difficult to point out the reasons for the ex-
plosion of the fentanyl epidemic, along with increases 
in the usage of heroin, as well as cocaine, as shown in 
Figs. 10 to 12 (46,285,286,303-305,308). The significant 
movement to control the opioid epidemic in the US was 
initiated with prescription drug monitoring programs, 
state regulations curbing opioid prescriptions, and in-
creasing the focus on education. Overall federal spend-
ing increased 128% from 2017 to 2018 with the major 
increases in federal spending due to treatment and re-
covery programs with costs ranging from approximately 
$599 million to 2.1 billion (286,314). Overall, total opi-
oid spending increased from $3.3 billion in 2007 to $7.4 
billion in 2018 in the US (286). 
4.4 Noninterventional Techniques in 
Managing Spinal Pain
There are many noninvasive or noninterventional 
techniques for managing spine pain including medica-
tions, exercise programs, physical therapy, acupuncture, 
massage, transcutaneous electrical nerve stimulation 
(TENS), biofeedback therapy and chiropractic treatments.
4.4.1 Medications
Nonopioid medications for treating low back pain 
include nonsteroidal anti-inflammatory drugs (NSAIDS), 
antidepressants and acetaminophen (330). Multiple sys-
tematic reviews evaluated recent randomized trials of 
medication treatment for patients with low back pain 
(331-334). 
In the treatment of patients with acute low back pain 
with NSAIDS, there was a high certainty that these medi-
cations were more effective than placebo for improving 
disability and a moderate certainty that they were more 
effective at providing short-term pain reduction. There 
was a low degree of certainty that NSAIDS were better 
than placebo in regards to global improvement and 
there was no difference in short-term pain reduction 
when comparing the selective COX-2 inhibitors to nonse-
lective NSAIDs. There was also a negligible difference in 
the rate of adverse events in patients using either NSAIDs 
or COX-2 inhibitors for acute low back pain.
In the treatment of chronic nonspecific low back 
pain, 6 of the 13 trials showed that NSAIDs were signifi-
cantly more effective than placebo for pain relief and 
are slightly more effective at improving the patients’ 
disability. This systematic review by Enthoven et al (332) 
showed no difference in efficacy between the different 
NSAIDs, which included both selective and nonselective 
NSAIDs and because the inclusion of RCTs that were at 
low risk of bias there was an overall reduction in the 
differences between the NSAIDs and placebos. Also due 
to the small sample sizes, there could be no conclusion 
regarding the occurrence of adverse events or whether 
NSAIDs are safe for long-term use.
When examining the evidence for the treatment 
of low back pain with acetaminophen, one recent sys-
tematic review concluded that there was insufficient 
evidence to assess the efficacy of acetaminophen in 
patients with low back pain (331). Another review fo-
cusing on the treatment of chronic low back pain with 
medication concluded that there was no significant 
difference between a NSAID (diflunisal) and acetamino-
phen for pain relief in patients with low back pain.
Other medications used to treat low back pain 
include antiepileptics and antidepressants. A recent sys-
tematic review analyzed both classes of medications and 
concluded that one type of antiepileptic (topiramate) was 
both safe and effective agent in the treatment of chronic 
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low back pain and produced significantly positive changes 
in pain sensitivity, patient disability, health-related QoL, 
and weight loss (334). The review also concluded that an-
tidepressants had a statistically significant improvement in 
low back pain when compared to placebo in patients be-
ing treated for chronic low back pain. The antidepressant 
medications, however, were also associated with signifi-
cantly more side effects when compared to placebo (334).





Number of patients Conclusions
Exercise Saragiotto 
et al, 2016 
(335)
29 RCTs  There is low to moderate quality evidence that MCE is 
effective for improving pain at short, intermediate and 
long-term follow-up with medium effect sizes (long-term, 
MD -12.97; 95% CI -18.51 to -7.42) when compared to 
minimal intervention. 
There was also a clinically important difference for 
function and global impression of recovery compared with 
minimal intervention.
There is very low to low-quality evidence that MCE is 
clinically more effective than exercise and electro-physical 
agents for pain, disability, global impression of recovery 
and QoL with medium to large effect sizes (pain at short-
term, MD -30.18; 95% CI -35.32 to -25.05).
Total patient number – 2,431
There is very low to moderate 
quality evidence that MCE has 
a clinically important effect 
compared with a minimal 
intervention for chronic low back 
pain.
There is very low to low-quality 
evidence that MCE has a clinically 
important effect compared with 
exercise plus electro-physical 
agents.
There is moderate to high-quality 
evidence that MCE provides 
similar outcomes to manual 
therapies and low to moderate 
quality evidence that it provides 
similar outcomes to other forms of 
exercises.
Overall, MCE is not superior to 
other forms of exercise
Byström 
et al, 2013 
(336)
16 RCTs (n = 1933)
80% with chronic 
LBP
The review included 
studies of subacute 
duration (4 to 12 
weeks) and of 
chronic duration > 6 
months)
Short-term (6 
weeks to 4 months), 
intermediate term 
(4 to 8 months) and 
long-term (8 to 15 
months)
1. Motor control exercises vs general exercise (n = 741) 
7 trials
• Short-term (6 trials, WMD −7.80 on 0 to 100 scale, 
95% CI −10.95 to −4.65)
• Intermediate term (3 trials, WMD −6.06, 95% CI 
−10.94 to −1.18)
• Effects were not statistically significant at long-term (4 
trials, WMD −3.10, 95% CI −7.03 to 0.83)
2. Motor control exercises vs minimal intervention (n = 
541; 3 trials)
• MCE was also associated with better function:
• Short-term (6 trials, WMD −4.65 on 0 to 100 scale, 
95% CI −6.20 to −3.11)
• Long-term (3 trials, WMD −4.72, 95% CI −8.81 to 
−0.63).
3. Motor control exercises vs multimodal physical therapy 
(n = 499) 4 trials
In CLBP, MCE was associated with lower pain scores 
versus minimal intervention:
• Short-term (WMD −12.48 on a 0 to 100 scale, 95% 
CI−19.04 to −5.93)
• Intermediate term (WMD −10.18, 95% CI −16.64 
to −3.72)
• Long-term (WMD −13.32 95% CI −19.75 to −6.90)
4. MCE vs other components of that intervention (n = 
152) 2 trials
MCE was also associated with better function:
• -Short-term (3 trials WMD -9.00 on 0 to 100 scale, 
95% CI −15.28 to −2.73)
• Intermediate term (2 trials WMD -5.62, 95% 
CI−10.46 to −0.77)
• Long-term (2 trials, WMD −6.64, 95% CI −11.72 
to −1.57)
For CLBP, motor control 
exercises was associated with 
lower pain intensity versus 
general exercise:
MCE = motor control exercise; RCTs = randomized controlled trials; MD = mean difference; N = number; LBP = low back pain; CLBP = chronic 




Exercise has typically been viewed as a moderately 
effective treatment for chronic low back pain but there 
is no clear evidence that indicates one form of exercise 
is more effective than another. Most of the current ex-
ercise recommendations are based upon motor control 
exercise (MCE) that focuses on establishing and main-
taining core muscle strength (Table 7). 
Of the 45 RCTs presented evaluating MCE on low 
back pain, there was supportive evidence that this 
treatment was associated with better pain control and 
patient function than minimal intervention (335,336). 
There was low to moderate evidence that MCE was 
clinically more important than minimal intervention 
for treating chronic low back pain and that it provided 
similar outcomes to other forms of exercise (335). This 
was found regardless of whether the pain scores were 
measured at short, medium or long-term follow-ups 
(335). There was very low or low-quality of evidence 
that MCE had a more clinically important effect than 
electro-physical agents (EPA) and moderate to high-
quality of evidence that MCE provided similar outcomes 
to other types of exercises. Overall, it was concluded 
that MCE was not superior to other forms of exercise.
When comparing the results of MCE on patients 
with mostly chronic low back pain and evaluating 
different follow-up times to compare MCE with gen-
eral exercise, minimal intervention, multimodal physical 
therapy and other forms of intervention it was found 
that MCE was associated with lower pain intensity than 
general exercise in the short and intermediate term 
but not in the long-term (336). It was found that MCE 
was associated with better function at all follow-up 
time points. As in previous systematic reviews, MCE was 
associated with lower pain scores and better function 
compared to minimal intervention at all follow-up time 
points (335,336). 
4.4.3 Physical Therapy and Multidisciplinary 
Rehabilitation
The goal of physical therapy is to improve pain and 
increase function to prevent unnecessary disability and 
to keep the patient’s low back pain from worsening. 
Physical therapy and multidisciplinary biopsychosocial 
rehabilitation (MBR) include a number of different 
treatment strategies such as exercise, rest, stretching, 
tai chi, yoga, massage, spinal manipulation and other 
treatments. In patients with chronic low back pain, 
physical therapy with exercise approach is a first line 
treatment that is routinely utilized.
Of the 83 studies with 8,816 patients evaluating 
physical therapy and rehabilitation interventions to 
treat patients with chronic low back pain, it was found 
that exercise therapy improved pain intensity, disability 
and long-term function when compared to nonexercise 
conventional care and behavioral therapy was effective 
for decreasing pain intensity compared to no treatment 
in the short-term (337). Multidisciplinary treatment was 
also found to be effective at reducing pain intensity 
and disability at short-term follow-up compared to no 
treatment (337). The evidence from the RCTs showed 
low-quality evidence for the efficacy of exercise therapy 
compared to conventional care and low-quality evi-
dence for the efficacy of behavioral therapy compared 
to no treatment (337). There was moderate evidence 
for the effectiveness of multidisciplinary treatment 
compared to no treatment or other active treatments in 
reducing pain in the short-term. The authors concluded 
that there was an insufficient amount of data to draw 
firm conclusions on the clinical effect of back schools, 
low-level laser therapy, patient education, massage, 
traction, superficial heat/cold, and lumbar supports for 
chronic low back pain.
In a systematic review of 41 RCTs, Kamper et al (338) 
found that MBR improves pain and disability more than 
conventional care in the short and long-term but there 
is no evidence that it improves work outcomes in the 
short or long-term. The authors also found that MBR 
improves pain and disability more than no MBR in the 
short-term and there is additional evidence that MBR 
improves pain, disability, and work outcomes more than 
physical treatments in the short and long-term (338).
4.4.4 Acupuncture
In treating low back pain, patients may seek alter-
native medical approaches to address their low back 
pain. One of the most common treatments among the 
alternative approaches is acupuncture. Despite the fact 
that it is interventional and invasive, it is included in this 
section. Acupuncture is a very old medical treatment 
that originated in the Far East and has gained increas-
ing interest in the west as a treatment for low back pain 
(339). Despite the increasing popularity of acupuncture, 
the effectiveness is often disputed and many system-
atic reviews and meta-analyses have investigated its 
effectiveness (340,341). Recently, three clinical practice 
guidelines have also been published with differing rec-
ommendations on the treatment of low back pain with 
acupuncture (342-344). Given these inconsistencies, the 
recent systematic reviews and meta-analyses are very 
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important for providing a systematic assessment of the 
strength and completeness of the current evidence. 
In 16 systematic reviews of over 35,000 patients with 
acute low back pain, evidence shows acupuncture is 
better at relieving pain than sham treatments but the 
evidence was somewhat inconsistent (340). In addition 
to providing substantive pain relief, this review showed 
that acupuncture had a positive effect on improving pa-
tients’ function. The summary of this systematic review 
showed that in patients with chronic low back pain, the 
evidence demonstrated that acupuncture consistently 
provides short-term pain relief and functional improve-
ments when compared to no treatment or acupuncture 
and another conventional treatment (340). Seven of the 
systematic reviews were of varying quality but showed 
that acupuncture produces more pain relief and func-
tional improvement than no treatment at short-term 
follow-up. Five systematic reviews found that acupunc-
ture used in addition to conventional therapy provided 
short-term improvements in pain and function in the 
treatment of patients with chronic low back pain (340). 
In another meta-analysis of 25 studies with over 
6,200 patients, acupuncture had a clinically meaningful 
reduction in pain when compared to sham treatments 
and an improvement in function immediately after the 
treatment when compared to other patients either not 
receiving treatment or receiving conventional therapies 
(341). When acupuncture was compared to medications 
including NSAIDs, muscle relaxants, and analgesics as 
well as conventional treatments, there were statistically 
significant differences between the control groups and 
the patients receiving acupuncture (341). Although 
acupuncture improved pain and function immediately 
after intervention and more than no treatment, sham 
or medications (NSAIDs, muscle relaxants or analgesics), 
the differences were small. 
Patients who received acupuncture in addition to 
conventional treatment had greater pain relief and 
improved function directly following the intervention 
and at the time of follow-up compared to those who 
received conventional treatment only (341). This meta-
analysis also reviewed electroacupuncture and found 
that this technique resulted in significantly less pain and 
improved activity immediately after the intervention 
compared to the control group (341). 
4.4.5 Massage
Massage has been traditionally thought to improve 
symptoms by providing pain relief through physical and 
mental relaxation and by increased the threshold of 
pain by the release of endorphins (345). The thought 
behind the mechanism of pain relief is that massaging 
a certain area stimulates large nerve fibers that have an 
inhibitory effect on T‐cells and pain relief follows (346). 
Massage may also have an effect on the autonomic ner-
vous system by shifting it from a state of sympathetic 
response to a state of parasympathetic response or 
vice versa (347). The mechanism between massage and 
symptom relief is not fully understood but there are nu-
merous trials and some literature reviews and systemic 
meta-analyses that investigate the efficacy of massage 
(348,349).
In a meta-analysis by Farber et al (348), the quality 
of evidence was found to be low to very low primar-
ily because of risk of bias and imprecision. They found 
that for acute low back pain, massage was better than 
inactive controls in the short-term for pain but not for 
function. It was also determined that for patients with 
subacute and chronic low back pain, massage was bet-
ter than inactive treatments for pain and function in 
the short-term but not in the long-term. The analysis 
also showed that when compared to active controls, 
massage was better for pain both in the short-term and 
at long-term follow-up. Functional improvement was 
found in patients with sub-acute and chronic low back 
pain as compared with inactive controls, but only at the 
short-term follow-up. 
The review by Furlan et al (349) included 8 of 13 
articles with a high risk of bias. In two of the studies, 
massage was superior to producing pain and functional 
improvements at short and long-term follow-ups. Eight 
studies showed that massage was similar to exercises, 
and better than joint mobilization, relaxation therapy, 
physical therapy, acupuncture, and self-care education 
for decreasing symptoms when compared to other 
active treatments. When positive effects of massage 
were present, the duration of these effects was one 
year after the end of treatment. Two studies showed 
that acupuncture massage gave rise to better results 
than Swedish massage and another trial concluded that 
Thai massage produces similar results to Swedish mas-
sage. Overall, there was moderate evidence of short 
and long-term improvement in pain and function with 
massage as compared with sham or other treatments 
but the differences in degree of improvement are small. 
The review showed that massage might be beneficial 
for patients with subacute and chronic low back pain, 
especially when combined with exercises and education. 
4.4.6 Transcutaneous Electrical Nerve Stimulation 
(TENS)
Despite the common usage of TENS for pain man-
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agement, evidence for its effectiveness is not conclusive. 
Due to this lack of optimal evidence TENS is not a treat-
ment that is typically covered by insurance and is often 
restricted for use in RCTs. Previous health technology as-
sessments and society led meta-analyses have found no 
benefit for TENS in patients with chronic pain (350,351). 
Some have criticized the recent society meta-analysis 
for a paucity of RCTs and the fact that the assessment 
did not compare the effectiveness of TENS with other 
nerve stimulation therapies (NSTs).
Studies comparing exercise therapy to passive ther-
apies such as TENS, low-level laser therapy, ultrasound, 
thermal therapy, and ultrasound found no statistically 
significant difference between the exercise therapy and 
the other therapies, including TENS, but there was some 
serious limitations and inconsistencies in this low-quality 
evidence (337). Two studies comparing TENS with acu-
puncture or percutaneous electrical nerve stimulation 
(PENS) found that TENS was better for controlling pain 
but three studies comparing the same modalities found 
that PENS and acupuncture were better for controlling 
pain in the short-term (337). The evidence quality was 
very low in showing that PENS and acupuncture are 
better than TENS at providing short-term pain relief. 
Another study compared TENS to a new biphasic TENS 
in regards to pain and functional outcomes and found 
no difference. Five other studies comparing TENS with 
sham TENS or PENS found no significant difference be-
tween the groups. Only one study showed a significant 
benefit of TENS for pain relief compared to sham at 
short-term follow-up. All of this comparison data com-
paring TENS to PENS and sham was of low-quality.
Overall, the meta-analysis by van Middlekoop (337) 
found no difference between TENS and other treat-
ments in regard to pain or functional outcomes when 
TENS was compared to other active interventions. The 
authors also noted that the findings of the Cochrane 
review from Khadilkar et al, when compared to their 
meta-analysis, were very similar in that they both con-
clude that TENS is not supported in the management of 
chronic low back pain (337,352).
A meta-analysis from Wu et al (353) showed the ef-
ficacy of TENS was similar to that of controls for provid-
ing pain relief and that other types of NSTs were more 
effective than TENS for providing pain relief. The only 
benefit they found for TENS was that it was better than 
control treatment in improving functional disability in 
the short-term (353).
The overall results of the Wu et al meta-analysis of 
RCTs comparing the effectiveness of TENS to controls 
and other NSTs suggest that TENS does not improve 
symptoms of lower back pain, but could offer short-
term improvement of functional disability (353). 
4.4.7 Chiropractic Treatments
The efficacy of spinal manipulative therapy (SMT) 
for treating chronic low back pain is debated and the 
recommendations for use are heterogeneous. In some 
health systems SMT is treated as a first line option, but 
in others it is most often recommended along with 
other spinal treatments or not recommended at all 
(354,355). There is also at least one recent review of 
guidelines that suggests that SMT should be considered 
as a second-tier treatment option after exercise and 
behavior therapy (356).
In most reviews, SMT is considered to represent any 
manual treatment of the spine. Mobilizations of the 
spine are typically low velocity or passive movement 
techniques as opposed to manipulation which uses 
a high velocity thrust applied to a synovial joint near 
the end of the range of motion (357). This thrust often 
produces an audible pop or crack that results from cavi-
tation of the joint.
There are many theories as to the mechanism of 
action of SMT and most of the hypotheses can be sepa-
rated into neurophysiological and biomechanical cat-
egories (358,359). The biomechanical theory proposes 
that SMT acts on a spinal lesion to reduce the mechani-
cal stresses and the neurophysiological theory suggests 
that SMT affects the primary afferent neurons from the 
paraspinal musculature and the neurons that control 
pain processing (360,361).
In a Cochrane review by Rubinstein et al (362), 
the authors found that there was moderate quality 
evidence indicating that SMT was no different than 
other treatments for short-term pain relief but that it 
produced a small improvement in function. They also 
found high-quality evidence that indicated that SMT 
had a small positive effect for short-term pain relief 
and small to moderate positive effects for improve-
ment in function when compared to other nonrecom-
mended therapies (362). These results were similar 
for intermediate and long-term outcomes. One study 
with a low risk of selection bias found no increased 
risk of adverse events associated with SMT. Most of the 
adverse events seen with SMT were transient and of 
mild to moderate severity (362). Overall, the authors 
found that SMT produces similar clinical results when 
compared to recommended therapies for patients with 
chronic low back pain and seemed to be better than 
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nonrecommended interventions for improvement of 
short-term function.
Coulter et al (184) published the results of a sys-
tematic review and meta-analysis of manipulation and 
mobilization for treating chronic low back pain which 
was composed of 51 trials meeting the inclusion crite-
ria, and 9 trials with 1,176 patients with sufficient data 
were included in the meta-analysis. They concluded that 
there is moderate quality evidence that manipulation 
and mobilization are likely to reduce pain and improve 
function for patients with chronic low back pain. In 
addition, they concluded that manipulation appears to 
produce a larger effect than mobilization, even though 
both therapies appear safe and that multimodal pro-
grams may be a promising option. 
Coulter et al (171) also performed a systematic 
review and meta-analysis for an appropriateness panel 
for manipulation and mobilization for treating chronic 
nonspecific neck pain. They included 47 randomized tri-
als with low risk of bias, including 4,460 patients with 
nonspecific chronic neck pain. They concluded that 
studies published since January 2000 provide low-mod-
erate quality evidence that various types of manipula-
tion and/or mobilization will reduce pain and improve 
function for chronic nonspecific neck pain compared to 
other interventions. Further, it appears that multimodal 
approaches, in which multiple treatment approaches 
are integrated, might have the greatest potential im-
pact. The studies comparing to no treatment or sham 
were mostly testing the effect of a single dose, which 
may or may not be helpful in clinical practice. They also 
hypothesized that given the low rate of serious adverse 
events, other types of studies with much larger sample 
sizes would be required to fully describe the safety 
of manipulation and/or mobilization for nonspecific 
chronic neck pain.
Rothberg and Friedman (363) in a systematic 
review of complementary therapies in addition to 
medication for patients with nonchronic, nonradicular 
low back pain concluded that available evidence does 
not support the use of spinal manipulation or excessive 
therapy in addition to standard medical therapy. They 
also concluded that there was insufficient evidence to 
determine if yoga or massage was beneficial. However, 
this study was criticized (364) for not including any stud-
ies beyond 2009 and there were multiple RCTs which 
were available for inclusion during the publication of 
this systematic review. 
Sherbourne et al (365) from RAND Corporation also 
described coping and management techniques used 
by chronic low back pain patients receiving treatment 
from chiropractors. The results showed that respon-
dents reported using an average 9 coping behaviors in 
the prior 6 months. Persons with chronic low back pain 
were proactive in their coping strategies and frequently 
used self-care coping strategies like those provided by 
chiropractors in patient education. Along similar lines, 
in another manuscript from RAND Corporation (366), 
the results showed that 79% of the sample gave posi-
tive responses to the time spent with the provider item 
and a majority of the patients rated their provider at 
the top of the scale. The results also showed that more 
chiropractic patients reported always getting answers 
to questions the same day and always seen within 15 
minutes of their appointment. 
Overall, these experiences provide information to 
interventional pain physicians and also the importance 
of multimodal treatment, including chiropractic treat-
ment apart from physical therapy, exercise program, 
and drug therapy. 
4.4.8 Biofeedback Therapy
Behavioral and psychological treatments have been 
shown to be effective in the treatment of chronic pain 
by decreasing pain and improving function, but reduc-
ing psychological distress (365). There is some evidence 
that psychological treatments are more effective than 
medication and physical therapy in the short-term (366).
Biofeedback is a psychological treatment that may 
be performed independently or as an adjunctive therapy 
along with physical therapy or cognitive behavioral 
therapy (CBT). During biofeedback treatments, patients 
receive sensory information about physiological pro-
cesses from their central nervous system (CNS) such as re-
spiratory rate, heart rate, or muscle tension. Biofeedback 
teaches the patient to self-regulate their physiological 
processes with the assistance of the biofeedback infor-
mation (366,367). The goals of the biofeedback sessions 
are to teach the patient to consciously reduce muscle ten-
sion or to positively affect their own coping mechanism.
There are different types of biofeedback treat-
ments including electromyographic, heart rate variabil-
ity and respiratory biofeedback with electromyographic 
biofeedback being the most common. There has been 
no obvious mechanism of action for biofeedback in 
the treatment of chronic low back pain; however, the 
benefits of biofeedback have been shown in a number 
of different chronic pain conditions (368). In previous 
meta-analyses, biofeedback has been shown to be more 
effective than cognitive behavioral therapy and physical 
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therapy (369,370). It has been difficult to establish con-
clusions on the efficacy of biofeedback therapy due to 
the heterogeneity of the biofeedback treatments and 
the common practice of including this treatment with 
others as an additive treatment.
Sielski et al (370) in a meta-analysis included an 
evaluation of controlled and uncontrolled chronic back 
pain studies that included biofeedback, to evaluate 
short-term and long-term effects of biofeedback on 
pain. This meta-analysis focused on manuscripts that re-
ported standalone biofeedback as a treatment or com-
prising at least one-fourth of the total treatment (370). 
The goal was to determine the efficacy of biofeedback 
compared to different control groups and to identify 
important components of the treatment effects. The 
authors found that biofeedback resulted in a significant 
small-to-medium reduction of pain that was durable 
out to an eight-month follow-up and that it was also 
effective in reducing depression, disability and muscle 
tension (370). Biofeedback was also found to improve 
the patients’ cognitive coping skills and these results 
remained stable at follow-up. The moderator analyses 
showed that longer biofeedback treatments were more 
effective for decreasing disability and that a greater 
proportion of biofeedback in the overall treatment 
strategy was more effective for reducing depression. 
They concluded that biofeedback treatment can be used 
as a standalone therapy or as an adjunctive intervention 
and can produce improvement on various pain-related 
outcomes both in the short-term and in the long-term. 
5.0 structural BasIs of spInal paIn
Key Question 3: What is the evidence for struc-
tural basis of spinal pain?
Chronic spinal pain is a complex and multifactorial 
phenomenon. Consequently, the high prevalence of 
chronic spinal pain, the numerous modalities of treat-
ments applied in management of the problem, and the 
growing social and economic costs continue to influence 
medical decision-making. Despite its commonality, both 
in primary care and tertiary care, it is often difficult to 
reach a definite diagnosis of the origin of spinal pain. 
Interventional techniques are based on the philosophy 
of a neurophysiologic basis, in that when present, a 
structural origin of pain is important with or without 
coexisting psychosocial abnormalities and comorbid 
conditions. A major source of exponential growth in 
treatment modalities is the inherent difficulty in obtain-
ing an accurate diagnosis. In the search of a diagnosis, 
an inaccurate or incorrect diagnosis, may lead not only 
to expensive diagnostic ventures, but to treatment 
failures resulting in wasted healthcare dollars, and di-
version of essential healthcare resources. Fundamental 
to proper treatment is an accurate diagnosis, which is 
based on the reliability of the test used to make the 
diagnosis. There are no universally accepted gold stan-
dards for the diagnosis of spinal pain, regardless of the 
suspected source (127-139,164,165,188,192,371-383). 
The majority of pain problems are not related to an eas-
ily identifiable cause. In addition, chronic pain may be 
confused with chronic pain syndrome, which is defined 
as a complex pain condition with physical, psychologi-
cal, emotional, and social components (7,384). Chronic 
pain and chronic pain syndrome often appear similar, 
and at times may coexist.
Epidural interventions including multiple types of 
epidural procedures and percutaneous epidural adhe-
siolysis are administered in disc-related pathology in-
cluding disc herniation, disc protrusion, discogenic pain, 
spinal stenosis, and radiculitis.
5.1 Lumbar Disc-Related Pathology, Spinal 
Stenosis, Post-surgery Syndrome
Chronic, persistent low back, lower extremity pain, 
and radicular pain may be secondary to disc herniation, 
disc disruption, disc degeneration, spinal stenosis, or 
post-lumbar surgery syndrome resulting in disc-related 
pain with or without radiculitis. 
5.1.1 Lumbar Disc-Related Degeneration
The spine is composed of five lumbar vertebrae 
and, between them, intervertebral discs which together 
constitute one quarter of the total length of the spine 
(385). In a healthy back, the intervertebral discs, being 
70-80% aqueous, are soft and compressive to preserve 
spinal movements, absorb shock impact, and distribute 
axial and torsional forces (386-388). Through the nor-
mal process of aging, the inner nucleus pulposus of 
the discs becomes replaced with fibrocartilage as the 
proteoglycan, water, and noncollagenous protein con-
centrations decrease, and the collagen concentration 
increases (389,390). This loss of fluid due to dropped 
oncotic pressure in the discs makes them thinner and 
less flexible, hindering their function (386-388). Carti-
laginous endplate erosion contributes to disc degenera-
tion by compromising the flow of oxygen and nutrients 
to the discs (388,391-393). Endplate defects, which may 
result from disc degeneration or trauma, can stimulate 
nociceptors within the discs (394-396).
Another age-related mechanism of disc degen-
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eration is the formation of small tears into the outer 
annulus fibrosis of the discs. This may be worsened by 
injury from daily activities and sports. This leads to disc 
space collapse and disc resorption as the nucleus pulpo-
sus streams out through the tears, causing the disks to 
bulge, protrude or rupture, leading to herniated discs. 
Herniated material may also contain cartilaginous end-
plate, fragmented apophyseal bone and annular tissue 
(397-399). The resulting instability may lead to abnor-
mal micro-motions, causing tension and irritation in the 
surrounding structures. The loss of disc height can lead 
to abnormal loading of apophyseal joints, which may 
in turn cause osteoarthritic changes (400). The space 
between vertebrae becoming narrower may lead to the 
production of osteophytes, which in rare cases apply 
pressure on the spinal cord or spinal nerve roots, further 
worsening pain and nerve function (401).
Herniated lumbar disc is a displacement of disc 
material (nucleus pulposus or annulus fibrosis) beyond 
the intervertebral disc space. Over the past 78 years, vo-
luminous literature has been published describing the 
epidemiology, diagnosis, and numerous treatment mo-
dalities for herniated disc pain, following the descrip-
tion of disc herniation by Mixter and Barr in 1934 (255). 
However, magnetic resonance imaging (MRI) findings 
of a herniated disc are not always accompanied by clini-
cal symptoms (402). The prevalence of a symptomatic 
herniated lumbar disc is about 1% to 3% (402) with the 
highest prevalence among people aged 30 to 50 years 
(403), with a man to woman ratio of 2:1 (404). In indi-
viduals aged 25 to 55 years, about 95% of herniated 
discs occur at the lower lumbar spine (L4/5 and L5/S1 
level); disc herniation above this level is more common 
in people aged over 55 years (405,406). Lumbar disc dis-
placement may present as internal disc disruption, disc 
prolapse, disc protrusion, disc extrusion, disc herniation, 
or simply discogenic pain. The estimated prevalence of 
lumbar radiculopathy or sciatica has been described as 
9.8 per 1,000 cases (407,408). It has been estimated that 
lumbar disc herniation occurs in 30% of the population 
at some time in their lifetime. Studies also have shown 
that sciatic symptoms may be present from 1.6% in the 
general population to 43% in select working popula-
tions in the US (408-411). Additionally, spontaneous 
resorption or regression of lumbar disc herniation has 
been reported in multiple assessments. Zhong et al 
(412), in a systematic review published in 2017 reported 
incidence of spontaneous resorption was 66.66%. The 
incidence in the United Kingdom was 82.94%, and in 
Japan was 62.58%. On the other end of the spectrum, 
Chiu et al (413) found a rate of spontaneous regression 
of 96% for disc sequestration, 70% for disc extrusion, 
41% for disc protrusion, and 13% for disc bulging. They 
also showed the rate of complete resolution of disc 
herniation was 43% for sequestered discs and 15% for 
extruded discs. Wang et al (414) performed a systematic 
review and meta-analysis and also discussed multiple 
systematic reviews performed. Overall, they showed an 
incidence of regression of 63% among nonsurgically 
treated symptomatic lumbar disc herniation patients. By 
discussing multiple studies, they showed that there was 
no significant regression before 4 months and after 10.5 
months to be the ideal time to find regression after the 
onset. The highest incidence rate (IR) of 96% was docu-
mented by Lee et al (415) with an average follow-up 
of 341 days. Ahn et al (416) also reported an IR of 69% 
with an average follow-up time of 8.5 months. Others 
(417-421) reported an IR of 62% to 64%. Wang et al 
(414) described that the follow-up time of the 6 studies 
with IRs of approximately 63% ranged from 8.5 to 12.9 
months with an average of 10.5 months. Furthermore, 
a multitude of conservative managements including 
epidural injections have been shown to be effective in 
managing chronic disc herniation (7,55-57,60-65). One 
study looking at alternative and integrative therapy 
showed positive long-term results of lumbar disc her-
niation patients receiving nonsurgical, complementary, 
and alternative medicine treatments with favorable re-
sults and high satisfaction rates. Lumbar radiculopathy 
secondary to disc herniation resolves spontaneously in 
23% to 48% of patients, but up to 30% to 70% will 
still have pronounced symptoms after one year, with 
5% to 15% of patients undergoing surgery (409,422). 
Even though first described by Wirshow in 1857, the 
pathophysiology and the mechanism of pain due to disc 
herniation remain controversial (423,424). 
The intervertebral disc has been implicated as a 
source of spinal pain based on decades of pre-clinical, 
clinical, and epidemiological research, though the 
precise mechanisms continue to be debated as the 
literature evolves (7,127,129,130,136,138,139,371,423,
424). Further, based on controlled evaluations, lumbar 
intervertebral discs showed the prevalence of internal 
disc disruption in 39% of a younger cohort of patients 
following injury (128), and 42% in a heterogenous 
population comprised of all age groups and all types 
of low back pain (425). Further, in a study that sought 
to determine the prevalence of discogenic pain without 
assessing internal disc disruption, the reported preva-
lence rate was 26% (137).
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Disc herniation may cause mechanical compres-
sion or inflammation. The normal intervertebral disc is 
avascular and aneural, except for the outer third of the 
annulus fibrosus. Maintaining a dynamic equilibrium 
between the synthesis and degradation of the extra cel-
lular matrix is pivotal in intervertebral disc homeostasis, 
but degeneration of the extra cellular matrix occurs in 
patients with low back pain. Ingrowth of nociceptive 
neural fiber into deeper parts of the degenerated in-
tervertebral disc is considered as one of the most widely 
accepted pathophysiological mechanisms related to 
chronic discogenic pain (426,427). Disc inflammation 
may promote axonal growth of afferent fibers innervat-
ing the disc by secreting pro-inflammatory mediators, 
such as tumor necrosis factor (TNF) and interleukin 6 
(IL-6) as disc degeneration proceeds (428-432). In addi-
tion, nerve growth factor (NGF) is known to be a trophic 
growth factor for sympathetic and sensory nerve cells 
and to stimulate their differentiation, growth, main-
tenance, and survival (433). Further, it also has been 
shown that NGF also shows a hyperalgesic property by 
sensitizing and sprouting sensory nerve fibers in painful 
pathologic conditions (434,435). It has also been pro-
posed that actions of NGF in painful intervertebral disc 
not only sensitize the sensory neuron, but also stimulate 
the peripheral nociceptive sensory neurons to grow into 
the intervertebral disc tissue where the extracellular 
matrix is degenerated in most cases (420). Inflammatory 
involvement has been extensively described (127,427-
437). Consequently, the proposed etiologies and radicu-
litis may be summarized to include neural compression 
with dysfunction, vascular compromise, inflammation, 
and biochemical influences. Risbud and Shapiro (438) 
described the pathophysiology of disc degeneration 
and pain showing that in the inflammatory milieu 
neurogenic factors, in particular NGF and brain-derived 
neurotrophic factor (BDNF) generated by the disc and 
immune cells along with a multitude of other factors 
including TNF and IL-6. Phospholipase A-2 induces an 
expression of pain associated with cation channels in 
the dorsal root ganglia (DRG). Risbud and Shapiro (438) 
also showed that disc degeneration is characterized by 
3 distinct, but overlapping phases in which cytokines 
play a central role with an initiating event resulting 
in phenotypic changes in production of cytokines and 
chemokines by both the nucleus pulposus and annulus 
fibrosus cells in the first phase, followed by further ap-
plication of the inflammatory response by infiltrating 
immunocytes, as well as neovascularization and nerve 
ingrowth into the structurally deficient disc tissues in 
the second phase. In the final phase, nerve endings are 
sensitized and the modulation of DRG pain channel 
activities are altered by inflammatory mediators and 
neurotrophins resulting in pain. Further, Olmarker et 
al (439,440) also showed that spinal nerve roots, when 
compressed, exhibited interneural edema, deprived 
nutritional supply (439) and loss of amplitude of nerve 
conduction (440). In fact, these experimental findings 
were confirmed by Kuslich et al (130), who reported that 
noncompressed nerve roots did not reproduce the pa-
tients’ pain when stimulated intraoperatively in awake 
surgical patients. Consequently, epidural procedures 
are suited in managing chronic lumbar disc herniation, 
with a natural history of radicular pain showing a favor-
able prognosis (55-65,70,71,75,76,436). Disc regression 
or resorption have been shown to be most favorable 
in disc sequestration (96%), disc extrusion (70%), and 
disc protrusion (40%); however, it was only 13% in disc 
bulging (413). Saal et al (420) reported that 90% of the 
patients showed good to excellent outcomes and 92% 
had achieved return to work status with nonoperative 
treatment of disc extrusions.
5.1.2 Lumbar Spinal Stenosis 
Spinal stenosis is the result of abnormal narrowing 
of the spinal canal, lateral recess or the intervertebral 
foramina, resulting in pressure on the spinal cord or 
nerve roots (441,442). The two lower motion segments 
(L3-L4 and L4-L5) are the most commonly affected 
related to being more vulnerable to rotatory strains 
(443). Spinal stenosis may develop by a combination 
of chronic mechanical compression and cord instabil-
ity. Along with ischemia, these factors may lead to 
neurologic symptoms or claudication (444-451). Some 
common causes of spinal stenosis include disc-related 
degeneration, osteophyte formation, herniated discs, 
arthritis, ligament or facet joint hypertrophy, epidural 
fat deposition, spinal tumors, and traumas (447-451). 
Adult degenerative scoliosis and degenerative spondy-
lolisthesis may lead to instability and facet hypertrophy, 
resulting in stenosis (441-444). 
Lumbar spinal stenosis is a common source of 
back and leg pain, and often involves weakness and 
numbness (441-443). More severe cases may present 
with neurological symptoms such as radiculopathy, 
myelopathy or cauda equina syndrome. Permanent 
numbness or paralysis can result from a long-term 
compression of spinal nerves or of the spinal cord. 
Lumbar spinal stenosis is the most common cause of 
spinal surgery in patients over 65 years old (441-444). 
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The prevalence of lumbar spinal stenosis increases with 
age, and is approximately 19.4% among individuals 
aged 60-69 years old (442,452). Nonetheless, it may de-
velop earlier due to injury or congenital factors (442). 
The rate of progression over time is variable, and may 
not always exhibit symptoms. Some studies report that 
approximately half of patients remain clinically stable, 
while a quarter worsen or improve (399,453,454). The 
symptoms of spinal stenosis may significantly affect 
patients’ mobility, functional autonomy and perfor-
mance in routine tasks (451).
The pathophysiologic mechanism is similar to disc 
herniation, even though the mechanical component 
is more significant with narrowing of the spinal canal 
or the intervertebral foramen resulting in either neu-
rogenic claudication or radiculitis. Epidural injections 
have been shown to be effective in managing lumbar 
spinal stenosis in multiple RCTs and systematic reviews 
(7,55,58,60,65,70,77,81,83). In addition, spinal stenosis 
patients have been shown to respond to percutaneous 
adhesiolysis (72-74).
5.1.3 Lumbar Post-surgery Syndrome 
Pain and disability in the low back and lower 
extremities following lumbar spine surgery has been 
hypothesized to be secondary to multiple causes in-
cluding epidural fibrosis, sacroiliac joint pain, disc her-
niation, discogenic pain, spinal stenosis, arachnoiditis, 
and facet joint pain, along with inappropriate surgery 
(7,72-74,221,228,265-267,269,277,455-477). Failed back 
surgery syndrome was defined by the International As-
sociation for the Study of Pain (IASP) as a phenomenon 
of persistent or recurrent pain, mainly in the lower back 
or legs, even after previously anatomically successful 
surgeries (478). The review of literature of recurrent 
pain after lumbar discectomy for lumbar disc hernia-
tion, in patients under the age of 70 years, showed fre-
quent or recurrent leg pain in 5% to 36% of patients 
2 years after the operation (477,479). Some literature 
also has shown occurrence rates variable from 10% 
to 40% (73,476,479,480). Even though the ongoing 
debate continues in reference to epidural fibrosis and 
its effect on multiple pain problems or lack thereof, de-
bate continues without an end (458,459,460,481,482). 
Nevertheless, Ross et al (460) showed that patients with 
extensive epidural fibrosis were 3.2 times more likely to 
experience recurrent radicular pain than those with less 
scarring. Electrophysiological evidence of neurologic 
disturbances caused by peridural scar formation was 
shown in experimental studies (464). Various additional 
abnormalities including mechanical tethering of nerve 
roots secondary to epidural fibrosis in the vertebral 
canal (465,466), disturbances in blood flow (467), and 
expression of proinflammatory cytokines causing irrita-
tion of exposed dorsal root ganglion and triggering 
painful responses have been described (468). In addi-
tion, osteopontin has been shown to play a major role 
in the formation of epidural fibrosis and a mark-up 
DRG response to peridural scar formation (461). Addi-
tional experimental evidence has implicated paraspinal 
muscle spasms, tail contracture, pain behaviors, tactile 
allodynia, epidural and perineural scarring, and nerve 
root adherence to the underlying discs and pedicle in 
animal models (469).
Wound healing after tissue injury involves 4 major 
coordinated and regulated steps: hemostasis, inflam-
mation, proliferation, and remodeling. Different fac-
tors can interfere with these steps, causing improper 
or impaired wound healing (473). Central to this is an 
increased inflammatory response with recruitment of 
polymorphonuclear neutrophils to the injury site. These 
cells help in the clearance of pathogens and foreign 
particles, but also lead to tissue injury with generation 
of reactive oxygen species (ROS) (483), excessive migra-
tion of fibroblasts and collagen deposition. Thus, exces-
sive scarring and adhesion formation occurs and can be 
exacerbated by pathological process such as infection, 
inflammation, and hematoma formation (484). Numer-
ous strategies have been tested to reduce adhesion 
formation post spinal surgery; however, there have not 
been any therapeutic breakthroughs to achieve this 
goal (473). 
Consequently, in post-lumbar surgery syndrome, 
a multitude of pathophysiologic bases have been de-
scribed including recurrent disc herniation, scarring and 
entrapment of the nerve roots and discogenic pain. 
These can be addressed with epidural interventions, 
either with epidural injections or percutaneous adhe-
siolysis. Multiple RCTs and systematic reviews have been 
performed with caudal epidural injections, as well as 
percutaneous adhesiolysis in post-lumbar surgery syn-
drome (56,58,60,72-74). 
5.2 Cervical Disc-Related Pathology, Spinal 
Stenosis, Post-Surgery Syndrome
Chronic, persistent neck and upper extremity pain 
and radicular pain may be secondary to disc herniation, 
discogenic pain, spondylosis, spinal stenosis, or post 
cervical surgery syndrome resulting in disc related pain 
with or without radiculitis.
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5.2.1 Cervical Disc-Related Pathology 
Intervertebral disc-related pain can be caused by 
structural abnormalities, such as disc degeneration and 
disc herniation, and biochemical effects such as inflam-
mation (7,134,436). 
Disc degeneration can be broadly classified into 
2 categories: internal disruption and herniation (485). 
Internal disruption refers to a pathway that ends with 
derangement of the internal nucleus pulposus and/or 
annular fibers with little or no external deformation 
(486). Initially, repetitive microtrauma slowly causes the 
formation of small circumferential micro fissures. These 
concentric fissures coalesce over time to cause forma-
tion of radial fissures that extend from the inner, gelati-
nous nucleus pulposus to the outer third of the annulus 
fibrosus (487). While the nucleus pulposus of each disc is 
not innervated, the outer annulus fibrosus is innervated 
anteriorly by the vertebral nerve and posterolaterally 
by the sinuvertebral nerve (488). Therefore, when the 
radial fissures invade the annulus, it is thought that 
they may become a source of discogenic pain (489,490). 
However, it should be noted that annular fissure tears 
can also be found in asymptomatic individuals. 
Recent studies on the etiology of discogenic pain 
have demonstrated that inflammatory cytokines such 
as TNF-α, IL-1 α/β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-17, IL-20, 
and IFN-γ are secreted by cells in degenerative discs 
(491). The expression of these cytokines has multiple 
effects. In particular, IL-1β has been found to increase 
NGF expression and TNF-α has been associated with up-
regulation of substance P (492). Further, levels of NGF 
and TNF-α have been found to be increased in painful 
discs (493). The increased presence of NGF in the disc 
is thought to contribute to discogenic pain by causing 
infiltration of nerve fibers into otherwise aneural tissue 
(492). Additionally, the increase in cytokine expression 
causes chemokine production, which, in turn, leads to 
recruitment of T-cells, B-cells, macrophages and mast 
cells. These cells cause matrix degradation and continue 
to amplify the inflammatory cascade (438,491).
The incidence of cervical disc herniation, however, is 
less common than lumbar disc herniations (134,436,494-
500). The cervical disc herniation is a common source of 
cervical radiculopathy. The incidence of cervical disc her-
niations has been reported from Rochester, Minnesota, 
with the annual incidence as 18.6 per 100,000 or 0.186% 
with incidence peaking in the sixth decade of life (501). 
However, the etiology of cervical spine disc herniation is 
multifactorial (497,502,503). The proposed risk factors 
include male gender, present cigarette smoking, heavy 
lifting, and frequent driving or occupation involving driv-
ing (497,502,503). Further, evidence also shows that inci-
dence of cervical disc herniation is higher in professional 
drivers, army aviators, and those who operate vibrating 
equipment (497,503). In addition, a study reported that 
history of physical exercise or trauma preceded the onset 
of symptoms in 14.8% of cases (501). 
The mechanical compression on the nerve root that 
is being irritated by the herniated disc material is an 
important factor in the production of neck and upper 
extremity pain. The mechanical, chemical, and inflam-
matory components produce ischemic neuropathy re-
lated to the alteration of blood flow patterns or defects 
in the neuronal transport mechanism of the nerve root 
itself. Radicular pain may occur in the absence of nerve 
root compression secondary to nucleus pulposus extru-
sion or inflammatory reaction to the chemicals. 
Multiple studies have shown the unique proper-
ties of spinal nerves and inflammatory mechanisms, 
explaining various mechanisms other than mechanical 
compression and compression affecting dorsal root gan-
glion (7,134,436,498,504-520). In fact, herniated cervical 
intervertebral discs have been shown to produce metal-
loproteinases, nitric oxide, interleukin-6, and prosta-
glandin E2 (505). These substances are considered to be 
potential irritants of spinal nerves or inflammation.
Cervical radiculopathy is a pathologic process that 
involves neurophysiologic dysfunction of the nerve 
root (521-523). This syndrome is characterized by myo-
tomal weakness, paresthesias, sensory disturbances 
and depressed muscle stretch reflexes, all of which 
are sequelae of a hypofunctional nerve root (485). In 
cervical radiculopathy, the hypofunctional nerve root is 
the result of nerve root compression. Direct nerve com-
pression causes a conduction block and interruption of 
axonal flow, as well as hypoxia and all of its associated 
effects (523). 
Most often, the cervical nerve root injury present 
in cervical radiculopathy is caused by intervertebral disc 
herniation (524). This mechanism of injury was first de-
scribed by Semmes and Murphey in 1943 (525). Since that 
time, numerous studies have demonstrated that cervical 
disk abnormalities are often present in asymptomatic 
individuals (526-529). Why can a cervical disc herniation 
cause radiculopathy in one patient, while another pa-
tient with a similar herniation may be asymptomatic? 
The reasons for this difference are not completely clear. 
However, it is thought that an inflammatory response 
to the cervical disc herniation is responsible for initiat-
ing the neurophysiologic dysfunction characteristic of 
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cervical radiculopathy (505-507,530,531). This theory is 
supported by evidence that nerve root inflammation, 
in the absence of frank compression may continue to 
cause disruptions in nerve root physiology (532). Inflam-
matory mediators may be secreted from a degenerated 
or herniated nucleus pulposus (491-493,523,533). Ad-
ditionally, the gradient of compression may also play a 
significant role in determining whether or not a disk 
herniation becomes symptomatic (534). 
Spondylitic changes represent the second most com-
mon cause of cervical radiculopathy. Spondylosis is an 
umbrella term, which covers the degenerative changes 
that develop in the spine over time: ligamentous hyper-
trophy, hyperostosis, disk degeneration, and facet and/
or uncovertebral joint arthropathy (535). Hypertrophy of 
the facet or uncovertebral joints may cause stenosis of 
the intervertebral foramina and subsequent nerve root 
compression (535,536). Osteophytes may also compress 
the adjacent nerve root. Other less common, but note-
worthy causes of cervical radiculopathy include facet 
joint cysts, nerve tumors (e.g., schwannomas), fibropro-
liferation, hematomas, and trauma (523,537,538).
The course and prognosis of cervical disc herniation 
has been studied in multiple manuscripts (500,501,539). 
A systematic review of the literature of the course and 
prognostic factors of symptomatic cervical disc her-
niation with radiculopathy (500) concluded that most 
patients with symptomatic cervical spine disc herniation 
with radiculopathy recovered. In addition, a clinical 
guideline (540) for the diagnosis and treatment cervical 
radiculopathy from degenerative disorders concluded 
that signs and symptoms of degenerative disorders of the 
cervical spine resulting in radiculopathy will be self-limited 
and will resolve spontaneously over a variable length of 
time without specific treatment. In another manuscript 
(539), it was shown that in the natural history of cervical 
radiculopathy, 43% of the patients had no further symp-
toms after a few months, 29% had only mild or intermit-
tent symptoms, and only 27% had disabling pain. The 
authors of the large epidemiologic prevalence study from 
Rochester, Minnesota (501) over a 5-year follow-up period 
showed that 31.7% of patients with symptomatic cervical 
radiculopathy showed symptoms recurrence, with only 
26% needing surgical intervention for intractable pain, 
sensory deficit or objective weakness (501). 
Based on the pathophysiology of cervical disc de-
generation, disc herniation, and resultant radiculopathy, 
multiple investigators have shown the effectiveness of 
cervical epidural injections in managing neck and upper 
extremity pain (55,58,60,64,70,76).
5.2.2 Cervical Spondylosis 
Degenerative changes of the cervical spine reach a 
prevalence of nearly 95% by age 65. These changes are 
associated with disc protrusion, neuroforaminal nar-
rowing, and spinal cord contour changes in up to 78% 
of asymptomatic individuals (539-541).
Spondylosis is a chronic degenerative condition of 
the cervical spine associated with the formation of osteo-
phytes and compression of the spinal cord. Spondylosis 
refers to degenerative changes of the spine involving the 
intervertebral discs, uncovertebral joints of Luschka, fac-
et joints, ligaments, and connective tissue of the cervical 
vertebrae. Degenerative changes of the cervical spine are 
seen in approximately 10% of individuals by age 25 and 
in 95% by age 65. The levels most commonly affected 
by both disc herniation and chronic spondylosis are C6/
C7, followed by C5/C6 as these are the cervical segments 
where the most extension and flexion occurs.
In most symptomatic cases, spondylosis is associated 
with aging and with compression of the spinal cord, 
producing either central or neuroforaminal stenosis in 
patients older than 55 (542).
Cervical spondylotic myelopathy refers to clinically 
evident spinal cord dysfunction with the presence of 
long-track signs due to compression of the spinal cord. 
Weakness or stiffness in the legs with unsteady gait, 
together with weakness or clumsiness in the hands, 
is pathonomic of cervical spondylotic myelopathy. 
The progression of weakness may be gradual in some 
patients or sudden in others following minor trauma. 
Some patients may complain of hesitancy on urination, 
even though loss of sphincter control or urinary inconti-
nence is rare and considered a late sign of myelopathy.
Cervical epidural injections, specifically in 
radiculopathy, are known to be helpful in managing 
cervical spondylosis. There are no specific studies con-
ducted for this purpose. However, the mechanism is sim-
ilar to spinal stenosis and disc herniation. Consequently, 
epidural injections fit the pathophysiological basis for 
epidural interventions. Epidural steroid injections are 
not routinely recommended in those patients who go 
on to develop spondylotic myelopathy.
5.2.3 Cervical Spinal Stenosis 
Cervical spinal stenosis is a common disease that re-
sults in considerable morbidity and disability (543-546). 
Degenerative change is the most common cause of 
cervical stenosis and can be due to disc herniation, os-
teophyte formation, or a combination of both, namely 
disc-osteophyte complex (547). 
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The normal AP diameter of the mid-cervical spinal 
canal is approximately 17-18 mm (548). Based on a large 
cadaveric study, cervical stenosis, or narrowing of the 
central cervical canal has an estimated US population 
prevalence of 4.9% (549). Cervical stenosis may be con-
genital, in which case it is secondary to short pedicles 
and bony abnormalities of the lateral masses and lami-
nae (550). More frequently, however, cervical stenosis 
is acquired--the result of cervical spondylosis. The path-
way to acquired cervical stenosis begins with gradual 
degeneration of the cervical intervertebral discs. As the 
discs degenerate and shrink, they pull away from the 
vertebral endplates, causing instability of the spinal 
segments. This instability may lead to hypertrophy and/
or calcification of the ligamentum flavum and/or pos-
terior longitudinal ligament, hypertrophy of the facet 
and/or uncovertebral joints and the formation of cysts 
on the joints and ligaments (551).
Tandem spinal stenosis is a degenerative disease that 
describes a double stenotic lesion involving the cervical 
and lumbar spine (546,552-555). Historically, tandem 
spinal stenosis accounts for between 5% and 60% of all 
cases of stenosis (546). However, cervical spinal stenosis is 
less common than lumbar spinal stenosis. Asymptomatic 
stenosis in the cervical and thoracic spines of patients 
with symptomatic lumbar stenosis has been reported 
in 23.9% in the cervical spine and 24.3% in the thoracic 
spine, with 12.1% with combined radiologic cervical and 
thoracic stenosis in addition to their symptomatic lumbar 
stenosis or triple stenosis (554). With increasing age, a 
large proportion of the population exhibits radiological 
signs of discopathy or spondylosis, leading to constriction 
of the spinal canal (543).
Cervical spinal stenosis may also cause myelopathy, 
which is broadly defined as a symptomatic dysfunction of 
the cervical spinal cord caused by compressive etiologies 
(543,545,546,555-557). However, cervical myelopathy can 
occur because of cord compression resulting from one 
of several physiological factors including spondylolysis/
congenital stenosis, disc herniation, ossification of the 
posterior longitudinal ligament, hypertrophy of the 
ligamentum flavum, and degenerative subluxation. For 
the past 4 decades, there have been several attempts 
to correlate the clinical severity of spinal stenosis with 
the degree of spinal cord compression on MRI (556-561). 
However, no methodology has been validated. In a recent 
manuscript, Karpova et al (545) assessed the reliability of 
quantitative MRI methods in the assessment of spinal ca-
nal stenosis and cord compression in cervical myelopathy. 
They concluded that the measurements of maximum ca-
nal compromise, maximum spinal cord compression, and 
compression ratio were reliable and correlated well with 
the clinical severity of cervical myelopathy.
Based on the pathophysiologic basis of cervi-
cal spinal stenosis, cervical epidural injections have 
been shown to be effective and are indicated 
(55,58,60,64,70,76). 
5.2.4 Cervical Post-surgery Syndrome 
Cervical post-surgery syndrome represents a cluster 
of symptoms following cervical spine surgery wherein 
the expectations of the patient and spine surgeon are 
not met. Animal models of post-lumbar laminectomy 
syndrome demonstrated paraspinal muscle spasms, tail 
contractures, pain behaviors, tactile allodynia, epidural 
and perineural scarring, and nerve root adherence to 
the underlying disc and pedicle (457,458,461,464,467-
477). It also has been postulated that there may be a fi-
nal common pathway with all the described etiologies, 
which results in peripheral and central facilitation po-
tentiated by inflammatory and nerve injury mechanisms. 
In a recent manuscript, Seichi et al (562) explored 
the mechanism of post-operative axial neck pain which 
is a common complication (563-574) even though neu-
rological recovery after laminoplasty is appropriate 
(566-568). They described that even though multiple 
factors, including surgical trauma to the posterior 
cervical muscles and the period of external immobili-
zation, have been suggested as causative factors for 
the development of pain (563-572), the precise mecha-
nism underlying the development of post-operative 
axial pain remains unclear (564). They described that 
post-operative axial pain is multifactorial in nature 
with soft tissue injuries, such as those that occur due 
to intraoperative damage of the posterior extensor 
musculature, are considered to be a major mechani-
cal factor in the development of post-operative axial 
pain (573,574). In addition to muscle damage, nerve 
tissue injuries sustained during surgery also have been 
suggested as a causative factor of post-operative axial 
pain (563,564). 
Based on the above pathophysiologic basis, epi-
dural interventions are performed in the cervical spine 
with appropriate outcomes (55,58,60,64,70,76). 
5.3 Thoracic Disc-Related Pathology, Spinal 
Stenosis, Post-surgery Syndrome
Thoracic disc related pathology, spinal stenosis, and 
post-surgery syndrome produce symptoms related to 
thoracic pain and radiculitis (7,135,546,575-580).
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5.3.1 Thoracic Disc Related Pathology
Thoracic discogenic pain is a much less frequent 
occurrence than cervical/lumbar discogenic pain. When 
considering the biomechanics of the spine, this is not 
surprising because the cervical and lumbar regions 
support more of the weight of the axial skeleton than 
the thoracic and sacral regions (581). Additionally, the 
coronal orientation of the thoracic zygapophyseal joints 
makes them more stable than those found in the cervi-
cal and lumbar spine (582). The presence of the ribs also 
provides additional stability to the thoracic vertebra. As 
a result, the intervertebral discs in the thoracic spine are 
less prone to degenerative changes than those in the 
cervical and lumbar regions. However, when thoracic 
discogenic pain does occur, it is typically the result of the 
same degenerative pathway that takes place in cervical 
and lumbar discs. Also, in similar fashion to the cervi-
cal and lumbar spine, thoracic disc herniations may be 
found in asymptomatic patients. It is important to note 
that the cord/canal ratio in the thoracic spine is 40%, 
compared to 25% in the cervical spine (583). Moreover, 
due to its tenuous blood supply, the thoracic spine is 
particularly susceptible to ischemic damage. Therefore, 
when thoracic disc herniations do lead to myelopathy, it 
is typically more severe than in the cervical and lumbar 
spine. 
Thoracic disc herniation is rare, with an estimate 
preference of 1 per million people or 0.0001%, con-
stituting a small proportion of overall disc herniations 
of 40 to 50 per 100,000 population or 0.04% to 0.05% 
(584). Consequently, as expected, surgical procedures in 
the thoracic spine make up only 0.15% to 4% of the 
procedures for disc herniation (585). Thoracic disc her-
niations are associated with progression, dominated by 
the risk of medullary compression; however, surgery for 
thoracic disc herniation has a poor reputation because 
of its technical difficulties and the risk of potentially 
serious hard to treat complications (579). 
Presence of asymptomatic stenosis has been es-
timated 11% to 37%. Thoracic disc herniation is most 
common in adults 30 to 50 years of age (579). Thoracic 
disc herniations are located below T7-T8 in 75% of the 
cases. Further, T11 to T12 disc is the most vulnerable 
because of greater mobility and posterior longitudinal 
ligament weakness at this level. Only 4% of thoracic disc 
herniations are located above T3-T4. The cases of tho-
racic disc herniations complicating proximal junctional 
syndrome have been reported after the thoracolumbar 
fusion (586). Thoracic disc herniations frequently cal-
cify or ossify (584). However, spontaneous regression of 
thoracic disc herniations with or without calcification 
or ossification have been reported (587). Thoracic disc 
herniations have been reported to be more common in 
Scheuermann's disease and also have been found in 3% 
to 37% with a history of trauma.
The herniated disc can be very large in volume. In 
fact, thoracic disc herniation is labeled as ‘giant’ when 
it occupies more than 40% of medullary canal on com-
puted tomography (CT) scan or MRI (585). The volume 
and calcified nature of herniation increases the risk of 
intradural extension due to erosion and progressive 
thinning of the dura, even though intradural extension 
is only present in 0.26% to 0.3% of all herniated discs, 
whereas it is present in 15% to 70% of joint calcified 
thoracic disc herniations.
The majority of patients may not present with ra-
dicular pain. Some may present only with thoracic pain. 
The mechanism of radicular pain is similar to cervical 
and lumbar spinal pain with mechanical compression 
and inflammation.
Thoracic discs also have been shown to be the cause 
of pain without disc herniation, mostly axial pain.
Based on pathophysiology of discogenic or ra-
dicular pain, epidural interventions are effective in 
post-surgery syndrome. However, there is only one RCT 
available in the literature (588) included in systematic 
reviews (55,58,60). Nevertheless, based on the response 
to discogenic pain in the lumbar and cervical spine, it 
appears appropriate when medical necessity arises and 
indications are met. 
5.3.2 Thoracic Spinal Stenosis
Thoracic spinal stenosis is a relatively rare disease 
characterized by narrow spinal canal and compression 
of the spinal cord and/or nerve root (580). In a systematic 
review, Chen et al (580) showed the results with diagno-
sis of ossification of the posterior longitudinal ligament 
(OPLL) in 18.7%, ossification of the ligamentum flavum 
(OLF) in 41.5% of the patients, and 7.4% were shown 
to have both OPLL and OLF. In addition, 32.4% were 
with thoracic disc herniation producing spinal stenosis. 
Thoracic OPLL occured mostly at the middle thoracic 
spine (43.4%), while OLF predominantly occurred at the 
lower thoracic spine (63.1%). Thoracic disc herniation 
was mainly localized in the middle (46%) and lower 
thoracic (50.3%) spine. Tandem spinal stenosis was 
observed in 52.1% with accompanying cervical diseases 
and 35.9% with lumbar diseases.
Even though thoracic myelopathy caused by spinal 
stenosis is less common than that of cervical and lum-
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bar disease (588). The outcomes are poor if surgery is 
performed (589). Multiple factors responsible for poor 
prognosis have been described including tenuous blood 
supply to the thoracic spinal cord (590,591), natural 
kyphotic curve of the thoracic spine which limits back-
ward movement of the spinal cord, especially during 
ventral compression. Also, thoracic spinal stenosis is a 
degenerative disease that progresses slowly and can be 
asymptomatic for a long time, resulting in irreversible 
neurological damage due to delayed diagnosis (592-
595). Finally, the multifactorial nature (589,596-598) 
of the disease involving many pathologic changes and 
a combination of multiple factors and co-existence of 
other spinal pathologies frequently leads to misdiagno-
sis and incorrect treatment (599). Consequently, even 
though options are poor, early diagnosis and optimal 
treatment are recommended.
Based on the pathophysiologic basis, epidural injec-
tions are indicated with all the appropriate precautions 
if medical necessity and appropriate indications are 
present, based on the results in lumbar and cervical 
spine (7,55,58,60,65,70,77,81,83). 
5.3.3 Thoracic Post-surgery Syndrome
Post thoracic surgery syndrome is rare compared to 
lumbar or cervical post-surgery syndromes due to the 
fact that surgical interventions constitute only a small 
proportion of overall surgical interventions for disc her-
niations for spinal stenosis. Even then, early diagnosis 
and appropriate management has been recommended 
(599). Surgical interventions are offered for managing 
disc herniation, as well as thoracic spinal stenosis and 
spondylosis. Meanwhile, thoracic surgical interventions 
are performed for scoliosis and other congenital defor-
mities (575,600-603). 
Epidural interventions are performed less frequent-
ly than in the lumbar and cervical spine for disc hernia-
tion, spinal stenosis, and discogenic pain; however, for 
thoracic post-surgery syndrome these procedures must 
only be performed if there is appropriate access avail-
able below the surgical level or with catheterization 
with or without adhesiolysis. 
6.0 pathophysIologIc BasIs of epIdural 
InterventIons
Key Question 4: What is the pathophysiologic 
basis of epidural interventions in spinal pain?
Multiple therapeutic spinal interventional tech-
niques are applied in managing chronic spinal pain. The 
rationale includes the commonality and complexity of 
spinal pain problems and ability of diagnostic blocks to 
identify sources of chronic spinal pain. The degenerative 
processes of the spine and the origin of spinal pain are 
complex without consistent correlation of radiographic 
changes to the clinical picture and prognosis. The ef-
fectiveness of a large variety of therapeutic interven-
tions used to manage chronic spinal pain has not been 
demonstrated conclusively (7). In fact, Best Practices 
in Pain Management from the HHS, has reviewed the 
available evidence in pain management and described 
interventional techniques as part of a continuum prior 
to surgical interventions and neuromodulation (78,79). 
Among multiple therapeutic interventional techniques 
with available evidence that are commonly applied are 
epidural injections including adhesiolysis.
Epidural injections have been in existence since 
the first descriptions of caudal epidural with local anes-
thetic for low back pain in 1901, as described by Sicard 
(604), Cathelin (605), and Pasquier and Leri (606). It is 
also important to note that Sicard (604,607,608) admin-
istered an epidural injection with local anesthetic only 
and reported several weeks of improvement. He ac-
quired the reputation as the “pain doctor” for treating 
patients from all over France (607,608). Consequently, 
epidural injections during the first 50 years were limited 
to local anesthetic alone (102,609-611), until reports of 
administration of steroids through sacral nerve root by 
Robecchi and Capra (612) and Lievre et al (613) in the 
early 1950s. 
Epidural injections are performed with an interlam-
inar or transforaminal approach in the lumbar, cervical, 
or thoracic spine. Caudal procedures are performed 
for lumbosacral disorders. Caudal and interlaminar 
epidurals have been the common procedures, but more 
recently, transforaminal epidural injections, specifically 
in the lumbosacral spine, have been reversing the trend 
(194,195). The caudal approach is the earliest described 
technique delivering the medication into the lumbar 
epidural space from the sacral hiatus, requiring larger 
volumes of medication in order to reach the target site 
(7,611,614). It is considered the safest and easiest tech-
nique. With the interlaminar approach, the medication 
is delivered more commonly into the posterior epidural 
space, but often into the ventral epidural space, spe-
cifically with paramedian or parasagittal techniques 
(614-617). 
In the lumbar transforaminal approach, the needle 
is inserted close to the nerve root, either superiorly or 
inferiorly, described as supraneural or infraneural ap-
proaches (7,614,618-623). However, the supraneural 
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approach, classically described as the safe triangle ap-
proach, has been associated with a multitude of com-
plications (621-624). Consequently, multiple infraneural 
approaches have been described (618-625). The major 
described advantage of transforaminal epidural injec-
tion appears to be the anatomical position and accu-
rate needle placement to enhance the effectiveness of 
epidural injection, even though safety is questionable 
with the supraneural approach when using particulate 
steroids. When performed under fluoroscopic guidance, 
superiority of any of the techniques has not been dem-
onstrated conclusively in the lumbar spine. 
In reference to thoracic and cervical transforaminal 
epidural injections, these have been associated with a 
multitude of complications (626-633). 
Percutaneous epidural adhesiolysis, also known 
as epidural neuroplasty, neurolysis, or lysis of epidural 
adhesions is an interventional pain management tech-
nique that has emerged over approximately the last 30 
years (634). The procedure is performed utilizing a rein-
forced catheter with mechanical adhesiolysis and with 
injection of multiple fluids. The goals of this procedure 
are not only to break down fibrous adhesions that may 
prevent free movement of structures in the interver-
tebral foramina and in the bony intervertebral canal, 
but also to remove any barriers or scars that prevent 
application of medication to structures believed to be 
the source of pain, and to provide targeted application 
of local anesthetics, corticosteroids, and other agents 
(72-76). 
6.1 Mechanism of Action Local Anesthetics 
and Steroids 
Several manuscripts have been published evaluat-
ing the role of steroids and local anesthetics for epidural 
injections. In a neural blockade, the rationale for inject-
ing local anesthetic is to block sensory signals. Even 
though they are often used for diagnostic purposes and 
believed to provide a temporary effect in acute pain, 
when used in chronic pain, they provide long-term 
relief very much beyond its pharmacological duration 
of action due to a decrease in sensitization and various 
other mechanisms (7,8,102,609,610). In clinical practice, 
steroids are typically combined with local anesthetics, 
with hopes of prolonging the duration of pain relief 
(56-58,60,61,102). 
The rationale for neuraxial steroid use is primarily 
based on the benefits of neural blockade, which include 
pain relief that outlasts by hours, days, and sometimes 
weeks. Neural blockade effectiveness is based on the 
postulation that it alters or interrupts nociceptive input, 
reflex mechanism of the afferent limb, self-sustaining 
activity of the neuronal pools in the neuroaxis, and 
the pattern of central neuronal activities (55-62). Con-
sequently, the pharmacological and physical actions of 
corticosteroids, along with local anesthetics have been 
the basis of such explanations.
6.1.1 Steroids 
Corticosteroids in neuraxial blockade have been 
postulated to reduce inflammation, either by inhibiting 
the synthesis or release of a number of proinflammatory 
substances, or by causing a reversible local anesthetic 
effect (55-62). There are several modes of action of 
corticosteroids including membrane stabilization, inhi-
bition of neural peptide synthesis or action, blockade 
of phospholipase A2 activity, local anesthetic effect, 
prolonged suppression of ongoing neuronal discharge, 
and suppression of sensitization of dorsal-horn neurons 
(102,635-646). Corticosteroids inhibit phospholipase 
A2, which converts membrane phospholipids into 
arachidonic acid and lysophospholipids (639,641,647). 
It is further followed by conversion to proinflammatory 
eicosanoids, including prostaglandins, thromboxanes, 
and leukotrienes. Pain is exacerbated and peripheral 
nociceptors are sensitized by inflammatory mediators. 
Thus, corticosteroids not only provide antiinflammatory 
effects, but also inhibit ectopic discharges from nerve 
fibers (641). Despite extensive use, there is no evidence 
that steroid injections are disease-modifying agents 
with a direct effect on pain generation or transmission, 
with an exception of inflammatory conditions such as 
rheumatoid arthritis (102). Further, there are no studies 
demonstrating the anti-inflammatory role of steroids 
or differentiation of inflammatory radiculopathies 
from noninflammatory radiculopathies (54,56-59,639). 
During the search for confirmation of the anti-inflam-
matory effect of steroids in epidural injections, multiple 
explanations relied on inflammatory component in 
lumbosacral radiculopathy. The first evidence suggest-
ing inflammation in patients with radiculopathy was 
published in 1981 (642). Ryan and Taylor (642) examined 
samples of cerebral spinal fluid during administration 
of intrathecal and epidural injections, and theorized 
that inflammation was a critical component of radicular 
pain, and that intraspinal steroids were likely to be most 
effective when this inflammation was still acute, before 
the pathology had progressed to nerve root fibrosis or 
axonal death. This led to the classification of 2 catego-
ries of radiculopathy, compressive and inflammatory. 
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Lindahl and Rexed (648) described inflammation, 
edema, and proliferative or degenerative changes in bi-
opsy samples from the posterior nerve roots of patients 
undergoing laminectomy. In lumbar disc herniation and 
radiculopathic pattern of symptoms, consideration for a 
primary biochemical inducement of pain over a mechani-
cal mechanism is a contemporary topic of spinal research. 
Even then, the exact pathomechanism by which a degen-
erative intervertebral disc leads to neural inflammation 
and pain had not been determined. Using modern tech-
niques of chemical analysis, biochemical markers which 
participate in the degenerative cascade and possibly with 
onset of pain (649) can be identified. While, Scuderi et 
al (649) were unable to identify the presence of inflam-
matory peptides in the epidural lavage of patients with 
symptomatic radicular pain due to herniated disc disease, 
de Souza Grava et al (650) indicated that specific cytokines 
released during the inflammatory process induced by the 
herniated intervertebral disc play a fundamental role in 
the development of mechanical and thermal hyperalge-
sia and that the maintenance of this inflammation may 
be the most important point for the chronification of the 
pain. In addition, Shamji et al (651) concluded that there 
was evidence of altered gait in a model of noncompres-
sive disc herniation with radiculopathy in a rat model. 
However, systematic inflammation was absent, but me-
chanical allodynia, local inflammation, and autoreactive 
immune activation were observed. Cuéllar et al (652) also 
developed an animal model for the study of biochemical 
changes that occur in the epidural space after interverte-
bral disc herniation. The performed epidural lavage in 48 
rats after L5 dorsal root ganglion exposure to autologous 
nucleus pulposus illustrating nucleus pulposus causing the 
elevation of IL-6, TNF-α, and IFN-γ - all attenuated by IFN-γ 
blockade. However, Brisby et al (653) showed inconclusive 
results after the assessment of proinflammatory cytokines 
in cerebrospinal fluid and serum in 39 patients with disc 
herniation and sciatica. They (653) showed that concentra-
tions of IL-8 in cerebrospinal fluid were increased in 12 out 
of 39 patients, and these increased levels of IL-8 correlated 
to a short duration of pain and to more pronounced her-
niation with normal concentrations of IL-1β, IL-6, IFN-γ, 
and TNF-α in cerebrospinal fluid and serum in almost all 
patients with lumbar disc herniation. However, they were 
unable to demonstrate any relationship between IL-8 
concentrations in cerebrospinal fluid and pain intensity, 
positive neurological findings, or a positive straight leg 
raising test. 
Thus, the role of various chemicals and inflammation 
has been extensively investigated with discogenic pathol-
ogy and radicular pain. The complex mechanism of disco-
genic pain includes chemical nociception leading to low 
back pain with or without disc herniation (7,134-136,654-
658). The research in animals has shown upregulation of 
various pain regulated molecules, such as calcitonin gene 
related peptide and Substance P, in the dorsal root gan-
glions neurons innervating degenerated intervertebral 
discs (7,657-659). In fact, in recent years epidural TNF-α 
inhibitory injections have been utilized to treat lumbar ra-
diculitis rather than epidural steroid injections (7,659-667).
In earlier studies, Berg (668) and Green (669) 
observed a consistent reduction in the swelling of in-
volved nerve roots coincidental with improvement in 
the patient’s sciatic symptoms with steroid administra-
tion. Thus, it is postulated that corticosteroids reduce 
inflammation either by inhibiting the synthesis or 
release of a number of pro-inflammatory substances 
or by causing a reversible local anesthetic effect 
(514,638,641,644,646,670-683). The various modes of ac-
tion of corticosteroids include membrane stabilization, 
inhibition of neural peptide synthesis or action, block-
ade of phospholipase A2 activity, prolonged suppres-
sion of ongoing neuronal discharge, and suppression of 
sensitization of dorsal horn neurons.
Epidural injections of betamethasone in a model 
of lumbar radiculopathy showed a significant effect 
on thermal hyperalgesia, while the administration of 
intravenous methylprednisolone significantly reduced 
the nerve root injury produced by epidural application 
of autologous nucleus pulposus in a pig experimental 
model (635-638,643-645). Another study concluded that 
lipopolysaccharide accelerated the process of herniated 
intervertebral disc resorption, whereas high-dose ste-
roids suppressed the process (644). Research studying the 
effects of local methylprednisolone on pain in a nerve 
injury model by inducing peripheral mononeuropathy 
showed that the heat hyperalgesia and mechano-allo-
dynia, but not mechano-hyperalgesia were depressed 
in the animals receiving corticosteroids; however, not in 
those treated with saline, with the effect remaining dur-
ing the 11 day test period (645). The effects of systemic 
methylprednisolone on acute nociception and on pain 
behavior in hyperalgesia were studied in normal and 
neuropathic rats (646). The results showed that chronic 
steroid treatment prevented the development of neu-
ropathic edema and completely blocked neurogenic 
extravasation; however, the findings also showed that 
corticosteroids did not affect nociceptive thresholds in 
normal or neuropathic hyperalgesic rats. 
Ever since the descriptions of Hollander et al (647) 
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in 1951, enthusiasm erupted with the temporary im-
provement of symptoms in many cases, but it was also 
tempered by warnings of the possibility of increasing the 
damage in joints subjected to excessive use in periods of 
freedom from symptoms. Their early publication in 1951 
(684) also noted that the results of treatment of the knee 
have been more encouraging than those of treatment of 
other joints, presumably because of the ease with which 
injection of the knee joint can be accomplished. 
6.1.2 Local Anesthetics 
Local anesthetics have been used ever since the 
discovery of the medicinal properties of cocaine, long 
before the compound was brought to Europe for 
its local anesthetic properties to be discovered (56-
58,102). Based on this foundation, regional anesthesia 
developed into interventional pain management. In 
1899, Tuffer (685) described therapeutic nerve blocks in 
pain management using spinal injections of cocaine to 
control pain from sarcoma of the leg. In 1903, Cushing 
described pain relief with nerve blocks (686), along with 
reports of trigeminal alcohol blockade (687). 
The development of caudal epidural injections for 
pain management began in 1901 (604-608) and inter-
laminar epidural injections in 1933 by Dogliotti (688). 
The effectiveness of local anesthetics in chronic pain 
is based on anti-inflammatory actions and the altera-
tion of multiple pathophysiologic mechanisms includ-
ing noxious peripheral stimulation, excess nociception 
resulting in the sensitization of the pain pathways, and 
excess the release of neurotransmitters causing complex 
central responses including hyperalgesia or wind-up, 
resulting in an increase in nociceptive sensitization of 
the nervous system, and phenotype changes which are 
also considered as part of the neuronal plasticity (55-
58,102,689-699). Sato et al (691) showed the prolonged 
analgesic effect of epidural ropivacaine in a rat model 
of neuropathic pain. Along those same lines, Tachihara 
et al (692) provided evidence that there is a lack of ad-
ditional benefit with nerve root infiltration for lumbar 
disc herniation by the addition of steroids to lidocaine.
7.0 dIagnosIs of dIsc-related pathology, 
spInal stenosIs, and radIculItIs 
Key Question 5: What are the noninterventional 
diagnostic methods in disc related pathology, spi-
nal stenosis, and post-surgery syndrome?
Spinal pain is one of the most common chronic pain 
conditions. Intervertebral discs, facet joints, sacroiliac 
joints, ligaments, fascia, muscle and nerve root dura have 
been shown to be capable of transmitting pain in the 
spine with resulting symptoms of axial and extremity pain. 
Disc herniation and spinal stenosis are diagnosed 
with physical examination, radiological assessment, and 
neurophysiological assessment. For chronic axial pain 
without disc herniation or radiculitis, the precision di-
agnostic blocks applied include facet joint nerve blocks, 
provocation discography, and sacroiliac joint blocks, 
and to a lesser extent, lumbosacral selective nerve root 
blocks or transforaminal epidural injections in the diag-
nosis of difficult radicular pain syndromes. 
7.1 Lumbar Spine
7.1.1 History and Physical Examination
The assessment of differential diagnoses is based 
on history, and physical examination which includes 
neurological examination, motor examination, sensory 
examination, reflex examination, and application of 
provocative maneuvers including straight leg raising 
test, crossed straight leg raising test, bowstring sign, 
and slump test. Deyo et al (700) showed that sciatica 
was highly sensitive for a clinically important herniated 
disc, as was old age for spinal stenosis and compression 
fractures. Subjective symptoms of numbness are consid-
ered reasonably sensitive (0.76), but not specific (0.33) 
as a sign of radiculopathy (136,701). Objective signs of 
numbness are reasonably sensitive, although numbness 
is not specific as a sign of radiculopathy. 
The sensory examination should cover the bilateral 
lower extremities to evaluate for all dermatomal or more 
diffuse sensory loss as seen in the peripheral neuropa-
thies with a stocking distribution of loss. Dermatomes 
may define the area of skin innervated by a single nerve 
root or peripheral nerve. A simple sensory examination 
involves testing for sensation for 3 dermatomes in the 
lower extremity, L4, L5, and S1. Sensation may be evalu-
ated using many different modalities, including vibra-
tion, proprioception, temperature, light touch, and pin 
prick (702). The sensitivity and specificity of the sensory 
examination in the diagnosis of lumbar disc herniation 
has been described to range from 16% to 66% for sensi-
tivity, and 51% to 86% for the specificity (702).
Radiation of pain needs to be carefully interpreted. 
Somatic referred pain is mostly in the buttock or lower 
extremity with any type of pain generators in the lum-
bar spine and should not be confused with radicular 
pain. The cardinal distinctions lie in the quality of pain 
and its behavior. Table 8 shows the differences between 
radicular and somatic pain. 
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Rubinstein and van Tulder (703) in a best 
evidence review of diagnostic procedures for neck 
and low back pain, showed that a number of fac-
tors can be identified which can assist the clinician 
in identifying sciatica due to disc herniation or 
serious pathology. However, they were unable to 
show any evidence based on history leading to a 
diagnosis not related to radicular pain. A neuro-
logic and musculoskeletal examination may assist 
in the diagnosis of radiculopathy or radicular pain 
with identification of disc herniation at various 
levels. Figure 14 illustrates the clinical features 
of posterolateral lumbar intervertebral disc her-
niation. Straight leg raising or cross straight leg 
raising and motor examination may be crucial in 
the assessment of disc herniation. Table 9 shows 
the diagnostic features for various levels of nerve 
root involvement. 
Radiculitis, radicular pain, or radiculopathy 
may be seen not only with herniation of the 
nucleus pulposus, but, also with central and fo-
raminal spinal stenosis, nerve root entrapment 
in the lateral recess, and other causes such as 
spondylolisthesis, spondylolysis, facet joint cysts, 
and epidural fibrosis, internal disc disruption, or 
discogenic pain without involvement of other 
structures. 
The presence of radiating pain needs careful 
evaluation and interpretation. Somatic type pain 
referred into the buttock and lower extremity can 
be expected with any of the pain generators of 
the lumbar spine. Determining the difference be-
tween referred pain and radicular pain is critical 
to arriving at the correct diagnosis and treatment 
plan (7). Anatomically, somatic/referred pain 
sources arise from the posterior segments or ele-
ments of the spine while radicular pain arises from 
the anterior segments. Typically, the presenting 
Table 8. Features of  somatic and radicular pain.
Somatic or Referred Pain Radicular Pain
Segment 
Causes
Posterior segment or element Anterior segment
Facet joint pain Disk herniation
Sacroiliac joint pain Annular tear




Dull, aching, deep Sharp, shooting, lancinating
Like an expanding pressure Like an electrical shock
Poorly localized
Back worse than leg Leg worse than back
No paresthesia Paresthesia present
Covers a wide area Well defined and localized
No radicular or shooting 
pain Radicular distribution
Modification
Worse with extension Worse with flexion
Better with flexion Better with extension
No radicular pattern Radicular pattern
Radiation
Low back to hip, thigh, groin Follows nerve root distribution
Radiation below knee 
unusual








Only subjective weakness Objective weakness
Atrophy rare Atrophy possibly present
Reflex 
Changes None




Only low back pain Reproduction of leg pain
No root tension signs Positive root tensions signs
Source: Manchikanti L, et al. Low back and lumbar radicular pain. In: 
Manchikanti L, Christo PJ, Trescot AM, Falco FJE (eds). Clinical Aspects of Pain 
Medicine and Interventional Pain Management: A Comprehensive Review. ASIPP 
Publishing, Paducah, KY, 2011, pp 87-114 (136).
Table 9. Diagnostic features for various levels of  nerve root involvement.





L3-4 L4 Low back; hip; anterolateral thigh, medial leg
Anteromedial 
thigh and knee Quadriceps
Extension of 
quadriceps Squat and rise
Knee jerk 
diminished
L4-5 L5 Above S1 joint; hip; lateral thigh and leg; dorsum of foot





great toe and foot Heel walking None reliable
L5-S1 S1
Above S1 joint; hip; 
posterolatera and thigh 
leg; heel
Back of calf; 











Source: Manchikanti L, et al. Low back and lumbar radicular pain. In: Manchikanti L, Christo PJ, Trescot AM, Falco FJE (eds). Clinical Aspects of 
Pain Medicine and Interventional Pain Management: A Comprehensive Review. ASIPP Publishing, Paducah, KY, 2011, pp 87-114 (136).
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symptoms of somatic or referred pain will be a deep dull 
ache, while lightening like, sharp shooting pain is found 
with radicular pain. Finally, finding on examination with 
somatic/referred pain will typically be without sensory, 
motor or reflex changes while the opposite is true for 
radicular pain (Table 8) (7). 
Physical examination for lumbar radiculopathy re-
lated to disc herniation in patients with low back pain of-
ten provides inaccurate and incomplete information. In a 
Cochrane database systematic review (704), the conclusion 
of 16 cohort studies and 3 case-controlled studies, the au-
thors concluded that in isolation diagnostic performance 
of most physical tests (scoliosis, paresis or muscle weakness, 
muscle wasting, impaired reflexes, sensory deficits) was 
poor. Some tests (forward flexion, hyperextension test, 
and slump test) performed slightly better, but the number 
of studies was small. Most studies assessed the straight leg 
raising test. The results in surgical populations were vari-
able compared to those with imaging. In surgical popula-
tions, characterized by a high prevalence of disc herniation 
(58% to 98%), the straight leg raise showed high sensitiv-
ity (pooled estimate 0.92, 95% CI: 0.87 to 0.95) with widely 
varying specificity (0.10 to 1.00, pooled estimate 0.28, 95% 
CI: 0.18 to 0.40). However, results of studies using imaging 
showed more heterogeneity and poorer sensitivity. The 
crossed straight leg raise showed high specificity of 0.90 
with consistently low sensitivity (0.28). Tawa et al (705) in 
a 2017 systematic review of accuracy of clinical neurologi-
cal examination in diagnosing lumbo-sacral radiculopathy, 
with inclusion of 12 studies assessed neurological examina-
tion. The diagnostic performance of sensory testing using 
MRI as a reference standard demonstrated a sensitivity of 
0.61 and a specificity of 0.63. Motor tests sensitivity was 
poor to moderate, ranging from 0.13 to 0.61. They showed 
that generally, the diagnostic performance of reflex test-
ing was notably good with specificity ranging from 0.60 
to 0.93 and sensitivity ranging from 0.14 to 0.67. They also 
showed that the straight leg raise test recorded a mean 
sensitivity of 0.84 and specificity of 0.78. Bellier et al (706) 
assessed a range of the different nerve root movements 
in cadavers to identify them during a passive straight leg 
raise. They concluded that the lumbo-sacral nerve roots 
in the spinal canal region move statistically significantly 
in response to the clinically applied straight leg raise test, 
except for L2 root during the left straight leg raise. This 
movement was symmetric and greater when a bilateral 
straight leg raise was applied. The anatomical results cor-
related with those observed empirically in clinical practice. 
Thus, the results may be variable with multiple observers. 
In an older study assessing the sensitivity and specificity of 
the slump and straight raising test in patients with lum-
bar disc herniation (707), the authors concluded that the 
Fig. 14. Clinical features of  a posterolateral lumbar 
intervertebral disc herniation.
Source: Manchikanti L, et al. Low back and lumbar radicular 
pain. In: Manchikanti L, Christo PJ, Trescot AM, Falco FJE 
(eds). Clinical Aspects of Pain Medicine and Interventional Pain 
Management: A Comprehensive Review. ASIPP Publishing, 
Paducah, KY, 2011, pp 87-114 (136). Reproduced with permission 
from authors and Pain Physician journal.
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slump test might be used more frequently as a sensitive 
physical examination tool in patients with symptoms of 
lumbar disc herniations. However, they also concluded 
that moving to its high specificity; the straight leg raise 
may especially help identify patients who have herniations 
with root compression requiring surgery. In this study, the 
results found that the slump test was more sensitive 0.84 
than the straight leg raise 0.52 in patients with lumbar disc 
herniations; however, straight leg raise was found to be 
a simply more specific test 0.89 than the slump test 0.83.
As mentioned above, central spinal stenosis can 
present with radiculitis, however, it will more typically 
present much differently than radiculopathy secondary 
to disc herniation. This clinical presentation will typically 
feature neurogenic claudication type symptoms. These 
patients will have little pain at rest or while sitting, 
however, upon standing and walking the patient will 
report heaviness in the legs, sensation of the legs going 
numb, and even the onset of low back pain. Classically, 
these symptoms are consistent and reproducible with 
the distance ambulated, relieved by forward flexion, 
recumbency or sitting. Lateral recess stenosis and re-
sultant nerve impingement in the foramen will present 
with or without back pain and leg pain radiating into 
the ankle or toes. Diagnosis of the other conditions 
mentioned require radiologic evaluation. Certainly, ra-
diologic evaluation can help to differentiate different 
types of spinal stenosis from a lumbar disc herniation, 
as well as conditions of the spine, which can result in 
radicular pain (7). 
Lateral recess stenosis with nerve entrapment 
mostly presents without low back pain and rare muscle 
weakness. The pain may radiate into the ankle and 
occasionally into toes. Further, radiologic examination 
often differentiates it from lumbar radiculopathy from 
disc herniation. 
The correlation of symptoms with MRI findings was 
assessed by Albert et al (708) in a cross-sectional diag-
nostic accuracy study of adult patients with radicular leg 
pain with positive neurological signs (average 2.8 signs 
– hypoalgesia, diminished reflexes, muscle weakness, 
positive straight leg raise test). They studied 93 patients 
with their pain charts and MRI correlation in an MRI 
confirmed single-level radiculopathy. The results show a 
wide overlap in pain patterns from compromised L5 and 
S1 nerve roots, but some distinguished features. The 
pain patterns had approximately 50% to 80% overlap 
with published dermatomes. However, clinicians were 
unable to determine with any accuracy above chance 
whether an individual pain drawing was from a person 
with a compromised L5 or S1 nerve root, and use of 
composite pain drawings did not improve that accuracy. 
As shown in Table 9, motor weakness may present at 
all levels. Lumbar radiculopathy is usually characterized 
by weakness affecting 2 or more muscles from the same 
spinal segment, but different peripheral nerves (186). 
Thus, an L5 radiculopathy may affect both the dorsal 
flexors of the foot and toes (peroneal nerve) and abduc-
tion of the hip (superior gluteal nerve). Consequently, 
strength examination should include the assessment of 
hip flexors L1 to L3, quadriceps L2 to L4, tibialis anterior 
L4 to L5, extensor hallucis longus L5, and the gastrocne-
mius – soleus (S1).
The sensitivity and specificity of muscle strength 
testing in patients with lumbar radiculopathy has been 
evaluated. Kerr et al (709) demonstrated reduced ankle 
dorsiflexion in 54%, in plantar flexion 13% of those with 
lumbar disc protrusions from L4 to S1 with an overall 
specificity of 89%. Multiple studies have shown sensitiv-
ity as low as 20%, whereas, specificity as high as 99%.
7.1.2 Imaging 
In managing low back pain, basic imaging with 
plain films and advanced imaging with CT scan and MRI 
are utilized. Due to its greater resolution of soft tissues 
and interosseous tissues, MRI is considered superior to 
CT scan for the demonstration of condition such as nerve 
tumors, cysts, infection, and other disorders. However, 
CT scan is superior to MRI in the demonstration of bone 
and the preferred modality for diagnosing of complex 
fractures or deformities. However, the studies show that 
sensitivity and specificity for plain CT, CT myelography, 
and MRI are the same, with an approximate sensitiv-
ity of 0.90 and specificity of 0.70 (710,711). Further, a 
positive and negative predictive value of 0.82 is also the 
same for all 3 modalities.
Studies in asymptomatic volunteers have shown a 
high prevalence of disc abnormalities with a herniated 
nucleus pulposus in 20% of individuals younger than 40 
years and in 27% of individuals older than 40 years on 
CT scan (711). MRI findings showed disc bulges and disc 
herniations with increasing frequency with age, with 
a high prevalence of asymptomatic disc herniations 
(712,713). Further, a positive relationship with symp-
toms and disc herniation has been shown in some cases 
even though it was not universal (714). The grading 
of lumbar disc herniation and nerve root compression 
(715) and interobserver and intraobserver variability in 
MRI evaluation of patients with suspected disc hernia-
tion continues to be debated (716).
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7.1.3 Electrodiagnostic Studies
The utility of electrophysiologic studies has been 
based on the ability to objectify abnormalities of nerve 
conduction resulting from radiculopathy and to identify 
the particular segment. Andersson and colleagues (717) 
in a consensus summary on the diagnosis and treatment 
of lumbar disc herniation concluded that, “although 
neurophysiological testing is frequently used to diagnose 
patients with radiculopathy associated with disc hernia-
tion, these tests are not clinically necessary to confirm the 
presence of radiculopathy.” However, neurophysiologic 
testing might be appropriate when the clinical situation 
is less clearly delineated and for differentiation of disc 
herniation from other neurologic disorders, such as neu-
ropathy or peripheral nerve entrapment. 
7.2 Cervical Spine
7.2.1 History and Physical Examination
Cervical spine pain is a common clinical condition af-
fecting activities of daily living and QoL in people around 
the world. It can manifest as neck pain as well as pain in 
the shoulder, trapezius, scapular areas as well as the upper 
extremities. The distinguishing features of cervical radicu-
lar pain and somatic referred pain are illustrated in Table 
10 (7). The cervical pain secondary to the disc can extend 
to the upper back and head and is associated with referred 
pain into the upper extremity. In the patients where disc 
and facet related conditions co-exist, the differentiation 
due to the overlapping symptoms can be challenging. 
Radicular pain is most likely to travel below the elbow, 
and somatic referred pain is most often limited to above 
the elbow, but radicular pain may be restricted to the 
upper back or shoulder girdle, and somatic pain may radi-
ate below the elbow (134,373). In contrast to the lumbar 
spine, paresthesia is considered to be more valid than the 
distribution of pain. The distribution of paresthesia in the 
hand is also considered more valid than the distribution of 
paresthesia in the forearm. In addition, paresthesia, with 
or without pain, occurs in 90% of patients with surgically 
proven radiculopathy due to disc prolapse (498,718). Ap-
proximately 45% of patients are unable to localize the 
paresthesia to a distinct region; and they present with dif-
fuse, nondermatomal symptoms. In general, paresthesia 
affecting the thumb or index finger is attributed to the C6 
dermatome; the middle finger, with or without involve-
ment of the index finger, is 
assigned to the C7 dermatome; 
and the little finger is assigned 
to the C8 dermatome (Fig. 15) 
(7).
Assessment of pain in the 
cervical region is based on a 
patient’s history and an ex-
tensive physical examination 
which includes a neurological 
examination; motor examina-
tion; sensory examination; 
reflex assessment; application 
of provocative maneuvers, 
including Spurling’s neck com-
pression test, shoulder abduc-
tion test, neck distraction test, 
Lhermitte sign, Hoffman sign, 
and Addison’s test (719). 
Table 11 shows the signs 
and symptoms of nerve root 
compression in the cervical re-
gion (7,314). Rubinstein and van 
Tulder (703), in a best evidence 
review, showed that a positive 
Spurling’s, traction/neck dis-
traction, and Valsalva can be 
Table 10. Distinguishing features of  cervical radicular pain and somatic referred pain.












Neck worse than arm
No paresthesia
Covers a wide area




Arm worse than neck











Neck to head, shoulder blades, 
upper back, radiation below elbow – 
unusual, no radicular pain
Follows nerve root distribution, 
radiation below elbow common, 
radicular and shooting pain
Signs
Sensory alterations Uncommon Probable
Motor changes Only subjective weaknessAtrophy is rare
Objective weakness
Atrophy may be present
Reflex changes None Commonly expressed but seen occasionally
Source: Manchikanti L, et al. Neck and cervical radicular pain. In: Manchikanti L, Christo PJ, Trescot 
AM, Falco FJE (eds). Clinical Aspects of Pain Medicine and Interventional Pain Management: A Compre-
hensive Review. ASIPP Publishing, Paducah, KY, 2011, pp 35-60 (134).
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used to establish a diagnosis of cervical radiculopathy. 
In a systematic review, the same authors found that no 
single provocative test had both a high sensitivity and 
high specificity (720). The Spurling’s test, neck traction 
test (lifting the head and relieving pain), and Valsalva 
maneuver were found to be highly specific. 
The other existing literature appears to support 
the high specificity, but indicates low sensitivity, and 
good to fair inter-examiner reliability for Spurling neck 
compression test, the neck distraction test, and shoulder 
abduction (relief test) (721). For Hoffman’s sign, the exist-
ing literature does not address inter-examiner reliability, 
but appears to indicate fair sensitivity and fair to good 
specificity (719). Numbness in the upper limb is a reason-
ably reliable sign (722), even though it is not a universal 
feature in patients with radiculopathy. The prevalence 
rate of numbness has varied significantly from 24% to 
48%, and 60% to as high as 86% (723). Numbness is most 
often seen in the C6 and C7 dermatomes, indicating the 
most frequent involvement of these nerve roots. The 
predictive validity of numbness was calculated to be 0.7. 
Consequently, Wainner and Gill (724) stated that with re-
gard to cervical radiculopathy, many investigators believe 
that, “given the paucity of evidence, the true value of the 
clinical examination is unknown at this time.”
Along the same lines, in a manuscript published 
in 2018, Thoomes et al (373) described the findings of a 
systematic review examining the value of physical tests in 
diagnosing cervical radiculopathy. They identified 5 diag-
nostic accuracy studies; however, only Spurling’s test was 
evaluated in more than one study, showing a high specific-
ity ranging from 0.89 to 1.00, with sensitivity ranging from 
0.38 to 0.97. They also showed that no studies were found 
that assessed the diagnostic accuracy of widely used neu-
rological tests such as key muscle strength, tendon reflex-
es, and sensory impairments. They concluded that there 
is limited evidence for the accuracy of physical examina-
Fig. 15. Dermatomal distribution of  C4, C5, C6, C7 spinal 
nerves.
Source: Manchikanti L, et al. Neck and cervical radicular pain. In: 
Manchikanti L, Christo PJ, Trescot AM, Falco FJE (eds). Clinical 
Aspects of Pain Medicine and Interventional Pain Management: A 
Comprehensive Review. ASIPP Publishing, Paducah, KY, 2011, pp 
35-60 (134). Reproduced with permission from authors and Pain 
Physician journal.




of  Lesion Referred Pain Motor Dysfunction Sensory Dysfunction Reflex Changes
C5 C4/5 Shoulder and upper arm
Shoulder muscles 
(deltoid-supraspinatus-infraspinatus) 
↓ abduction and external rotation
↓ Upper and lateral aspect 
of the shoulder ↓ Biceps reflex
C6 C5/6 Radial aspect of forearm
Biceps and brachialis muscles
↓ flexion of the elbow and supination
Radial aspect of forearm ↓ Thumb reflex and brachioradialis reflex
C7 C6/7 Dorsal aspect of forearm
Triceps muscle
↓ extension of the elbow
↓ Index and middle digits ↓ Triceps reflex
C8 C7/T1 Ulnar aspect of forearm
Intrinsics of the hand
↓ adduction and abduction
↓ Ring and little digits No change
Source: Manchikanti L, et al. Neck and cervical radicular pain. In: Manchikanti L, Christo PJ, Trescot AM, Falco FJE (eds). Clinical Aspects of Pain 
Medicine and Interventional Pain Management: A Comprehensive Review. ASIPP Publishing, Paducah, KY, 2011, pp 35-60 (134).
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tion tests for the diagnosis of cervical radiculopathy. They 
further stated that when consistent with patient history, 
clinicians may use a combination of Spurling’s, axial trac-
tion, and an arm squeeze test to increase the likelihood of 
a cervical radiculopathy, whereas as a combined result of 
4 negative neurodynamic tests (upper limb, neurodynamic 
test, arm squeeze test, shoulder abduction (relief) test, and 
traction-distraction test) and an arm squeeze test could be 
used to rule out the disorder. 
7.2.2 Imaging
In reference to imaging, Rubinstein and van Tulder 
(703), in a best evidence review of diagnostic procedures 
for neck and low back pain, concluded that in patients 50 
years of age or older, plain spinal radiography together 
with standard laboratory tests are highly accurate in 
identifying the underlying systemic disease; however, 
plain radiography is not a valuable tool for nonspecific 
neck pain. They also showed that no systematic reviews 
were identified which examined the diagnostic accuracy 
of diagnostic imaging in those with neck pain. 
When applicable, the American College of Radiol-
ogy recommends a cervical spine series of x-rays as 
an initial study including lateral, anteroposterior, and 
oblique views. Disc-space narrowing, subchondral scle-
rosis, and osteophyte formation can be evaluated on 
lateral views. Attention to comparing disc height at one 
level to adjacent levels as well as foraminal stenosis can 
be pertinent in some cases (725,726). CT imaging may be 
required to visualize C7 adequately. Flexion and exten-
sion and lateral bending films can be used to diagnose 
instability.
Based on the above discussion, plain radiog-
raphy is not of much significant use in neck pain or 
radiculopathy. Myelography is an invasive and stress-
ful investigation. This can show the deformations 
produced by intradural, dural, and some extradural 
lesions of the cervical vertebral canal. However, it does 
not demonstrate a lesion directly, and it demonstrates 
those affecting the lateral reaches of the cervical spine 
nerves poorly, if at all (727). Conventional CT scan pro-
vides axial images, in which the lateral reaches of the 
intervertebral foramina can be seen. CT myelography is 
considered to be an accurate and reliable test and has 
proven to be superior to myelography in the diagnosis 
of cervical disc protrusions; however, it is an expensive 
and invasive test. MRI is the choice of imaging in the 
modern era, replacing myelography, CT scan, and CT 
myelography. MRI is considered to be as accurate as 
CT myelography for detecting cervical nerve root com-
pression, even though it may be slightly inferior for 
detecting bony impingement of nerve roots (545,728). 
As observed with MRI, the prevalence of numerous 
abnormalities of the cervical spine in asymptomatic 
individuals is a concern (546,728,729). Boden et al (526) 
demonstrated in a study of asymptomatic subjects, 
10% of patients under age 40 had disc herniations, and 
in patients over 40, 20% have foraminal stenosis and 
8% had disc herniations. Hence, a diagnosis of cervical 
radicular pain is considered definite only after care-
ful evaluation and corroboration of history, physical 
examination, imaging, electrodiagnostic and in some 
cases, diagnostic injectional studies. 
7.2.3 Neurophysiologic Testing 
Neurophysiologic testing with electromyography 
and nerve conduction studies offers no advantage in 
radiculopathy. However, they are of significant value 
in the identification and differentiation of cervical 
radiculopathy with a peripheral lesion (549,730,731). 
According to Narayanaswami et al (730), the specificity 
of EMG for diagnosing radiculopathy has been reported 
to be 77%, while average sensitivity is 73%. This review 
further noted the sensitivity lower, 40% for mild to 
moderate radiculopathy and higher, 80% moderate to 
severe radiculopathy. The diagnosis changed in only 2/60 
cases with the addition of clinical information. Intra-
rater reproducibility was 80%, 87% for radiculopathy 
and 73% for normal studies. Inter-rater agreement was 
63%, 70% for radiculopathy and 53% for normal stud-
ies. Inter-rater agreement for denervation was 90% and 
re-innervation was only 60%. They further noted the 2 
to 3-week delay in the onset of the positive sharp waves 
and fibrillation potentials could yield falsely negative 
results done at onset of radiculopathy. In their 2011 
clinical guidelines, the North American Spine Society 
notes insufficient evidence to make a recommendation 
for or against the use of electromyography for patients 
in whom the diagnosis of cervical radiculopathy is un-
clear after clinical examination and MRI (540).
The most common causes of cervical nerve root 
compression are cervical spondylosis, disc degeneration, 
disc herniation, and spinal stenosis. However, numerous 
other causes exist. Radiculopathy is a shooting, radiat-
ing pain that extends into the hand, or with paresthesia 
in forearm and hand, accompanied by objective neuro-
logic signs with sensory loss, objective motor weakness, 
or hyporeflexia. In difficult cases, without radicular 
symptoms, diagnostic interventions applied include very 
rarely selective nerve root blocks, associated with high 
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risk, and more commonly, cervical provocation discogra-
phy. Thus, for these guidelines cervical nerve root blocks 
have not been assessed. 
In most cases, cervical disc herniation, spinal steno-
sis, radiculitis, and symptomatic spondylosis are diag-
nosed by imaging and neurophysiologic testing. How-
ever, when there is no correlation between radiologic 
pathology and clinical assessment, cervical provocation 
discography and cervical selective nerve root blocks 
have been recommended (127,732,733). 
7.3 Thoracic Spine
7.3.1 History and Physical Examination 
Assessment is based on history, physical examina-
tion, neurological examination, and imaging. Quite 
often it is difficult to identify the differences between 
somatic and radicular pain which is more complex in 
the thoracic spine than lumbar or cervical spine in 
that symptoms are similar in various conditions in the 
thoracic spine based on the description of neurological 
myotomes and dermatomes in multiple reviews and 
textbooks. Neurological assessment includes tone, co-
ordination, proprioception, and abdominal and lower 
limb reflexes. As it is well known, the plantar reflex is 
particularly important in assessing spinal cord function. 
Dura mater signs include neck flexion and the slump 
test (135).
7.3.2 Imaging 
In reference to imaging, age-related changes are ex-
tremely common in the thoracic spine in asymptomatic 
subjects. The great majority of patients with radiologic 
osteoarthritis are asymptomatic. A high prevalence of 
anatomic irregularities has been found in asymptomatic 
patients (734,735). Even though plain radiograph is the 
most common imaging technique, it does not satisfy the 
objective of identification of the cause of the pain and 
there is concern that plain radiographs are not sensi-
tive enough to exclude disease. CT myelography is an 
alternative investigation in patients who have contrain-
dications to MRI (736). MRI though commonly utilized, 
raises concerns that it is too sensitive, thus giving rise to 
false-positive findings. In most instances, it can reliably 
distinguish infection, fracture, and tumor (726).
7.3.3 Neurophysiologic Testing
The utility of electrophysiologic/electrodiagnostic 
studies have been based on the ability to objectify ab-
normalities of nerve conduction and electromyography 
resulting from radiculopathy and to identify the par-
ticular segment. 
Although the majority of patients who are diag-
nosed with thoracic spine pain due to the previously 
mentioned conditions, may undergo conservative mo-
dalities and treatments (737). These may also include 
noninvasive interventions, and are based on diagnostic 
imaging, as well as in some cases noninvasive diagnostic 
interventions (737). 
In the cases of patients where further diagnostic 
procedures, separate from imaging need to be per-
formed, may require diagnostic interventions with 
provocation discography to identify discogenic pain 
and/or controlled diagnostic facet joint nerve blocks to 
diagnose or eliminate facet joint pain (737).
8.0 therapeutIc epIdural InterventIons
Key Question 6: Are the available therapeutic 
epidural injections and adhesiolysis in managing 
chronic spinal pain effective?
Epidural interventions are provided through caudal, 
interlaminar, and transforaminal approaches. Percuta-
neous adhesiolysis is provided through caudal, inter-
laminar and transforaminal approaches in the lumbar 
spine. Inherent variations, differences, advantages, and 
disadvantages applicable to all epidural interventions, 
including percutaneous adhesiolysis, with assessment of 
effectiveness and outcomes, all of the procedures are 
considered as separate entities. Furthermore, response 
is also considered separate, along with indications for 
various pathological conditions (disc herniation and/or 
radiculitis, central spinal stenosis, foraminal stenosis, 
post-surgery syndrome, and discogenic pain without disc 
herniation) which are variable. Consequently, outcomes 
are assessed based on pathology for each approach. 
8.1 Evidence Review and Synthesis 
Methodology is described in Section 2. Briefly, 
identification of systematic reviews and studies for the 
review, which included relevant RCTs and observational 
studies when indicated with description of appropriate 
outcomes and follow-up was performed. All the studies, 
including systematic reviews, RCTs, and observational 
studies must have included the primary outcome pa-
rameter of pain relief and other secondary outcomes 
such as functional status improvement. Short-term relief 
was considered as less than 6 months of improvement 
in pain and function, whereas at least one year of pain 
relief with improvement in functional status was consid-
ered as long-term improvement. 
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As described in the methodology section: literature 
search, search strategy, methodologic quality or bias as-
sessment, data collection and analysis were performed. 
If each region had at least 5 RCTs meeting the in-
clusion criteria, no observational studies were included. 
However, if there were less than 5 in RCTs, observational 
studies are considered. Assessment was limited to cau-
dal, interlaminar, and transforaminal in the lumbar 
region, along with percutaneous adhesiolysis in the 
lumbar region. In cervical and thoracic regions, only 
interlaminar epidural procedures were assessed. 
8.1.1 Literature Search 
Available published literature in different languag-
es and from all countries was considered for inclusion 
in the study provided it discussed relevant interventions 
with outcome evaluations. The literature search includ-
ed the period from 1966 through November 2020, and 
was performed utilizing the following sources:
1.  PubMed at https://pubmed.ncbi.nlm.nih.gov/ 
2.  Cochrane Library at https://cochranelibrary.com/ 
3. Systematic reviews and cross references
4.  Google Scholar at https://scholar.google.com/ 
5. Clinical trials at https://clinicaltrials.gov 
6.  All other sources including non-indexed journals 
and abstracts
The search was filtered to identify RCTs and system-
atic reviews.
8.1.2 Search Strategy
The search strategy emphasized chronic spinal pain 
conditions and therapeutic epidural injections including 
caudal, interlaminar, transforaminal or percutaneous 
adhesiolysis interventional approaches.
Search criteria were as follows: (((((((((((((((((chronic 
low back pain) OR chronic mid back OR upper back 
pain) OR chronic neck pain) OR disc herniation) OR dis-
cogenic pain) OR herniated lumbar discs) OR nerve root 
compression) OR lumbosciatic pain) OR postlaminec-
tomy) OR lumbar surgery syndrome) OR cervical surgery 
syndrome) OR thoracic surgery syndrome) OR radicular 
pain) OR radiculitis) OR sciatica) OR spinal fibrosis) OR 
spinal stenosis) AND ((((((((((epidural injection) OR peri-
neural injection) OR interlaminar injection) OR perira-
dicular infiltration) OR transforaminal injection) OR cau-
dal injection) OR percutaneous adhesiolysis) OR epidural 
neuroplasty) OR facet joint adhesiolysis) OR “Injections, 
Epidural”[Mesh]) and applied Filters for Clinical Study, 
Clinical Trial, Meta-Analysis, Randomized Controlled 
Trial, Review, Systematic Review, Technical Report, Twin 
Study, Validation Study Sort by: Publication Date
8.1.3 Methodologic Quality or Bias Assessment
Methodologic quality assessment of RCTs was per-
formed using Cochrane review criteria and the IPM-QRB 
criteria for RCTs. 
Quality assessment of systematic reviews was per-
formed into 3 categories:
1. Low-quality: This category with either a systematic 
review or meta-analysis, with conversion of studies 
or transferring them into a different category, such 
as placebo to active control, against the intent of the 
authors of the original manuscripts, without consent, 
and without STRONG scientific basis, even though 
they may be of high, moderate, or low methodologic 
quality based on PRISMA, AMSTAR or SIGN.
2. Moderate quality: This category included the ma-
jority of the systematic reviews, methodologically 
sound, which followed the appropriate principles 
without violation of practices, with either a sys-
tematic review or meta-analysis with conventional 
dual-arm analysis only. 
3. High-quality: In this category, the systematic re-
views methodologically sound, with inclusion of 
appropriate, high-quality principles, with conven-
tional dual-arm meta-analysis and single-arm meta-
analysis without violation of standards and keeping 
the intent of the original manuscripts. 
Systematic reviews and meta-analysis were per-
formed if they were not performed in the past. 
8.1.4 Results
Our comprehensive literature search criteria lead to 
the inclusion of 47 systematic reviews (56-58,60-68,70-
77,81,83,87,155,188,271,615,667,738-756). The results 
are shown in Fig. 16.
8.2 Systematic Reviews 
We identified 47 systematic reviews, ranging from 
evaluating the placebo effect of sodium chloride solu-
tion to multiple network analyses, comparative analysis 
of local anesthetics and steroids, particulate versus 
nonparticulate steroids, technical comparisons of 3 ap-
proaches, and effectiveness in various conditions.
Among major systematic reviews comparing mul-
tiple modalities, 4 systematic reviews met inclusion 
criteria (99-101,155,753). 
Guo et al (101), in a network meta-analysis compar-
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ing the efficacy and toler-
ability of the treatments 
for sciatica, concluded that 
epidural steroid was recom-
mended as a good interven-
tion due to superiority in 
reducing ODI. Further, in 
this manuscript, they also 
identified intravenous and 
subcutaneous anti-TNF-α 
as the optimal treatment 
for both acute and chronic 
sciatica patients. 
Lewis et al (99,100) in 
a systematic review and 
network meta-analysis 
of comparative clinical 
effectiveness of manage-
ment strategies for sciatica, 
including surgical interven-
tions, concluded that this 
was the first manuscript 
comparing many different 
strategies for sciatica in 
the same systematic review 
and meta-analysis. Their 
findings supported the ef-
fectiveness of epidural in-
jections in the same line as 
disc surgery and nonopioid 
medication. 
Lee et al (753) comparing the nonsurgical treat-
ments for patients with radicular pain from lumbosacral 
disc herniation concluded that epidural injection was 
strongly recommended with high degree of evidence 
and transforaminal approach was more strongly recom-
mended than caudal approach. 
Cho et al (155) also performed a systematic review 
of treatment outcomes for patients with failed back 
surgery syndrome and concluded that percutaneous ad-
hesiolysis provided better improvement than spinal cord 
stimulation. Cho et al showed in this review significant 
evidence for both percutaneous adhesiolysis and spinal 
cord stimulation with a recommendation of Level A for 
epidural adhesiolysis for 6 to 12 months of pain relief 
and functional improvement and Level B for spinal cord 
stimulation. 
Among the 47 systematic reviews, 3 systematic re-
views addressed the questions related to placebo and 
active-control agents (56-58).
A single systematic review of high-quality by 
Manchikanti et al (56) evaluated if epidural injection 
of sodium chloride solution was a true placebo or it is 
an active control agent. In this systematic review, they 
also performed conventional dual arm and a single arm 
analysis. In this analysis, they used 20% improvement 
from baseline pain scores or disability as clinically sig-
nificant parameter, even though in all other reviews, 
they used 50% improvement in pain and disability as 
the criterion standard. They included 8 trials meeting 
inclusion criteria, with 2 trials utilizing fluoroscopic im-
aging and one study utilizing ultrasound. With dual arm 
meta-analysis, there was no significant difference be-
tween epidural sodium chloride solution and epidural 
steroids with sodium chloride solution. However, with 
single arm analysis, both epidural saline and epidural 
steroids with saline were effective in reducing 20% of 
pain; however, only reducing disability scores by 10% to 
12%. The authors concluded that both epidural saline 
Fig. 16. Flow diagram illustrating the literature used for evaluating therapeutic lumbar, cervical, 
and thoracic epidural.
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and epidural steroids with saline showed effect beyond 
placebo with strong evidence, that neither epidural 
saline, nor epidural steroids with saline or placebo and 
that both are effective. 
One such systematic review and meta-analysis by 
Manchikanti et al (57) assessed the effectiveness of 
epidural bupivacaine, with or without steroids, adminis-
tered for low back and lower extremity pain. It included 
4 independent studies; one on interlaminar approach 
and three on transforaminal epidural injections, all of 
which were ranked as high-quality based on Cochrane 
review criteria and IPM-QRB criteria. In this review also, 
the authors utilized a conventional dual arm and single 
arm meta-analysis showing significant effectiveness of 
both bupivacaine and bupivacaine with steroids with 
a single arm analysis, even though both of them were 
similar with dual arm analysis. The review concluded 
that epidurally administered bupivacaine acts as an 
active agent rather than a placebo (Level I evidence), 
and that bupivacaine administered alone was almost 
equally effective as when administered with steroids 
(Level II evidence). These findings clearly show that local 
anesthetic is not a placebo and the approach in all the 
active-controlled trials with local anesthetic converting 
into placebo-controlled with conclusion of local anes-
thetics as ineffective leads to inappropriate conclusions 
and misinformation (67-69,80). 
A similar systematic review and meta-analysis by 
Knezevic et al (58) of high-quality investigated the 
evidence supporting the effectiveness of epidural li-
docaine, with or without steroids, in managing spinal 
pain. In this analysis, the authors utilized extensive 
methodologic quality assessment criteria, along with 
conventional dual arm and single arm meta-analysis. 
Of the 15 manuscripts meeting the inclusion criteria, 4 
addressed caudal epidural injections, 2 lumbar transfo-
raminal injections and 5 lumbar interlaminar epidural 
injections. The results showed similar improvements 
in pain and function with the epidural administration 
of lidocaine alone or with steroids, both for short-and 
long-term (Level II evidence). This study also once again 
demonstrated that utilizing single arm analysis clear ef-
fect of each modality was demonstrated with lidocaine, 
as well as lidocaine with steroids. It is inappropriate to 
judge that lidocaine is a placebo. They also showed lack 
of publication bias. Consequently, both had similar ef-
fectiveness, but translated into lack of effectiveness of 
any modality with negative conclusions. Once again, this 
study clearly shows that local anesthetic lidocaine is not 
placebo and it is inappropriate assessments performed 
provides erroneous conclusions and misinformation. 
Similar to the above manuscripts, a systematic re-
view and meta-analysis by Lee at al (61), which was of 
moderate quality, assessed the effectiveness of epidural 
injections consisting of local anesthetic or saline with 
or without steroids for the management of lumbosa-
cral disc herniation. The qualitative study included 14 
manuscripts, and the quantitative study included 13 
manuscripts. The included studies were considered as 
high-quality, but the evidence was deemed moderate 
due to inconsistencies and lack of single arm analysis. 
The study found that the addition of steroids to local 
anesthetic or saline provided better effectiveness com-
pared to injections of local anesthetics or saline without 
steroid, at 6-month follow-up to one year, with no sig-
nificant differences after one year.
Mesregah et al (64), in a moderate quality review, 
also evaluated the clinical effectiveness of interlaminar 
epidural injections of local anesthetic with or without 
steroids for managing chronic pain utilizing 4 studies 
available meeting inclusion criteria, they showed the 
addition of steroids to anesthetic injected was not as-
sociated with better pain and functional score outcomes 
compared with anesthetic injected alone in patients 
with chronic neck pain based on conventional dual arm 
analysis. Overall, the conclusions are similar to other sys-
tematic reviews shown above indicating local anesthetic 
lidocaine is not a placebo. Such conclusions are mislead-
ing and are misinformation. 
Zhao et al (65) in a systematic review and conven-
tional meta-analysis of moderate quality confirmed the 
similar effects associated with lidocaine alone versus in 
combination with steroids in the management of lum-
bar disc herniation and lumbar central spinal stenosis 
with the inclusion of 7 trials. These results again confirm 
the impressions shown above. 
Bicket et al (66) in a moderate quality systematic 
review and meta-analysis evaluating the “control” in-
jections in RCTs included 43 studies with 3,641 patients. 
Under the control injections, they included sodium 
chloride solution, as well as local anesthetic solutions. 
Nevertheless, they concluded that epidural nonsteroid 
injections may provide improved benefit compared with 
nonepidural injections on some measures. However, 
they have not performed a single arm analysis. They also 
have not utilized appropriate methodologic criteria. 
In addition, they utilized manuscripts which included 
epidural injections performed without fluoroscopy. 
Even then, in other manuscripts published by Cochrane 
review (68,69), one of the senior authors of the above 
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manuscript (66) as a coauthor claimed that due to lack 
of effectiveness of local anesthetics, they were consid-
ered as placebo, providing conflicting and contradicting 
information, leading to inappropriate conclusions and 
misinformation to communities in general.
Manchikanti et al (76) in a moderate quality review 
also published a comparison of efficacy of saline, local 
anesthetics, and steroids in epidural and facet joint 
injections for the management of spinal pain in a sys-
tematic review of RCTs; however, without meta-analysis. 
They included a total of 13 trials. They showed the ef-
fectiveness of local anesthetic alone and local anesthetic 
with steroids to be equally effective except in lumbar 
disc herniation, where the superiority of local anesthetic 
with steroids was demonstrated in short-term follow-
up, whereas there was no difference with long-term 
follow-up. 
Shanthanna et al (102) in an extensive high-quality 
systematic review and meta-analysis of RCTs assessed 
the effectiveness of the addition of corticosteroids to 
local anesthetics for chronic noncancer pain injections. 
They included 71 trials and reached the conclusion that 
addition of corticosteroids to local anesthetics has only 
small benefits and a potential for harm. They further 
concluded that injection of local anesthetic alone could 
be therapeutic, beyond being diagnostic. They recom-
mended that a shared decision based on patient pref-
erences should be considered and high doses must be 
avoided, along with a series of steroid injections.
Multiple systematic reviews were conducted assess-
ing the effectiveness beyond comparison of local anes-
thetic alone or local anesthetic with steroids. Among 
these, 2 moderate quality systematic reviews (60,76) 
assessed multiple spinal regions. The description of the 
manuscript by Manchikanti et al (76) is provided above. 
The results applied to multiple spinal regions. Similarly, 
Kaye et al (60) assessed the efficacy of epidural injec-
tions in managing chronic spinal pain utilizing a best 
evidence synthesis with assessment of multiple spinal re-
gions. This systematic review was performed, however, 
without meta-analysis. It was considered as a moderate 
quality publication. In this review, they included 52 
RCTs with a placebo control or an active control design 
meeting inclusion criteria. The results showed that the 
evidence in managing lumbar disc herniation or radicu-
litis was Level II for long-term improvement, either with 
caudal, interlaminar, or transforaminal epidural injec-
tions with no significant differences among the groups. 
The evidence was Level II for long-term management 
of cervical disc herniation with interlaminar epidural 
injections. The evidence was Level II to III in managing 
thoracic disc herniation with an interlaminar approach. 
The evidence was Level II for caudal and lumbar inter-
laminar epidural injections with Level III evidence for 
lumbar transforaminal epidural injections for lumbar 
spinal stenosis. The evidence was Level III for cervical 
spinal stenosis management with interlaminar epidural 
injection. They also showed evidence of Level II for axial 
or discogenic pain without facet arthropathy or disc 
herniation treated with caudal or lumbar interlaminar 
epidural injections in the lumbar region, whereas it was 
Level III in the cervical region treated with cervical inter-
laminar epidural injections. The evidence for post-lum-
bar surgery syndrome was Level II with caudal epidural 
injections and for post cervical surgery syndrome. It was 
Level III with cervical interlaminar epidural injections. 
Among the multiple systematic reviews available, 
the majority were conducted in the lumbar spine. In 
addition, systematic reviews included prevention of 
surgery with epidural injection administration, compari-
sons between steroids (particulate vs. nonparticulate 
steroids), the role of etanercept, and comparative analy-
sis of techniques. 
Lee et al (62) conducted a systematic review of 27 
studies to compare the benefits of transforaminal versus 
interlaminar epidural injections in patients with lumbo-
sacral disc herniation in this moderate quality system-
atic review. Despite the low-grade evidence due to the 
inconsistency and imprecision of the included studies, 
the authors reported more favorable, though not sig-
nificant, outcomes for the transforaminal epidural for 
short-term (2 weeks to 1 month) and long-term (4 to 6 
months) pain reduction, as well as short- and long-term 
functional improvement.
Similar to the above review, Lee et al (63), in a 
moderate quality systematic review and meta-analysis, 
compared clinical efficacy of transforaminal and caudal 
epidural steroid injection in lumbar and lumbosacral 
disc herniation. In this assessment, they utilized 6 stud-
ies, showing 4 articles supporting the superiority of 
transforaminal epidural injection over caudal epidural 
injection, one article showed no significant difference, 
and one article supported the superiority of caudal 
epidural steroid injection to transforaminal epidural in-
jection. Even though they concluded that meta-analysis 
showing short- and long-term trends towards better 
clinical efficacy with transforaminal epidural injections 
than caudal epidural injections, there was no statistical 
significance, and the evidence level was low because of 
inconsistencies and imprecisions. 
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Manchikanti et al (75) performed a moderate qual-
ity systematic review without meta-analysis assessing 
short and long-term relief for lumbar disc herniation. 
With literature search up to June 2013, they included 
23 RCTs of high and moderate methodologic quality 
for analysis. The results showed that evidence for the 
efficacy of all 3 approaches for epidural injection un-
der fluoroscopy was strong for short-term (less than 6 
months) and moderate for long-term (greater than 6 
months) based on the Cochrane rating system with 5 
levels of evidence best evidence synthesis. 
Manchikanti et al (81) performed a comparative 
systematic review and meta-analysis assessing epidural 
injections for lumbar radiculopathy and spinal stenosis 
in response to a publication by Chou et al (80). Chou 
et al converted all active-controlled trials into placebo-
control with inappropriate conclusions as others (67-69). 
In a high-quality comparative systematic review and 
meta-analysis, Manchikanti et al (81) included 39 RCTs 
with 9 placebo-controlled trials evaluating epidural 
corticosteroid injections, either with sodium chloride 
solution injection or bupivacaine compared to placebo 
injections. In addition, they used 12 studies comparing 
local anesthetic alone to local anesthetic with steroids. 
They also performed a meta-analysis of 5 studies utiliz-
ing sodium chloride or bupivacaine with steroid showing 
lack of efficacy. A comparison of lidocaine to lidocaine 
with steroids in 7 studies showed significant effective-
ness from baseline to long-term follow-up periods. Me-
ta-analysis showed a similar effectiveness for pain and 
function without noninferiority of lidocaine compared 
to lidocaine with steroids at 3 months and 12 months. 
This review highlighted the differences between appro-
priate and inappropriate analysis and reviewers of sys-
tematic reviews downgrading the manuscripts without 
appropriate information and most importantly, utilizing 
lidocaine as a placebo.
Manchikanti et al (77) in a moderate quality system-
atic review assessed the efficacy of epidural injections 
in the treatment of lumbar central spinal stenosis. With 
assessment through 2014, the author showed Level II evi-
dence for long-term improvement for caudal and lumbar 
interlaminar epidural injections, whereas they showed 
Level III evidence for transforaminal epidural injections 
for short-term improvement only. They also concluded 
that the interlaminar approach appears to be superior to 
the caudal approach and the caudal approach appears to 
be superior to the transforaminal approach. 
Bhatia et al (754) in a moderate quality systematic 
review and meta-analysis assessed the effectiveness of 
transforaminal epidural steroid injections for treating 
lumbosacral radicular pain from herniated interverte-
bral discs. They included 8 RCTs. They concluded that 
transforaminal epidural steroids provide modest anal-
gesic benefit at 3 months in patients with lumbosacral 
radicular pain secondary to herniated intervertebral 
discs, but they have no impact on physical disability or 
incidence of surgery. There was a high degree of hetero-
geneity among the publications. 
Liu et al (752) evaluated the effectiveness of trans-
foraminal versus caudal routes for epidural steroid 
injections in managing lumbosacral radicular pain, in a 
moderate quality systematic review and meta-analysis 
in 2016. They utilized 6 prospective and 2 retrospective 
studies involving 664 patients. They concluded that 
both transforaminal and caudal approaches are effec-
tive in reducing pain and improving functional scores, 
and they also demonstrated similar effectiveness in the 
management of lumbosacral radicular pain, in contrast 
to Lee et al (63). 
Meng et al (750) evaluated epidural injections with 
or without steroids in managing chronic low back pain 
secondary to lumbar spinal stenosis in a low-quality 
systematic review. Overall, they included 13 RCTs; how-
ever, some of them were duplicates. They concluded 
that both epidural injections with steroids or with local 
anesthetic alone provided significant pain relief and 
functional improvement in managing chronic low back 
pain secondary to lumbar spinal stenosis, and the inclu-
sion of steroids confers no advantage compared to local 
anesthetic alone. This is another manuscript emphasiz-
ing that lidocaine is not a placebo. 
Sharma et al (743) assessed the effectiveness and 
risks of fluoroscopically guided lumbar interlaminar 
epidural steroid injections in a systematic review with 
comprehensive analysis of published data in a low-
quality systematic review. They assessed 71 primary 
studies. They reported that there were no explanatory 
or placebo-controlled studies and all pragmatic studies 
identified were of low-quality, yielding evidence com-
parable to observational studies. However, they have 
not performed methodologic quality analysis and also 
inappropriately assessed the RCTs converting them into 
active-controlled RCTs. Nevertheless, they concluded 
that the body of evidence regarding the effectiveness of 
fluoroscopically guided interlaminar epidural steroid in-
jections is of low-quality. They also concluded that stud-
ies suggested a lack of effectiveness of fluoroscopically 
guided lumbar interlaminar epidural steroid injections 
in treating primarily axial pain, regardless of etiology. 
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They further commented that most studies on radicu-
lar pain due to lumbar disc herniation and stenosis do, 
however, report statistically significant short-term im-
provement in pain. Their analysis and conclusions are 
rather confusing and indicates their clear bias towards 
transforaminal epidural injections. 
Smith et al (742) described transforaminal injections 
of steroids for treatment of radicular pain performed a 
comprehensive review of the published data. However, 
they considered it to be a comprehensive systematic 
review; however, it appears to be a narrative review or 
very low-quality systematic review. They concluded that 
there was strong evidence that lumbar transforaminal 
epidural injection of steroids is an effective treatment 
for radicular pain due to disc herniation. There is lack of 
high-quality evidence demonstrating their effectiveness 
for the treatment of radicular pain due to spinal ste-
nosis, though small studies suggest a possible benefit. 
They also made a statement that lumbar transforami-
nal injection of nonparticulate steroids is as effective 
as injection with particulate steroids. Apart from lack 
of methodologic quality assessment and lack of meta-
analysis, their bias is clear in favor of transforaminal 
epidural injections. 
The same group of authors from the Spine Inter-
vention Society (SIS) performed a systematic review 
with comprehensive analysis of the published data of 
the effectiveness and risks of nonimage guided lumbar 
interlaminar epidural steroid injections. With inclusion 
of a large number of publications (92), they concluded 
that in patients with lumbar radicular pain secondary 
to disc herniation or neurogenic claudication due to 
spinal stenosis, nonimage guided lumbar interlaminar 
epidural steroid injections appear to have clinical ef-
fectiveness limited to short-term pain relief. Therefore, 
in a contemporary medical practice, these procedures 
should be restricted to the rare settings where fluoros-
copy is not available. However, these results are similar 
to the results they published with fluoroscopy guided 
lumbar interlaminar epidural steroid injections (743) 
raising multiple questions of their own biases. 
Zhai et al (738) evaluated epidural injections with 
or without steroid in managing chronic low back and 
lower extremity pain with a meta-analysis of RCTs in a 
low-quality assessment. The authors utilized multiple 
duplicates and have not performed single arm analysis. 
Nevertheless, this meta-analysis confirms that epidural 
injections of local anesthetic with or without steroids 
have beneficial but similar effects in the treatment of 
patients with chronic low back and lower extremity pain. 
Yang et al (739) assessed epidural steroid injection 
versus conservative treatment for patients with lumbo-
sacral radicular pain with a meta-analysis of RCTs in a 
moderate quality publication. With the inclusion of 6 
RCTs, they concluded that the use of epidural steroid 
injections is more effective for alleviating lumbosacral 
radicular pain than conservative treatment in terms 
of short-term and intermediate-term. In addition, the 
patients also reported more successful outcomes after 
receiving epidural steroid injections when compared to 
conservative treatment. However, this effect was not 
maintained at long-term follow-up. 
Wei et al (740) published comparison of transfo-
raminal versus interlaminar epidural steroid injections 
in low back pain with lumbosacral radicular pain in a 
moderate quality meta-analysis of the literature in 
2016. They included 931 patients from 9 RCTs and 4 
observational studies. They concluded that transforami-
nal epidural steroid injection to manage low back pain 
provided superior short-term pain relief and equal func-
tional improvement when compared to interlaminar 
epidural injection. There was no statistically significant 
difference between groups with regard to procedure, 
frequency, surgery rate, and ventral epidural spread.
Pairuchvej et al (744) performed a systematic review 
and meta-analysis of moderate quality comparing short 
and mid-term outcomes of lumbar transforaminal epi-
dural injections with preganglionic and postganglionic 
approach in lumbosacral radiculopathy published in 
2018. They concluded that postganglionic epidural ste-
roid injection has a statistically significant higher chance 
of effectiveness when compared to preganglionic epi-
dural steroid injection. They concluded that in terms of 
pain scores and complications, there were no statistically 
significant differences between the 2 groups. The results 
were generally homogenous and with little publication 
bias, they believed that these should be generalizable. 
Due to multiple complications related to transforaminal 
epidural injections with particulate steroids, infraneural 
and supraneural approaches have been suggested. Pre-
ganglionic refers to supraneural approach and postgan-
glionic refers to infraneural approach.
Manchikanti et al (70) performed a systematic re-
view without meta-analysis for epidural injections to 
assess if they provide long-term relief of neck and upper 
extremity pain. They included 7 manuscripts meeting 
inclusion criteria. Of these, 4 assessed the role of inter-
laminar epidural injections for managing disc herniation 
or radiculitis, and 3 assessed these injections for manag-
ing central spinal stenosis, discogenic pain without facet 
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joint pain, and post-surgery syndrome. They concluded 
that with qualitative best evidence synthesis, there is 
Level II evidence for the efficacy of cervical interlaminar 
epidural injections with local anesthetic with or without 
steroids, based on at least one high-quality relevant RCT 
in each category for disc herniation, discogenic pain 
without facet joint pain, central spinal stenosis, and 
post-surgery syndrome.
In contrast to the mostly positive systematic re-
views, 2 systematic reviews with one update (67,69,80) 
have shown lack of effectiveness of epidural steroids. 
They all showed lack of effectiveness of epidural ste-
roids. The common denominator being conversion of 
active-controlled trials into placebo-controlled trials 
and considering local anesthetic as placebo. They also 
have additional issues with their publications, including 
conflicts of interest, publication bias, and inappropriate 
data synthesis. Manchikanti et al (81) performed a com-
parative analysis of Chou et al’s publication (80) which 
also applies to other systematic reviews showing their 
deficiencies and providing contrary results. 
Bui and Bogduk (749) performed a systematic review 
of the effectiveness of CT guided, lumbar transforaminal 
injection of steroids in a low-quality systematic review. 
They were only able to include 4 studies with success rate 
being reported between 34% and 62%. They concluded 
that evidence-base for CT guided lumbar transforaminal 
injection of steroids is meager. Further, this interven-
tion is not more effective than fluoroscopically guided 
injection and is not demonstrably safer. The authors also 
commented that with using techniques of “As Low As 
Reasonably Achievable” (ALARA) fluoroscopy times are 5 
times less than that of low dose CT protocol and 18 to 40 
times less than a standard CT protocol.
Chang Chien et al (615) in a systematic review of 
comparative studies for lumbosacral radicular pain 
of transforaminal versus interlaminar approaches to 
epidural steroid injections, in a low-quality system-
atic review without meta-analysis utilized 5 prospective 
studies with 249 patients. Their results showed that only 
in short-term the results were in favor of transforaminal 
with 15% difference compared to interlaminar epidural 
injections for pain relief. However, there was no differ-
ence at 1 or 6 months. They concluded that both trans-
foraminal epidural steroid injections and interlaminar 
epidural steroid injections are effective in reducing pain 
and improving functional scores. In addition, transfo-
raminal epidural steroid injections provided nonclinical-
ly significant superiority to interlaminar epidural steroid 
injections only at 2-week follow-up. Further, based on 2 
studies, interlaminar epidural steroid injection provided 
nonclinically significant superiority to transforaminal 
epidural injections in function improvement. 
Arirachakaran et al (756) assessed comparative out-
comes of epidural steroids versus placebo after lumbar 
discectomy in lumbar disc herniation in a systematic 
review and meta-analysis of RCTs of moderate quality. 
They included a total of 12 studies and analyzed the 
pooled data with 9 studies having undergone conven-
tional discectomy and 3 studies having undergone mini-
mally invasive surgery discectomy, with a total of 1,006 
patients. They concluded that there were no significant 
differences in reference to morphine consumption and 
hospital stay or complications between the 2 groups. This 
systematic review is a very unusual review and the stud-
ies they included are also extremely unusual. Epidural 
steroids are not recommended following the surgery in 
the immediate intraoperative period. This manuscript 
provides an opportunity to discourage such usage. 
Jing et al (667) assessed efficacy and safety of etan-
ercept in the treatment of sciatica in a systematic review 
and meta-analysis which was of moderate quality. They 
concluded that etanercept treatment was associated 
with a significantly reduced pain in leg and back com-
pared to placebo and may possibly improve leg pain 
relief compared to steroids, but failed to improve ODI. 
They also concluded that etanercept should be recom-
mended for sciatica with caution because of heteroge-
neity. However, the drug is not approved or available in 
the US for epidural usage purposes. 
Three systematic reviews were performed assess-
ing particulate and nonparticulate steroids in epidural 
injections (745,747,748). 
Feeley et al (747) performed a systematic review 
and meta-analysis of moderate quality assessing par-
ticulate and nonparticulate steroids in spinal epidurals. 
They concluded that particulate steroids were not de-
monstrably better in relieving pain compared to their 
nonparticulate counterparts. These conclusions are 
based on 4 studies with 300 participants.
Mehta et al (745) in a systematic review of moder-
ate quality assessed efficacy of particulate versus non-
particulate corticosteroids in epidural injections. From 
inclusion of multiple heterogenic studies, they conclud-
ed that there was no statistically significant difference 
in terms of pain reduction or improved functional out-
come between when performing cervical transforaminal 
epidural injection, whereas lumbar radiculopathy due 
to stenosis or disc herniation, transforaminal epidural 
using particulate versus nonparticulate was equivocal 
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in reducing pain and improving function. Consequently, 
the authors recommended nonparticulate steroids.
Makkar et al (748) published a systematic review and 
meta-analysis of the current literature of particulate and 
nonparticulate steroids for transforaminal epidural injec-
tions. In this analysis, they included 7 studies comprising 
3,542 patients in the particulate group and 856 patients 
in the nonparticulate group. The results showed better 
improvement with Visual Analog Scale (VAS) by 0.53 in 
the particulate group compared to the nonparticulate 
group. However, nonparticulate group had a larger pro-
portion of patients with more than 50% pain relief than 
the particulate group. They concluded that since the use 
of particulate steroids seems to be associated with slight-
ly better VAS scores only, clinicians need to weigh their 
clinical relevance in light of complications and US Food 
and Drug Administration (FDA) recommendations on the 
use of particulate steroids. However, FDA recommenda-
tion is for all types of steroids. Consequently, it appears 
that all 3 studies show there was no significant differ-
ence; however, all 3 systematic reviews included cervical 
transforaminal epidural injections, even though Makkar 
et al (748) included predominantly lumbar transforami-
nal epidural injections. Considering that local anesthetics 
alone are equally effective to particulate steroids in most 
instances, these differences are minimal, specifically with 
clinical relevance.
Helm et al (83) in a recent publication evaluated 
transforaminal epidural steroid injections in a systemat-
ic review and meta-analysis, which was of high-quality. 
In this analysis, they included 18 RCTs with 11 trials 
evaluating radicular pain due to disc herniation. They 
also performed single arm meta-analysis in addition 
to conventional dual arm analysis. They showed Level 
I evidence for use of transforaminal epidural injections 
for radicular pain from disc herniations. However, the 
evidence was Level IV for central stenosis, failed back 
surgery syndrome, and Level V for radicular pain from 
foraminal stenosis and for axial pain. 
There have been multiple publications of systematic 
reviews with percutaneous adhesiolysis. The effective-
ness of percutaneous adhesiolysis for managing chronic 
pain due to lumbar central spinal stenosis was examined 
in a high-quality systematic review and meta-analysis (9 
studies) by Manchikanti et al (73). The authors found 
Level II evidence for both the short- and long-term 
improvement in pain and function in response to the 
intervention. The authors in this manuscript also uti-
lized conventional dual and single arm meta-analysis 
illustrating effectiveness with both types of analysis. 
Another high-quality systematic review and meta-
analysis by Manchikanti et al (72) looked at the efficacy 
of percutaneous adhesiolysis in the treatment of chronic 
refractory lower back and lower extremity pain due to 
post-laminectomy surgery syndrome. Their analysis 
included 4 systematic reviews and 4 RCTs. All but one 
systematic review, which was deemed low-quality, dem-
onstrated Level I evidence for the efficacy of percutane-
ous adhesiolysis in this patient population. 
Manchikanti et al (74) in a systematic analysis of 
findings of reviews looked at various systematic reviews 
performed on the subject of percutaneous adhesiolysis 
and determined that except for a few of them, one par-
ticular systematic review by Brito-García et al (87) was 
inappropriately performed. Manchikanti et al (74) in this 
manuscript also reexamined the evidence and performed 
the systematic review of 4 RCTs utilized in the previous 
systematic reviews and concluded that there was Level I 
evidence for percutaneous adhesiolysis based on signifi-
cant evidence from published RCTs and 3 of the 4 system-
atic reviews in post-lumbar surgery syndrome. 
Systematic reviews were also performed to assess 
surgery sparing effect of epidural injections, both in 
lumbar spine and cervical spine. Bicket et al (271) in a 
review of 26 randomized controlled studies with meta-
analysis showed that patients receiving epidural steroid 
injections were less likely to undergo surgery than those 
who received control treatment, providing moderate 
evidence. The results also showed that evidence sug-
gested that between one-third and half of patients con-
sidering surgery who undergo epidural steroid injection 
can avoid surgery; however, with low level of evidence. 
Koltsov et al (272) in assessment of incidence and 
risk factors of subsequent surgery in patients receiving 
lumbar epidural steroid injections showed that within 
6 months, 12.5% of epidural steroid injection patients 
underwent lumbar surgery, whereas by one year, 16.9% 
had surgery, and by 5 years, 26.1% had surgery. The 
authors concluded that in the long-term, more than 
one out of every 4 patients undergoing epidural steroid 
injection for lumbar herniation or stenosis subsequently 
had surgery, and nearly one of 6 had surgery within the 
first year. While the authors attempted to present a 
negative view because of surgical orientation, avoiding 
surgery in 76% of the patients, specifically on a long-
term basis, is considered phenomenal. These authors 
also started with the negative connotation that up to 
30% of patients had surgery within one to 2 years fol-
lowing lumbar epidural steroid injection and up to 49% 
had surgery within 5 years (273-277), with roughly half 
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of patients requiring a second epidural steroid injection 
to achieve their surgery-sparing results (273,274,278) 
implying that one epidural steroid injection must pro-
vide total relief, similar to surgery, or better. Further, all 
the studies assessing these factors also misunderstand 
active-controlled trials to placebo-controlled trials as do 
Cochrane reviews and other academicians. 
In contrast, in the cervical spine, Kleimeyer et al 
(188) from the department of orthopedic surgery, in the 
assessment of cervical epidural steroid injections and the 
incidence of subsequent surgery, showed that within 6 
months of cervical epidural steroid injections, 11.2% of 
patients underwent surgery, increasing to 14.5% by one 
year, and 22.3% by 5 years. Overall, they concluded that 
following cervical epidural steroid injections, over 1 in 
5 patients underwent surgery within 5 years, showing 
75% response rate as in lumbar spine, again which will 
be considered as excellent improvement and outcomes. 
8.3 Randomized Controlled Trials
Based on extensive search criteria, numerous manu-
scripts were identified and considered for inclusion. Of 
the 180 manuscripts of epidural interventions, includ-
ing adhesiolysis trials, identified, multiple trials were 
excluded for not meeting inclusion criteria. Only studies 
performed under fluoroscopic guidance with a minimum 
of 6 months follow-up were included. Subsequently, 43 
trials and 2 observational studies were included. Only 
fluoroscopic guided procedures were utilized, based on 
philosophy that fluoroscopy provides the best results as 
described in the literature and also preferred method 
from Centers for Medicare and Medicaid Services (CMS), 
and other medical policies. While ultrasound is evolving, 
it continues to be in infancy with comparative studies. 
Further, 6-month follow-up as minimum was utilized as 
it indicates long-term follow-up of the patients with epi-
dural injections, mostly multiple procedures, rather than 
expecting a single procedures and expecting to last on a 
long-term basis. It becomes difficult to extrapolate the 
short-term results to long-term; consequently, 6-month 
follow-up was utilized. Further, multiple manuscripts 
which have been excluded from the inclusion have 
been listed with description of characteristic features in 
manuscripts by Kaye et al (60) and Knezevic et al (58). 
Knezevic et al (58) also showed lack of publication bias. 
8.3.1 Methodological Quality Assessment 
A methodological quality assessment of the RCTs 
meeting inclusion criteria was carried out utilizing Co-
chrane review criteria (154) and IPM-QRB criteria (153) 
as shown in Appendix Tables 2 and 3. Nonrandomized 
studies were assessed utilizing IPM-QRBNR (157) as 
shown in Appendix Table 4.
8.4 Caudal Epidural Injections
Thirty-three studies examined caudal epidural 
injections for effectiveness (757-789). Following the 
application of our criteria for inclusion, 10 RCTs (765-
770,779,783,784,786) met the inclusion criteria with 
procedures being performed under fluoroscopic guid-
ance and with a minimum of 6 months of follow-up, 
with publication of appropriate outcome parameters 
(765-770,779,783,784,786). Twenty-three studies were 
excluded due to many of them being performed with-
out fluoroscopy, and some studies describing short-term 
outcomes or inadequate reporting. Multiple studies 
published at various intervals were utilized as one 
study with the final publication. Consequently, multiple 
studies utilized in previous systematic reviews failed to 
meet the inclusion criteria (56,57,67,69,75-77). Using 
Cochrane and IPM-QRB criteria, 6 of the 10 studies were 
determined to be high-quality (762,765-767,770,784) 
and 4 of 10 were determined to be moderate quality 
(769,779,783,786). Appendix Table 5 shows methodo-
logic quality assessment utilizing Cochrane review cri-
teria, Appendix Table 6 shows methodologic quality as-
sessment utilizing IPM-QRB criteria and Table 12 shows 
descriptive characteristics of caudal epidural injections.
Manchikanti et al conducted 4 studies (762,765-
767). They used an identical protocol in each study: an 
active control design with a 2-year follow-up. These 
studies evaluated the efficacy of epidural injections in 
2 groups: one group received a local anesthetic only 
and the other group received a local anesthetic with a 
steroid. In these 4 studies, a total of 480 patients were 
evaluated for one of the following conditions: lumbar 
disc herniation; lumbar discogenic pain without facet 
joint or sacroiliac joint pain; lumbar central spinal ste-
nosis; and lumbar post-surgery syndrome.
Each of these trials reported that caudal epidural 
injections, whether with local anesthetic only or local 
anesthetic with steroid, were efficacious in 50% to 80% 
of those treated. These patients were divided into those 
who responded to the treatment and those who did not. 
A responsive patient was one who had at least a 50% 
improvement in both pain and function for 3 weeks 
with the initial 2 injections. Those who responded and 
those who did not, were not significantly different for 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Responsive group patients in all 4 studies had supe-
rior outcomes; however, it should be noted that none of 
the studies had a placebo control. But each study only 
enrolled patients with chronic pain, and homogeneity 
was maintained because the patients in each study had 
a similar diagnosis. Each study established the efficacy of 
local anesthetic with steroid for the pathology treated; 
in addition, the patients in the disc herniation study had 
a higher quality of pain relief at 6 and 12 months. The 
mechanisms of action of local anesthetics and steroids 
have an abundance of experimental and clinical evi-
dence (55-58,102,604-608,689-699). Further, there have 
been previous descriptions concerning the effectiveness 
of sodium chloride injected into the epidural space and 
joint spaces (76,436,698). 
Among the newer studies published in 2017, 
Singh et al (779), in a prospective randomized assess-
ment, studied transforaminal epidural injections versus 
caudal epidural injections for single level prolapsed 
lumbar intervertebral disc. In this study, they utilized 80 
patients with 40 patients in each group. Both groups 
received steroids and local anesthetic; however, there 
was significant difference in the volumes, which were 
rather high. Patients in the caudal group received 2 mL 
of methylprednisolone (80 mg) with 10 mL of lignocaine 
2% diluted in 20 mL of normal saline. Further, a total of 
3 caudal epidural injections were given at intervals irre-
spective of previous epidural injection effect. However, 
transforaminals were given by a single injection of 2 mL 
of methylprednisolone 80 mg mixed with 5 mL of ligno-
caine (7 mL total), a high volume, using a supraneural 
technique. For the outcomes, they utilized pain relief as 
well as ODI. More importantly, they assessed the patients 
with more than 50% relief. In the transforaminal group, 
pain was reduced by more than 50% until 6 months, 
while in the caudal group, more than 50% reduction 
of pain was maintained until one year. The reduction 
in ODI in the transforaminal group was 52.8% until 3 
months, 48.6% until 6 months, and 46.7% at one year, 
while in the caudal group, the improvement was 64.6%, 
65.1% and 65.4% at corresponding follow-up periods. 
They concluded that caudal epidural was more effective 
or superior to transforaminal, with an increased ease of 
administration. 
Pandey (769) assessed the efficacy of epidural ste-
roid injection in the management of lumbar prolapsed 
intervertebral disc in comparative evaluation with cau-
dal, interlaminar, and transforaminal approaches. They 
included a total of 140 patients with randomization into 
3 groups with 80 patients utilizing the caudal approach, 
40 patients by transforaminal approach, and 8 patients 
by interlaminar approach using a simple randomization; 
however, this randomization is not uniform. Utilizing 
Japanese Orthopaedic Association (JOA) scores they cal-
culated the improvement at 6 months and one-year and 
effectiveness of the medication for each route. Their 
results showed that one-year after injecting the steroid, 
all three routes were found to be effective in improving 
JOA scores with caudal route showing improvement in 
74.3%, interlaminar showing improvement in 77.7%, 
and transforaminal route in 90%. They also showed that 
the transforaminal route was significantly more effec-
tive than the caudal and interlaminar at both 6 months 
and one-year after injection. No significant differences 
were seen between the caudal and interlaminar ap-
proaches. The limitations of this study include unequal 
randomization and lack of data showing significant 
improvement.
Kamble et al (770) studied 90 patients randomized 
to 3 groups with approaches of caudal, interlaminar, and 
transforaminal with randomization with 30 patients in 
each group in a single level disc prolapse patients con-
firmed by MRI. They followed the patients for 12 months 
and the results were compared using change in VAS 
score and ODI; however, they presented only 6 month 
results. Their results showed the change in pain scores 
were statistically different at 1 and 6 month intervals 
such that a higher change was observed by the trans-
foraminal route as compared to the other two. There 
was no difference in change of scores between the in-
terlaminar and caudal routes. For ODI scores, a greater 
change was seen in delivery at all times, as compared to 
the other 2. There was no difference in change of scores 
between the interlaminar and caudal routes at any 
time of the assessment. The VAS scores changed from 
7.1 to 2.6 at 6-month follow-up in the transforaminal 
group compared to 7.0 to 3.4 in the interlaminar group, 
and 7.2 to 3.5 in the caudal group. Similarly, ODI scores 
changed from 37.7 to 16.8 in the transforaminal group 
compared to 36.9 to 21.4 in the interlaminar group and 
38.3 to 21.9 in the caudal group. Overall, these findings 
showed positive results. However, as shown above, posi-
tive results with transforaminal were superior. It should 
be noted that the 12-month results were not published 
and also 50% relief was not assessed.
Among the older studies, Ackerman and Ahmad 
(783) compared the efficacy of caudal epidural injec-
tions with lumbar interlaminar and transforaminal epi-
dural injections. This was a relatively small study show-
ing the superiority of both lumbar interlaminar and 
Pain Physician: Epidural Guidelines 2021 24:S27-S208
S90  www.painphysicianjournal.com
transforaminal epidural injections over caudal epidural 
injections. The authors utilized both local anesthetic 
and steroids.
Dashfield et al (784) assessed and compared caudal 
epidural steroid injections with targeted steroid place-
ment during spinal endoscopy for chronic sciatica. Their 
study showed that epidural injections without passage 
of endoscopy equipment was superior.
Murakibhavi and Khemka (786) compared caudal 
epidural steroid injections in a RCT of disc herniation 
with conservative treatment measures which included 
medication as well as physiotherapy, whereas the 
intervention group received caudal epidural steroid 
injections with 20 mL of normal saline, 2 mL of 2% 
preservative-free lidocaine, and 2 mL or 80 mg of tri-
amcinolone acetate. The authors showed complete 
long-term relief in 86% of the patients in the caudal 
epidural group compared to 24% in the conservative 
management group. This was a moderate quality trial, 
without blinding, comparing conservative modalities to 
epidural injections.
Among the excluded studies, there was only one 
study by Iversen et al (785), utilizing a placebo design, 
however, without fluoroscopy, but with ultrasound and 
injection of steroid without local anesthetic. The study 
was highly deficient in multiple aspects with substantial 
criticism advanced (790-792). This study illustrates nu-
merous flaws. As a first concern, the selection criteria 
are overtly broad. A significant proportion of patients 
(n = 17) did not even have to undergo randomization 
because their symptoms improved between assessment 
and randomization indicating the inclusion of short-
term or subacute pain. In addition, after the randomiza-
tion, 5 patients had spontaneous improvement before 
the first injection. A large proportion of patients were 
excluded due to neurologic compression, including cau-
da equina syndrome. They also attributed most of their 
results to natural course. Patient selection appears to be 
quite inappropriate. In chronic pain settings with long-
lasting pain, patients undergoing various modalities of 
treatments would already have responded to a natural 
course or placebo effect. Further, while MRI was utilized 
as the criteria for disc herniation, ultimately the authors 
included clinically proven radiculopathy for inclusion 
criteria. Multiple flaws with the procedure include ul-
trasound identification of caudal epidural space, which 
the authors claim is appropriate for caudal even though 
they concede it was not appropriate for transforaminal. 
Ultrasound identification is not appropriate for either 
caudal or for transforaminal. Further, the injection was 
not only nontargeted with an unproven technique, 
namely ultrasound, but also included large volumes of 
sodium chloride solution without local anesthetics and 
relatively small volumes of triamcinolone. It also ap-
pears, somewhat surprising, that only 17 patients of the 
345 declined to participate in the study, even though it 
is a placebo-control study.
Sayegh et al (782) studied patients with either 
acute or subacute sciatica. This randomized controlled 
study reported significant improvement for those re-
ceiving local anesthetic alone or with steroids. However, 
they reported that adding steroids provided a superior 
outcome because the onset of relief was faster, longer 
lasting, and of a higher quality.
Park et al (773) studied the role of caudal epidural 
steroid injection for the treatment of unilateral lower 
lumbar radicular pain utilizing a single-blinded ran-
domized design comparing ultrasound-guided versus 
fluoroscopy-guided procedures. They included a total of 
110 patients with 55 patients in each group. In a short-
term follow-up of 12 weeks, they showed improvement 
with pain and function in both groups.
Revel et al (787) studied forceful epidural injections 
for the treatment of lumbosciatic pain with postop-
erative lumbar spine fibrosis. They included 60 patients 
with persistent or recurrent lumbosciatic pain after 
surgery and with epidural fibrosis. This was a moderate 
quality study with positive results.
Datta and Upadhyay (776) compared 3 different 
steroid agents for treatment of low back pain through 
caudal approach with allocation of patients into 4 
groups with one group receiving local anesthetic alone 
(bupivacaine), whereas 3 groups received 3 types of 
steroids utilizing bupivacaine and with total dose 
equivalent to 210 mg of methylprednisolone or 3 injec-
tions with methylprednisolone acetate, triamcinolone 
acetonide, or betamethasone acetate. All injections 
were administered with 10 to 15 mL volume of 0.125% 
bupivacaine alone or bupivacaine mixed with 80 mg of 
methylprednisolone, 80 mg of triamcinolone, or 15 mg 
of dexamethasone. The procedures were performed 
blindly without fluoroscopy and a significant proportion 
of patients had disc herniations at L3/4, either individu-
ally or in combination, in the majority of the patients 
(the level at which caudal epidural has poor spread pat-
tern), specifically when performed without fluoroscopy. 
VAS improved the most in the methylprednisolone and 
triamcinolone groups from baseline scores of 7.4 to 
4.9 in the methylprednisolone group and 4.8 in the 
triamcinolone group. In contrast, the dexamethasone 
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group improved from 7.3 to 5.2 and local anesthetic 
alone group improved from 7.2 to 6.18. These results in 
a short-term follow-up show that methylprednisolone 
and triamcinolone with local anesthetic in rather high 
doses were more effective than high dose dexametha-
sone and bupivacaine alone. Thus, the results show that 
there is significant improvement with steroids when 
local anesthetics are added.
Huda et al (789), utilizing a blind approach, assessed 
70 patients. They compared methylprednisolone or tri-
amcinolone mixed with bupivacaine and normal saline 
with a total of 20 mL volume. In the methylprednisolone 
group, at the end of 6 months, 68.5% of the patients 
reported improvement, whereas improvement was seen 
in 40% of the patients in the triamcinolone group. The 
results are impressive considering that patients received 
only one injection of steroid with bupivacaine.
8.4.1. Evidence Synthesis
Based on the available studies, qualitative and 
quantitative analysis were performed. Qualitative analy-
sis data was derived from the data from this assessment. 
Quantitative analysis data was derived from a multitude 
of previous systematic reviews, which included conven-
tional dual-arm analysis and single-arm analysis.
In the present assessment, there were 2 RCTs 
(769,770) comparing caudal, interlaminar and transfo-
raminal groups in managing disc herniation. In both 
studies, caudal and interlaminar epidurals were equiva-
lent, whereas transforaminal was shown to be some-
what superior. In contrast, Ackerman and Ahmad (783), 
which was included in this analysis, showed superiority 
of both lumbar interlaminar and transforaminal epi-
dural injections over caudal epidural injections. It must 
be noted that this was a very small study.
However, Singh et al (779) compared selective nerve 
root blocks and caudal epidural injection for single level 
prolapsed lumbar intervertebral disc in a prospective 
randomized study. They showed significantly better im-
provement with caudal epidural injections at 6 months 
and one year. They utilized 3 caudal epidural injections 
compared to one transforaminal epidural injection. 
Consequently, the value of this study and results in 
reference to superiority are questionable, even though 
they show that both approaches are effective.
In the present review, there were no studies meet-
ing inclusion criteria with placebo control. All of the 
studies meeting inclusion criteria were of an active con-
trol nature. Four studies by Manchikanti et al presented 
2-year relief with positive response in disc herniation, 
central spinal stenosis, axial or discogenic pain, and 
post-lumbar surgery syndrome. 
Overall, 7 studies provided the results of 
caudal epidural injections in disc herniation 
(765,769,770,779,783,784,786). All of them were judged 
to be positive. Consequently, the evidence for caudal 
epidural injections in disc herniation, with inclusion of 
7 relevant medium to high-quality studies is Level I with 
strong recommendation. Comparative studies of caudal, 
interlaminar, and transforaminal show equal effective-
ness of caudal and interlaminar. However, superiority of 
transforaminal epidural injections was demonstrated in 
two studies (769,770). Thus, based on relevant studies, 
there is Level III evidence that transforaminal are supe-
rior to caudal epidural injections and Level III evidence 
that caudal epidural injections are equivalent to lumbar 
interlaminar epidural injections. 
The evidence for central spinal stenosis is Level III to 
II based on a single RCT (767), which is an active control, 
with inclusion of 100 patients with 24-month follow-
up with moderate to strong recommendation in select 
patients. 
The evidence for axial or discogenic pain after 
elimination of facet joint pain and sacroiliac joint pain 
is Level II based on one active control RCT (762) with 
inclusion of 120 patients and a 2-year follow-up with 
moderate to strong recommendation. 
For post-surgery syndrome, based on one high-
quality relevant RCT (766), the evidence is Level II with 
moderate to strong recommendation. 
Cost utility analysis was also favorable for caudal 
epidural injections in all 4 conditions studied, namely, 
disc herniation, central spinal stenosis, post-lumbar 
surgery syndrome, and axial discogenic pain (795). The 
cost utility analysis showed cost for one-year quality-
adjusted life year (QALY) of $2,172.50 for direct costs 
and $3,627.24 for total cost with addition of indirect 
costs. There was no significant difference among the 
groups; however, among various conditions, for disc 
herniation total cost was $3,682.35 per one-year QALY. 
For axial or discogenic pain after ruling out the facet 
joint and sacroiliac joint pain, it was $3,567.42, spinal 
stenosis it was $3,598.85, and for post-surgery syndrome 
it was $3,658.43 for one-year QALY. 
Multiple systematic reviews have assessed the role 
of caudal epidural injections with or without steroids in 
managing pain in the lumbar spine for various condi-
tions, including disc herniation, discogenic pain without 
disc herniation, central spinal stenosis, and post-surgery 
syndrome. Only a few systematic reviews focused on 
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analyzing the evidence for caudal epidural injections, 
either alone or comparatively. Manchikanti et al (75-
77,81) and Kaye et al (60) evaluated caudal epidural 
injections separately and in combination with inter-
laminar and transforaminal epidural injections in the 
lumbar spine. All of these studies uniformly showed the 
effectiveness of caudal epidural injections and basically 
included the same studies. 
In addition, Lee et al (63), compared the clinical effi-
cacy of transforaminal and caudal epidural steroid injec-
tions in a systematic review utilizing 6 studies showing 
somewhat the superiority of transforaminal epidural in-
jections over caudal epidural injection in 4 articles, with 
one article showing no significant difference, and one 
article supporting the superiority of caudal epidural ste-
roid injection to transforaminal epidural injection. Their 
conclusion was towards better clinical efficacy with 
transforaminal epidural injections. However, there was 
no statistical significance and the evidence was low be-
cause of inconsistencies and imprecisions. Consequently, 
the clinical relevance is not determined. 
Manchikanti et al compared caudal epidural stud-
ies with interlaminar and transforaminal epidural 
studies (614,793,794). In one of those studies (614), 
they compared the efficacy of caudal, interlaminar, and 
transforaminal epidural injections in managing lumbar 
disc herniation by looking at whether one method was 
superior to the other. They included 3 RCTs with 120 
patients in each trial with 60 patients receiving local 
anesthetic only and 60 patients in each trial receiving 
local anesthetic with steroids. Analysis showed similar 
efficacy for caudal, interlaminar, and transforaminal 
approaches in managing chronic pain and disability 
from disc herniation. While there were differences in 
relief patterns, they were not statistically significant. At 
12 months, significant improvement (considered as at 
least 50% pain relief and improvement in ODI scores for 
function from baseline) of 72% was shown in the caudal 
group, 85% in the interlaminar group, and 57% in the 
transforaminal group. However, further analysis with 
only responsive patients showed 84% improvement in 
the caudal group, 86% in the interlaminar group, and 
73% in the transforaminal group. Overall, there was no 
significant difference between groups. However, it ap-
pears that interlaminar may be somewhat better than 
caudal. 
Manchikanti et al (793) also compared the effec-
tiveness of caudal epidural with lumbar interlaminar 
epidural in central spinal stenosis. Similar to the above 
study, they derived the data from 2 previously published 
RCTs. Results showed significant improvement in pa-
tients suffering with chronic lumbar spinal stenosis with 
caudal and interlaminar epidural approaches up to 2 
years. However, the interlaminar group showed signifi-
cant difference between caudal and interlaminar with 
interlaminar being superior to caudal in spinal stenosis. 
Manchikanti et al (794) also studied the difference 
between caudal and lumbar interlaminar injections in 
chronic lumbar axial discogenic pain. They utilized 2 
RCTs from each group. In this assessment, the lumbar 
interlaminar approach was shown to be superior to the 
caudal approach. The primary outcome measure, with 
significant improvement being defined as pain relief 
and functional status improvement of at least 50% from 
baseline, was reported at 20-month follow-up in 72% 
who received local anesthetic only utilizing the lumbar 
interlaminar approach and 54% who received local 
anesthetic only utilizing a caudal approach. Further, in 
patients receiving local anesthetic with a steroid, the re-
sponse rate was 67% of those who had a lumbar inter-
laminar approach and 68% of those who had a caudal 
approach at 12 months. Consequently, they concluded 
that the response was significantly better in the lumbar 
interlaminar group who received local anesthetic only, 
77% versus 56% at 12 months, and 72% versus 54% at 
24 months. 
8.5 Lumbar Interlaminar Epidural Injections
Lumbar interlaminar epidural injections were stud-
ied for effectiveness in 53 studies (617,769,770,783,796-
843). Of the 53 studies considered for inclusion, only 13 
RCTs met inclusion criteria. (617,769,770,783,797,799,8
01,804,817,818,821,823,843). Appendix Table 7 shows 
Cochrane review criteria assessment results, whereas, 
Appendix Table 8 shows criteria by IPM-QRB. Table 13 
shows characteristic features of fluoroscopic RCTs of 
lumbar interlaminar epidural injections. Using both 
Cochrane and IPM-QRB criteria, 10 studies (617,770,797
,799,801,804,817,821,823,843) were rated high, while 4 
were rated moderate quality (769,783,818). 
Manchikanti et al conducted 3 of these studies 
(797,799,801). They used an identical protocol in each 
study: an active control design with a 2-year follow-up. 
These studies evaluated the efficacy of epidural injec-
tions in 2 groups: one group received a local anesthetic 
only and the other group received a local anesthetic 
with a steroid. In these 3 studies, a total of 360 patients 
were evaluated for one of the following conditions: 
lumbar disc herniation; lumbar discogenic pain without 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































spinal stenosis. Similar outcomes were seen in 
60% to 84% of the patients in these studies. Both 
Cochrane and IPM-QRB rated these studies as 
high-quality (10 of 12 and either 43 or 44 of 48, 
respectively).
These studies divided patients into respon-
sive and nonresponsive groups. A patient was 
considered responsive if a 50% improvement 
in pain and function was achieved in the first 3 
weeks with the initial 2 injections. Nonresponsive 
patients in each pathology studied were: inter-
laminar injections of local anesthetic only - 10 
with disc herniation, 5 with discogenic pain, and 
9 with central stenosis; local anesthetic with ste-
roids—1 with disc herniation, 6 with discogenic 
pain, and 7 with central stenosis. These results 
show that there were many in the nonresponsive 
local anesthetic disc herniation group, but no 
differences were noted between the subgroups 
in the other pathologies studied. Also, the addi-
tion of steroids to the local anesthetic appears to 
result in superior outcomes for pain at 6 months 
and functional status at 12 months for those 
with disc herniation (797). Patients who do not 
respond to local anesthetic alone for disc hernia-
tion may achieve a better outcome with the addi-
tion of steroids. Of interest is the fact that none 
of these studies had a placebo group.
Two studies were conducted by Ghai et al 
(617,804). In the first study (617), they compared 
parasagittal interlaminar and transforaminal epi-
dural steroid injections without local anesthetic 
in 62 patients. The results showed significant im-
provement at 3 months, 6 months, and 12 months 
in 78%, 75%, 69% of patients in the parasagittal 
interlaminar group compared to 77%, 77%, 77% 
in the transforaminal epidural group. This was a 
relatively small active control trial with a long-
term follow-up assessing the role of parasagittal 
interlaminar epidural injections and transforami-
nal epidural injections, showing equal improve-
ment with steroids without local anesthetic. In 
the second study, Ghai et al (617) compared local 
anesthetic alone with local anesthetic with ste-
roids in disc herniation or radiculitis. In an active-
control trial of 34 patients in the local anesthetic 
group and 35 in the local anesthetic with steroid 
group, they administered 8 mL of local anesthetic 
of 0.5% lidocaine, or 6 mL of local anesthetic with 
steroid of 80 mg of methylprednisolone. The re-
Pain Physician: Epidural Guidelines 2021 24:S27-S208
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sults showed effectiveness in both groups at the end of 
12 months. There was a superiority of steroids at the 
3-month assessment; however, this dissipated over time.
Ökmen and Ökmen (817) published a randomized, 
blinded, prospective study of efficacy of interlaminar 
epidural steroid administration in multilevel interver-
tebral disc disease with chronic low back pain in 2017. 
Their inclusion criteria were low back pain of more than 
6 months, pain unresponsive to conservative treatment 
methods, presence of MRI findings, disc bulge and pro-
trusion for the definite diagnosis of lumbar disc pathol-
ogy, the presence of nerve root compression symptoms, 
and VAS above 5. They also had significant exclusion 
criteria. They studied 98 patients with injection of 10 
mL of 0.25% bupivacaine in 50 patients and bupivacaine 
and steroid in 48 patients receiving 10 mL of 0.25% bu-
pivacaine in addition to 40 mg of methylprednisolone 
with all procedures performed at L4/5 intervertebral 
space in prone position under the guidance of C-arm 
fluoroscopy. They treated patients with a second epi-
dural injection if they did not exhibit 50% reduction in 
VAS score on day 15. Results showed a statistically sig-
nificant difference between the groups in the VAS and 
ODI scores measured at 3, 6, and 12 months between 
the groups less than 0.05. The VAS and ODI scores were 
higher in the local anesthetic group compared with the 
steroid group at all time points. They also showed that 
patients requiring a second injection did not show any 
significant difference between the groups. Overall, this 
is a well-designed study and showed effectiveness of 
local anesthetic mixed with steroids. Further, this is the 
first study utilizing the interlaminar approach showing 
effectiveness of mixture with bupivacaine in contrast to 
lidocaine (58,759,762,765,797,799,801).
Friedly et al (278,818) conducted a large study with 
a poor and complicated design, which was not practical, 
with high volume glucocorticoid steroid injection, but 
low volume lidocaine alone injections. They provided 
interlaminar epidural injections with lidocaine of 1-3 
mL, 0.5% to 1%, whereas either interlaminar or trans-
foraminal epidural injections with 1-3 mL of 0.25% to 
1% of lidocaine. In addition to this, glucocorticoid was 
added in rather high doses in the group for glucocorti-
coid as much as 60-120 mg of triamcinolone, 6-12 mg of 
betamethasone, and 60-120 mg of methylprednisolone. 
There was no equivalency in these doses. Administra-
tions were highly variable based on practice patterns. 
There was a total of 200 patients in each group. Howev-
er, the interlaminar approach with lidocaine alone was 
139 compared to 143 in the groups with steroids and 
61 had transforaminal lidocaine alone, whereas 57 had 
transforaminal lidocaine with glucocorticoids with ex-
tremely high doses. The study period lasted 6 weeks. The 
authors failed to assess the most common parameter, 
i.e., 50% improvement, with pain and physical function 
and the proportion of the patients. After 6 weeks, the 
analysis was performed. without separation of inter-
laminar and transforaminal and with a large crossover 
of the patients. Thus, it became an observational study. 
Further, repeat injections were very infrequent. During 
the first 6 weeks, only 76 patients (38%) in lidocaine 
alone group, and 80 patients (40%) in corticosteroid 
plus lidocaine group received a second injection. None 
of them received 3 injections (818). It is not a practical 
approach. In addition, during 6 to 12 weeks, 91 patients 
(47.2%) in the lidocaine alone group received one injec-
tion and 26 patients (13.5%) received 2 injections, while 
none received 3 or more. During the same period, in the 
corticosteroid and lidocaine groups, 67 patients (34.7%) 
received one injection and 28 or 14.5% received 2 injec-
tions. Finally, from 12 weeks to 12 months, over 66% 
did not receive any additional injections (278). Only 12, 
or 6.6%, in the lidocaine alone group, and 16.4%, or 
31, in the corticosteroid plus lidocaine group received 
one additional injection, while 12.6% and 13.8%, with 
lidocaine alone or lidocaine with steroids, respectively, 
received 3 or more injections. Overall, very few patients 
received more than 3 injections. This is not a common 
practice. Generally, responsive patients receive one in-
jection once in 3 months, that is at least 4 injections if 
they are not responding in the therapeutic phase, and 
2 to judge in the diagnostic phase. Further, analysis was 
not very clear. There was no analysis performed using 
the proportion of patients obtaining 50% or greater re-
lief. Further, there was no analysis separately provided 
for lumbar interlaminar epidural injections compared 
to transforaminal epidural injections. They also re-
ported significant side effects because of the high dose 
of steroids in the steroid group. Based on the strictest 
criteria, this manuscript did not meet inclusion criteria. 
However, to avoid criticism, this manuscript was utilized 
in the analysis, which essentially showed similar effec-
tiveness with lidocaine alone or lidocaine with steroids 
and significant effectiveness from baseline to follow-up 
periods utilizing mean improvement with leg pain in-
tensity and disability index. Overall, despite a multitude 
of issues related to the study, this can be considered 
to be a positive study which shows lidocaine alone is 
also effective, similar to with steroids, and also provides 
basis that it is not a placebo. Finally, their conclusion 
www.painphysicianjournal.com  S99
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was that epidural injections of corticosteroid plus lido-
caine offered no benefit from 6 weeks to 12 months 
beyond that of injection of lidocaine alone. Further, 
they also opined that repeated injections of either type 
offered no additional long-term benefit if injection in 
the first 6 weeks did not improve pain. While this was 
affirmed by Manchikanti et al in multiple manuscripts 
(759,762,765,797,799,801,844), lack of effectiveness 
was contradictory. If they consider a 2-point change in 
leg pain intensity as a significant difference and their 
results showed that leg pain intensity was reduced by a 
minimum of 2.2 ± 2.9 to 2.9 ± 3.1, the study presented a 
successful outcome rather than a lack of outcome with 
similar effects of lidocaine alone and lidocaine with 
steroids. This study also received extensive importance 
being published in the New England Journal of Medi-
cine and also AHRQ funded. However, it also received 
substantial criticism in a full manuscript publication 
(844) and letters to the editor (845-848).
Candido et al (843) assessed the correlation of pain 
relief with concordant pressure paresthesia during 
parasagittal interlaminar lumbar epidural injections 
with local anesthetic alone or with local anesthetic and 
steroids with 53 patients randomized to each group. Pa-
tients were administered 120 mg of methylprednisolone 
acetate, combined with preservative free lidocaine, and 
normal saline with a total volume of 4 mL. They showed 
effectiveness of steroid mixed with local anesthetic with 
lateral parasagittal interlaminar approaches in 55% of 
the patients at one-year follow-up with pain and func-
tion. The results were superior in the parasagittal group 
with pain relief, disability, and opioid intake.
Pandey (769) studied a comparison of caudal, trans-
foraminal, and interlaminar routes in a randomized 
trial. However, the number of patients were unevenly 
distributed with 82 patients treated by the caudal 
route, 40 by the transforaminal route, and 18 by the 
interlaminar route. One of the disadvantages in this 
study is disproportionate randomization with a small 
proportion of patients in the transforaminal group 
showing significant improvement and therefore may 
not be statistically or clinically significant. Outcome 
scores were calculated at 6 month and one year and 
the effectiveness of medication was calculated for each 
route. All patients were treated with methylpredniso-
lone 80 mg in 2 mL. The steroid was mixed with normal 
saline, 26 mL, plus 2% xylocaine 2 mL for the caudal 
route, 2% xylocaine 4 mL for the interlaminar route, 2% 
xylocaine 1 mL for the transforaminal route. However, 
the volume was high for caudal route procedures. The 
results showed, at one year, average JOA scores of 15.39 
baseline changing to 24.02 for caudal, 15.57 to 26.55 for 
transforaminal, whereas for interlaminar, it was 15.33 
to 24.72. The rate of improvement was 50% to 100% 
in 74% of the patients in the caudal group, 78% in the 
interlaminar group, and 90% in the transforaminal 
group. Analysis showed significantly more effectiveness 
of transforaminal than caudal and interlaminar routes 
at both 6 months and one year after injection. However, 
no significant difference was seen between the caudal 
and interlaminar routes. The manuscript did not provide 
the number of injections in any of the groups.
Kamble et al (770) in an RCT of comparison of 
transforaminal epidural, lumbar interlaminar epidural, 
and caudal epidural steroids included 90 patients with 
30 patients in each group. Even though the manuscript 
stated that all patients were followed up to 12 months 
and the results were compared using change in VAS and 
ODI, the published results, in fact, were only up to 6 
months. In the transforaminal group, the patients were 
given 40 mg of triamcinolone acetate with 1 mL of bu-
pivacaine and 2 mL of lignocaine at each level. For the 
interlaminar epidural injections, they provided 40 mg of 
triamcinolone acetate with 1 mL of bupivacaine and 1 
mL of lignocaine in a dilution of 10 mL of normal saline. 
Similarly, for caudal epidural injections, they injected 40 
mg of triamcinolone acetate with 1 mL of bupivacaine 
and 2 mL of lignocaine in a dilution of 10 mL of nor-
mal saline. A maximum of 3 injections were used per 
patient with a minimum interval of 2 weeks between 
subsequent injections. The results showed significant 
change at 6-month follow-up of VAS for transforaminal 
from 7.1 ± 0.7 to 2.6 ± 0.7, and for interlaminar from 
7.0 ± 0.7 to 3.4 ± 1.4. For caudal, the VAS was 7.2 ± 0.6 
at baseline, which reduced to 3.5 ± 1.0. Two patients 
in the transforaminal group and 3 patients in each of 
the interlaminar and caudal groups underwent surgi-
cal intervention with a change from 6.672% to 10%. 
It would have been interesting to see their results at 
one year; however, these were not available. There 
was no significant difference between interlaminar and 
caudal epidural steroids. However, transforaminal was 
judged to be superior for both short and long-term as 
compared to interlaminar and caudal epidural steroid 
injections for a single level disc prolapse.
Ackerman and Ahmad (783) compared caudal, in-
terlaminar, and transforaminal epidural injections. They 
reported similar efficacy for caudal and transforaminal 
injections, but superiority for transforaminal in mid-
term results in a small, moderate-quality trial.
Pain Physician: Epidural Guidelines 2021 24:S27-S208
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In a study that received widespread attention, but 
failed to meet inclusion criteria, Carette et al (827) report-
ed that at 3 months neither normal saline nor saline with 
depo-methylprednisolone injected in the lumbar epidural 
spine was effective, despite some initial improvement 
reported with the saline and steroid injection. Their meth-
odology and conclusions have been criticized (849-852).
8.5.1 Evidence Synthesis 
Based on the available studies, qualitative and 
quantitative analysis was performed. Qualitative analy-
sis data was derived from the data from this assessment. 
Quantitative analysis data was derived from a multitude 
of previous systematic reviews, which included conven-
tional dual-arm analysis and single-arm analysis. Of the 
13 studies included in this assessment (278,617,769,770
,783,797,799,801,804,817,818,821,823,843), there were 
no placebo-controlled trials meeting the inclusion crite-
ria. Among these, 4 studies assessed the role of epidural 
procedures with local anesthetic with or without steroid 
(797,804,817,823). One study (799) exclusively included 
central spinal stenosis with interlaminar epidural injec-
tions with local anesthetic with or without steroids. One 
study (801) was performed in axial or discogenic pain 
with local anesthetics or local anesthetics with steroids 
in axial or discogenic pain after eliminating facet joint 
pain, as well as sacroiliac joint pain. Eight of the 14 
studies were comparative analysis with interlaminar 
compared to transforaminal epidural injections (617,7
69,770,783,818,821,823,843). Among these, 3 studies 
(769,770,783) studied and compared all 3 modalities 
including caudal, interlaminar, and transforaminal epi-
dural injections. Four (278,617,818,821,843) compared 
interlaminar with transforaminal epidural injections. 
All of them included disc herniation patients except for 
Friedly et al (278,818), including only patients suffering 
with spinal stenosis. All the studies evaluating disc her-
niation without other modality of treatment showed 
positive results. One of these studies had 24-month 
follow-up and all others had at least one year follow-up. 
While all the studies utilized lidocaine with or without 
steroids, Ökmen and Ökmen (817) utilized bupivacaine 
instead of lidocaine. The comparative studies showed 
generally superiority of transforaminal epidural injec-
tions over interlaminar epidural injections in managing 
disc herniation. With central stenosis, overall, 3 studies 
were identified. The first study by Manchikanti et al 
provided a 24-month follow-up with 120 patients in a 
randomization of 60 patients in each group showing 
positive results at 24 months with repeat injections. 
Friedly et al (818) showed inconclusive results in a poorly 
designed and performed trial despite its publication in 
New England Journal of Medicine and AHRQ funding. 
Based on these high and moderate quality studies, the 
level of evidence is Level I for disc herniation with strong 
recommendation, Level II for spinal stenosis with moder-
ate to strong recommendation, Level II for axial or disco-
genic pain with moderate to strong recommendation. 
Multiple systematic reviews have been performed 
assessing lumbar interlaminar epidural injections. The 
focus has been either on transforaminal or lumbar in-
terlaminar epidural injections. Overall, the results have 
been positive except in reviews of inappropriate analy-
sis. Manchikanti et al (75-77,81), Knezevic et al (58), and 
Kaye et al (60) performed analysis separating into cau-
dal, interlaminar, and transforaminal epidural injections 
with evidence levels of I to II based on the RCTs. 
Appropriately performed cost utility analysis also 
showed lumbar interlaminar epidural injections to be 
cost effective within the range of multiple interven-
tional techniques and significantly better than surgi-
cal interventions at 2-year follow-up (853). However, 
inappropriately performed cost utility analysis showed 
lack of cost effectiveness (854). Manchikanti et al (853) 
performed cost utility analysis of lumbar interlaminar 
epidural in the treatment of lumbar disc herniation, 
central spinal stenosis, and axial or discogenic low back 
pain in 360 patients with 3 RCTs, with a total estimated 
cost including direct and indirect costs of $3,425 for disc 
herniation, $3,527 for axial or discogenic pain without 
disc herniation, $2,961 for central spinal stenosis, and 
an overall average cost for lumbar interlaminar epidural 
injections of $3,301 respectively. 
8.6 Lumbar Transforaminal Epidural Injections
Lumbar transforaminal epidural injections’ 
effectiveness were evaluated in 43 studies (273-
276,617,618,660,662-664,666,699,700,783,820,821,855-
881). After application of inclusion criteria with fluoro-
scopic guidance, 6-month follow-up with reporting of 
appropriate outcomes, 13 RCTs met inclusion criteria (2
73,276,617,769,770,783,818,821,856,857,860,879,881). 
Methodologic quality assessment was performed utiliz-
ing Cochrane review criteria as shown in Appendix Table 
9 and IPM-QRB criteria as shown in Appendix Table 10. 
Table 14 shows the descriptive characteristic features of 
included studies. Evaluation with both Cochrane and 
IPM-QRB criteria, 9 were high-quality (273,276,617,77

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Karppinen et al (856) conducted a high-quality 
study as graded by both Cochrane and IPM-QRB criteria. 
Their study looked at the efficacy of a single injection 
of either sodium chloride solution or local anesthetic 
with steroid. They followed patients for up to one year. 
Patients who received sodium chloride fared better at 
3 months and 6 months, but there was no significant 
difference at one year. However, in a subgroup analy-
sis (882), they reported that in patients who had disc 
protrusions, local anesthetic with steroid had a better 
efficacy than just sodium chloride. There has been 
significant related criticism (883,884). In addition, Karp-
pinen et al (882) also calculated cost effectiveness of 
periradicular infiltration for sciatica based on subgroup 
analysis of an RCT. Obviously, these types of assessments 
never yield appropriate cost effectiveness results. 
Manchikanti et al (860) conducted an active control 
trial that followed 120 patients for 2 years. They used 
an infraneural approach, injecting either local anes-
thetic alone or local anesthetic with steroid. At the end 
of the 2-year study period, 65% of those who received 
local anesthetic alone and 57% who received local an-
esthetic with steroid had significant improvement in all 
measured categories: pain intensity, function, and med-
ication reduction. A subcategory analysis of patients 
who responded to the treatment—determined as those 
who had at least a 50% improvement in pain and func-
tion for 3 weeks with the first 2 injections—reported 
that 80% of those who received local anesthetic alone 
saw improvement and 73% of those who received local 
anesthetic with steroid saw improvement.
Tafazal et al (881) conducted a study on spinal 
stenosis and disc herniation treated either with local 
anesthetic alone or local anesthetic with steroid. Only 
disc herniation inclusion criteria were met. Superior re-
sults were reported for sciatica with similar efficacy for 
local anesthetic alone and local anesthetic with steroid.
Cohen et al (876), in a seemingly flawless study, as-
sessed epidural steroid injections compared to gabapen-
tin for lumbosacral radicular pain. However, the study 
had numerous flaws including using a safe triangle 
approach when injecting particulate steroids, a flawed 
design and analysis of the data, and an inordinately 
high proportion of patients who withdrew from the 
study even at the 3-month follow-up (632,633,885,886). 
Consequently, the study was excluded. The inclusion cri-
teria were also extremely weak with some patients who 
had less than 3 months of pain and some who had 3 to 
6 months. The gabapentin dosage was higher than usu-
ally administered in clinical settings at 1800 to 3600 mg 
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per day without proven efficacy (211). Overall, this trial 
showed no significant improvement in either group.
Ghahreman et al’s (274) follow-up period was even 
shorter - only one month. Their study was also small but 
included multiple arms. Consequently, the study was 
excluded. They reported that local anesthetic with ste-
roids was vastly superior to local anesthetic alone: 54% 
improvement versus only a 7% improvement. This study 
also had an arm that received a true placebo—sodium 
chloride solution injected away from the nerve root. 
They reported a lack of efficacy for this placebo, but 
when one study arm was injected with sodium chloride 
into the source of pain, there was a significant effect, 
though not as great as local anesthetic with steroids.
In a small study by Riew et al (275,276), patients 
with disc herniation were injected either with local 
anesthetic alone or local anesthetic with steroid. Their 
outcome measure was avoidance of surgery; 33% of 
those in the local anesthetic alone group and 71% in 
the local anesthetic with steroid group avoided surgery. 
While both treatments were deemed effective, local 
anesthetic with steroid was deemed superior.
The remaining trials were of an active control 
nature with Vad et al (879) comparing transforaminal 
epidural injections with local anesthetic with steroid 
with trigger point injections, demonstrating an over-
whelming superiority for transforaminal epidural injec-
tions; however, this was a moderate quality trial, barely 
meeting inclusion criteria. Ackerman and Ahmad (783) 
compared caudal, interlaminar, and transforaminal ap-
proaches which showed transforaminal to be superior 
to interlaminar and caudal; however, this was a small 
trial with only a 6-month follow-up; it was also of 
moderate quality. Jeong et al (857) compared a gangli-
onic and pre-ganglionic approach in a large population; 
however, with only a 6-month follow-up, no significant 
difference was shown between pre-ganglionic and gan-
glionic approaches. Similarly, Park et al (618) assessed 
the role of transforaminal epidural injections using a 
supraneural approach, otherwise known as a safe tri-
angle approach, comparing it to the Kambin triangle 
approach. This was a relatively small study showing no 
significant difference between both approaches at 3 
months, not included in evidence synthesis. Rados et al 
(821) and Ghai et al (617) compared interlaminar epi-
dural injections with transforaminal, while Rados et al 
(821) utilized a standard epidural injection technique; 
Ghai et al (617) utilized a parasagittal interlaminar 
approach. Rados et al (821) showed the superiority of 
transforaminal in a small study and they (617) showed 
no significant difference with a parasagittal approach 
compared to a transforaminal approach.
As described in the section on interlaminar epidural 
injections, Friedly et al (818) conducted an inappropriate 
and flawed assessment combining lumbar interlaminar 
epidural injections with lumbar transforaminal epidural 
injections. There were multiple flaws in the design as 
well as the analysis leading to an inappropriate inter-
pretation and conclusions (844).
In one trial (273), transforaminal epidural injec-
tions were compared with particulate versus nonpar-
ticulate corticosteroids. Comparative effectiveness of 
transforaminal with particulate versus nonparticulate 
corticosteroid showed effectiveness of triamcinolone 
and dexamethasone with pain relief and improvement 
in functional status up to 6 months, without clear differ-
ences between groups. 
Among the newer studies (769,770), Pandey (769) 
assessed the efficacy of epidural steroid injection in 
management of lumbar prolapsed intervertebral disc in 
comparative evaluation with caudal, interlaminar, and 
transforaminal approaches. They included a total of 
140 patients with randomization into 3 groups with 80 
patients using the caudal approach, 40 patients by the 
transforaminal approach, and 8 patients with interlami-
nar approach by a simple randomization; however, this 
randomization is not uniform. Utilizing JOA scores they 
calculated the improvement at 6 months and one-year 
and effectiveness of the medication for each route. Their 
results showed that one-year after injecting the steroid, 
all three routes were found to be effective in improving 
JOA scores with caudal route showing improvement in 
74.3%, interlaminar showing improvement in 77.7%, 
and transforaminal route in 90%. They also showed that 
the transforaminal route was significantly more effec-
tive than caudal and interlaminar at both 6 months and 
one-year after injection. No significant differences were 
seen between the caudal and interlaminar approaches. 
The limitations of this study include unequal randomiza-
tion and lack of data showing significant improvement.
Kamble et al (770) studied 90 patients randomized 
to 3 groups with approaches of caudal, interlaminar, and 
transforaminal with randomization with 30 patients in 
each group in a single level disc prolapse patients con-
firmed by MRI. They followed the patients for 12 months 
and the results were compared using change in VAS 
score and ODI; however, they presented only 6-month 
results. Their results showed the change in pain scores 
were statistically different at 1- and 6-month intervals 
such as that a higher change was observed by trans-
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foraminal route as compared to the other two. There 
was no difference in the change of scores between in-
terlaminar and caudal routess. For ODI scores, a greater 
change was seen in transforaminal at all times as com-
pared to the other 2. There was no difference in change 
of scores between interlaminar and caudal route at any 
time of the assessment. The VAS scores changed from 
7.1 to 2.6 at 6-month follow-up in the transforaminal 
group compared to 7.0 to 3.4 in the interlaminar group, 
and 7.2 to 3.5 in the caudal group. Similarly, ODI scores 
changed from 37.7 to 16.8 in the transforaminal group 
compared to 36.9 to 21.4 in the interlaminar group and 
38.3 to 21.9 in the caudal group. Overall, these results 
showed positive results; however, as shown above, 
positive results with transforaminal being superior, but 
the 12-month results were not published and also 50% 
relief criteria was not performed.
While the studies considered here concen-
trated on steroids, there is also significant literature 
on tumor necrosis factor alpha (TNF-α) inhibitors 
(660,662,666,861,863,865,887-890). 
Freeman et al (863) performed a randomized, dou-
ble-blind, placebo-controlled trial of transforaminal epi-
dural TNF-α for the treatment of symptomatic lumbar 
disc herniation. They included 49 subjects with lumbosa-
cral radicular pain secondary to lumbar disc herniation 
and treated them with either TNF-α or placebo. Inclu-
sion criteria were lumbosacral radicular pain secondary 
to lumbar disc herniation and an average leg pain inten-
sity of 5/10 or more. Patients received 2 transforaminal 
epidural injections, 2 weeks apart, and were assessed 
for efficacy up to 26 weeks for the second injection. 
The primary outcome measure was the change in mean 
daily worse leg pain. They utilized multiple outcome 
measures. The results showed transforaminal epidural 
injection was carried out with the injection of 2 mL of 
injectate. The injectate was variable, ranging from 0.5 
mg, 2.5, 12.5 mg of etanercept, and placebo. Essentially, 
there were 12 patients in each group, except for 2.5 mg 
of etanercept group, where there were 13 patients. The 
results showed that 43 of the 49 randomized patients 
completed the study. Patients receiving 0.5 mg of etan-
ercept showed a clinically and statistically significant 
reduction in mean daily worst leg pain compared with 
the placebo cohort from 2 to 26 weeks for both the per 
protocol population and the intention-to-treat analysis. 
Fifty percent of these subjects reported 100% reduction 
in worst leg pain at 4 weeks post treatment compared 
with 0% subjects in the placebo cohort. Improvement 
in all secondary outcomes were also observed in the 0.5 
mg etanercept cohort. The overall incidence of adverse 
events was similar in placebo and all etanercept cohorts. 
Improvement was seen in all groups; however, the best 
results were obtained in 0.5 mg etanercept group, 
rather surprisingly.
Dagar et al (865) in a study of transforaminal epi-
dural etanercept followed the patients for 2 months 
with injection of 2 transforaminal epidural injections 
of etanercept, 2 mg, 2 weeks apart, assessing the effi-
cacy up to 3 months after the second injection. Results 
showed 31 of 33 enrolled patients completed the study 
and showed clinically and statistically significant reduc-
tion in VAS for leg pain and back pain and ODI.
Cohen et al (660) performed transforaminal 
epidural injection of etanercept with 3 groups of 6 
patients who received etanercept in escalating doses. 
Two patients in each group received sham saline injec-
tion. They also conducted concurrent animal studies 
to assess the histologic changes and functional deficits 
in beagle dogs treated with perineural transforaminal 
etanercept. Clonidine was safety tested extensively, 
and only after these studies demonstrated no histo-
logical damage or neurologic deficits, open-label and 
prospective trials conducted, ultimately resulting in 
the FDA approval for epidural administration in cancer 
neuropathic pain (887,888). After the initial phase of 
this epidural etanercept study the authors were advised 
of the need for investigational new drug requirement 
for nonfood drug administration approved drugs for 
neuraxial administration. The human study was tempo-
rarily halted until the patients who had been studied 
to date received MRI showing absence of pathology, 
and screening MRI procedures were then mandated for 
subsequent patients. Since then, multiple other studies 
have been conducted. Cohen et al (660) did not show a 
dose response relationship with increasing doses of the 
active agents as others. However, this aspect is troubling 
because the mechanism of binding and inactivation of 
TNF-a suggests that there should be a dose response. 
There was very little difference in ODI numerical im-
provement, particularly in the higher dose etanercept 
group as compared to saline.
Other studies included intravenous administra-
tion of etanercept (662). Some included short-term 
follow-up, whereas a few other studies included intra-
venous administration. Okoro et al (662) in a 3-month 
follow-up with intravenous administration concluded 
that small numbers of trial participants limited the 
statistical analysis; however, they also concluded that 
the trend appears to show no benefit to the use of 
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etanercept over placebo in the pharmacological treat-
ment of sciatica. Korhonen et al (664), also adminis-
tering intravenous, with one-year follow-up showed 
the long-term results of this randomized trial did not 
support the use of TNF-α compared with placebo for 
lumbar radicular pain. A further study in a subgroup of 
patients, especially in the presence of Modic changes, 
appears to be warranted. Ohtori et al (666) studied 
transforaminal approach and provided only 2 weeks of 
follow-up, comparing with dexamethasone. They con-
cluded that epidural administration with only 2 weeks 
of administration TNF-a inhibitor into the spinal nerve 
produced pain relief. 
Wei et al (861) compared lidocaine with steroids 
and lidocaine with TNF-α inhibitor in the treatment of 
lumbar stenosis. In this RCT, they included 30 patients in 
each group and also followed them through 6 months. 
Overall results showed significant improvement in 
patients receiving lidocaine and TNF-α inhibitor with 
VAS and the disability index. There was no significant 
difference in the groups with lidocaine with steroids 
(Diprospan) or lidocaine only groups. 
Overall, it appears that TNF-a inhibitor drugs may 
have an effect in lumbar radicular pain. In an edito-
rial, Huntoon (887) reviewed pre-clinical and clinical 
evidence of TNF-a inhibitor. It appears that there may 
be a role for TNF-a blockers in managing radicular pain. 
The risk may be that the FDA has a Black Box Warn-
ing placed in May 2008, because of the potential for 
several adverse occurrences. Thus, the use of etanercept 
must be weighed against these risks (anaphylaxis, im-
mune deficiency, sepsis, tuberculosis, reactivation or 
novel infection), and the rare possibility of lymphoma. 
To understand the true incidence of infections of the 
neuraxis would likely require thousands of applications 
of these drugs over many years to compare them to ste-
roids (887). Further, the high incidence of radicular pain 
worldwide mandates a safe therapy, because of the po-
tential for high incidence of sciatica worldwide and also 
high incidence of high prevalence of epidural injections 
in the elderly which mandates a safe therapy. Thus, 
many trials have to be shown to be safe and effective. 
Huntoon (887) raised the possibilities of issues related to 
inadvertent injection into a radicular artery. The authors 
thus far do not comment on these issues. Further, all 
of them utilized supraneural approach, which is prone 
to causing intraarterial injections. Consequently, it is 
strongly cautioned against attempting to inject etan-
ercept until further studies have been performed. In 
addition, cost is also a major factor.
8.6.1 Evidence Synthesis 
The evidence was synthesized based on qualita-
tive and quantitative analysis. Qualitative analysis was 
performed based on present assessment, whereas quan-
titative analysis was utilized from previous systematic 
reviews, which included conventional dual-arm and sin-
gle-arm analysis in multiple manuscripts. In this analysis, 
with the inclusion of 13 RCTs (273,275,617,769,770,783
,818,821,856,857,860,879,881), there was only one RCT 
utilizing sodium chloride solution (856), which was con-
sidered as placebo even though there are a multitude of 
questions in relation to injecting sodium chloride solu-
tion over an active structure (56). The remaining were 
all active-controlled trials. Consequently, a total of 12 
of 13 studies focused on disc herniation with transfo-
raminal epidural injections. Friedly et al (278,818) stud-
ied central and foraminal spinal stenosis. Other studies 
were comparative analysis between lumbar interlami-
nar and transforaminal epidural injections or caudal, 
interlaminar, and transforaminal epidural injections or 
preganglionic and postganglionic approaches or com-
parative analysis among the drugs with dexamethasone 
and triamcinolone (273,617,843) and all 3 approaches 
were utilized (699,700,783). In disc herniation, among 
the 5 RCTs included, the only trial which is considered 
as placebo-controlled has shown lack of effectiveness 
even though in subgroup analysis, they felt it was ef-
fective and also they performed cost utility analysis. The 
remaining 4 trials (275,860,879,881) showed positive 
results. The larger studies by Manchikanti et al with 
120 patients and 24-month follow-up showed positive 
results at 24 months (860). However, these results were 
not superior to interlaminar epidural injections or caudal 
epidural injections (614). Tafazal et al (881) in studying 
150 patients with radiculitis secondary to disc herniation 
or spinal stenosis showed positive results with no signifi-
cant difference with local anesthetic alone or with local 
anesthetic and steroid. Vad et al (879) in a moderate 
quality study showed positive results with a 12-month 
follow-up in 50 patients receiving transforaminal epidur-
al injections. Further, multiple other studies comparing 
interlaminar and transforaminal in disc herniation also 
showed positive results (617,699,700,783,841,857). The 
quantitative analysis and previous systematic reviews 
also showed positive evidence. Consequently, the evi-
dence for transforaminal epidural injections in lumbar 
disc herniation is Level I with strong recommendation.
Riew et al (275) in a small study of 55 patients uti-
lized bupivacaine alone or bupivacaine with steroids to 
assess the avoidance of surgery. They showed that 71% 
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of the steroid group chose not to have to surgery and 
33% of bupivacaine group not to have surgery. Overall, 
bupivacaine with steroids were effective even though 
bupivacaine alone was not effective. 
For spinal stenosis, Friedly et al (818) performed 
a poorly designed and executed study with negative 
results for transforaminal epidural injections. Tafazal et 
al (881) also studied spinal stenosis, along with disc her-
niation in a total of 150 patients with 64 patients with 
spinal stenosis. They also showed positive results with 
local anesthetic, as well as steroids. However, there was 
no significant difference between steroid and local an-
esthetic. Consequently, the level of evidence is Level IV 
to III with moderate recommendation of transforaminal 
epidural injections in managing central spinal stenosis. 
One study (273) also evaluated the role of dexa-
methasone versus triamcinolone showing equivocal re-
sults in a relatively small study without local anesthetic. 
One study (857) compared ganglionic and preganglionic 
approaches with a 6-month follow-up showing the ef-
fectiveness of both approaches. The studies comparing 
interlaminar epidural injections with transforaminal 
(617,699,700,783,821) showed either equivalent im-
provement or superiority of transforaminal epidural 
injections in managing disc herniation. Thus, overall 
evidence is Level III with moderate to weak recommen-
dation for transforaminal epidural injections for disc 
herniation over lumbar interlaminar or caudal epidural 
approaches. 
Multiple systematic reviews also have been per-
formed assessing lumbar transforaminal epidural injec-
tions. Overall, the results have been positive except in 
reviews with inappropriate analysis.
8.7 Percutaneous Adhesiolysis
Literature search for percutaneous adhesiolysis in 
the lumbar spine yielded a total of 29 studies (891-919) 
and 9 RCTs (891-901) meeting inclusion criteria. 
For this analysis, we also utilized observa-
tional studies for post-lumbar central spinal stenosis 
(908,910). There were 6 RCTs of post-surgery syn-
drome (893,894,896-899,901), 2 RCTs of spinal stenosis 
(891,892,900), and only one RCT assessing disc herniation 
(895). Appendix Table 11 shows Cochrane review criteria 
for RCTs. Appendix Table 12 shows IPM-QRB criteria for 
RCTs, whereas Appendix Table 13 shows IPM-QRBNR 
for nonrandomized or observational studies. Table 15 
shows characteristic features of various randomized and 
nonrandomized studies in assessing effectiveness data.
Manchikanti et al (72) performed a systematic 
review and meta-analysis of the effectiveness of percu-
taneous adhesiolysis in managing post-lumbar surgery 
syndrome and showed Level I or strong evidence with 
inclusion of 6 RCTs (893,894,896,897,901,902) and 4 
observational studies (903-906), with 7 of the studies 
providing results of at least 12 months of follow-up. All 
of the studies included in the analysis showed positive 
results. The randomized trials assessing response rate 
based on significant improvement of 50% pain relief 
and functional status have shown 70% (893,894) and 
72% (897) of the patients with significant improve-
ment at 1-year follow-up, and 88% at 2-year follow-up 
(893,894). Other studies also have shown significant 
improvement (903,906). Meta-analysis also showed sig-
nificant improvement with percutaneous adhesiolysis in 
comparison with epidural injections and with a single-
arm meta-analysis for the active control studies.
Manchikanti et al (73) also performed a system-
atic review and meta-analysis with inclusion of 2 RCTs 
(891,892,900) and 4 observational studies (892,908-910) 
with Level II or moderate evidence in the systematic re-
view and meta-analysis. The primary outcome or hard 
endpoint was the proportion of patients with 50% pain 
relief and improvement in functionality, whereas sec-
ondary outcome measures, or soft endpoints, were pain 
relief and/or improvement in functionality. The positive 
results were observed from all the studies included in this 
analysis, even though balloon inflated catheters showed 
superior results compared to catheter adhesiolysis. Among 
the randomized trials, one randomized trial (891,892) as-
sessing response rate based on significant improvement of 
50% pain relief and functional status has shown a success 
rate of 76% at 12 months, compared to 4% in the caudal 
epidural group. The second RCT (900) with only 6-month 
followup available comparing catheter-based adhesiolysis 
with inflatable balloon catheter showed superior results 
with the balloon inflatable catheter. Further, among the 
observational studies, one study followed the patients for 
24 months with a 71% improvement rate. Surprisingly 
enough, in this systematic review, superior results were 
observed in appropriately conducted long-term studies 
(891,892). Single arm meta-analysis also showed signifi-
cant improvement from baseline with 38% improvement 
of pain relief and 30% improvement of functional status 
overall combining all the studies. Further, the available 
data shows superior results when significant improvement 
was utilized as the primary outcome parameter at 12 
months as well as 24 months in over 70% of the patients. 
All the studies had at least 12 months of appropriate out-
comes available. 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In reference to disc herniation, multiple studies 
have been performed; however, there has been only 
one high-quality randomized, double-blind, placebo-
controlled trial (895). Other studies (897-899) also in-
cluded a small number of patients with disc herniation. 
None of the observational studies met inclusion criteria. 
Gerdesmeyer et al (895) performed the trial in pa-
tients with chronic radicular pain lasting longer than 4 
months, which failed to respond to conservative treat-
ment. After screening 381 patients, 90 patients were 
enrolled. They were randomly assigned to receive either 
percutaneous neurolysis or placebo with concealed al-
location. The primary outcome measure was differences 
in percentage of change of ODI scores 3 months after 
intervention. Secondary outcome measures were differ-
ence in percent change of ODI scores and VAS at 6 and 
12 months after intervention and success rates defined 
as at least 50% reduction in ODI and VAS scores (mean 
change from baseline) at 3, 6, and 12 months after 
treatment. With strict criteria, they also used extensive 
statistical analysis. The methodology included a 3-day 
lysis procedure in both groups. The lysis procedure was 
performed with adhesiolysis and following the place-
ment of the catheter with injection of 10 mL of 0.25% 
bupivacaine through the catheter followed by 10 mL 
of preservative free saline containing 150 units per mL 
of hyaluronidase, saline (10 mL 10%) containing 40 mg 
of triamcinolone being injected slowly along with 2 mL 
of 0.25% bupivacaine. The catheter was left in place 
and on each of the next 2 days, 10 mL of 0.25% bu-
pivacaine was injected through the catheter, followed 
by the slow injection of 10 mL of 10% saline and 2 mL 
of 0.25% bupivacaine, then the catheter was removed. 
In the placebo group, however, a needle and catheter 
were inserted, similar to lysis group, except the needle 
was intentionally inserted so it did not enter the spinal 
canal and the catheter was inserted into the subcuta-
neous tissues overlying the effected level. Each patient 
received through the catheter 10 mL of preservative 
free saline on each of the next 2 days, then the catheter 
was removed. Subsequent to the 3 injection series, all 
subjects were prescribed physical therapy with no ac-
tivity restrictions. Patients were provided with rescue 
medication of paracetamol. The results showed the ODI 
and VAS scores, as well as the success for ODI versus 
VAS were significantly better at 3, 6, and 12 months in 
the lysis group versus the control group. The ODI in the 
lysis group improved 55.3 ± 11.6 to 26.4 ± 10.8 after 3 
months. The placebo group improved from 55.4 ± 11.5 
to 41.8 ± 14.6. In addition, VAS improved 6.7 ± 1.1 to 2.9 
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± 1.9 in the active group and from 6.7 ± 1.1 to 4.8 ± 2.2 
after placebo. Twelve-month follow-up showed further 
improvement and the differences were significant. The 
main advantages of this study have been that they truly 
utilized a placebo response by placing the catheter sub-
cutaneously without entering the spinal canal. Twelve-
month outcomes showed 50% improvement in VAS in 
69% of patients in the placebo group and 94% of the 
patients in the lysis group, whereas, ODI greater than 
50% improvement was seen in 35% of the patients in 
the placebo group and 90% of the patients in the lysis 
group with significant differences as shown in Table 16. 
8.7.1 Evidence Synthesis 
Evidence synthesis in this manuscript was derived 
from qualitative and quantitative analysis. Qualitative 
analysis was performed based on the present assess-
ment, whereas quantitative analysis was utilized from 
previous systematic reviews, which included conven-
tional dual-arm and single-arm analysis in multiple 
manuscripts. In the present analysis 6 RCTs assessed the 
role of adhesiolysis in post-lumbar surgery syndrome 
(893,894,896-899,901). All studies were subjected to 
conventional dual-arm and single-arm analysis by 
Manchikanti et al (72). There was one study with 2-year 
follow-up (893,894) showing short-term and long-term 
effectiveness of adhesiolysis on post-lumbar surgery syn-
drome in 82% of the patients in the adhesiolysis group 
with multiple procedures. The 5 RCTs assessed patients 
for one-year (893,894,897,898,899,901), and all of them 
showed positive results with short-term and long-term 
improvement. One trial (896) provided only 6 month 
relief showing short-term improvement. Thus, evidence 
for lumbar post-surgery syndrome is Level I with strong 
recommendation.
In spinal stenosis, percutaneous adhesiolysis was 
studied in 2 RCTs (891,892,900) and 2 observational stud-
ies (908,910). A single study (891,892) showed positive 
results with 71% of patients responding in adhesiolysis 
group at 24-month follow-up. The results were 76% 
at end of one-year with significant improvement with 
average procedures of 6.4 per 2 years. The second RCT 
(900) compared balloon adhesiolysis with percutane-
ous adhesiolysis in 44 patients. They showed successful 
adhesiolysis in inflatable balloon group, consequently 
this study is considered as negative for percutaneous 
adhesiolysis and positive for balloon adhesiolysis. An-
other observational study with a single-arm (908), also 
showed adhesiolysis with a single combined treatment 
of balloon inflated catheter with positive results. The 
study had a small number of patients and also several 
patients were missing. The second retrospective (910) as-
sessment which included patients with spinal stenosis as 
well as post-lumbar surgery syndrome showed 45% suc-
cessful response at 6 months in 78 patients considered 
as positive. Thus, the level of evidence is considered as 
Level II with moderate to strong recommendation based 
on lack of other available treatments. 
For chronic recalcitrant disc herniation, there is one 
high-quality RCT as described here (895). Other random-
ized trials also utilized a small proportion of patients with 
chronic disc herniation (897-899). Overall the results have 
been positive in all the studies, consequently, the level of 
evidence is II with moderate to strong recommendation 
in patients with chronic disc herniation failing to respond 
to conservative modalities including epidural injections.
Cost utility analysis by Manchikanti et al (920) as-
sessing post-lumbar surgery syndrome and lumbar 
central spinal stenosis with percutaneous adhesiolysis 
showed direct costs of $2,652 for post-lumbar surgery 
syndrome and $2,649 for lumbar central spinal steno-
sis for one-year QALY. Overall costs for one-year QALY 
were $4,428.84 for post-lumbar surgery syndrome and 
Table 16. Follow-up data 3, 6, and 12 months after intervention.






ODI 41.8 ± 14.6 26.4 ± 10.8 < 0.01 **
VAS 4.8 ± 2.2 2.9 ± 1.9 < 0.01 **
> 50% improvement ODI 7/42 (17%) 26/45 (58%) < 0.01 **
> 50% improvement VAS 12/42 (29%) 31/45 (69%) < 0.01 **
Outcome of primary criteria 6 months after intervention
ODI 37.3 ± 13.1 11.9 ± 8.7 < 0.01 **
VAS 3.8 ± 1.6 1.4 ± 0.9 < 0.01 **
> 50% improvement ODI 4/37 (11%) 31/42 (74%) < 0.01 **
>50% improvement VAS 14/36 (39%) 32/42 (76%) = 0.01 **
Outcome of primary criteria 12 months after intervention
ODI 30.7 ± 14.2 9.6 ± 9.3 < 0.01 **
VAS 2.8 ± 1.5 1.2 ± 1.0 < 0.01 **
> 50% improvement ODI 9/26 (35%) 28/31 (90%) < 0.01 **
> 50% improvement VAS 18/26 (69%) 29/31 (94%) < 0.032 **
** indicate significance P < 0.05
ODI = Oswestry disability index; VAS = Visual Analog Scale
Adapted and modified with permission from: Gerdesmeyer L, et al. 
Percutaneous epidural lysis of adhesions in chronic lumbar radicular 




$4,423.83 for lumbar central spinal stenosis, which in-
cluded direct and indirect costs. 
As described earlier, Manchikanti et al (72) per-
formed a conventional dual-arm and a single-arm 
meta-analysis in post-lumbar surgery syndrome showing 
significant improvement in pain relief and ODI scores. 
Similarly, Manchikanti et al (73) in a systematic review 
and meta-analysis of spinal stenosis showed the results 
of single-arm analysis with significant improvement 
with percutaneous adhesiolysis.
8.8 Cervical and Thoracic Interlaminar 
Epidural Injections
For this analysis, cervical and thoracic interlaminar 
epidural injections were combined based on the recom-
mendation of CMS and the American Medical Associa-
tion (AMA) Current Procedural Terminology (CPT) Com-
mittee as a single region and due to the lack of multiple 
studies in the thoracic region. Our search criteria yielded 
a total of 22 studies (588,921-941) meeting the initial 
inclusion criteria. However, with elimination of nonfluo-
roscopic guided treatments and also short-term follow-
ups, a total of 7 RCTs were included in the analysis with 
6 trials in the cervical spine (922,924,925,927,932,941), 
and one trial in the thoracic spine (588). We also in-
cluded 2 observational studies (937,940) in the cervical 
spine with long-term follow-up. Appendix Table 14 
shows Cochrane criteria, Appendix Table 15 shows IPM-
QRB criteria for RCTs, whereas Table 17 shows descrip-
tive characteristics of cervical and thoracic interlaminar 
epidural injections. 
Seven randomized trials (588,922,924,925,927,932,941) 
and 2 observational studies (937,940) met the inclusion cri-
teria. Cochrane and IPM-QRB criteria graded 6 of the RCTs 
to be of high-quality (588,922,924,925,927,941) and one of 
them to be of moderate quality (932).
Manchikanti et al conducted 4 active control studies 
in the cervical spine (922,924,925,927) and one (588) in 
the thoracic spine. These studies enrolled 416 patients in 
the cervical spine and 110 patients in the thoracic spine 
and examined the use of local anesthetic alone or local 
anesthetic with steroid for the following etiologies: disc 
herniation, discogenic pain without facet joint pain, 
central spinal stenosis, and post-surgery syndrome. Only 
one study (925) had a minimum one-year follow-up and 
the other 4 had a 2-year follow-up. Both Cochrane and 
IPM-QRB criteria graded all of them as high-quality.
All 5 of these studies found there to be similar re-
sults for the efficacy of the 2 injectates in each etiology. 
These studies analyzed outcomes based on subgroups 
that were either responsive or nonresponsive to the 
treatment that was received. A responsive patient was 
one who received at least 3 weeks of 50% improvement 
with the first 2 treatments. Responsive group patients 
in all etiologies had superior outcomes. All the studies 
showed positive results achieving 68% to 80% pain re-
lief with functional status improvement. 
McCormick et al (941) published a prospective ran-
domized comparative trial of targeted steroid injection 
via epidural catheter compared to standard interlaminar 
approach for the treatment of unilateral cervical radicular 
pain at C5-6 with 76 participants. The criteria were rather 
strict with radicular pain, MRI pathology, consistent with 
clinical symptoms and signs, a numeric pain score of 4 or 
higher, nonresponsiveness of conservative therapy, but 
utilized 4-week duration of pain as the inclusion criteria. 
Procedures were performed under fluoroscopic guidance 
with injection of 2 mL of triamcinolone acetate 40 mg/mL 
diluted in 1 mL of 1% preservative free lidocaine. They had 
multiple primary and secondary outcome measures includ-
ing pain relief, NDI, and pain disability index, along with 
Global Impression of Change, daily morphine equivalent, 
and medication quantification scale (MQS) III scores. At 
one-month follow-up in the catheter and standard epi-
dural injection groups, 26 or 72% and 23 or 60% of the 
participants reported 50% or greater NRS reductions and 
a similar number reported improvement in NDI. The au-
thors did not report 50% pain relief beyond one-month; 
however, other parameters showed at 3 months and 6 
months significant reductions in pain from the baseline of 
6 to 2.5 at 3 months, 2 at 6 months in the standard group; 
whereas, it was 7 and 2 at 3 months, and 2 at 6 months 
in the targeted catheter group. NDI scores also improved 
from 21 to 15.5 at 3 months and 8 at 6 months in the 
standard intervention group compared to a baseline of 19 
with changes of 10.5 and 7.5 at 3 months and 6 months in 
the targeted catheter group. It appeared that both were 
effective, however, the targeted group tended to do bet-
ter. Further, they also reported that there was a trend of 
lower incidence of cervical spine surgery in the targeted 
group during the 6-month follow-up. 
Cohen et al (932) performed a double-blind RCT as-
sessing a conservative management group that received 
medication and physical therapy with an epidural injec-
tion group that received steroid alone and with a com-
bination group that received epidural steroids as well as 
conservative management. The study may be criticized 
for various flaws in the design as well as its analysis with 
a large number of noncompliant patients; it appears 
that patients may have done better around 3 months 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(942). Thus, the results of this trial are considered unde-
termined. Further, the authors did not provide informa-
tion on the number of injections.
Multiple observational studies are available; however, 
there were only 2 studies meeting inclusion criteria per-
formed under fluoroscopic guidance (937,940). Joswig et 
al (937) evaluated the role of repeat epidural steroid injec-
tions for cervical disc herniation. They performed cervical 
epidural injections with the interlaminar approach in 45 
patients for cervical disc herniation. They showed 30 of 
them responded and 15 showed lack of response. Among 
these, 8 of them underwent surgery, while 7 of them re-
ceived a second injection. The initial response lasted for 12 
months and a subsequent second injection response also 
lasted 12 months in almost all patients with one patient 
being lost to follow-up. The relief is somewhat superior to 
previous studies. Further, they also injected 0.5% bupiva-
caine with steroid mixture of 2 mL, which we considered as 
a risky technique in the cervical spine due to the potential 
for subarachnoid leakage of the fluid or subarachnoid 
puncture utilizing subarachnoid injection. 
The second study was by Beyaz and Eman (940) uti-
lizing fluoroscopically guided cervical interlaminar ste-
roid injections in patients with cervical pain syndromes. 
They used various types of conditions in their study 
including disc herniation, degenerative disc disease, 
and cervical spinal stenosis. Only 9 patients had stenosis 
and 26 patients had discal pathology, all others had de-
generative pathology among the 65 patients included 
in the study. In this study, the authors injected a total 
of 5 mL of 80 mg of triamcinolone acetonide with 3 mL 
of bupivacaine 0.25% into the epidural space similar to 
the other study which is considered to be risky in the US. 
They reported significant improvement in pain scores 
from before the injection to 12-month follow-up. Over-
all, 51 patients or 80% had perfect/good scores. They 
reported no complications in the study.
Among the older studies, which were not included 
in this analysis, but were included in the other previous 
analysis, Castagnera et al (929), Stav et al (930), and 
Pasqualucci et al (931) were utilized due to lack of mul-
tiple randomized trials, meeting appropriate inclusion 
criteria of 50 patients. The patients included were 24 by 
Castagnera et al (929), 42 by Stav et al (930), and 40 by 
Pasqualucci et al (931). Overall, all 3 trials showed positive 
results either comparing local anesthetic with steroids or 
steroid plus morphine (929) with steroid plus morphine 
showing positive results. Stav et al (930) compared local 
anesthetic with steroids to intramuscular steroid and the 
epidural local anesthetic with steroids injection group 
showed positive results. Pasqualucci et al (931) assessed 
bupivacaine with methylprednisolone acetate, compar-
ing single versus continuous infusion groups with signifi-
cant improvement in both groups, with the continuous 
improvement group showing better results.
8.9 Evidence Synthesis
Qualitative analysis was performed and quantita-
tive analysis was obtained from previously published 
studies (58,64).
The evidence synthesis based on the present review 
of the available literature shows there were 3 RCTs 
(922,932,941) studying cervical disc herniation. One 
of the 2 observational studies focused on cervical disc 
herniation (937). Among these studies, Manchikanti et 
al (922) studied 120 patients with a 24-month follow-up 
with multiple procedures performed as pain returned 
with a total of 5-6 procedures per 2 years. They showed 
significant improvement at 2-year follow-up with 72% 
utilizing local anesthetics and 68% utilizing local an-
esthetic and steroids with significant improvement in 
pain and function. However, in the responsive group, 
it was 77% with local anesthetic and 80% with local 
anesthetic and steroids. In a recent study, McCormick et 
al (941) studied 76 patients and compared the standard 
interlaminar epidural injection with targeted cervical 
interlaminar epidural steroid injection with 40 and 36 
patients in each group providing a 6-month follow-up. 
This study showed positive results. Cohen et al (932) 
compared a conservative treatment group with 59 
medical therapy patients, an epidural injection group 
with 58 patients and a combination therapy group with 
55 patients where they administered epidural steroid 
injection and pharmacotherapy with gabapentin and 
physical modalities. They showed that 57% with positive 
relief the combination therapy group at 3 months and 
44% at 6 months. Combination therapy with various 
components, along with drug therapy and a structured 
exercise program or other physical interventions is the 
common practice. Consequently, this can be judged as 
a positive study. The observational report also showed 
positive results in 45 patients (937). However, they used 
0.5% bupivacaine 1 mL mixed with 40 mg of triam-
cinolone. Bupivacaine is not recommended for cervical 
epidural injections due to its untoward effects in case of 
leakage or subarachnoid puncture. Thus, overall the evi-
dence is Level I with strong recommendation for inter-
laminar epidural injections in managing disc herniation. 
In the assessment for spinal stenosis, a single RCT by 
Manchikanti et al (925) utilizing 60 patients with one-
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year follow-up showed positive results in 73% with local 
anesthetic and 70% with local anesthetic and steroids. 
However, in the responsive group, overall significant im-
provement was higher with 90% in the local anesthetic 
group versus 89% in the local anesthetic with steroids, 
with overall 3 to 4 injections during the whole year. One 
of the observational studies also included cervical spinal 
stenosis patients. However, these numbers were extremely 
low. Consequently, this does not provide any additional 
evidence. Thus, based on one relevant high-quality RCT 
(925), the evidence is Level II with moderate to strong 
recommendation. 
For axial discogenic pain or patients without facet 
joint pain, a single study with 120 patients by Manchikanti 
et al (924) with 2-year follow-up showed positive results in 
overall groups in 73% with local anesthetic and 70% with 
local anesthetic and steroids. However, the response was 
better with 78% with local anesthetic versus 75% with 
steroids at the end of 2 years with 5 to 6 cervical epidural 
procedures over a period of 2 years. Thus, based on one 
relevant high-quality RCT, evidence is Level II with moder-
ate to strong recommendation. 
In cervical post-surgery syndrome, there was only one 
RCT (927) with inclusion of 116 patients with 58 patients 
in each group with either local anesthetic or local anes-
thetic with steroids with 24-month follow-up showing in 
all-inclusive patients, significant improvement in 69% in 
the local anesthetic group and 71% in the local anesthetic 
with steroid group. However, in the responsive groups, 
positive response with local anesthetic was 74% versus 
local anesthetic with steroid in 79%. Similar to other stud-
ies by this group, repeat injections were performed 3 to 
4 during the first year and a total of 5 to 6 over a period 
of 2 years. Consequently, the evidence is Level II to I with 
moderate to strong recommendation. 
For thoracic pain, there was only one RCT by 
Manchikanti et al (588) with 110 patients with 55 patients 
in each group with the inclusion of all types of thoracic 
pain patients. At 24-month follow-up, the results showed 
71% improvement with local anesthetic only and 80% 
improvement with local anesthetic with steroid when all 
patients were considered. However, the response was bet-
ter if responsive patients were considered with 80% utiliz-
ing local anesthetic alone versus 86% with local anesthetic 
and steroids with 5 to 6 total procedures during a period 
of 2 years. 
The evidence for thoracic epidural injections is Level II 
with moderate to strong recommendation. 
However, in the present review, the addition of 
steroids may provide better improvement in the cervical 
spine based on RCTs and observational studies consider-
ing various issues with local anesthetic administration in 
the cervical spine. It may be appropriate to avoid local 
anesthetics except in certain circumstances with extreme 
caution.
Cost utility analysis also was performed for cervi-
cal epidural injections and thoracic epidural injections 
(943,944). In the assessment of the cost utility in cervical 
disc herniation, post-surgery syndrome, or discogenic 
pain, utilizing 2-year data, with 356 patients, average 
cost including direct costs and indirect costs was $3,785.89 
per one-year improvement in QOL (943). The cost was 
somewhat higher for axial discogenic pain at $4,028.55, 
compared to disc herniation at $3,475.38 and post-surgery 
syndrome at $3,856. Evaluation of cost utility of the tho-
racic interlaminar epidural injections (944) showed with a 
2-year follow-up with one-year QOL improvement includ-
ing direct and indirect costs of $3,245; however, in only 
responsive participants it was $3,148.73. In this study, the 
authors also calculated cost utility in 10 nonresponsive par-
ticipants, which was $45,440 per one-year improvement in 
QoL. This emphasizes the fact that is inappropriate to use 
patients in nonresponsive studies or negative studies for 
cost utility analysis. 
Multiple systematic reviews performed in the past 
(58,60,64,70) have shown significant improvement with or 
without steroids with significant evidence levels. Kaye et al 
(60) showed Level II evidence for long-term management 
of cervical disc herniation with interlaminar epidural injec-
tion. The evidence is Level II to III in managing thoracic 
pain, and cervical spinal stenosis, cervical discogenic axial 
pain, and cervical post-surgery syndrome. Mesregah et al 
(64) showed the addition of steroids to anesthetic injec-
tate was not associated with better pain and functional 
score outcomes compared with anesthetic agent alone in 
patients with chronic neck pain. Knezevic et al (58) also 
showed no significant difference between local anesthetic 
alone compared to local anesthetic with steroids. 
8.10 Summary of Evidence
Analysis of summary of evidence for disc herniation, 
spinal stenosis, discogenic pain, and post-surgery syn-
drome is presented based on the present review of the 
evidence in conjunction with appropriately performed 
systematic reviews published in the literature.
8.10.1 Disc Herniation
8.10.1.1 Caudal
For caudal epidural injections in managing disc 
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herniation with multiple relevant, moderate to high-
quality fluoroscopically guided epidural injections 
with or without steroids trials, and results of previous 
systematic reviews, the evidence is Level I with strong 
recommendation for long-term effectiveness.
8.10.1.2 Lumbar Interlaminar
For lumbar interlaminar epidural injections with 
multiple relevant moderate to high-quality fluoroscopi-
cally guided epidural injections with or without steroids 
trials, and relevant previous systematic reviews, the 
evidence is Level I with strong recommendation for 
long-term effectiveness.
8.10.1.3 Lumbar Transforaminal
For lumbar transforaminal epidural injections with 
inclusion of multiple moderate to high-quality RCTs of 
fluoroscopic transforaminal epidural injections with or 
without steroids, and inclusion of findings of relevant 
previous systematic reviews, the evidence is Level I with 
strong recommendation for long-term effectiveness.
The evidence shows no significant difference 
between caudal and interlaminar epidural injections, 
whereas, the evidence also shows some superiority of 
transforaminal epidural injections over caudal and in-
terlaminar epidural injections in achieving long-term 
improvement with epidural injections.
8.10.1.4 Percutaneous Adhesiolysis
Based on the present assessment with one relevant 
high-quality, placebo-controlled, RCT, the evidence is 
Level II with moderate to strong recommendation for 
long-term effectiveness for percutaneous adhesiolysis 
in patients nonresponsive to conservative management 
and fluoroscopically guided epidural injections.
8.10.1.5 Cervical Interlaminar
In the cervical spine, for managing cervical disc 
herniation, based on relevant moderate to high-quality 
RCTs and published systematic reviews, fluoroscopically 
guided cervical interlaminar epidural injections, show 
evidence is Level I with strong recommendation for 
long-term effectiveness. 
8.10.1.6 Thoracic Interlaminar
In the thoracic spine, for thoracic disc herniation, 
based on one relevant high-quality RCT using fluoroscopic 
guidance with or without steroids and previously published 
systematic reviews, the evidence is Level II with moderate 
to strong recommendation for long-term effectiveness. 
8.10.2 Spinal Stenosis
8.10.2.1 Caudal
For lumbar central spinal stenosis, the evidence 
based on present assessment and previously available 
systematic reviews, based on one high-quality RCT, 
the evidence is Level III to II with moderate to strong 
recommendation for long-term improvement with fluo-
roscopically guided caudal epidural injections.
8.10.2.2 Lumbar Interlaminar
For lumbar central spinal stenosis, with evidence 
synthesis with inclusion of relevant moderate to high 
RCTs and previously published systematic reviews, 
the evidence is Level II with moderate to strong 
recommendation with fluoroscopically guided lum-
bar interlaminar epidural injections for long-term 
improvement.
8.10.2.3 Lumbar Transforaminal
For lumbar spinal stenosis, based on the present 
analysis of moderate to high-quality RCTs and previously 
available systematic reviews, the evidence is Level IV to 
III with moderate recommendation with fluoroscopi-
cally guided lumbar transforaminal epidural injections 
for long-term improvement. 
8.10.2.4 Percutaneous Adhesiolysis
The evidence of percutaneous adhesiolysis in 
lumbar spinal stenosis with present evidence syn-
thesis with relevant, moderate to high-quality RCTs, 
observational studies and systematic reviews, is Level 
II with moderate to strong recommendation for 
long-term improvement after failure of conservative 
management and fluoroscopically guided epidural 
injections.
8.10.2.5 Cervical Interlaminar
For cervical spinal stenosis, based on present 
evidence synthesis with one high-quality RCT and pre-
viously published systematic reviews, the evidence is 
Level II with moderate to strong recommendation for 
fluoroscopically guided cervical interlaminar epidural 
injections with long-term improvement. 
8.10.3 Axial Discogenic Pain 
8.10.3.1 Caudal
The evidence for lumbar axial discogenic pain with-
out facet joint pain or sacroiliac joint pain is Level II with 
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moderate to strong recommendation for caudal epidural 
injections based on one fluoroscopically guided high-
quality RCT for long-term effectiveness. 
8.10.3.2 Lumbar Interlaminar
Based on one high-quality RCT with long-term fol-
low-up and previous systematic reviews, the evidence is 
Level II for discogenic pain after exclusion of facet joint 
pain and sacroiliac joint pain with moderate to strong 
recommendation for fluoroscopically guided lumbar 
interlaminar epidural injections with or without steroids 
for long-term effectiveness.
8.10.3.3 Cervical Interlaminar
Based on the present evidence synthesis with one 
relevant high-quality RCT with long-term follow-up, 
with fluoroscopically guided cervical interlaminar epi-
dural injection with or without steroids, the evidence 




The present evidence synthesis based on one 
relevant high-quality RCT with long-term improve-
ment and previously performed systematic reviews, 
the evidence is Level II with moderate to strong rec-
ommendation with fluoroscopically guided caudal 
epidural injections with or without steroids for long-
term effectiveness.
8.10.4.2 Cervical Interlaminar
The present evidence synthesis based on one rele-
vant high-quality RCT with long-term improvement and 
previously performed systematic reviews, the evidence 
is Level II to I with moderate to strong recommendation 
with fluoroscopically guided cervical interlaminar epi-
dural injections with or without steroids for long-term 
effectiveness.
8.10.4.3 Percutaneous Adhesiolysis
Based on present evidence synthesis with multiple 
moderate to high-quality RCTs in conjunction with pre-
viously published systematic reviews, the evidence for 
percutaneous adhesiolysis in managing post-lumbar sur-
gery syndrome is Level I with strong recommendation 
for long-term improvement after failure of conserva-
tive management and fluoroscopically guided epidural 
injections.
9.0 cost utIlIty analysIs for epIdural 
InterventIons
Key Question 7: What is the evidence for cost 
effectiveness of epidural interventions including 
percutaneous adhesiolysis in managing chronic spi-
nal pain?
To understand the cost utility of epidural interven-
tions, it is crucial to focus on the origins and relevance 
of healthcare costs and the multiple means to reduce 
the impact on healthcare without affecting access to 
quality care and patient choices. Over the years, cost 
utility analysis has taken an important pivotal role in 
the provision of value-based healthcare with consid-
eration of high-quality healthcare in conjunction with 
either increasing the access or at least not curtailing it 
(175-178,945-952). The economic impact of spinal pain is 
described in Section 3. 
The data available from cost utility or cost effective-
ness analysis provides policymakers and providers with 
knowledge to compare treatment strategies and to 
choose appropriate resource allocation with optimiza-
tion of relative priorities among various interventions 
(951). While it is simple and easy to calculate the direct 
costs of an intervention, it is often difficult to assess in-
direct costs, specifically in interventional pain manage-
ment (795,853,943,944,953,954). Consequently, indirect 
measures are utilized in measuring the overall costs.
Over the years, multiple cost utility or cost effective-
ness studies have been performed in the US. Despite 
this knowledge, healthcare costs in managing spinal 
pain only continue to escalate with increasing disability. 
However, based on the Affordable Care Act (ACA), cost 
effectiveness is not utilized as a basis for coverage or 
other analysis in the US (175,176,955-958). Thus, indirect 
measures are utilized based on the utilization and overall 
costs to the governmental programs, whereas private 
insurers routinely utilize cost utility analysis in their 
policy developments. In contrast, in other countries with 
universal healthcare, such as the United Kingdom, cost 
effectiveness and cost utility analysis are often utilized 
as the basis for coverage (959). In the United Kingdom, 
these assessments are based on health technology assess-
ment guidance. However, even though in principle the 
US does not consider cost utility analysis for coverage, in 
action the importance of high-quality with low expenses 
has been stressed with numerous public policy decisions 
including the ACA, physician quality reporting systems 
(PQRS), value-based payment (VBP) systems, merit-based 
incentive payment systems (MIPS), and accountable inter-
ventional pain management (945,956-958). 
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9.1 Cost Effectiveness or Cost Utility Analysis 
The purpose of cost utility analysis in health eco-
nomics is to estimate the ratio between the cost of 
a health-related intervention and the benefit it pro-
duces in terms of numbers of years lived in full health 
by the beneficiaries. Thus, it is considered as a special 
case of cost-effective analysis, and both of the terms 
are often used interchangeably. In the scenario of cost 
utility analysis, cost is measured in monetary units; 
however, in cost benefit analysis, benefits do not have 
to be expressed in monetary terms. Among the earlier 
publications, Kepler et al (946) showed that one-year 
cost of QoL gained was less than $100,000 in only 45% 
of the studies assessed. In a similar study by Indrakan-
ti et al (947), a greater value was demonstrated on 
studies of nonoperative treatments while comparing 
surgical interventions. They showed highly variable 
costs for QALY, ranging from $304 to $579,527, with a 
median cost of $13,000. 
Dagenais et al (951,952,960) assessed the cost of 
illness and cost utility studies in the US and interna-
tionally and their role in informed decision-making 
concerning interventions for low back pain. In their 
assessment of cost of illness studies (951,952,960,961), 
they provided a breakdown on direct costs. The larg-
est proportion of direct medical costs for low back 
pain was spent on physical therapy (17%) and inpa-
tient services (17%), followed by pharmacy (13%) and 
primary care (13%). In their assessment of the role 
of cost utility evaluations (951), their results showed 
most studies were from the United Kingdom and were 
published 3 years prior to their publication in 2009. 
The results have been highly variable for surgi-
cal interventions versus nonsurgical interventions, 
specifically in relation to calculation of direct and 
indirect expenses. Multiple studies comparing surgical 
interventions with nonsurgical interventions showed 
mixed results with surgical care with a significant 
incremental benefit by some, with others showing 
lack of advantage of surgical care. In fact, the most 
quoted cost utility analysis comes from the data from 
SPORT study. Tosteson et al (962) showed cost effec-
tiveness of surgical treatment for lumbar disc hernia-
tion at $69,403 per QALY for the general population, 
and $34,355 for the Medicare population per QALY. 
They also studied cost effectiveness of spinal stenosis 
surgeries (963). In this assessment (963), the results 
showed cost effectiveness of spinal stenosis at $77,600 
per QALY gained, with $115,600 per QALY gained for 
degenerative spondylolisthesis. Cost effectiveness 
analysis of posterior cervical fusion for degenerative 
spondylolisthesis showed a $20,547 per QALY in one 
study (374). Anterior cervical discectomy and fusion in 
obese patients was cost effective at $52,816. Further, 
anterior cervical discectomy and fusion in obese pa-
tients was cost effective at QALY of $68,070 compared 
to nonobese patients at $52,816 QALY, which was not 
significantly different between the 2 (374). 
Multiple studies also have been published on non-
surgical therapies, including epidural injections as an 
inclusion therapy of various modalities, or individual 
monotherapy (964-971). However, these studies were 
more extensive in the lumbar spine than the cervical 
spine. 
9.2 Physical Therapy and Chiropractic 
In studies performed with physical therapy in 
managing low back pain, specified as nonspecific in 
origin, the incremental cost effectiveness of $4,594 
per QALY was shown with physical therapy (964). 
However, a favorable cost utility of $2,216 per QALY 
for spinal stabilization physiotherapy was demon-
strated with individualized physiotherapy (965). Other 
data also exists in relation to physiotherapy compared 
to advice alone, which showed cost effectiveness of 
physiotherapy in low back pain of 6 weeks duration, 
at a cost utility of $6,379 per QALY (966). In another 
study, cost effectiveness of primary care manage-
ment, with or without early physical therapy for acute 
low back pain (967), showed better QoL in patients 
receiving early physical therapy after one year, even 
though costs were higher, further calculating data in 
this study (967). The incremental cost effectiveness 
ratio was $32,058 per QALY. These results have been 
stressed despite the costs to initiate early physical 
therapy to reduce the risk of extensive advanced im-
aging or other invasive procedures for low back pain 
(968-971). Physical therapy is also extensively recom-
mended for strengthening purposes prior to surgical 
interventions, or in conjunction with other modalities 
of treatments, leading to structured exercise program, 
and also after surgical interventions. 
The evidence is minimal for the long-term effec-
tiveness of physical therapy as an individual modality, 
or even in conjunction with other modalities; however, 
it may contribute to faster recovery in multidisciplinary 
management (971-975). Adogwa et al (976,977), showed 
the average cost per patient utilizing therapy to be 
$4,010, with 67% of patients with lumbar spinal stenosis 
undergoing physical therapy, most commonly combined 
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with other medical management. Physical therapy costs 
also include repeat therapy, need for additional durable 
medical equipment such as lumbosacral arthrosis, TENS 
units, and electronic stimulation units. Patient’s failure 
in compliance with continuing to do home exercises 
after being discharged may also account for suboptimal 
outcomes (973). Lilly et al (978) nonoperative described 
assessment of nonoperative management strategies in a 
herniated lumbar disc population, showing positive re-
sults. Among the total of 278,000 patients with interver-
tebral disc herniation, 97% were successfully managed 
with nonoperative treatments, while 3% failed maximal 
nonoperative therapy (MNT) and underwent a lumbar 
microdiscectomy. The treatments included physical 
therapy, as well as other modalities.
Analysis of complementary and alternative medical 
treatments, including chiropractic management for cost 
effectiveness compared to no treatment, a placebo, phys-
ical therapy, or usual care in reducing pain immediately 
or at short-term after initiation of the treatment, showed 
significantly greater effectiveness of complementary and 
alternative medical treatments (171,184,979-984). Alter-
native treatments have increased substantially over the 
years reaching into a multibillion-dollar industry. In 2007, 
a total cost of over $33 billion was spent out-of-pocket 
on visits to complementary and alternative medicine 
practitioners, and purchases of products, classes, and 
materials (981). The estimates in 2020 show that comple-
mentary and alternative medicine market may be worth 
over $296 billion by 2027. Thus, patients with spinal pain 
spend considerable amounts out-of-pocket for medical 
massage, acupuncture, Chinese medicine, and over-the-
counter (OTC) and durable medical equipment. These 
costs are often not measurable. 
Clinical and cost effectiveness of chiropractic treat-
ments have been studied in multiple investigations. 
Coutler et al (184) in a systematic review and meta-
analysis, which included 51 trials and 9 trials utilized for 
meta-analysis, showed moderate quality evidence that 
manipulation and mobilization are likely to reduce pain 
and improve function for patients with chronic low back 
pain. Herman et al (982) assessed multiple nonpharma-
cological interventions for cost effectiveness than usual 
care. Utilizing a Marko model, the results showed that 
from this societal perspective, all but 2 of the therapies 
were cost effective at less than $50,000 per QALY for 
typical patient mix and most were cost saving. From the 
payer perspective, fewer were cost saving, but the same 
number were cost effective. Assuming all patients in the 
model have high impact chronic pain increases, the ef-
fectiveness and cost effectiveness of most, but not all, 
therapies indicating that substantial benefits are possible 
in subpopulations. Coutler et al (171) showed the effec-
tiveness of manipulation and mobilization for treating 
chronic nonspecific neck pain. Hays et al (983) assessed 
group and individual level change on health-related QoL 
in chiropractic patients with chronic low back or neck 
pain in a 3-month longitudinal study, which is rather 
short-term. However, they showed that chiropractic care 
was associated with significant group-level improvement 
in health-related QoL over time, especially in pain. Only a 
minority of the individuals in the sample got significantly 
better. They concluded that this study suggested some 
benefits of chiropractic on functioning and well-being of 
patients with low back and neck pain. 
Leininger et al (980) published a manuscript on the 
cost effectiveness of spinal manipulative therapy, su-
pervised exercise and home exercise in 241 older adults 
with chronic mechanical neck pain. Results showed the 
authors in this manuscript assessed the cost effective-
ness of home exercises with advice (HEA), SMT plus 
HEA and supervised rehabilitative exercise (SRE) plus 
HEA. Total costs for SMT plus HEA were 5% lower than 
HEA and 47% lower than SRE plus HEA. SMT plus HEA 
resulted in a greater reduction of neck pain over the 
year relative to HEA. Differences in disability and QALY’s 
favored SMT plus HEA. The authors showed that the 
probability that adding SMT to HEA is cost effectiveness 
at willingness to pay thresholds of $50,000 to $200,000 
per QALY gained ranges from 0.75 to 0.81. The results 
also showed that if adopting a healthcare perspective, 
cost for SMT plus HEA were 66% higher than HEA, re-
sulting in an incremental cost-effectiveness ratio (ICER) 
of $55,975 per QALY gained. 
9.3 NonSurgical Treatments Compared to 
Surgical Treatments 
Evidence for the effectiveness of the interventional 
techniques has been demonstrated and may be variable 
due to multiple reasons, including the specialists assess-
ing the cost utility providing the least effectiveness of 
5% for nonoperative treatments, and not applying the 
actual costs and QoL improvement for interventions 
(976-978,985-991). While the cost of nonsurgical treat-
ment may seem extensive, surgical treatments have 
additional costs associated with risks of complications, 
including costs of repeat operations and cost of care of 
failed surgical interventions. A significant proportion of 
the patients undergoing interventional pain manage-
ment techniques have already undergone surgical inter-
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ventions on multiple occasions or surgical interventions 
are not feasible. 
Adogwa et al (977) performed a 5-year cost analysis 
of long-term cost of maximum nonoperative treat-
ments in patients with symptomatic lumbar stenosis or 
spondylolisthesis that ultimately required surgery. They 
assessed a total of 4,133 eligible patients from 498,000 
(0.8%), undergoing one, 2, or 3-level posterior lumbar 
instrumented fusion. A significant portion of patients 
had comorbid factors with 20.8% smokers, 44.5% with 
Type 2 diabetes mellitus, and 38.2% with obesity. They 
showed the maximum nonoperative treatments utiliza-
tion as 66.7% used NSAIDS, 84.4% used opioids, 58.6% 
used muscle relaxants, 65.5% received lumbar epidural 
steroid injections, 66.6% attended physical therapy or 
occupation therapy, and 25% attended chiropractic man-
agement. They showed total direct costs associated with 
all MNT prior to index fusion of $4,010 on nonoperative 
treatments per patient. Overall, 45.5% of the cost was 
on epidural injections, followed by 18% for NSAIDS, and 
14.2% for opioid costs. Surprisingly in this assessment, 
PT-OT with a greater number of patients attending had 
lesser costs compared to chiropractic visits. However, 
these patients were continuously active within the insur-
ance system for at least 5 years before lumbar fusion. In 
utilizing cost utility, authors have ignored the fact that 
these patients have been active and have responded to 
the treatments with improvement in quality of life. They 
also ignored the fact of costs, not only for surgical in-
tervention, but indirect costs, along with follow-up care, 
failed surgery with returning to the same modalities of 
treatments, including spinal cord stimulation or intrathe-
cal infusion systems and repeat surgery. 
Cummins et al (991) assessing cost and utilization of 
nonoperative therapy for chronic back pain studied 1,411 
patients within the SPORT. They analyzed the nonopera-
tive treatment patients with intervertebral disc hernia-
tion, spinal stenosis, and degenerative spondylolisthesis 
with stenosis received prior to enrollment. With regards 
to patients with either spinal stenosis or degenerative 
spondylolisthesis, they determined that prior opioid use 
occurred in 29% and 27% of patients, OTC medication 
use in 31% and 27%, chiropractic treatment in 33% and 
26%, and emergency department presentation in 7% 
and 4%. However, more importantly, 70% of the patients 
with spinal stenosis or degenerative spondylolisthesis 
with stenosis, 70% of the patients received preoperative 
physical therapy, 55% to 60% had received injections, 
and 50% to 60% used anti-inflammatory medication. 
Daffner et al (992) retrospectively analyzed 30,709 
patients by identifying the charges involved in the 
conservative management of lumbar disc herniation 
eventually requiring discectomy in the 90 days preop-
eratively. The average cost per patient over this time 
period was $3,445, with 32% of this total coming from 
charges for injections, 31% from diagnostic imaging, 
13% from outpatient visits, 11% from physical therapy 
visits, 2% from chiropractic visits, and other expenses 
less than 2%. In this analysis, they also included both 
diagnostic as well as therapeutic charges. 
Tosteson et al (993) in a study comparing surgi-
cal treatment of spinal stenosis without degenera-
tive spondylolisthesis also published the nonsurgical 
care and cost effectiveness. The analysis included 634 
participants with stenosis and 601 participants with 
degenerative spondylolisthesis with associated steno-
sis. Of these, 62% of the participants with stenosis and 
61% of participants with degenerative spondylolis-
thesis had surgery. Total adjusted mean nonoperative 
care costs were similar. Diagnostic tests were reported 
more frequently among those treated surgically. For 
either disease groups, epidural or trigger point use was 
higher among patients treated nonoperatively. Among 
patients with stenosis, 45% were nonoperative man-
agement and 30% were surgery recipients, whereas it 
was 46% for nonoperative management and 29% for 
surgery recipients for degenerative spondylolisthesis 
with stenosis. Opioid use was higher among those re-
ceiving surgery in both groups, 71% surgery recipients 
and 35% in the nonoperative management group. The 
total costs for nonoperative management for spinal 
stenosis were $13,359, whereas they were $16,046 
for degenerative spondylolisthesis with spinal steno-
sis, which included total direct and indirect costs. In 
contrast, for surgical interventions, they were $26,222 
versus $42,081 for degenerative spondylolisthesis with 
spinal stenosis. Cost effectiveness was 1.37 and 1.33 for 
nonoperative management and it was 1.54 and 1.55 for 
surgical interventions for spinal stenosis and degenera-
tive spondylolisthesis with spinal stenosis. While there 
seems to be not much difference in the calculated cost 
effectiveness for QALY, they described that cost util-
ity was better for surgical interventions. With stenosis 
surgery, improved health with a QALY gain was 0.17, 
at a cost of $77,600, ranging from $49,600 to $120,000 
per QALY gained. For degenerative spondylolisthesis, 
QALY gain was 0.23 at a cost of $115,600, ranging from 
$90,800 to $144,900 per QALY gained. 
Tosteson et al (962,963) also assessed cost effective-
ness of surgical versus nonoperative treatment for lum-
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bar disc herniation over a period of 2 years. This analysis 
showed total costs of $27,341 for surgery for disc hernia-
tion in a commercial population and $20,150 in a Medi-
care population. For nonoperative care, the costs were 
$13,135. The mean cost per QALY gained for surgery 
was $69,403 in the general population and $34,355 for 
the Medicare population over a 2-year period. Tosteson 
et al (993), in another manuscript, provided the data on 
comparative effectiveness evidence from SPORT compar-
ing surgical versus nonoperative care for spinal stenosis, 
degenerative spondylolisthesis, and intervertebral disc 
herniation. They showed that cost per QALY gained 
decreased for spinal stenosis from $77,600 at 2 years to 
$59,400 at 4 years, for degenerative spondylolisthesis, 
costs decreased from $115,600 to $64,300 and for inter-
vertebral disc herniation, from $34,355 to $20,600.
The same group, with Lurie as the first author 
(994), published the 8-year results of the SPORT for 
disc herniation. In this analysis, they showed that pa-
tients undergoing surgical intervention continued to 
do better than nonoperative treatment. The results 
after 10 years also showed continuing improvement 
in the results (995). 
Spinal cord stimulators were assessed for cost util-
ity in multiple studies (996-998) in the management 
of chronic pain of failed back surgery syndrome, com-
plex regional pain syndrome (CRPS), peripheral arte-
rial disease (PAD), and refractory and angina pectoris. 
Kumar et al (996) showed cost utility at Canadian 
dollars (CAD) $9,293, CAD $11,216, CAD $93,050, and 
CAD $99,084 for failed back surgery syndrome, CRPS, 
PAD, and refractory angina pectoris, respectively, per 
QALY gained.
Taylor et al (997) demonstrated that the incremen-
tal cost effectiveness of spinal cord stimulation com-
pared with conventional medical management was 
£5,624 per QALY, with an 89% probability that spinal 
cord stimulation is cost effective at a willingness to 
pay the threshold of £20,000. They also showed that 
compared with reoperation, the incremental cost ef-
fectiveness of spinal cord stimulation was £6,392 per 
QALY, with an 82% probability of cost effectiveness at 
the £20,000 threshold. 
However, Hollingworth et al (998) in an analysis 
of the cost effectiveness of spinal cord stimulation for 
failed back surgery syndrome in a workers’ compensa-
tion population showed that the mean medical cost 
per spinal cord stimulation patient over 24 months was 
$52,091, which was $17,291 higher than the pain clinic 
group and $28,128 higher than in the usual care group.
9.4 Cost Utility of Epidural injections
Cost utility or cost effectiveness analysis of epi-
dural interventions was published in multiple manu-
scripts as a single modality (795,853,854,943,944,953,
954,999). Earlier investigations and some more recent 
investigations have utilized inaccurate methodol-
ogy, extrapolating from patients who have failed to 
respond to epidural injections (854,999,1000). Often 
it is difficult to understand methodologies showing 
inappropriate results with inappropriate calculation 
of the economic impact of treatments (961). Dage-
nais et al (989) described cases with high income and 
disproportionately excessive charges for treatments 
received, showing a nonoperative cost of $53,595 for 
one attack of acute radiculitis, with each transforami-
nal epidural injection costing $2,500. Inappropriate 
analysis in interventional pain management appears 
to be a common phenomenon. 
Price et al (854), in an RCT of clinical and cost 
utility analysis, showed interlaminar epidural injec-
tions with inappropriate design of the study. They 
based their results on improvement at 3 weeks in 
one patient, based on the trial protocol of £16,816 to 
£23,963, depending on the number of epidural ste-
roid injections needed to treat. They also showed that 
if only one epidural was provided, the total charge 
to purchasers to improve one patient at 3 weeks was 
£7,936 to £11,306. Obviously, not only was the RCT 
flawed, but also the cost utility analysis and all the in-
ferences drawn on this study. It was performed with-
out fluoroscopic guidance and has not been included 
in many systematic reviews or guidelines. 
Whynes et al (999) evaluated a small number of 
patients modeling resource use and data from other 
studies. They studied 39 patients over a period of 13 
weeks showing the QALY gain. They showed mean 
cost of an injection was £219, with a cost quality 
ratio of 2 injections, amounting to £8,975 per QALY 
gained. They also concluded that when provided in 
an outpatient setting, epidural steroid injections are 
short-term, but nevertheless, cost effective means of 
managing chronic LBP. However, this study is faced 
with extensive criticism due to a small number of pa-
tients and data extrapolation from 3 weeks of relief. 
Carreon et al (1000) assessed in their surgical 
practice from June 2012 to July 2013 if appropriate 
outcome parameters were available. Their results 
showed that of the 421 patients who had received 
lumbar epidural steroid injections, 323 patients, or 
77%, had data available with EQ-5D, 145 patients, or 
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45%, had a QALY gain at a cost of $62,175 per QALY 
gained (mean 0.117), 127, or 40%, had a loss in QALY 
(mean 0.120), and 51 patients, or 15%, had no change 
in QALY. Many of them were precluded from surgery. 
The cost utility per QALY gained was at $62,175. The 
assessment is very crude. There is significant bias as 
patients may be seeing the surgeon to obtain surgical 
intervention. Further, since these are surgical refer-
rals, they may have already failed epidural injections 
with expectation of surgical interventions with high 
levels of nocebo experience and potential lack of 
medical necessity. However, it is not acceptable in the 
US to perform these procedures in Medicare patients 
without documentation of adequate relief. They also 
showed in some cases, patients have received 6 proce-
dures per year, which is unusually high. Consequently, 
the results of this study are unreliable for any type of 
clinical utility.
Multiple studies were performed by Manchikanti 
et al (795,853,920,943,944) including: caudal, lumbar, 
cervical, and thoracic interlaminar epidural injections, 
and lumbosacral percutaneous adhesiolysis. 
A cost utility analysis of fluoroscopic caudal epi-
dural injections with or without steroids (795) was 
performed based on 4 RCTs with lumbar disc hernia-
tion, axial discogenic LBP, central spinal stenosis, and 
post-lumbar surgery syndrome (765,766-768). A total 
of 480 patients were studied with 120 patients in 
each disc herniation and discogenic pain group, 140 
patients in the post-surgery syndrome, and 100 pa-
tients in the spinal stenosis group, with utilization of 
2-year data outcomes with calculation of 2-year data 
of cost utility analysis as shown in Fig. 17 and Table 
18. Significant improvement was seen in all groups 
of patients with local anesthetic only or with steroids 
except for the spinal stenosis group at 12 months 
and 24 months. The average cost for improvement of 
one-year quality of life, with inclusion of direct costs 
and indirect costs were $3,628 with caudal epidural 
injections. There were no differences among the costs 
in each category (Table 18).
Cost utility analysis of lumbar interlaminar epi-
dural injections (853) in the treatment of lumbar disc 
herniation, central spinal stenosis, and axial discogen-
ic low back pain was assessed in 360 patients utilizing 
the data from 3 RCTs (797,799,801). As shown in Fig. 
18, there was significant improvement clinically rang-
ing from 65% to 73% at 2-year follow up. As shown 
in Table 19, the total estimated cost including proce-
dural costs, costs of medical and other indirect costs 
for one-year improvement in QoL was shown to be 
$3,301 overall. 
Response from RCTs was also performed in pa-
tients receiving cervical interlaminar epidural injec-
tions in the treatment of cervical disc herniation, 
post-surgery syndrome, or discogenic pain (943) as 
shown in Fig. 19. The results showed positive response 
in 71% of the patients receiving cervical epidural injec-
tions with local anesthetic alone or with steroids at 24 
months. There was no difference between 6-month fol-
low up, 12-month follow up, and 24-month follow up. 
The average costs, including direct and indirect costs, 
were $3,785.89 for one-year improvement in QoL (Table 
20). 
Cost utility of thoracic interlaminar epidurals 
was also evaluated (944). A single RCT with a 2-year 
follow-up of clinical effectiveness was utilized. This 
study showed significant improvement in these pa-
tients (Fig. 20). This study included 110 patients with 
a 2-year follow-up (588). Methodology was similar 
to the other studies by Manchikanti et al. Cost utility 
analysis showed direct procedural cost of $1,943.19, 
whereas total estimated cost per QALY was $3,245.12 
(Table 21). 
Cost utility of percutaneous adhesiolysis was per-
formed (920) in post-lumbar surgery syndrome and 
central spinal stenosis in the lumbar spine utilizing 2 
RCTs (893,894).
The results of 2 RCTs of low back pain (891-894) 
with 60 and 70 patients over a 2-year follow-up with the 
actual reimbursement data showed direct cost expenses 
of $2,652 for post-lumbar surgery syndrome and $2,649 
for lumbar central spinal canal stenosis. With the addi-
tion of 67% for indirect costs, the total cost for one-year 
quality of improvement is $4,429 for post-lumbar sur-
gery syndrome and $4,424 for lumbar central spinal ste-
nosis (920). Figure 21 and Table 22 show the outcomes 
and cost utility analysis of percutaneous adhesiolysis. 
Figure 22 shows ranges of cost utility analysis in 
various commonly utilized procedures in the US. Thus, 
the costs of epidural injections are within the range. 
Further, the costs utility with one-year improvement of 
all interventional pain management techniques, except 
for spinal cord stimulation, were below $5,000. Ap-
propriately performed studies show cost effectiveness, 
whereas, inappropriate inclusion criteria and studies 
favoring surgery show lack of effectiveness. 
In addition to the procedures on the spine, cost 
utility shows that it is lower than many other chronic 
diseases. Tosteson et al (963) in their manuscript de-
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scribed that spinal stenosis fusion surgery at a cost of 
$115,600 per QALY improvement may be considered as 
too expensive. In another manuscript (995), they also 
summarized the evidence from the SPORT by address-
ing outcomes and costs for 3 types of spine problems. 
Their results showed that after 4-year follow-up, pa-
tients with 3 spine conditions that may be treated sur-
gically or nonoperatively, have systematic differences 
in value endpoints. The average surgical patient enjoys 
better health outcomes and higher treatment satisfac-
tion but incurs higher costs. However, for those who 
are not candidates for surgical interventions and those 
who are opposed to surgery or their medical status 
contraindicates surgery, treatment with epidural in-
Fig. 17. Proportion of  patients with significant reduction in Numeric Rating Score and Oswestry Disability Index (≥ 50% 
reduction from baseline) for caudal epidural injections.
Reproduced with permission from authors and Pain Physician journal.
Table 18. Analysis of  cost effectiveness of  caudal epidural injections in managing pain and disability of  disc herniation, discogenic 










Number of patients 120 120 100 140 480
Total number of procedures for 2 years 601 647 400 696 2344
Number of treatments for 2 years per patient (mean ) ± SD 5.0 ± 2.55 5.4 ± 2.63 4.0 ± 2.57 5.0 ± 2.76 4.9 ± 2.67
Number of weeks with significant improvement for all 
patients in the study in weeks for 2 years 6294 7254 4305 7096 24949
Significant improvement in weeks per procedure (mean) 
± SEM 9.4 ± 7.23 10.7 ± 8.25 9.7 ± 13.54 8.4 ± 6.14 9.5 ± 8.92
Number of weeks with significant improvement per 
patient for 2 years 52.5 ± 38.46 60.4 ± 37.71 43.1 ± 41.52 50.7 ± 38.71 52.0 ± 39.33
Total Cost ($)
Physician $74,761.00 $81,729.00 $45,944.00 $88,776.00 $291,210.00
Facility $192,225.00 $216,268.00 $132,468.00 $210,168.00 $751,129.00
Total $266,986.00 $297,997.00 $178,412.00 $298,944.00 $1,042,339.00
Cost per procedure ($)
Physician $124.40 $126.30 $115.10 $127.60 $124.30
Facility $319.80 $334.30 $332.00 $302.00 $320.60
Total $444.20 $460.60 $447.10 $429.50 $444.90
Cost per 1-week QALY ($) $42.42 $41.08 $41.44 $42.13 $41.78 
Cost per 1-year QALY ($) $2,205.79 $2,136.18 $2,155.03 $2,190.68 $2,172.50 
Cost per 2-year QALY ($) $4,411.59 $4,272.36 $4,310.07 $4,381.37 $4,344.99 
Average Total cost per patient for 2 years $2,225.00 $2,483.00 $1,784.00 $2,135.00 $2,172.00 
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terventions seems appropriate. They also showed that 
longer follow-up periods after the surgery at 4 years 
and 10 years, cost effectiveness per QALY improved 
significantly (962,994). 
Further, the epidural interventions may avoid the 
surgery in a significant portion of patients (188,271-
274,278) providing better value. 
10.0 coMplIcatIons and sIde effects of 
epIdural InterventIons 
Key Question 8: What are the adverse conse-
quences and harms and related precautions in pro-
viding epidural procedures? 
Complications related to epidural injections are 
rare, but can be serious and devastating , specifically 
in cervical spine (623,866,1001-1038). They are usually 
Fig. 18. Proportion of  patients with significant reduction in Numeric Rating Score and Oswestry Disability Index (≥ 50% 
reduction from baseline) with lumbar interlaminar epidural injections.
Reproduced with permission from authors and Pain Physician journal.
Table 19. Cost utility analysis of  lumbar interlaminar epidural injections in managing pain and disability of  disc herniation, 
discogenic pain, and spinal stenosis.
Disc Herniation Discogenic Pain Spinal Stenosis Total 
Number of patients 120 120 120 360
Total number of procedures for 2 years 682 714 644 2040
Number of treatments for 2 years per patient (mean ) ± SD 5.7 ± 2.5 6.0 ± 2.5 5.4 ± 2.6 5.7 ± 2.6
Number of weeks with significant improvement for all patients in the 
study in weeks 7667 7900 8074 23641
Significant improvement in weeks per procedure (mean ) ± SD 10.8 ± 5.7 10.5 ± 5.9 13.2 ± 12.7 11.5 ± 8.8
Direct procedural costs without drug costs ($)
  Physician $85,443 $93,250 $66,342 $245,036
  Facility $216,942 $227,649 $208,994 $653,585
  Total $302,385 $320,899 $275,336 $898,620
Direct costs per procedure ($)
  Physician $125.28 $130.60 $103.02 $120.12 
  Facility $318.10 $318.84 $324.52 $320.38 
  Total $443.38 $449.44 $427.54 $440.50 
Average total direct costs per patient in 2 years $2,519.88 $2,674.16 $2,294.47 $2496.17 
Direct procedural improvement in quality of life ($) $2,050.87 $2,112.25 $1,773.28 $1,976.58 
Indirect costs including drug costs for 1-year improvement in quality 
of life ($) $1,374.08 $1,791.68 $1,188.10 $1,324.31
Total estimated costs including procedural costs, costs of medicine and 
other indirect costs for 1-year improvement in quality of life ($) $3,425 $3,527 $2,961 $3,301
Total costs ($) for one-year improvement of quality of life
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related to either the needle placement or drug activ-
ity. Medical-legal analysis has revealed the causes of 
injury are multifactorial, involving aspects of technical 
execution, clinical judgment, communication with the 
patient and other medical providers, and documenta-
tion (1019). 
Interventional pain management physicians ap-
proach the epidural space by a caudal, transforaminal, or 
interlaminar technique. Transforaminal epidurals have 
been associated with more adverse events after injection 
of corticosteroids. This is due to an inadvertent injection 
into or mechanical damage of the critical vasculatures 
Fig. 19. Proportion of  patients with significant reduction in numeric rating score and neck disability index (≥ 50% reduction 
from baseline) for cervical interlaminar epidurals.
Reproduced with permission from authors and Pain Physician journal.
Table 20. Analysis of  cost effectiveness of  cervical epidural injections in managing pain and disability of  disc herniation, discogenic 










Number of patients 120 120 116 356
Total number of procedures for 2 years 689 654 627 1971
Number of treatments for 2 years per patient (mean ) ± SD 5.7 + 2.4 5.4 + 2.7 5.4 + 2.6 5.5 + 2.5
Number of weeks with significant improvement for all patients in the study 
in weeks 8,093 7,900 7,254 23,247
Average total relief in two year per patient
Significant improvement in weeks per procedure (mean ) ± SD 11.6 + 7.7 12.6 + 12.0 11.4 + 8.6 11.9 + 9.6
Total Cost ($)
Physician $89,321 $95,130 $82,162 $266,614
Facility $286,117 $221,033 $239,971 $747,121
Total $375,439 $316,163 $322,133 $1,013,735
Cost per procedure ($)
Physician $129.64 $145.46 $131.04 $135.27
Facility $415.26 $337.97 $382.73 $379.06
Total $544.90 $483.43 $513.77 $514.33
Average total direct costs per patient in 2 years $3,128.66 $2,634.69 $2,777.01 $2,847.57
Direct procedural improvement in quality of life ($) per one year $2,412.31 $2,081.07 $2,309.20 $2,267.57
Indirect costs including drug costs for 1-year improvement in quality of life 
($) $1,616.25 $1,394.32 $1,547.16 $1,519.27
Total estimated costs including procedural costs, costs of medicine and other 
indirect costs for 1-year improvement in quality of life ($) $4,028.55 $3,475.38 $3,856.36 $3,785.89
All the payments based 2018 allowed rates
SD = standard deviation
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Fig. 20. Illustration of  reduction (at least 50%) in pain and Oswestry Disability Index from baseline for thoracic interlaminar 
epidurals.
Reproduced with permission from authors and Pain Physician journal.
that supply the brain or spinal cord when injectates are 
administered via this approach (886,1020,1021). 
Caudal epidural steroid injections have been 
thought to be a safer approach for treating pain in 
lumbar stenosis. However, there are reports of rare neu-
rological deficits that are transient or permanent. These 
include cauda equina syndrome in patients with spinal 
stenosis, spinal infarction, chemo toxicity, vascular-
occlusion, and epidural hematoma (1020,1022). 
Cervical and lumbar interlaminar epidural steroid in-
jection and transforaminal epidural steroid injection are 





Number of patients 100 10 110
Total number of procedures for 2 years 586 20 606
Number of treatments for 2 years per patient (mean ± SD) 5.9 ± 2.3 2.0 ± 0.8 5.5 ± 2.5
Number of weeks with significant improvement for all patients in the study in weeks 7879 18 7897
Average total relief in 2 years per patient 78.8 ± 25.6 1.8 ± 2.1 71.8 ± 3302
Significant improvement in weeks per procedure (mean ± SD) 13.6 ± 10.1 0.9 ± 1.1 13.2 ± 10.2
Total cost
Physician $66,765.68 $2252.75 $69,018.43
Facility $218,918.99 $7165.98 $226,084.97
Total $285,684.67 $9418.73 $295,103.40
Cost per procedure ($)
Physician $11.93 $112.64 $113.89
Facility $373.58 $358.30 $373.08
Total $487.52 $470.94 $486.97
Average total direct costs per patient in 2 years $2856.85 $941.87 $2682.76
Direct procedural improvement in quality of life ($) per 1 year $1885.47 $27,209.66 $1943.19
Indirect costs including drug costs for 1-year improvement in quality of life ($) $1263.54 $18,230.47 $1301.93
Total estimated costs including procedural costs, costs of medicine and other indirect 
costs for 1-year improvement in quality of life ($) $3148.73 $45,440.13 $3245.12
Table 21. Analysis of  cost-utility of  thoracic epidural injections.
All the payments based 2018 allowed rates
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to the irritated nerve roots. The transforaminal epidural 
steroid injection allows for a more direct approach into 
the anterolateral neuroforaminal space where inflamma-
tion due to a posterolateral disc displacement commonly 
resides. Transforaminal epidural spread of corticosteroid 
has been associated with improved pain and functional 
outcome improvements, although the evidence has been 
refuted in some of the literature. 
In the last decade, the use of epidural steroid injec-
tions has come under scrutiny. In 2011, the label for tri-
amcinolone was updated, warning against epidural use. 
In April 2014, the FDA issued a warning that epidural 
steroid injections can cause “rare but serious adverse 
events, including loss of vision, stroke, paralysis, and 
death.” mainly based on case reports of direct spinal 
cord injury and of infarctions related to cervical transfo-
raminal placement of particulate steroids, although the 
FDA warning and package insert revisions covered all 
steroids including dexamethasone (1039). In the FDA’s 
risk assessment between 1997 and 2014, a total of 90 
serious and sometimes fatal neu-
rologic events were reported to 
the FDA Adverse Event Reporting 
System (FAERS), including cases of 
paraplegia, quadriplegia, spinal 
cord infarction, and stroke. Fur-
ther, compounded glucocorticoids 
used in epidural injections also 
have been associated with fungal 
meningitis (1040-1049), but cases 
involving contaminated products 
were not included in the case 
series under consideration. How-
ever, potential causes of various 
adverse events including multiple 
Fig. 21. Proportion of  patients with significant reduction in Numeric Rating Score and 






Number of patients 70 60 130
Total number of procedures for 2 years 397 385 782
Number of treatments for 2 years per patient (mean ± SD) 5.7 ± 2.73 6.4 ± 2.32 6.0 ± 2.56
Number of weeks with significant improvement for all patients in the study in weeks 4,979 4,704 9,686
Significant improvement in weeks per procedure (mean ± SD) 13.2 ± 12.6 11.7 ± 2.97 12.5 ± 9.47
Total cost ($)
Physician 87,082 83,112 170,140
Facility 166,891 156,529 323,420
Total 253,919 239,641 493,560
Cost per procedure ($)
Physician 219.21 215.88 217.57
Facility 420.38 406.56 413.58
Total 639.59 622.44 631.15
Cost for 1-week improvement in quality of life 51.00 50.94 50.96
Cost for 1-year improvement in quality of life 2,652 2,649 2,650
Cost for 2-year improvement in quality of life 5,304 5,298 5,299
Average total cost per patient for 2 years 3,627 3,994 3,797
Table 22. Analysis of  cost-effectiveness of  percutaneous adhesiolysis injections in managing pain and disability of  lumbar spinal 
stenosis and postsurgery syndrome.
$ is adjusted to 2012
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causes and those involving technique related problems 
such as intrathecal injection, epidural hematoma, direct 
spinal cord injury, and embolic infarction after inadver-
tent intra-arterial injection. The FDA sought to determine 
the central question regarding the role of glucocorticoids 
themselves in these adverse events (1050).
Inadvertent vascular mechanical or occlusive injury 
is believed to be the leading cause of the infarctions. 
This may be due to intravascular injection of particulate 
steroids, arterial injury, dissection, dislodgement of 
plaque causing embolism, or arterial muscle spasm. The 
embolization path is believed to start through the peri-
radicular arteries, which exit the neural foramen and 
accompany the nerve to the spinal cord. Although most 
complications have been seen with particulate steroid 
and cervical spine transforaminal epidural steroid injec-
tions, case reports of spinal infarction have been seen 
with nonparticulate lumbar steroid injections such as 
dexamethasone as well (1021).
Transforaminal epidural steroid injections are asso-
ciated with other complications as well. Transforaminal 
epidural steroid injections, compared to interlaminar 
epidural steroid injections, are associated with an 
increased risk of intradiscal injection (1025,1026). Ad-
ditionally, transforaminal epidural steroid injections do 
not decrease the risk of known complications of inter-
laminar epidural steroid injections, such as dural and 
subdural punctures, hematoma formation, and cauda 
equina syndrome (1021,1022). Although complications 
are rare, they can be catastrophic, and the implementa-
tion of safety guidelines based on common practice has 
been attempted. The FDA convened a panel of experts, 
including pain medicine experts, to determine specific 
techniques of this procedure that may reduce potential 
harm, but evidence was lacking, and consensus was not 
reached on all the items (632,1039). Consequently, the 
Multisociety Pain Workgroup (MPW), without inclusion 
of the ASIPP, approved multiple safeguards to prevent 
neurologic complications after epidural steroid injec-
tions (632); however, there were many issues involved. 
Consequently, it was opposed by ASIPP (1039). Follow-
ing this, ASIPP also petitioned the FDA asking them to 
prevent the safeguards from being mandatory and also 
requested them to remove the safety warning (1051). 
However, the FDA denied the request to remove the 
safety warning or limiting to cervical transforaminal 
epidural injections, but agreed with the second item 
that safeguards were not required (1050).
Fig. 22. Ranges of  cost utility analysis in various commonly utilized procedures in the United States.
Reproduced with permission from authors and Pain Physician journal.
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As described by Racoosin et al (1050) in the assess-
ment of the risk from the FDA in reference to serious 
neurologic events after epidural corticosteroid injection, 
they emphasized the fact that even though inadvertent 
intra-arterial injection is one mechanism for serious 
neurologic events, there were other potential causes. 
They quoted a study by the American Society of Anes-
thesiologists (ASA) Closed Claims Project showing that 
in cases of cervical procedures for chronic pain that led 
to malpractice claims, direct needle trauma to a nerve 
or the spinal cord was the most common procedure re-
lated event. Further, this study (1052) found that of the 
cervical epidural procedures that were associated with 
spinal cord injury, two-thirds were performed with an 
interlaminar approach and one-third with the transfo-
raminal approach (1052). The FDA also clarified that the 
recently published clinical consideration for healthcare 
providers (1050) recommendations came from the work-
ing group, not the agency, as had been requested by the 
ASIPP petition (1051). Consequently, the class warning 
published in 2014 for all injectable glucocorticoid prod-
ucts labels carrying, “serious neurologic events, some 
resulting in death, have been reported with epidural 
injection of corticosteroids” and the safety and that the 
“safety and effectiveness of epidural administration of 
corticosteroids have not been established and cortico-
steroids are not approved for this use (1050).” In their 
final determination, the FDA determined that the class 
warning was warranted based on its analysis of FAERS 
cases and reports in the medical literature of serious 
neurological events. Further, the warning did not dis-
tinguish any difference in the risk associated with the 
various injection approaches, locations of spinal injec-
tions, or glucocorticoid formulation, because the data 
suggested that each approach, location, and formula-
tion was associated with some risk of neurologic injury. 
At the same time, they have not approved or mandated 
the safeguards recommended by MPW.
Epidural steroid injections are associated with a 
number of minor complications and side effects, such 
as exacerbation of pain, vasovagal reaction, and steroid 
side effects such as facial flushing and hyperglycemia, 
which do not involve any permanent impairment 
(55,1027,1027). Of great concern however, are the 
rare but major complications such as epidural abscess, 
discitis, and hematoma formation, radiculo-medullary 
artery injury due to needle or injection with particulate 
steroids, spinal cord infarction, stroke and spinal cord 
injury that can result in severe permanent disability, 
paralysis, or death (7). 
Other complications include extra epidural place-
ment with subcutaneous injection; subdural injection, 
dural puncture with post-lumbar puncture headache 
(more common in interlaminar lumbar epidurals), nerve 
damage, intracranial air injection or increased intracra-
nial pressure; and pulmonary embolism. Less common 
complications include transient blindness (1029), retinal 
hemorrhage and necrosis (1030,1031), spinal cord in-
farct by caudal (1006), placement of needle into filum 
terminale (1005), serous chorioretinopathy (1032,1033), 
persistent recurrent intractable hiccups (1034), pneumo-
cephalus (1009), chemical meningitis (1035), arachnoidi-
tis (1037), and discitis (1036). 
Recommendations have been made to limit or 
avoid the use of epidural steroid injections of cortico-
steroids in high-risk patients, such as the elderly, during 
the COVID-19 pandemic (1053). Steroid distancing has 
also been advocated as a result (55). Additionally, ASIPP 
has issued guidelines on evidence-based risk mitigation 
and stratification during COVID-19 for return to inter-
ventional pain practice as well as triaging interventional 
pain procedures during COVID-19 or related elective 
surgery restrictions that risk and acuity stratify epidural 
steroid injections (51,52).
Apart from COVID-19 issues, steroids continue 
to present with multiple problems including vascular 
embolism related to particulate steroids when utiliz-
ing transforaminal epidural injections. These are seen 
with particulate steroids such as triamcinolone or depo-
methylprednisolone. In contrast, betamethasone, which 
is a smaller particulate steroid, shows less prevalence of 
the side effects and lesser suppression of glucocorticoid 
synthesis, leading to fewer complications (55).
10.1 Side Effects of Steroids 
The pharmacokinetics of corticosteroids continues 
to be complex. With intramuscular administration, ab-
sorption of the water-soluble sodium phosphate and 
sodium succinate source is rapid, whereas the rate of ab-
sorption of lipid soluble acetate and acetonide is much 
slower (1054-1058). The subject of interest for this dis-
cussion is the role of systematic absorption of epidural 
steroids, which has been explored in multiple reports. 
Janicki et al (1057) reported pharmacokinetic analysis 
of methylprednisolone after epidural administration in 
rabbits, with only traces of methylprednisolone being 
detected at 6 and 12 hours after administration of the 
highest epidural dose of the drug (5 mg/kg). Further, 
plasma methylprednisolone doses at all sampling times 
for the epidural doses of 2.5 and 1.25 mg/kg were also 
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not detectable. Jacobs et al (1055) have also reported 
being unable to detect methylprednisolone in blood 
samples. Friedly et al (1058) in a study of the systemic 
effects of epidural steroid injections for spinal stenosis 
showed that of the 200 patients receiving corticoste-
roid, 32 patients or 20.3% experienced cortisol reduc-
tion at 3 weeks of ≥ 50% compared with 10 patients 
(6.7%) treated with lidocaine only. The effect on 
3-week cortisol changes did not differ by patient level 
characteristics. They also showed that those treated 
with methylprednisolone or triamcinolone had an aver-
age 3-week cortisol reduction of 41% and 41.6% from 
baseline, respectively. Further comparison with patients 
treated with betamethasone or dexamethasone, found 
no significant changes with cortisol and they were simi-
lar to lidocaine alone. They concluded that the higher 
rates of cortisol suppression at 3 weeks in those receiv-
ing epidural corticosteroid injections, particularly with 
longer acting insoluble corticosteroid formulations, are 
consistent with sustained systemic absorption of cor-
ticosteroid. Hooten et al (1059) showed that terminal 
elimination half-life of lumbar epidurally administered 
triamcinolone in a noncompartmental analysis was 523 
hours (almost 22 days), and the peak triamcinolone con-
centration of 4.1 ng/mL was detected within 24 hours 
after administration. This elimination half-life after 
lumbar epidural administration is much longer than the 
elimination half-life of intravenous administration and 
is likely explained by the suspension and re-distribution 
of the depo preparation within the epidural fat and the 
epidural anatomy (1060).
Risk of reductions in bone density have been re-
ported in high dose steroids (1061-1064), though lower 
doses were potentially safe. Symptomatic hypothalamic-
pituitary-adrenal (HPA) suppression has been reported 
occasionally. Abdul et al (1063) in 2017 reported that, 
after one epidural injection of 80 mg of methylpredniso-
lone, 87% of patients exhibited HPA axis suppression at 
day 7 post-injection, 43% at day 14, and 7% at day 28. 
Habib et al (1064) in 2013, found a dose dependent effect 
in a study examining the magnitude and duration of this 
suppression after a single epidural injection of methyl-
prednisolone. Eighty-six percent of the patients who 
received an 80 mg dose were reported to have laboratory 
confirmed HPA axis suppression one week post-injection 
compared to 53% of those receiving a 40 mg dose; 20% 
of all participants had continued suppression at 4 weeks 
post-injection. Steroid solubility is a factor in endocrine 
influence; longer-acting agents (triamcinolone and 
methylprednisolone) have been found to suppress corti-
sol production for a longer duration than more soluble 
agents (dexamethasone and betamethasone) (1058).
Corticosteroids have anti-inflammatory effects; 
they reduce pain related to inflammation by down-
regulation of the immune function as well as reduction 
of inflammatory cells and mediators (lymphocytes, 
macrophages, and mast cells) (1065,1066). Although 
it has not been directly studied, the endocrine disrup-
tion from a single epidural steroid injection suggests 
similar systemic effects on immune response. The use of 
systemic corticosteroids can adversely affect the innate 
(immediate) immune response by impairing the ability 
of neutrophils to migrate to infection sites as well as 
macrophage and monocyte function. The adaptive im-
mune response (which leads to immunological memory) 
is also negatively affected by corticosteroids, as the 
capability of plasma cells to produce immunoglobulins 
IgG and IgA is reduced by 10 to 20% after exposure. 
Injection therapy plausibly has similar effects to the oral 
administration effects described in the literature.
Consequently, adverse immune influences of corti-
costeroids during an influenza infection is of increased 
concern for those prescribed or injected with corticoste-
roids, with specific concern during the current COVID-19 
pandemic. Meta-analysis of orally administered cortico-
steroid versus placebo demonstrates an increased risk of 
influenza infection within the steroid group. One study 
found a dose-dependent relationship for infection risk, 
showing a relative risk of 1.5 with low doses of steroids 
and a relative risk greater than 8 with doses above 40 
mg/day (1067). In another study, rheumatoid arthritis 
patients taking oral prednisone had relative risks ranging 
from 1.4 (< 5 mg/day dose) to 2.3 (> 10 mg/day dose) for 
hospitalization due to pneumonia compared to rheuma-
toid arthritis patients not taking oral prednisone (1068). 
Although data for single-dose exposure to corticoste-
roids is limited, early evidence is provided in a report on 
an observational cohort from the Mayo Clinic. Over five 
influenza seasons, an increased incidence of influenza 
infection was associated with steroid injection compared 
to no injection (1069). There are currently no studies 
specifically examining the relationship between cortico-
steroid injections and COVID-19, however, the findings 
presented here raise concern for a potential relationship.
Thus, the literature surrounding infrequent adverse 
effects of epidural corticosteroids continues to accumu-
late (1070-1072), with alterations in blood glucose levels 
among patients with diabetes (1073,1074), and pro-
longed effects on the HPA axis (1075). Further, it has also 
been reported that systemic side effects are common with 
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long-term administration of steroids (1058,1076,1077). 
Lamer et al (1070) in a study of 8 patients also assessed se-
rum triamcinolone levels following cervical interlaminar 
epidural injection. Data of the pharmacokinetics showed 
peak triamcinolone concentration (C max) of 5.4 ng/mL 
median value within 22.1 hours (T max) of administra-
tion. The terminal elimination half-life was 219 hours, 
the median value. They also compared the results of this 
study with the previous study of lumbar interlaminar epi-
dural injections (1059) and showed similar patterns. This 
comparison also showed that while the pharmacokinetic 
profile is similar, the T max is earlier and T ½ is shorter 
for the cervical compared to the lumbar epidural steroid 
injection. In similar lines with other investigators, re-
cently, Sim et al (105) assessed the relationship between 
epidural steroid dose and separation of HPA access. In 
the analysis of 30 patients with administration of triam-
cinolone, either 40 mg or 20 mg, they showed that 40 
mg triamcinolone group showed longer HPA separation, 
19.7 ± 3.1 days compared to triamcinolone 20 mg group 
(8.0 ± 2.4 days) and the recovery rate of triamcinolone 40 
mg group was lower than that of 20 mg group with a sig-
nificant difference (P value > 0.015) as shown in Fig. 23.
In another manuscript, Chon and Moon (1078) re-
ported that in all subjects who received epidural steroid 
injections with triamcinolone acetate, 40 mg were sup-
pressed temporarily but were restored after a mean of 
19.9 ± 6.8 days.
The data also shows that intravenous triamcinolone 
acetonide pharmacokinetics using the soluble form have 
been previously determined, demonstrating a half-life 
of approximately 1.5 to 2 hours (1079-1080). However, 
in contrast to intravenous administration, intra-articular 
knee injection of a suspension of acetonide showed 
vastly different results wherein 
triamcinolone acetonide was 
detected in serum for more than 
2 weeks and the half-life ranged 
from 77 to 446 hours (1081). Thus, 
it is crucial to understand the 
different mechanisms of short-
acting and long-acting drugs, 
along with particulate sizes. It is 
also hypothesized that there is 
less sequestration of particulate 
steroids in the cervical epidural 
space, consequently with faster 
absorption. Table 23 shows the 
profile of commonly used epidural 
steroids based on the data derived 
from multiple sources (1054-
1056,1076,1082-1084). Table 24 
Fig. 23. Changes with HPA separation and SC duration with lumbar epidural 
triamcinolone, either 40 mg or 20 mg.


















Hydrocortisone 20 mg NA 1 1 NA NA NA
Depomethylprednisolone 
(Depo-Medrol) 4 mg 40-80 mg 5 0.5 1-6 weeks 1-3 weeks NA
Triamcinolone acetonide 




Soluspan) 0.6 mg 6-12 mg 25 0 1-2  weeks NA NA
NA = not applicable 
Data adapted and modified from: McEvoy et al (1054), Jacobs et al (1055), Kay et al (1056), Hsu et al (1076), Mikhail et al (1083,1084), and Schim-
mer and Parker (1082).
Table 23. Profile of  commonly used epidural steroids.
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shows formulations of commonly used epidural ste-
roids. Dexamethasone is not being discussed since it 
is a nonparticulate and short-acting steroid with the 
least side effects, but it is associated with some side 
effects.
Overall, systemic side effects are significant with 
the influence of corticosteroids on the metabolism of 
carbohydrates, fats, proteins, and purine. They can 
also affect electrolyte and water balance and may af-
fect the functions of the CNS and of the cardiovascular, 
renal, endocrine, reproductive, and immune systems, 
as well as the bones and muscles (1077). Long-term ef-
fects may be caused directly by excess glucocorticoid 
in the circulation or indirectly through suppression of 
the HPA. It is also common that patients presenting to 
interventional pain management may be taking long-
term steroids for multiple medical problems and also 
may be receiving intra-articular steroid injections.
The specific effects on the immune system are 
especially worrisome during the COVID-19 pandemic. 
While there are no data available with regard to the 
effects of epidural administration of glucocorticoids 
on the immune system, there are data available re-
garding systemic administration with high dose glu-
cocorticoid therapy, equivalent to doses of 40 mg or 
more of prednisone per day. With high doses, there 
is an immediate risk of infection due to inhibition of 
phagocyte cell function, which abates after comple-
tion of therapy (1085). In patients with rheumatoid 
arthritis, acute effects of 1 gm of intravenous meth-
ylprednisolone showed development of leukopenia 
within 2 hours of the dose, which peaked at 6 hours, 
and resolved by 24 hours. In addition, doses of less 
than 40 mg, considered as low to moderate, have 
been shown to reduce T lymphocytes with delayed 
hypersensitivity responses. With long-term low dose 
usage, some inhibition of immune responses may in-
crease with the duration of therapy (1086). Multiple 
issues related to vaccination have been discussed in 
the past (1087-1089); however, not specifically with 
the COVID-19 virus. Considering the literature, short-
term therapy with low dose within appropriate dura-
tion of 6 to 13 weeks may not have any significant 
effect. The Advisory Committee on Immunization 
Practices (ACIP) (1090) and the CDC (1091) advise to 
defer live vaccinations for at least one month after 
discontinuation of high dose systemically absorbed 
glucocorticoid therapy administered for 14 days.
10.2 Side Effects of Local Anesthetics
Historically, the use of procaine was extensively 
utilized following cocaine; however, the introduction 
of lidocaine in 1948 and bupivacaine, which was in-
troduced in 1963, has been extensively used outside 
of the epidural space with lidocaine also used for 
intra-articular injections in chronic pain management. 
The mechanism of action of intravenous lidocaine in 
neuropathic pain cannot be explained by blockade of 
voltage-gated Na+ channels alone. The clinical effects 
include reduction of spontaneous pain, allodynia, 
and hyperalgesia. Further, local anesthetic infusions 
have been utilized in various types of pain provid-
ing longer term relief than the expected duration 
of the local anesthetic (1092). Local anesthetics also 
have systemic and local toxic effects. Systemic toxicity 
relates to the relatively narrow difference between 
therapeutic plasma levels and toxic levels (1093). Peak 
plasma levels are determined by the dose and rate of 
systemic absorption. The genes controlling the sub-
unit of Na+ channels give rise to different pharmaco-
logical and biophysiological profiles of Na+ channels 
through the body (1092). Overall, levobupivacaine 










20 mg/mL 40 mg/mL 80 mg/mL 40 mg/mL 40 mg/mL 6 mg/mL
Polyethylene glycol 3350 29.5 29.1 28.2 30 -- --
Polysorbate 80 1.97 1.94 1.88 2 0.4 --
Benzyl alcohol 6.9 6.8 6.59 -- -- 3.4
Dibasic sodium phosphate 9.3 9.16 8.8 9 9 --
Edetate disodium -- -- -- -- -- 7.1
Edetate disodium -- -- -- -- -- 0.1
Benzalkonium chloride -- -- -- -- -- 0.2
Table 24. Formulations of  commonly used epidural steroids.
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has lower systemic toxicity than other amides because 
of its lower affinity for cardiac channels (1094). Intra-
articular local anesthetics may cause chondrotoxicity; 
however, chondrotoxicity is worse with bupivacaine 
or mepivacaine. While methemoglobinemia is a major 
issue with prilocaine, benzocaine and lidocaine can 
also cause methemoglobinemia (1095,1096).
Local anesthetic toxicity affects 2 organs that 
inherently are less tolerant of anaerobic metabo-
lism, the heart and brain. Cardiac toxicity is mostly 
related to accidental intravascular injection, leading 
to the conduction disturbances, contractile dysfunc-
tion, and ventricular arrhythmias that are seen in 
local anesthetic induced cardiac toxicity (1097). More 
importantly, for interventional pain physicians, the 
incidence of cardiac toxicity increases with bupiva-
caine, a longer acting anesthetic. Bupivacaine blocks 
inactive sodium channels during the cardiac potential 
at a concentration of 0.2 mcg. Bupivacaine binding 
is described as “fast-in, slow-out” fashion as it binds 
very quickly to a large portion of sodium channels 
during the cardiac action potential, but releases from 
the channel slowly during diastole, resulting in a 
large proportion of medication accumulating at 60 to 
150 beats per minute. Local anesthetic toxicity may 
become a serious issue, even though adverse effects 
are rare. From minor symptoms to major cardiac or 
CNS effects, local anesthetic system toxicity is an im-
portant consequence in interventional pain manage-
ment. The epidemiology of local anesthetic toxicity 
has been reported from zero events to 25 per 10,000 
nerve blocks. One study reported seizures of 79 of 
10,000 brachial plexus block procedures (1098,1099).
Lidocaine at 5 to 10 mcg/mL will also result in a 
substantial sodium channel blockade during cardiac 
action potential. However, in contrast to bupivacaine, 
lidocaine follows the “fast-in, fast-out” principle, 
meaning it releases from sodium channels rapidly 
during diastole. This allows for a quick recovery, and 
reduced incidence of cardiac toxicity even compared 
to bupivacaine. Consequently, during a cardiac arrest, 
it may be crucial to continue resuscitation measures 
until bupivacaine is completely released. CNS changes 
include agitation, confusion, dizziness, drowsiness, 
dysphoria, auditory changes, tinnitus, perioral numb-
ness, metallic taste, and dysarthria. Without adequate 
recognition and treatment, these signs as symptoms 
can progress to seizures, respiratory arrest, and/or 
coma.
Historically, local anesthetic literature suggests 
that cardiac toxicity is often presented after anteced-
ent CNS toxicity (1097). However, with more potent 
local anesthetics, cardiac toxicity may precede CNS 
toxicity. Lidocaine was utilized far more frequently 
than bupivacaine. Subarachnoid blockade with bupi-
vacaine may turn out to be a disaster, specifically in 
the cervical spine. Consequently, injections of bupiva-
caine in the cervical or thoracic spine is contraindicat-
ed. Even then, lidocaine is also injected in extremely 
low concentrations of 0.5%. In the cervical spine, one 
must still be careful with appropriate visualization 
of the epidural space without any subdural or sub-
arachnoid filling. Failure to follow basic principles can 
result in respiratory arrest, as well as cardiac arrest.
10.3 Radiation Safety
Other complications of epidural interventions 
include radiation exposure, when guided under fluo-
roscopy. This is a potential problem with damage to 
eyes, skin, and reproductive organs (1100-1104).
The ALARA principle should be respected when x-
ray is used because excessive radiation to a patient or 
a physician can cause radiation injury or a stochastic 
effect such as neoplasm and genetic mutation (1104). 
Radiation exposure used in pain procedures is 
related to factors such as the skill of the operator, the 
distance of the operator from the patient, the orienta-
tion of the operator’s head, the distance of the image 
detector from the patient, the beam collimation, the 
tube configuration, the tube voltage and filtration, 
and the complexity of the procedure (1102).
Fortunately, most studies regarding radiation 
exposure during fluoroscopy-guided pain interven-
tions have concluded that exposure levels are below 
the yearly limit established by the International Com-
mission on Radiological Protection (ICRP). However, 
exposure to low levels of ionizing radiation over the 
long-term cannot be accurately predicted. These long-
term, low-level ionizing radiation exposures may not 
acutely destroy cells, but may lead to cell damage and 
genetic mutations that can lead to sequelae years 
later (1103). 
10.4 Complications of Lysis of Adhesions and 
Neuroplasty
Lysis of adhesion was first introduced into the 
lexicon of interventional pain medicine techniques in 
1989 (1105). Since that introduction, the procedure 
has grown in acceptance and application to include 
epiduroscopy and transforaminal approaches to the 
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relief of pain secondary to adhesions (911,1105). 
While the procedure was initially introduced in the 
lumbar space, the application of the concept has ex-
panded for use in the thoracic and cervical spine as 
well (1106,1107). The complications that associated 
with the procedure are well defined and include well 
described procedure-related issues with neuraxial ac-
cess and intervention such as post procedure discom-
fort, dural puncture/tears and post-dural puncture 
headache, infection, nerve injury, transient neuro-
logic syndrome, to the more rare and higher clinical 
impact adverse events such as seizure, visual impair-
ment, neurogenic bladder, cauda equina syndrome, 
and contrast-induced rhabdomyolysis (7,1105-1108). 
Reviewing more recent literature, to date, no 
studies evaluating lysis of adhesions or neuroplasty 
in the cervical spine have evaluated complications 
or complication rates. The studies performed in this 
region have only evaluated effectiveness (1106). One 
randomized, double blinded, pilot study compared 
mechanical lysis of adhesions with chemical lysis using 
corticosteroid and hyaluronidase in the lumbar spine 
(911). This study suggested an improved outcome with 
steroid + hyaluronidase with regard at six months and 
one year but no complication rate was noted (1109). 
A recent study evaluated neuroplasty in 430 consecu-
tive patients with single level lumbar disc herniation 
demonstrating a tendency in the treatment group to 
avoid need for decompressive surgery (911). Again, in 
this study, the complication rate was not mentioned. 
Including the Marchesini report (1110), 22 complica-
tions were reported in 246 subjects with no lasting 
sequela though several of the transient symptoms 
were ominous in nature upon presentation.
11.0 IMplIcatIons antIthroMBotIc and 
antIcoagulant therapy 
Key Question 9: What are the implications of 
antithrombotic and anticoagulant therapy and epi-
dural interventions? 
Implications of antithrombotic and anticoagulant 
therapy during interventional procedures has been 
updated and multiple guidelines have been developed 
by various organizations (103,1111-1113). The use of 
prescription medications to manage thrombosis risk 
and the ease of availability of OTC and herbal products 
that mediate or modulate the coagulation cascade is 
increasing (103,1111-1127). Interventional pain physi-
cians frequently encounter the challenge of the po-
tential risk of bleeding or thrombosis in perioperative 
management of the patients receiving antithrombotic 
and anticoagulant therapy (1031,1122,1126,1128-
1150). Modulation of anticoagulant and antithrom-
botic therapy during performance of interventional 
techniques is one of the major clinical decisions often 
made without precise evidence-based literature to 
support existing opinions (103,1122,1126,1128-1150). 
Leading causes of morbidity and mortality worldwide 
include cardiovascular and cerebrovascular disease 
(1113,1114,1118,1121,1151-1154). Additionally, one 
of the leading causes of disability and functional im-
pairment across the globe is chronic persistent pain 
(3-7,39,40,168,196-200,303). Therefore, the overlap 
between chronic persistent pain and cardiovascu-
lar disease has a synergistic impact on physical and 
psychological health, affecting the performance of 
social responsibilities, including work and family life. 
Antithrombotic therapy has a clear evidence-based 
foundation with a favorable risk-benefit profile for 
prevention and management of cardiovascular dis-
ease, including limiting the present and future bur-
den of cardiac or cerebrovascular infarcts (103,1112-
1114,1127,1155-1168). A significant portion of 
patients with established cerebrovascular, cardiovas-
cular, or peripheral vascular disease who are receiving 
antithrombotic therapy, are commonly in need of 
interventional pain management. 
Based on published guidelines, derived by 
clinical case reports and consensus, a large subset 
of clinicians report stopping antiplatelet therapy 
and consider this concept as a standard of care 
(103,1126,1130,1133,1135,1169-1175). Although 
the overall incidence of bleeding complications 
and epidural hematoma in the nonobstetric epi-
dural literature has been reduced, the incidence 
has been higher with procedures involving cervical 
and thoracic spine in interventional procedures and 
is growing, with or without anticoagulant therapy 
(103,1128-1138,1148-1150,1176-1195). Of note, 
the clinical literature reports of incidences of epi-
dural hematoma cases accompanying interventional 
techniques and neuraxial techniques are increas-
ing rapidly (103,1126,1128,1138,1150,1196-1212). 
While some reports indicate a decreasing incidence 
of bleeding complications related to neuraxial tech-
niques (1209), multiple studies have been performed 
assessing the prevalence and risks related to bleed-
ing complications and epidural hematoma with 
neuraxial procedures, specifically epidural injections 
(103,1126,1128-1138,1146,1147,1150,1204-1212). In 
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fact, anticoagulants have been described to cause the 
most serious adverse events in the US. According to 
the CDC, in the US in 2011, 48% of the US popula-
tion were taking a prescription medicine in any given 
month, and 11% were taking 5 or more prescribed 
medicines. The FDA estimated that the number of 
reports it receives represents only the tip of the “ice-
berg” (1213). Among the healthcare providers and 
patients, anticoagulant drugs, Warfarin and dabiga-
tran, were on the top (1213).
Significant risks of withdrawing antiplatelet ther-
apy include cardiovascular, cerebrovascular, and pe-
ripheral vascular thrombosis. In addition, the risks are 
higher in chronic pain patients as chronic psychosocial 
stress causes a hypercoagulable state, as reflected by 
increased procoagulant molecular fibrinogen (or co-
agulation factor 7), reduced fibrinolytic capacity and 
increased platelet activity (103,1111,1212,1214,1215). 
Stress has been shown to affect coagulation activity 
via an influence on the regulation of genes coding 
for coagulation and fibrinolysis molecules (1215) with 
increase in hormonal levels (1216-1218) and an un-
derlying surge of catecholamine and cortisol induced 
hypercoagulability (1218). A prior systematic review 
and meta-analysis explored the hazards of discontinu-
ing or altering aspirin regimens among patients at 
risk for coronary artery disease (1157). Importantly, in 
patients at moderate to high risk for coronary artery 
disease, withdrawal or noncompliance with aspirin 
therapy was associated with 3-fold higher risk of 
major adverse cardiac events and the risk was mag-
nified in patients with coronary stents. The findings 
support the recommendation that aspirin discontinu-
ation in this patient population should be advocated 
only under circumstances where the risk of adverse 
outcomes caused by bleeding risk clearly outweighs 
that of catastrophic atherothrombotic events. These 
findings have been confirmed in later studies (1158-
1165,1212). Conversely, recently published large-scale 
evidence (1123-1125) shows lack of benefit of aspirin 
for primary prevention of cardiovascular events, but 
aspirin therapy is associated with increased bleeding 
episodes. Thus, current evidence suggests that the 
risks of coronary events related to patients abstaining 
from their antiplatelet medications during the peri-
operative period are more serious when compared to 
the risks of continuing antiplatelet therapy through 
the perioperative period.
Multiple publications (103,1129,1130,1138,1142,
1204,1207) have also supported the concept of con-
tinuing antiplatelet/anticoagulant agents in patients 
undergoing various interventional pain procedures in 
light of identical complication rates as compared to 
the patients who stop taking these for a particular 
recommended period. It should be noted that there 
are only a few clinical reports of an epidural hema-
toma available in patients undergoing interventional 
therapies for chronic pain, which included patients 
both continuing and discontinuing antithrombotic 
therapy. 
11.1 Prevalence and Risk Assessment of 
Studies 
Multiple studies have been published as-
sessing the prevalence, as well as the risk of 
bleeding with interventional techniques (1128-
1131,1134,1137,1138,1146-1150). In a survey of prac-
tice patterns among interventional pain physicians 
in 2012, Manchikanti et al (1128) showed that the 
majority of physicians discontinued antithrombotic 
agents; however, this study also showed that there 
were a significantly higher number of complications 
related to thromboembolic events of a total of 162 
compared to hemorrhagic complications of a total of 
55 in this population. 
In a prospective evaluation of bleeding risks 
for interventional techniques in chronic pain, 
Manchikanti et al (1129) assessed the rates of adverse 
events in patients undergoing interventional tech-
niques on antithrombotic therapy with cessation or 
without cessation and compared them to a group of 
patients without antithrombotic therapy. While the 
results showed differences in milder complications, 
there were no reports of hemorrhagic complications 
requiring any type of treatment. In this assessment, 
the authors studied all types of procedures with 1,227 
of 1,831 continuing aspirin compared to 604 of 1,831 
discontinuing them. Similarly, they also studied 100 
patients on clopidogrel with continuation, whereas, 
226 patients were discontinued. Further, there were 
128 patients with aspirin and other agents with con-
tinuation and 151 were discontinued. The procedures 
performed included cervical epidural injections with 
continued aspirin in 249 patients, thoracic epidural in 
30 patients, lumbar interlaminar epidural in 128 pa-
tients, lumbar transforaminal in 144 patients, whereas 
528 patients for caudal epidural injections, and 148 
for percutaneous adhesiolysis. In reference to clopi-
dogrel, it was continued in 10 patients undergoing 
cervical epidural, one patient with thoracic epidural, 
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14 patients with lumbar epidural, 44 patients with 
caudal epidurals, 10 with lumbar transforaminal epi-
dural, and 21 with percutaneous adhesiolysis. There 
were a large number of facet joint interventions and 
other treatments. 
Warner et al (1150) in a manuscript describing 
bleeding and neurological complications in 58,000 
interventional pain procedures showed that prepro-
cedural aspirin or nonsteroidal anti-inflammatory 
drug therapy was prevalent in 17,825 procedures or 
30.7% of the procedures without significant bleed-
ing complications. Out of total of 58,066 procedures 
performed in the study, 22.4% of the procedures 
were performed with perioperative administration 
of aspirin within 7 days, 12.1% of the patients with 
administration of nonsteroidal anti-inflammatory 
drugs within 7 days, 1.6% of clopidogrel within 7 
days. The study also included 3,880 lumbar epidural 
injections, 304 thoracic interlaminar injections with 
a large number of epidural injections with over 50% 
of the epidural injections not assigned to a region. 
They concluded that bleeding complications were 
rare in patients undergoing low or intermediate risk 
pain procedures even in the presence of antiplatelet 
medication. 
Lagerkranser (1148), and Lagerkranser and 
Lindquist (1149) have published an extensive review 
of neuraxial blocks and spinal hematoma in 2 parts 
from 1994 to 2015 covering demographics, risk fac-
tors, diagnosis, treatment, and outcome. They also 
considered previous reviews published in 1992, 1994, 
and 1996 case reviews, analyzing 29, 61, and 51 cases 
of spinal hematoma after neuraxial blocks, respec-
tively, between 1906 and 1996, in 147 manuscripts 
(1149). In managing chronic pain with epidural injec-
tions, they identified 21 hematomas, 17 (5 cervical, 4 
thoracic, and 8 lumbar) after epidural injections, and 
4 after percutaneous application of spinal cord stimu-
lators. However, they did not identify the number 
of patients developing hematoma with appropriate 
cessation of antithrombotic therapy based on recom-
mended guidelines. Overall, they showed that 37% of 
the patients who were not on antihemostatic drugs, 
whereas 63% were on antihemostatic drugs with 47 
of the cases, receiving more than one antihemostatic 
drug, and 12 receiving 3 such drugs. Further, they 
also had 6 reports which were indeterminate. Conse-
quently, the number of patients without antithrom-
botic therapy, but with hematoma formation seems 
to be almost 40%. 
Lagerkranser (1148) showed that an annual av-
erage of 7.5 published cases of spinal hematoma in 
the years 1994 to 2015, compared to an average of 
only 2.5 case reports per year from 1976 to 1993. They 
also identified that there has been a transition from a 
male to female dominance among patients suffering 
from post-neuraxial blockade and spinal hematoma 
particularly among the elderly women. They identi-
fied bloody tap at the introduction of a neuraxial 
needle or catheter as a major risk factor, but multiple 
attempts to reach the spinal canal do not seem to in-
crease the risk of spinal hematoma. Their results also 
showed that 80% of the patients developing spinal 
hematoma had severe neurological symptoms with 
paresis or paralysis. When compared over time, out-
comes have improved significantly (1148). The results 
showed that among patients subjected to surgical 
evacuation of the hematoma, outcomes were best if 
surgery was performed within 12 hours from the first 
sign of motor dysfunction. However, even patients 
operated on after more than 24 hours had relatively 
favorable outcomes. Further, outcomes after surgical 
evacuation of the epidural hematoma were satisfac-
tory, compared to subdural hematoma, which had 
poor outcomes. They recommended that suspicion 
of spinal hematoma calls for the consultation of a 
surgeon without delay. MRI was the recommended 
diagnostic tool. Surgical evacuation within 12 hours 
from the sign of motor dysfunction seems to lead to 
the best outcome, even though many patients oper-
ated on as late as after more than 24 hours did regain 
full motor function (1148). 
Appendix Table 16 describes the studies assessing 
the risk of thrombosis and bleeding with interven-
tional pain management techniques. All but 2 studies 
in this assessment are related to performing interven-
tional techniques without cessation of antithrombotic 
therapy (1128-1131,1134,1136-1138,1145,1147). Only 
one study (1128) was related to an online physician 
survey and study of spinal hematoma with neuraxial 
blocks. Among all the studies, only 2 studies included 
epidural injections (1129,1138). All others have per-
formed a large portion of procedures with low risk or 
intermediate risk including transforaminal epidural 
injections. 
A systematic review of risks and benefits of 
seizing or continuing anticoagulant medication for 
image-guided procedures for spine pain by Smith et al 
(1130), including 14 manuscripts assessing the role of 
antithrombotics in interventional pain management. 
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They showed that procedures involving interlaminar 
access carry a nonzero risk of hemorrhagic complica-
tions, regardless of whether anticoagulants are seized 
or continued. For other procedures, hemorrhagic 
complications have not been reported, and case se-
ries indicate that they are safe when performed in 
patients who continue anticoagulants. Among the 
reports they reviewed, 3 of them reported the ad-
verse effects of seizing anticoagulants, with serious 
consequences, including death. They concluded that 
other than for interlaminar procedures, the evidence 
does not support the view that anticoagulant and 
antiplatelet medication must be seized before image-
guided spine pain procedures.
Thus, based on the evidence presented from re-
views and primary studies, it appears that there is no 
significant difference whether antithrombotic therapy 
is discontinued or continued in reference to the bleed-
ing. A majority of the authors have studied intermedi-
ate and low risk procedures without the inclusion of 
epidural injections. The only one study reviewing spinal 
cord stimulation also showed lack of increased risk with 
continuation of aspirin and other NSAIDs. Consequently, 
cessation of anticoagulant medication is recommended 
only for interlaminar epidural injections in consultation 
with the patient and other healthcare providers manag-
ing antithrombotic medications, instead of seizing by 
providing them with mandatory instructions to stop for 
7 to 10 days, or even longer.
11.2 Reports of Thromboembolic Events
There have been multiple reports of thromboem-
bolic events with the discontinuation of antithrom-
botics and anticoagulants prior to performance of 
interventional procedures. Manchikanti et al (1128) 
in an assessment of practice patterns of perioperative 
management of antiplatelet and anticoagulant ther-
apy in interventional pain management reported 162 
thromboembolic events compared to 55 serious bleed-
ing complications from epidural hematomas. This 
study showed thromboembolic events were 3 times 
more frequent than bleeding complications. Further, 
they also showed bleeding complications from epi-
dural hematomas were similar whether antiplatelet 
therapy was continued or discontinued with an oc-
currence of 26 versus 29 respectively; in this survey 
the sample sizes were not provided. Consequently, it 
is difficult to assess the exact risk of bleeding compli-
cations and similarly thromboembolic events. Endres 
et al (1138) reported 9 patients with thromboembolic 
events after cessation of anticoagulant therapy out 
of 1,626 procedures. These complications included 2 
deaths 5 strokes, one pulmonary embolism, and one 
myocardial infarction in patients when anticoagu-
lants were stopped; however, they have not reported 
any bleeding complications in patients where antico-
agulants were continued. Kumar et al (1219) reported 
a case of pulmonary embolism after discontinuation 
of warfarin during a spinal cord stimulation trial. Linn 
et al (1220) also reported right middle cerebral artery 
infarction with persistent left hemiparesis, neglect 
and dysarthria with L5-S1 epidural steroid injection 
after discontinuation of warfarin for 9 days prepro-
cedure. Manchikanti et al (1204) in providing 2 case 
reports and a literature review described 2 cases of 
thromboembolic complications with cessation of anti-
thrombotic therapy. Table 25 shows reported throm-
boembolic and cardiovascular complications related 
to discontinuation of antiplatelet or anticoagulation 
therapy.
Table 25. Thromboembolic and cardiovascular complications related to discontinuation of  antiplatelet or anticoagulation therapy.
Study Type of  study Complications
Endres et al (1138) Observational report of interventional 
techniques
•  2 patients died
•  5 suffered strokes
•  1 suffered pulmonary embolism
•  1 suffered myocardial infarction
Kumar et al (1219) Case report of dorsal column stimulator 
trial
•  Pulmonary embolism without lasting complications
Linn et al (1220) Case report of L5/S1 epidural steroid 
injection
•  Right middle cerebral artery infarction with persistent left 
hemiparesis, neglect, and dysarthria
Manchikanti et al (1128) Online survey •  Reports of epidural hematoma: 55 
•  Reports of thromboembolic complications: 162
Manchikanti et al (1204) Case report and literature review of 
interventional techniques




11.3 Case Reports of Bleeding 
Complications
There were multiple case reports discov-
ered citing epidural hematoma in patients 
with or without continued antithrombotic 
therapy during an interventional technique 
(1196-1204,1210,1221-1242). 
Multiple reports of bleeding and epidural 
hematoma associated with interventional tech-
niques in patients without antithrombotic therapy 
have been published (1176-1178,1180,1181,1183-
1 1 9 4 , 1 2 0 2 , 1 2 0 4 , 1 2 0 7 , 1 2 0 8 -
1222,1225,1227,1231,1233,1234,1238,1240,1242-
1249), whereas several reports of bleeding in 
patients with discontinued antithrombotic 
therapy also have been published (1196,1199-
1201,1204,1205,12101223,1228-1230,1232). 
Reports of bleeding complications and epi-
dural hematoma in patients with continuation 
of antiplatelet therapy with interventional 
techniques also have been published. Mul-
tiple reports of bleeding complications with 
continuation of anticoagulant therapy dur-
ing interventional techniques were identified 
(1197-1199,1202,1203,1224,1239,1241).
Figures 24-26 show summary reports of 
several epidural hematomas with epidural 
injections, acupuncture and dry needling, and 
spinal cord stimulation lead placement in pa-
tients without antithrombotic therapy, with 
antithrombotic therapy withheld for an ap-
propriate duration, and with antithrombotic 
therapy continued. A total of 46 epidural hema-
tomas were described in 43 case reports. There 
were 23 in the cervical spine, 8 in the thoracic 
spine, and 15 in the lumbar spine. Of these, 21 
patients were not on antiplatelet therapy, 9 pa-
tients had their antithrombotic therapy discon-
tinued, 14 continued antithrombotic therapy, 
and 2 cases were due to fish oil and one case of 
ketorolac and paroxetine. Further, as shown in 
Fig. 26, epidural injections were responsible for 
33 cases of hematomas, 7 cases were secondary 
to acupuncture or dry needling and 6 were re-
lated to spinal cord stimulation. There was one 
case report of caudal epidural injection with 
cilostazol (1241), and in one case report, we 
were unable to obtain full manuscript (1246). 
Cases of chronic subdural hematoma and cases 
of abdominal hematomas were not included. 
Fig. 24. Epidural hematoma incidence based on presence or absence of  
anticoagulant/antiplatelet therapy following administration of  epidural 
injections.
Fig. 25. Epidural hematoma incidence based on spinal regions
Fig. 26. Epidural hematoma cases reported based type of  procedure
Pain Physician: Epidural Guidelines 2021 24:S27-S208
S144  www.painphysicianjournal.com
11.4 Guidelines and Recommendations
Guidelines and recommendations were based on 
risk stratification, pharmacology of antithrombotics 
and anticoagulants, and the application of available 
evidence.
11.4.1 Risk Stratification 
Interventional techniques performed in the spine 
and other regions for chronic cancer and noncancer 
pain patients face variable risks depending on antico-
agulant or antithrombotic therapy, age, anatomy, the 
specific region of interest, and obesity. Consequently, 
various authors have described procedural classifi-
cations according to the potential risk for serious 
bleeding. 
Raj et al (1250) stratified risk scores based on 
technique related bleeding risk and patient-related 
bleeding risk factors. This risk classification took 
various factors into consideration including a sharp 
or blunt needle, as well as the use of fluoroscopy and 
lack of fluoroscopy. 
Breivik et al (1133), in a comprehensive topical re-
view of reducing risk of spinal hematoma from spinal 
epidural and pain procedures, based their recommen-
dations on an extensive review of 166 case reports 
published from 1994 through 2015 (1148,1149), phar-
macology of drugs, and available clinical evidence re-
lating to complications whether the antithrombotics 
were continued or discontinued.
Narouze et al (1111) provided guidance for in-
terventional spine and pain procedures in patients 
on antiplatelet and anticoagulant medications. They 
provided an extensive review of the literature, con-
sidered pharmacology, and current literature with 
development of risk stratification.
Deer et al (1112) provided recommendations on 
bleeding and coagulation management in neuro-
stimulation devices. They also provided bleeding risk 
stratifications for neuromodulation procedures. Their 
classification showed spinal cord stimulation trial and 
implant, dorsal root ganglion stimulation, and intra-
thecal catheter and pump implant as high to inter-
mediate risk neuromodulation procedures. Further, 
they classified deep brain stimulation and motor cord 
stimulation as high-risk neuromodulation procedures. 
This is in contrast to other guidance where spinal cord 
stimulation trial and implant, dorsal root ganglion 
stimulation, and intrathecal catheter and pump im-
plant are considered as high risk.
Oprea et al (1126) published risk stratification, 
perioperative, and periprocedural management of 
patients receiving anticoagulant therapy based on 
Low-Risk Procedures Intermediate-Risk Procedures* High-Risk Procedures*
1. Trigger point and muscular injections 
(including piriformis injection)
2. Peripheral joints 
3. Peripheral nerve blocks 
4. Sacroiliac joint and ligament injections and 
nerve blocks 
5. Caudal epidural injections 
6. Ganglion impar blocks
1.  Facet joint interventions (intra-articular 
injections, nerve blocks and radiofrequency 
neurotomy) 
2.  Lumbar transforaminal epidural injections 
at L4, L5, S1 
3. Lumbar intradiscal procedures 
4. Hypogastric plexus blocks 
5. Lumbar sympathetic blocks
6. Peripheral nerve stimulation trial and 
implant
7.  Pocket revision and implantable pulse 
regenerator/ intrathecal pump replacement
8. Caudal percutaneous adhesiolysis 
9.  Lumbar percutaneous disc decompression 
(L4/5 or below) 
10. Lumbar vertebral augmentation (below 
L4) 
11. Intervertebral spinous prosthesis 
12. Lumbar discography 
1. Cervical, thoracic, and lumbar interlaminar 
epidurals 
2. Cervical, thoracic and lumbar above L3 
transforaminal epidural injections 
3. Spinal cord stimulator trial and implant 
4. Percutaneous adhesiolysis with interlaminar 
or transforaminal approach 
5. Percutaneous disc decompression (above 
L4/5) 
6. Sympathetic blocks (stellate ganglion; 
thoracic splanchnic, celiac plexus) 
7. Thoracic and cervical intradiscal 
procedures 
8. Vertebral augmentation, lumbar (above L4), 
thoracic and cervical 
9. Intrathecal catheter and pump implant 
10. Interspinous prosthesis and MILD®
Table 26. Classification of  interventional techniques based on the potential risk for bleeding.
*Patients with high risk of bleeding (e.g., old age, history of bleeding tendency, concurrent uses of other anticoagulants/antiplatelets, liver cirrhosis 
or advanced liver disease, and advanced renal disease) undergoing low or intermediate-risk procedures should be treated as intermediate or high 
risk, respectively.
Source: Kaye AD, et al. Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques: 
American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2019; 22:S75-S128 (103).
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bleeding risk for each procedure, pharmacology, and 
evidence of the risk of the development of bleeding 
complications as well as thromboembolic risks.
Lagerkranser (1148), and Lagerkranser and 
Lindquist (1149), published an extensive review of 
neuraxial blocks and spinal hematoma with review of 
100 case reports published from 1994 to 2015 with 
demographics and risk factors, as well as diagnosis, 
treatment, and outcomes. They described multiple 
risk factors related to hemostasis, elderly females, and 
spinal disorders and complicated blocks, especially 
spinal stenosis and “bloody taps,” whereas multiple 
attempts do not seem to increase the risk of bleed-
ing. Further, they conceded that in a large number of 
cases, no risk factor was reported. 
Multiple factors and the available literature in 
reference to the adverse consequences of antico-
agulant and antithrombotic therapy with interven-
tional techniques were utilized in developing risk 
stratification. The following classification for inter-
ventional techniques has been developed (Table 26) 
(103,1126,1128-1136,1148,1149,1239,1250). The clas-
sification describes low risk, intermediate risk, and 
high-risk procedures. However, based on comorbid 
medical conditions and other risk factors of coagu-
lopathies and concurrent use of other anticoagulants 
and antiplatelets, the procedural risk classification 
may be changed from low risk to intermediate, and 
intermediate to high risk.
Of all the low risk procedures as shown in Table 
26, the caudal epidural injection was the only one 
which has reported an epidural hematoma with 
continuation of cilostazol (1241). This is extremely un-
usual and probably coincidental. Consequently, with 
caudal epidural injections and other low risk proce-
dures, antithrombotic and anticoagulant therapy may 
be continued with the appropriate guidelines.
Intermediate risk procedures include multiple 
procedures performed, constituting a great propor-
tion of the procedural prevalence. This risk stratifi-
cation is somewhat different from the one proposed 
by American Society of Regional Anesthesia and Pain 
Medicine (ASRA) (1111). Justifiably, we have included 
caudal percutaneous adhesiolysis into intermediate 
risk procedures as there have not been any case re-
ports. Further, lumbar transforaminal epidural injec-
tions at L4, L5, S1, and sympathetic blocks have been 
included in these categories due to 2 case reports 
of lumbar transforaminals resulting in hematoma 
without antithrombotic therapy and 2 case reports 
of sympathetic blocks. Lumbar interlaminar epidural 
injections performed between L5 and S1 are included 
in the intermediate risk procedures; whereas, pro-
cedures performed at L4-5 and at higher levels are 
included in the high risk procedures. A majority of 
the lumbar epidural hematomas developed despite 
the discontinuation of antithrombotic therapy, and 
these were performed above the L5-S1 interspace. 
If epidural hematoma develops at L5-S1 it will have 
significantly higher space availability to be asymp-
tomatic and to be managed conservatively. 
The high-risk procedures include the majority of 
the procedures performed in the cervical and tho-
racic spine. These guidelines are in contrast to ASRA 
guidelines with the inclusion of cervical, thoracic, and 
lumbar due to the available literature and potential 
issues related to epidural hematoma requiring surgi-
cal exploration and spinal cord damage.
11.5 Pharmacologic Aspects and Hemostasis 
Monitoring
The main categories of antithrombotics and 
anticoagulants are described as; platelet inhibitors, 
interfering with platelet aggregation (clumping) and 
thrombus formation; anticoagulants interfering with 
formation of the clotting, thereby reducing fibrin 
formation and preventing clots from forming and 
expanding; and fibrinolytics interfering with the final 
clot.
Monitoring of hemostasis is performed with 
multiple standard tests including platelet count, acti-
vated partial thromboplastin time (APTTa), and inter-
national normalized ratio (INR) (1133). A normal INR 
is considered as 0.9 to 1.2. Consequently, for epidural 
injections, an INR of less than 1.5 is ideal for high risk 
and moderate risk procedures, and less than 1.8-2.00 
is ideal for low risk procedures. 
Additional advanced hemostatic tests for moni-
toring of hemostasis include multiple viscoelastic tests 
like thromboelastography or thromboelastrometry 
extensively used to evaluate liver disease (1251). How-
ever, this parameter has been studied for safe epidural 
catheter removal with the conclusion that the tests 
were not well validated in this context and there were 
frequent false negative test results (1252,1253). Even 
then, a clearly abnormal curve indicates deranged 
hemostasis and must be taken seriously (1253,1254). 
11.5.1 NSAIDS and Aspirin 
NSAIDs inhibit cyclooxygenase enzymes COX1 
and COX2, which inhibit prostaglandin production 
to decrease the inflammatory response. Thus, NSAIDs 
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have analgesic effects and are used for minimizing 
pain. Thromboxane A2 is produced via COX1 enzyme 
activity, which is a potent thrombus activator. Aspirin 
is an irreversible inhibitor of COX1 and has significant 
clinical benefits for preventing thrombus formation. 
In response to aspirin, more prostacyclin is produced 
by endothelial cells, but there is no additional throm-
boxane made as there are no nuclei in platelets, thus, 
there is a greater percent of prostacyclin to throm-
boxane, thinning the blood. Elevated bleeding risk is 
a concern for a small portion of patients, but adverse 
effects are rare. Prostacyclin (PGI2) synthesis from vas-
cular endothelial cells is dependent on COX2 and has 
anti-platelet effects. High doses of aspirin reduce PGI2 
production which can abolish the anti-platelet effect 
of low dose aspirin. Low-dose aspirin anti-platelet 
effects last for 7-10 days, as bone marrow directed 
platelet renewal is required for clotting to resume. 
Low-dose aspirin therapy is well established to reduce 
the risk of cardiovascular events in patients with acute 
coronary syndromes, cerebral infarct, or occlusive 
vascular disease (1255). However, recently published 
large scale evidence (1121,1123-1125) shows a lack 
of benefit with aspirin for the primary prevention of 
cardiovascular events, while it does increase the risk 
of bleeding. 
Table 27 shows pharmacokinetic and pharmaco-
dynamic characteristics of aspirin and NSAIDs. Time 
to 50% recovery of platelet function with aspirin is 
shown as 3 days (1133). Antiplatelet function of ir-
reversible inhibitors is dependent mainly on platelet 
regeneration than drug half-life. 
For other NSAIDs, unlike aspirin, the platelet ef-
fects of these drugs are directly related to systemic 
plasma drug concentrations and influenced by the 
pharmacokinetic clearance of these medications. It 
takes approximately 5 half-lives for systematic elimi-
nation. Recommendations (103,1111,1112) have been 
revised for aspirin, whether to continue or discon-
tinue in the perioperative period for interventional 
pain procedures. Decision-making is based on the rea-
son for aspirin utilization, a multitude of risk factors 
including vascular anatomy surrounding the target 
area, degree of the invasiveness of the procedure, 
and potential sequelae associated with perioperative 
bleeding. Thus, aspirin for primary prophylaxis can be 
stopped without any hesitation. The major consider-
ation in withholding aspirin is the thromboembolic 
risk. Based on the available evidence, it appears that 
aspirin discontinuation for 4 days may be sufficient. 
In contrast, for nonsteroid anti-inflammatory agents, 
recommended discontinuation by ASRA is one day for 
diclofenac, ibuprofen, and Ketoralac. Recommended 
discontinuation time is 2 days for etodolac and indo-
methacin. Discontinuation is about 4 days for meloxi-
cam and Naprosyn, 6 days for Nabumetone, and 10 
days for piroxicam and Oxaprozin. However, the evi-
dence for stopping NSAIDS agents other than aspirin 
seems to be very limited. Stopping these drugs may 
become a practical issue and patients may not like 
it to stop all the drugs and complain of significantly 
more pain. Consequently, based on the available, 
very limited, evidence, the clinician may continue or 
discontinue. In reference to ketorolac, this is used 
Table 27. Characteristics of  aspirin and NSAIDs.
Aspirin or acetylsalicylic acid (Oral 
Low Dose)
NSAIDs
Target COX -1 irreversible COX-1 reversible, COX-2
Time to peak effect 0.5 hours Varies
Plasma Half Life 0.5 hours Variable from 1 to 72 hours
Renal elimination + +
Time to 50% recovery of platelet function 3 days 1 day
Hours to C-Max 0.5 hours ~0.5 hours
Metabolism Hepatic Hepatic
Bioavailability 60% 50-95%
Antihemostatic effect ++ +
NSAID = non-steroidal anti-inflammatory drug; COX = cyclo-oxygenase
Rating of antihemostatic effect and renal elimination: (+) = insignificant; + = low; ++ = moderate; +++ = pronounced; ++++ = high.
Source: Kaye AD, et al. Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques: 
American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2019; 22:S75-S128 (103).
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intraoperatively or postoperatively. Consequently, it 
is not advisable to administer ketorolac to patients 
during or after epidural injections.
11.5.2 Adenosine Diphosphate Receptor Inhibitors
Adenosine diphosphate (ADP)-receptor inhibitors 
inhibit platelet aggregation. The drugs in this category uti-
lized for clinical applications include Clopidogrel (Plavix®), 
Prasugrel (Effient®), Ticlopidine (Ticlid®), and Ticagrelor 
(Brilinta®). Table 28 shows comparative pharmacokinetics 
and pharmacodynamics of ADP-receptor inhibitors.
Clopidogrel is the prototypical thienopyridine drug 
that inhibits the P2Y12 receptor. The P2Y12 receptor is 
activated by ADP binding and promotes platelet aggre-
gation. Depending on the dosage schedule, the maximal 
platelet aggregation inhibitory effects of clopidogrel 
are reached within 3 to 7 days. After discontinuation, 
recovery of platelet inhibition occurs 50% after 3 days 
and full recovery after one week (1256). Eighty percent 
of subjects demonstrated normal platelet aggregation 
by the 4th day (1256). Other studies have demonstrated 
the recovery of platelet function after the cessation of 
aspirin in volunteers in surgical patients after 3 days 
in volunteers and within 4-6 days in surgical patients 
(1257). In this study, by day 6 all of the subjects had 
restored platelet aggregation to at least 85% of the 
baseline level. 
Ticlopidine also belongs to the thienopyridine group 
and is maximally aggregated after 8 to 11 days of a 500 
mg per day dosage schedule. After withdrawal of 72 hours, 
there is still a lingering effect as there is an irreversible inhi-
bition of platelet function (1258). Prasugrel acts by antago-
nizing ADP at the platelet’s purine receptors, and aggrega-
tion is thus noncompetitively and irreversibly inhibited. 
Prasugrel, or Effient, has significantly higher irre-
versible antiplatelet activity compared to clopidogrel 
with time to peak effect of one hour. Thus, administra-
tion of the first dose results in around half of the plate-
lets being inhibited within the first hour of taking this 
medication. Following three to five days of therapy, the 
steady-state inhibition of platelet aggregation reaches 
around 70% (1259). As a prodrug, prasugrel is rapidly 
metabolized to active and inactive metabolites. These 
metabolites have varying elimination rates, although 
the active metabolites have an elimination half-life of 7 
hours, with a wide range of 2-15 hours (1260).
Lastly, a distinct ADP-receptor inhibitor is Ticagre-
lor, which directly inhibits P2Y12 receptors (1259-1263). 
While Ticagrelor is metabolized to active metabolites, the 
original compound is responsible for the majority of the 
Table 28. Comparative pharmacokinetics/pharmacodynamics of  ADP-receptor inhibitors.
 Clopidogrel (Plavix®) Prasugrel (Effient®) Ticlopidine (Ticlid®) Ticagrelor (Brilinta®)
Target P2Y12ADP P2Y12ADP
P2Y12ADP, also inhibits 




activity ++ +++ ++ ++++
Time to Cmax 3-7 days 3-5 days 8-11 days 2-4 hours
Time to peak effect 4 hours to 4 days 1 hour 3-5 days 2.5 hours
CYP metabolism
CYP1A2, CYP2B6, 
CYP2C9, CYP2C19 and 
CYP3A4/5
CYP450-mediated 
(primarily CYP3A4 and 
CYP2B6) 
Cytochromes P450 CYP3A4
Bioavailability > 50% ≥ 79% > 80% 36%
Protein binding 94–98% Active metabolite: ~98% 98% >99.7%
Plasma half-life 7-8 hours (inactive metabolite)
~7 hours (range 2 hours to 
15 hours)
12 hours (single dose) 4-5 
days (repeated dose)
7 hours (ticagrelor), 8.5 
hours (active metabolite 
AR-C124910XX)
Renal elimination 50% kidney, 46% biliary
Urine (~68% inactive 
metabolites); feces (27% 
inactive metabolites)
Renal and fecal Biliary
Time to 50% recovery 
of platelet function 3 days 3 days 6 days 1.5 days
CYP = cytochrome P450
Source: Kaye AD, et al. Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques: 
American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2019; 22:S75-S128 (103).
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inhibitory effects (1262,1263). A notable advantage of Ti-
cagrelor is rapid effect, with peak platelet inhibition after 
2 to 4 hours of intake (1264). These medications undergo 
hepatic conversion to active metabolites, which are then 
eliminated by the kidneys (1265). In addition, glycoprotein 
IIB/IIIA receptors are less activated, causing a reduction in 
fibrinogen fixation and platelet crosslinking.
ADP inhibitors were described as responsible for the 
formation of an epidural hematoma after central neur-
axial blockade in 2.5% of 160 cases or 4 cases. In the pres-
ent assessment, clopidogrel either in combination with 
aspirin or ticlopidine was utilized in a total of 3 cases, with 
2 cases being discontinued appropriately and one case it 
was continued. Thus, ADP inhibitors with reports available 
for only one or 2 drugs showed any relevance in 8% of 
the cases with only one case or 2.6% of cases where it was 
continued and in 5% of the cases it was discontinued. This 
is similar to the reports from Lagerkranser et al (1148).
11.5.3 Phosphodiesterase (PDE) Inhibitors
Phosphodiesterase inhibitors include Cilostazol (Ple-
tal®) and Dipyridamole (Persantine®). These medications 
selectively inhibit phosphodiesterase, which leads to an 
increase in intracellular cyclic adenosine monophosphate 
(cAMP) and subsequent reversible inhibition of platelet 
aggregation (1266). Additionally, Dipyridamole blocks 
thromboxane synthase, the thromboxane receptor, and 
the cellular reuptake of adenosine into platelets, red blood 
cells, and endothelial cells. This results in increased ad-
enosine in the extracellular space and inhibition of forma-
tion of cytokines and proliferation of smooth muscle cells. 
Absorption of Dipyridamole occurs in the gastrointestinal 
tract and is pH dependent. Gastric acid suppressors and 
proton pump inhibitors inhibit absorption, which can be 
prevented via buffered additives added to the medication 
(1267). An additional advantage of Cilostazol is inhibition 
of PDE3A, which is selective to vascular smooth muscle cells 
and results in vasodilatation. Cilostazol is administered at 
100 mg twice daily and reaches maximum plasma levels 
after three hours. It is eliminated via hepatic metabolism 
and is excreted in the urine (1268). Thus, cilostazol is con-
traindicated in those with severe renal insufficiency. For 
interventional procedures, phosphodiesterase inhibitors 
have been considered as safe to continue. However, risk 
may increase with the addition of aspirin. Limited data 
exists evaluating the risk of perioperative surgical bleed-
ing with cilostazol (1270) and no standard perioperative 
guidelines are available (1269). Further, if the medication 
is discontinued, at 50 hours (approximately 5 half-lives), 
less than 5% of the drug remains in plasma and improve-
ments in platelet aggregation have been demonstrated, 
despite continuous prior dosing (1270).
There is a single case report of bleeding complications 
associated with an interventional technique (1241). In this 
case report, the patient underwent a caudal epidural injec-
tion developing an epidural hematoma extending from L2 
through S1 with concomitant central canal compromise, 
severe at L2-3 and L3-4 levels. This patient had received, in 
the past, lumbar interlaminar epidural injection without 
any side effects. Emergency decompression laminectomy 
was carried out with the patient making full recovery. 
This is the only case report in interventional techniques. 
Cilostazol alone without aspirin is recommended to be 
continued during interventional techniques. Lagerkranser 
et al (1148) also reported 2 cases of phosphatase inhibitors 
with dipyridamole with an incidence of 1.3% in 160 cases. 
Overall cilostazol is considered as a low risk drug and its 
continuation is appropriate.
11.5.4 Glycoprotein GPIIb/IIIa Inhibitors
A final common component of platelet aggregation 
is the glycoprotein IIb/IIIa receptor. Specialized medica-
tions inhibit this receptor, potently inhibiting platelet 
aggregation while being reversible (1220). 
Abciximab (ReoPro®) is a Fab fragment of a human-
ized monoclonal antibody directed against the GFPIIb 
receptor. Abciximab inhibits over 80% of ADP-induced 
platelet aggregation and is given via IV administration. 
Additionally, thrombin generation is inhibited by Abcix-
imab, which quickly binds to platelets with high affinity.
Eptifibatide (Integrilin®) is a cyclic peptide inhibitor 
of the fibrinogen binding site on the GPIIb receptor. 
Tirofiban (Aggrastat®) is an additional glycoprotein IIb/
IIIa receptor inhibitor, reaching maximum efficacy after 
4 hours of administration, with 50-80% inhibition of 
platelet aggregation (1271). Platelet function normal-
izes 8 to 24 h after stopping the IV infusion.
There were no case reports secondary to the de-
velopment of epidural hematoma in patients receiving 
glycoprotein IIB/IIIA. Additionally, it appears that these 
drugs are not commonly used for prevention of throm-
boembolic activity. 
11.5.5 Low-Molecular Weight Heparin
Low molecular weight heparins (LMWHs) inhibit the 
coagulation cascade via binding to antithrombin, which 
leads to a conformational change of antithrombin, which 
accelerates inhibition of factor Xa. LMWH has advantages: 
relatively high bioavailability, longer half-life, and ability 
for use once per day. Maximum efficacy levels are observed 
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after 3-4 hours post subcutaneous administration, and 
elimination occurs after 4-6 hours in those with normal 
renal function (1272). High molecular weight heparins 
(HMWH) catalyze the inhibition of clotting factors IXa, 
Xa and thrombin by greatly enhancing antithrombin III 
activity, by causing a conformational change in ATIII ex-
posing its reactive site. Testing is required to determine 
the dose effect on coagulation via partial thromboplastin 
time (PTT). HMWH is not absorbed by GI tract due to its 
large molecular weight, therefore IV or SC injection must 
be used. The short half-life of (HMWH approximately 1h) 
means frequent injections or continuous infusion, and it is 
thus not considered suitable in an outpatient setting.
Low molecular weight heparin is one of the common-
ly used drugs and has been implicated in multiple cases of 
epidural hematoma. Lagerkranser et al (1148) showed low 
molecular weight heparin being responsible for the high-
est number of cases in 31% of the reports. Our reports also 
show 2 cases of warfarin with bridging with LMWH being 
responsible for epidural hematoma (1229,1230), both in 
the lumbar spine. 
11.5.6 Warfarin
Oral anticoagulants inhibit the synthesis of vitamin K-
dependent clotting factors, which are factor II, VII, IX, and 
X. Warfarin blocks the gamma-carboxylation of glutamate 
residues in prothrombin and factors VII, IX, and X. This re-
sults in biologically inactive coagulation factor molecules. 
Vitamin K epoxide reductase is the enzyme that catalyzes 
the carboxylation reaction. Therapeutic doses of warfarin 
inhibit vitamin K epoxide reductase, which prevents the 
reductive metabolism of the inactive vitamin K epoxide 
to its active hydroquinone form. Synthesis is the primary 
target of oral anticoagulants (warfarin), therefore the 
effects of these medications are not apparent until previ-
ously-existing clotting factor turnover has occurred. Factor 
half-lives vary, from factor VII at 6-8 hours to factor II at 
50-80 hours (1273). Thus, it has a slow onset of action (8-12 
hours) as existing clotting factors must be depleted, and 
the maximal effect occurs 3-5 days after administration. 
Warfarin is monitored by PT and INR, which is a normalized 
ratio of the patient’s PT to that of a control sample (1273). 
Age, female gender, and preexisting medical conditions 
such as hepatic, cardiac, and renal disease modify the pa-
tient’s response to warfarin. Asian patients, for example, 
have higher sensitivity to warfarin and require lower doses 
than those patients of European descent (1273). Dietary 
changes may alter the patient’s clotting ability, and those 
on Warfarin are advised to avoid grapefruit and cranberry 
products, eat a consistent amount of leafy greens and 
other high vitamin K containing foods and are advised to 
limit herbal supplement intake of garlic, ginger, gingko 
biloba, ginseng, and fish oil. Warfarin may be reversed 
with administration of vitamin K, which is associated with 
multiple side effects. 
Warfarin is one of the most common drugs utilized in 
patients undergoing interventional techniques. Multiple 
complications have been reported with case reports of 
epidural hematoma in patients with warfarin, despite be-
ing stopped per the guidelines. 
Lagerkranser et al (1148) reported warfarin con-
tributing to spinal hematoma in 11% of the cases. They 
showed cases of warfarin which were stopped appropri-
ately with 2 of them also receiving enoxaparin with a 
similar incidence of around 10%.
11.5.7 Direct Thrombin Inhibitors
Direct thrombin inhibitors include Dabigatran 
(Pradaxa®), Argatroban (Acova™), Bivalirudin (Angio-
max®), Lepirudin (Refludan®), Desirudin (IPRIVASK®), and 
Hirudin as shown in Table 29. Of all the direct thrombin 
inhibitors, Dabigatran may be reversed by Idarucizumab 
(Praxbind®), which was approved in 2015. 
Dabigatran etexilate is an oral anticoagulant and is a 
prodrug that is converted to dabigatran in the plasma. Af-
ter an oral dose, the peak effect is reached within 2 to four 
hours, and plasma half-life is 13 hours on average (1274). 
Dabigatran dose recommendations depend on renal effi-
cacy in the patient receiving the medication. In those with a 
creatinine clearance of greater than 30mL/minute, 150 mg 
is taken orally twice daily. For patients with lower creatinine 
clearance, 75mg twice daily is recommended. Dabigatran’s 
function is via factor inhibition and not clotting factor 
depletion, thus, the administration of clotting factors is 
anticipated to be less effective in reversing the effects of 
dabigatran. Dabigatran is mostly cleared by the kidneys. In 
those with normal kidney function, dabigatran is excreted 
in 1-2 days post-discontinuation. This also depends on renal 
sufficiency of the patient taking the medication. There is 
one case report with epidural hematoma despite its dis-
continuation for 7 days prior to interventional techniques 
(1215). Lagerkranser et al (1148) also reported on a case of 
spinal hematoma out of 160 cases. 
Argatroban is a small molecule direct thrombin 
inhibitor that is administered intravenously. It reaches 
steady-state plasma concentrations in 1-3 hours and is me-
tabolized via the liver. It has a half-life of 50 minutes and 
is monitored by PTT. As it is metabolized hepatically, it is 
a viable alternative for Dabigatran, which is metabolized 
renally (1275).
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Time to Cmax 2-4 hours 1-3 hours 2 minutes 4 hours 1-3 hours 3 hours
Time to peak 
effect 0.5 – 2 hours 2 hours 15 min 0.5-2 hours 2 hours 3-4 hours
Metabolism
Metabolized via 
conjugation into 4 
acyl glucuronides, 




thought to be 
metabolized by 
release of amino 
acids via catabolic 




from the C-terminus 






Bioavailability 3-7%(Oral) 100% IV 100%  IV application only
100% (injection 
or infusion) 100% 100% IV
Protein binding 35% 54% no n/a n/a n/a
Plasma half-life 13 hours 50 minutes




1.3 hours 2-3 hours 80 minutes
Renal elimination 80% urine Liver Yes Yes Yes Renal, about 48% (35% unchanged)
Linear PK Yes Yes Yes Yes Yes Yes




12 hours 2 hours 0.5 hours 1.5 hours 2 hours 2 hours
Reversal agents Praxbind NA NA NA NA NA
CYP = cytochrome P450; IV = intravenous
Source: Kaye AD, et al. Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques: 
American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2019; 22:S75-S128 (103).
Bivalirudin works by binding specifically to the 
catalytic site, in addition to the anion-binding exosite of 
circulating and clot-bound thrombin. Bivalirudin is cleared 
by the kidney and thus is dose-dependent on overall renal 
function. It has as a half-life of 25 minutes in those with 
normal renal function, but this may be doubled in those 
with severe renal insufficiency (1276).
Desirudin is a subcutaneously administered direct 
thrombin inhibitor and is indicated for the prevention of 
venous thromboembolism after total joint replacement. 
It is recommended that dosage adjustment and aPTT be 
monitored in patients with moderate-to-severe renal 
impairment. After intravenous administration, desirudin 
is removed rapidly via the renal system, with 90% of the 
dose removed from the plasma within 2 hours. Plasma 
concentrations decline with a mean half-life of 2-3 hours. 
Subcutaneous administration demonstrates a half-life of 
2 hours (1277).
Hirudin has specific activity on fibrinogen and binds 
to and inhibits only activated thrombin, making it an 
extremely potent direct thrombin inhibitor. Thus, hirudin 
dissolves the formation of clots and thrombi and has 
therapeutic value in coagulation disorders. It is also able 
to act on complexed thrombin and does not alter other 
serum protein function or activity (1278). Hirudin has a 
half-life of 2-3 hours and is monitored by a PTT, allowing 
close titration over a wide range of anticoagulative clini-
cal desires. Activated clotting time (ACT) and prothrombin 
time (PT) are insensitive for monitoring hirudin.
11.5.8 Direct Factor Xa Inhibitors
Direct factor Xa inhibitors such as Rivaroxaban 
(Xarelto®) have been commonly used in the US (Table 30). 
Of multiple Xa inhibitors available, apixaban (Eliquis) and 
rivaroxaban (Xarelto®) can be reversed by Andexanet alfa 
(Andexxa®), a coagulation factor Xa (recombinant), which 
has been approved by the FDA for the urgent reversal of 
the anticoagulant effect in 2018 (1279). 
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Rivaroxaban (Xarelto®) has dual renal and hepatic 
clearance, with around one-third of the drug being 
active with each route of metabolism. This dual route 
of clearance makes accumulation less likely than other 
medications that are solely hepatically or renally cleared. 
Rivaroxaban is orally administered and has a half-life of 
5.7 to 9.2 hours. Plasma protein binding of rivaroxaban 
is 92-95%. One third of the absorbed dose is excreted in 
the urine, and two-thirds of the dose is excreted as an 
inactive metabolite in the feces and urine. Rivaroxaban 
has the potential for drug interactions with medications 
that are P-glycoprotein inhibitors and those metabo-
lized by CYP3A4 (1280).
Apixaban (Eliquis®) is a specific factor Xa inhibi-
tor like its counterpart, rivaroxaban. It is rapidly ab-
sorbed and reaches peak concentrations in 1-2 hours 
(1281,1282). Apixaban has an oral availability of 45% 
and has a relatively complex elimination pathway with 
both direct renal and intestinal excretion, with the lat-
ter being the majority (1282,1283). Edoxaban (Savaysa® 
or Lixiana®) was approved for the prevention of venous 
thromboembolisms following lower limb orthopedic 
surgery in 2011 and is an oral direct factor Xa inhibitor 
that inhibits free factor A and prothrombinase activity. 
It has also been approved for the prevention of stroke 
and systemic embolism. Peak plasma concentrations 
are reached 1.5 hours after oral administration, and it 
has an elimination half-life of 10-14 hours when taken 
at 60mg once daily. It is excreted via both hepatic and 
renal systems (1284). It is orally available, and not re-
moved by dialysis.
Betrixaban (Bevyxxa®) is a potent oral factor Xa 
inhibitor that recently received FDA approval. It has 
exemplified promising results, as it has low hERG af-
finity and has reduced bleeding risk and prevented 
thromboembolism in clinical trials for orthopedic knee 
surgery (1285-1287). Betrixaban has the smallest per-
cent of renal clearance, is INR/PTT insensitive, and has 
minimal liver metabolism. Another selective factor Xa 
inhibitor, Fondaparinux (Arixtra®) is 100% bioavailable 
and achieves maximum concentration in 1.7 hours of 
administration (1288). Its extended half-life of 17 to 21 
hours allows once-daily dosing (1289).
There were no case reports in the present assess-
ment; however, Lagerkranser et al (1148) showed 2 
cases of spinal hematoma with rivaroxaban yielding 
1.3% prevalence among 160 cases developing spinal 
hematoma.
11.5.9 Thrombolytic Agents
Fibrinolysis is caused by thrombolytic agents via 
conversion of plasminogen and thrombi to plasmin to 
destroy clots. These “clot busters” such as recombinant 
tissue-type plasminogen activator (tPA), streptokinase, 
urokinase, tenecteplase, and reteplase are enzymes 
that have effects on both circulating and tissue type 
plasminogen. The half-life of these thrombolytic drugs 
is generally a few hours, but the inhibition of plasmino-











Target Xa Xa Xa Xa Xa
Time to Cmax 1-3 hours 2-4 hours 1-2 hours 3-4 hours 2 hours
Time to peak effect 3-4 hours 2-4 hours 1-2 hours 3-4 hours 2-3 hours
CYP Metabolism 15% 32% NR NR n/a
Bioavailability 66% 80% >45% 34% 100%
Transporter P-gp P-gp/BCRP P-gp P-gp P-gp
Protein binding 87% >90% 55% 60% 94%
Plasma Half-life 8-15 hours 9-13 hours 8-10 hours 37 hours 17-21 hours
Renal elimination 25% 33% 35% < 1% 100%
Linear PK Yes No Yes n/a Yes
Time to 50% recovery 
of Xa 12 hours 12 hours 12 hours 19-27 hours 12 hours
Reversal AGENTS Andexxa Andexxa NA NA NA
BCRP = breast cancer resistance protein; CYP = cytochrome P450; NR – not reported; P-gp = P-glycoprotein
Source: Kaye AD, et al. Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques: 
American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2019; 22:S75-S128 (103).
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gen and fibrinogen may last for up to 27 hours after 
administration (1290).
There were no reports of epidural hematoma de-
velopment in patients receiving thrombolytic agents in 
our analysis; however, Lagerkranser et al (1148) reported 
4 cases or 2.5% in the review of 160 cases of spinal he-
matoma. Among the miscellaneous agents, Chien et al 
(1198) reported a case of epidural hematoma in a patient 
receiving fluoxetine, fish oil, and vitamin E. There was 
also another case report by Jenkie et al (1203) with fish 
oil and the development of cervical epidural hematoma 
leading to surgical intervention for decompression. La-
gerkranser et al (1148) also reported one patient on 
selective serotonin receptor inhibitor of 160 cases.
11.5.10 Cannabis (TCH and CBD)
Cannabis is a genus of plants of the Cannaba-
ceae family and contains more than 500 compounds 
- 120 cannabinoids and 80 biologically active chemical 
compounds (1291-1293). Cannabis interacts with the 
endocannabinoid system, composed of a network of 
receptors (CB1 and CB2), signaling molecules, and en-
zymes. Two common compounds found in cannabis are 
Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), 
available as oral solid and semisolid dosage forms, oils, 
topicals, and transdermal patches. However, because 
medical cannabis is not regulated, exact doses and 
contents of CBD:THC are unknown. Daily doses are 
highly variable, generally, they should not exceed THC 
daily dose-equivalent of 30 mg/day (1294). THC and 
CBD provide differential effect with the THC eliciting 
psychoactive effects with medical benefits particularly 
for neurological disorders (1295,1296), whereas CBD can 
help to moderate and subdue psychosis-inducing effects 
of THC (1297). While they have shown benefit to some 
extent for neurodegenerative disorders such as multiple 
sclerosis, glaucoma, food intake disorders, involuntary 
motor disorders, schizophrenia, and sleep conditions, 
they have been used frequently in chronic pain legally or 
illegally. Thus, patients on THC and CBD may present for 
interventional techniques. Side effects of cannabis and 
anticoagulant or antiplatelet agents has been described. 
Cannabis has the potential to interfere with the effec-
tiveness of multiple antithrombotic and anticoagulant 
agents and may cause antithrombotic effects. Greger et 
al (1291) published a review of cannabis and interactions 
with anticoagulant and antiplatelet agents. With me-
tabolism of THC and CBD, primarily by the hepatic P450 
enzymatic pathway and UPD-glucuronosyltransferase 
(UGT), the interactions are proposed (1298-1301). Case 
reports with increased INR in patients on warfarin with 
smoking THC have been described (1302-1305). Cannabis 
may also alter concentrations of direct-acting oral coagu-
lants including rivaroxaban, dabigatran, and edoxaban 
(1306-1309). CBD also may impact the metabolism of 
direct acting oral anticoagulants leading to increased 
concentrations (1310). Interactions have been reported 
with clopidogrel with cannabis as it has been shown to 
inhibit CYP2C19 and enzyme responsible for converting 
clopidogrel to its active metabolite (1311,1312). 
The current knowledge is limited in reference to the 
effects on interventional techniques. While interactions 
with warfarin may be monitored with INR, interactions 
with other drugs is more difficult. There have not been 
any reports of epidural hematoma associated with THC 
or CBD; however, there have been suggestions of with-
holding cannabis and CBD for 5 days prior to high-risk 
interventional procedures. 
11.5.11 Omega-3 Fatty Acids and Vitamin E
Vitamin E is a fat-soluble plasma antioxidant, com-
posed naturally of 4 tocopherols (α, β, γ, and δ) and 4 
tocotrienols. Vitamin E is most commonly utilized as a 
dietary supplement. As an antioxidant, vitamin E has 
been promoted as a therapeutic agent in cardiovascular 
disease. Platelet aggregation is abnormally increased in 
patients with cardiovascular disease to modulate plate-
let aggregation. Vitamin E has been shown in animal 
and human studies to normalize the bioactivity of nitric 
oxide, but the precise mechanism of action is unknown 
(1313,1314). Vitamin E has been shown to attenuate 
platelet aggregation and delay thrombus formation 
by a decrease in free radical generation, as well as an 
increase in endogenous superoxide dismutase and ni-
tric oxide synthase expression and activity (1315-1317). 
However, in vivo reports have been less convincing. 
Even then, it is a common practice to advise patients 
preparing for surgical procedures or epidural injections 
to temporarily refrain from the use of vitamin E, along 
with other antiplatelet agents. Several studies have 
convincingly shown that coagulation (PT, PTT, bleeding 
time) is not affected by the dietary supplementation of 
vitamin E (1318-1320). A study by Dereska et al (1313) 
investigated the effect of vitamin E supplementation on 
platelet aggregation, coagulation profile, and bleeding 
time in healthy individuals. In this experiment with 42 
healthy volunteers with a 2 week abstinence period 
from the use of antiplatelet agents, followed by deter-
mination of baseline platelet aggregation properties 
and coagulation studies, patients were given moderate 
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dose vitamin E (800 IU of dl-α-tocopherol acetate) for 
14 days with reevaluation of platelet aggregation and 
coagulation profile. The results showed that dietary 
supplementation with moderate dosage of synthetic 
vitamin E did not significantly prolong bleeding or 
platelet aggregation in vivo. The effect of vitamin E 
on platelet aggregation in vitro does not appear to be 
reproducible in vivo. Therefore, they concluded that, 
perioperative discontinuation of vitamin E may not be 
necessary. Even though vitamin E has been discontinued 
commonly, specifically prior to interlaminar epidural 
procedures, similar to aspirin and antithrombotics, there 
have not been any case reports of epidural hematoma 
with either with any of the interventional procedures, 
including spinal cord stimulation. 
Similar to vitamin E, fish oil or omega-3 fatty acids 
have been used as dietary supplements. Fish oil has been 
used to treat a number of conditions, which include 
asthma, diabetes mellitus, rheumatoid arthritis, inflam-
matory bowel disease, systemic lupus erythematosus, 
hyperlipidemia, and cardiovascular disease. In patients 
who take fish oil supplements, the omega-3 fatty acids 
compete for incorporation into the platelet cell mem-
branes, thereby increasing the ratio of omega-3 fatty 
acids. These effects translate to increases in bleeding 
time and a reduction in ADP, collagen, and epineph-
rine-induced platelet aggregation in patients taking 
omega-3 fatty acid supplements (1321,1322). Begtrup 
et al (1322) performed a systematic review and showed 
there was no impact of fish oil supplements on bleeding 
risk. In this review, they identified 52 publications with 
32 publications on healthy subjects and 20 publications 
on patients undergoing surgery. They concluded that 
fish oil supplements reduced platelet aggregation in 
healthy subjects. However, this biochemical effect was 
not reflected in increased bleeding risk during or after 
surgery evaluated in RCTs. Consequently, this systematic 
review did not support the need for discontinuation of 
fish oil supplements prior to surgery or other invasive 
procedures. Two case reports have been published with 
cervical epidural hematomas following cervical epidural 
injection (1176,1203). These 2 case reports do not con-
firm that fish oil is the causative agent; however, it is 
essential to exert significant caution. 
11.5.12 Selective Serotonin-Norepinephrine 
Reuptake Inhibitors (SSRIs)
Selective serotonin reuptake inhibitors (SSRIs) have 
also been implicated in alteration of bleeding since 
serotonin is an integral component in the hemostatic 
cascade. It is released from dense intercellular granules 
and acts as a platelet agonist causing activation and 
recruitment of additional platelets. This antiplatelet ef-
fect may explain why bleeding and bruising (1206) and 
possibly even treatment of acute coronary syndrome 
has been reported for patients taking SSRIs (1323,1324). 
Consequently, SSRIs have been shown to have signifi-
cant effect on platelet aggregation and thus primary 
hemostasis (1323-1326). SSRIs deplete serotonin in plate-
lets, decreasing platelet binding affinity, and platelet 
secretion (1327,1328). Paroxetine has been shown to 
decrease intraplatelet serotonin concentration by 83% 
and inhibit platelet plug formation as reflected by a 
32% prolongation of closure time (1329). 
Auerbach et al (1330) in a multicenter retrospective 
study conducted to examine the perioperative use of 
SSRIs, analyzing more than 500,000 patients. The results 
showed that patients receiving SSRIs had increased risk 
for adverse events, including higher odds of bleeding 
(1330). Thus, there is a potential for SSRIs to be caus-
ative of bleeding with epidural injections; however, 
their significance as a single factor is not known. 
11.5.13 Herbal/Alternative Therapies
Garlic has a dose-dependent effect on bleeding, as 
it contains a compound called ajoene. Derived from al-
licin, the compound that provides garlic’s flavor, ajoene 
inhibits granule release and fibrinogen binding and ad-
ditionally inhibits aggregation of platelets via a variety 
of mechanisms. Prostacyclin, forskolin, indomethacin, 
and dipyridamole are all altered via ajoenes inhibition of 
granule release (1331,1332). Ginkgo Biloba has been used 
for thousands of years, and its mechanism is not entirely 
understood. Ginkgo is thought to antagonize platelet 
activating factor (PAF) and collagen leading to inhibition 
of platelet aggregation, resulting in several reports of 
spontaneous bleeding. Flavonol glycosides and terpene 
glycosides have been suggested to be the chemical com-
pounds responsible for the increased bleeding events 
after intake of this medication (1333,1334). Ginseng is 
commonly used and reduces the effect of warfarin, de-
clining peak INR levels. Ginsenosides are the major active 
ingredient of ginseng, and possibly induce cytochrome 
P450 enzymes to increase the metabolism of Warfarin 
and thus reduce its effect (1335).
11.6 Recommendations
Table 31 shows guidelines for antithrombotic medi-
cation management during interventional spine proce-
dures. This table also shows comparisons of ASIPP and 
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ASRA guidelines. These recommendations differ from 
our previously published guidelines, as well as from ASRA 
guidelines based on the present analysis of the evidence. 
General recommendations based on ASRA guide-
lines (1111) are to discontinue the drugs for 5 half-lives; 
however, the exception to the 5 half-life recommenda-
tion should occur in individuals with hepatic dysfunction, 
and renal dysfunction including nephrotic syndrome.
12.0 guIdelInes for therapeutIc epIdural 
InterventIons 
`These guidelines for the delivery of therapeutic 
epidural interventions provide an algorithmic approach 
based on the best available evidence on the epidemi-
ology of various identifiable sources of chronic spinal 
pain, specifically epidural interventions. This approach is 
designed to promote the efficient use of interventional 
pain management techniques based on the best avail-
able evidence. However, this may not be applicable in 
each and every patient. The purpose of the described 
approach is to provide a disciplined approach to the use 
of spinal interventional techniques in managing spinal 
pain. This approach includes evaluation, diagnostic, and 
therapeutic approaches, which in turn avoid unneces-
sary care, as well as poorly documented practices. 
This algorithmic approach does not dictate the 
standard of care – these are guidelines. Furthermore, 
with space constraints, details of comprehensive initial 
evaluations and all the findings are not provided. Only 
relevant descriptions are provided. 
12.1 Documentation Requirements
Documentation is to provide evidence of informa-
tion. Documentation includes evaluation and manage-
ment services, procedural services, and billing and cod-
ing. While the purpose of documentation is to provide 
information, it reflects the competency and character of 
the physician (7,504,1336-1339). 
Medical necessity requires appropriate diagno-
sis and coding by the International Classification of 
Diseases, 10th Revision, (ICD-10-CM) to justify services 
rendered and indicates the severity of a patient’s con-
dition (1340). The Balanced Budget Act (HR 2015, Sec-
tion 4317) requires all physicians to provide diagnostic 
information for all Medicare/Medicaid patients starting 
from January 1, 1998 (1340-1343). Medical necessity 
is defined in numerous ways (1344,1345). The Centers 
for Medicare and Medicaid Services (CMS) (1342,1343) 
defines medical necessity as follows: “. . .no payment 
may be made under part A or part B for any expense in-
curred for items or services which . . .are not reasonable 
and necessary for the diagnosis or treatment of illness 
or injury or to improve the functioning of a malformed 
body member.” 
Further, reasonable and necessary are defined as 
follows (1342): 
• Service must be:
• Safe and effective
• Not experimental or investigational   Appropri-
ate, including the duration and frequency that is 
considered appropriate for the service in terms of 
whether it is:
• Furnished in accordance with accepted stan-
dards of medical practice for the diagnosis 
or treatment of the patient’s condition or to 
improve the patient’s function
• Furnished in a setting appropriate to the pa-
tient’s medical needs and condition
• Ordered and/or furnished by qualified 
personnel 
• One that meets, but does not exceed, the pa-
tient’s medical need
• At least as beneficial as an existing and avail-
able medically appropriative alternative. 
12.1.1 Elements of Documentation 
Federal, state, third party payer, and managed care 
plans rely heavily on provider documentation when as-
sessing the claims for various parameters. These include: 
•  Was the billed service actually rendered or provided 
to the patient? 
•  Was the level of service or extent of the service ac-
curately reported? 
•  Was the service or procedure medically necessary? 
•  Was the claim sent to the correct primary insurer 
for the service or procedure performed?
12.1.2 Types of Documentation 
Documentation includes evaluation and manage-
ment services and interventional techniques. Docu-
mentation for spinal interventional techniques may 
vary based on whether the procedure was performed 
in a facility setting such as hospital outpatient depart-
ment or ambulatory surgery center versus in a physi-
cian’s office.
12.1.2.1  Documentation of Interventional Procedures 
All spinal interventional techniques are considered 
surgical procedures. 
Documentation requirements are as follows: 
•  History and physical. 
•  Indications and medical necessity. 
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•  Intra-operative procedural description. 
•  Post-operative monitoring and ambulation. 
•  Discharge/disposition.
12.1.2.2 History and Physical 
The physician’s history should include the following 
elements:
•  Documentation of the signs and symptoms war-
ranting the interventional procedure. 
•  A listing of the patient’s current medications 
including dosages, route, and frequency of 
admission. 
•  Any existing co-morbid conditions and previ-
ous surgeries. 
•  Documentation of any social history or con-
ditions which would have an impact on the 
patient’s care upon discharge from the facility 
following the procedure.
The physician’s physical examination should not 
only reflect the relevance of the interventional proce-
dure, but also the type of anesthesia planned. Gener-
ally, for interventional techniques, if no anesthesia is to 
be administered, the physical examination is limited to 
the assessment of the patient’s mental status and an ex-
amination specific to the proposed procedure, including 
any co-morbid conditions.
However, if intravenous sedation or any other 
type of anesthesia is planned, the physical examina-
tion should also include documentation of the results 
of an auscultatory examination of the heart and lungs, 
and an assessment and written statement about the 
patient’s general health, in addition to the assessment 
of mental status and an examination specific to the 
proposed procedure and any co-morbid conditions.
12.1.2.3 Documentation of Indications and Medical 
Necessity
Medical necessity must be established for each 
and every procedure and encounter (1337,1338,1342). 
General documentation requirements for all spinal 
interventional techniques for indications and medical 
necessity are as follows:
1. Complete initial evaluation including history and 
physical examination.
2. Physiological and functional assessment, as neces-
sary and feasible.
3. Definition of indications and medical necessity, as 
follows:
• Suspected organic problem.
• Nonresponsiveness to conservative modalities 
of treatment.
• Pain and disability of moderate-to-severe 
degree.
• No evidence of contraindications such as severe 
spinal stenosis resulting in intraspinal obstruc-
tion, infection, or predominantly psychogenic 
pain.
• Responsiveness to prior interventions with im-
provement in physical and functional status for 
repeat blocks or other interventions.
• Repeating interventions only upon return of 
pain and deterioration in functional status.
12.1.2.4 Procedural Documentation
This includes a description of the procedure, post-
operative monitoring, and discharge/disposition (1338) 
(Table 32).
12.2 Comprehensive Algorithm 
Figure 27 illustrates an algorithmic approach for 
the evaluation and management of a chronic pain 
patient (7). Appropriate history, physical examina-
tion, and medical decision-making are essential to the 
provision of appropriate documentation and patient 
care. Not covered in this algorithm are socioeconomic 
issues and psychosocial factors that may be important 
in the clinical decision-making process. A comprehen-
sive and complete evaluation will assist in complying 
with regulations, providing appropriate care, and 
fulfilling an algorithmic approach.
12.3 Lumbar Epidural Interventions 
Based on the comprehensive review of literature 
and available evidence, there is Level I evidence with a 
Table 32. Procedural documentation guidelines for 
interventional techniques.
1. History and physical 
2. Indications and medical necessity 










4. Post-operative monitoring 
5. Discharge and instructions
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Fig. 27. A comprehensive algorithm for the evaluation and management of  chronic spinal pain.
Reproduced with permission from authors and Pain Physician journal.
strong recommendation for caudal epidural injections, 
lumbar interlaminar epidural injections, and lumbar 
transforaminal epidural injections in managing radicu-
lar pain or disc herniation. Additionally, the evidence is 
Level III to II with a moderate to strong recommenda-
tion for caudal, Level II for lumbar interlaminar epidural 
injections with moderate to strong recommendation in 
managing spinal stenosis. The level of evidence is IV to 
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Fig. 28. A suggested algorithm for therapeutic interventional techniques in management of  chronic low back pain.
Reproduced with permission from authors and Pain Physician journal.
III with moderate recommendation for lumbar transfo-
raminal epidurals in managing lumbar spinal stenosis. 
The evidence for post-surgery syndrome is Level II with 
a moderate to strong recommendation for caudal epi-
dural injections. The evidence for axial discogenic pain 
is Level II with moderate to strong recommendation for 
caudal and lumbar interlaminar epidural injections. The 
evidence assessment is based on contemporary practice 
in interventional pain management settings for all the 
procedures performed under fluoroscopy (Fig. 28). 
In patients with post-lumbar surgery syndrome, 
spinal stenosis, and recalcitrant stenosis after failure to 
respond to fluoroscopically directed epidural injections, 
percutaneous adhesiolysis is considered (72-76,895). 
Based on the current literature, the evidence is Level I 
with a strong recommendation for percutaneous adhe-
siolysis in managing post-lumbar surgery syndrome and 
Level II with a moderate to strong recommendation in 
managing lumbar spinal stenosis and recalcitrant disc 
herniation with chronic low back and/or lower extremity 
pain nonresponsive to conservative modalities including 
fluoroscopically directed epidural injections.
The next step in the radicular pain algorithm is 
implantable therapy with spinal cord stimulation or 
implantable infusion systems. Spine cord stimulation 
is recommended to the patient population for whom 
all other appropriate medical options have been tried 
without sufficient improvement in pain control.
12.4 Cervical Epidural Procedures
The current evidence for cervical interlaminar 
epidural injections in disc herniation is Level I with 
strong recommendation. The evidence in discogenic 
pain and spinal stenosis is Level II with moderate to 
strong recommendation and Level II to I with moder-
ate to strong recommendation for post-surgery syn-
drome (Fig. 29).
12.5 Thoracic Epidural Procedures
Disc protrusions and herniations are much less com-
mon in the thoracic spine than the lumbar or cervical 
spine. Nonetheless, very few patients who present with 
thoracic radiculitis, post-surgery syndrome, spinal steno-
sis, and radiculitis without disc protrusion, and patients 
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Fig. 30. A suggested algorithm for therapeutic interventional techniques in the management of  chronic thoracic pain.
Reproduced with permission from authors and Pain Physician journal.
Fig. 29. A suggested algorithm for therapeutic interventional techniques in management of  chronic low back pain.
Reproduced with permission from authors and Pain Physician journal.
failing to show evidence of facet joint pain are candidates 
for epidural injections (Fig. 30). Epidural injections are 
most commonly provided through an interlaminar route 
rather than transforaminal which is associated with high 
risk. Thoracic interlaminar epidural injections show Level 
II evidence with moderate to strong recommendation.
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12.6 Therapeutic Lumbar Epidural 
Interventions
Epidural procedures are applied in the cervical, 
thoracic, and lumbosacral regions. While these include 
diagnostic, as well as therapeutic interventions, these 
therapeutic and diagnostic interventions hold much less 
importance for epidural procedures rather than diagnostic 
facet joint interventions. 
The indications, frequency, and total number of in-
terventions have been considered important issues, even 
though debated and poorly addressed. These are based 
on flawed assumptions from nonexistent evidence. Over 
the years, some authors have recommended one injection 
for diagnostic as well as therapeutic purposes. Some have 
preached 3 injections in a series irrespective of a patient’s 
progress or lack thereof; whereas, others suggest 3 injec-
tions followed by a repeat course of 3 injections after 3-, 
6-, or 12-month intervals. There are also proponents who 
propose that an unlimited number of injections with no 
established goals or parameters should be available. A 
limitation of 3 mg per kilogram of body weight of steroid 
or 210 mg per year in an average person and a lifetime 
dose of 420 mg of steroid also have been advocated; how-
ever, with no scientific basis. The comprehensive review of 
the literature in preparation of these guidelines and re-
view of all the systematic reviews has not shown any basis 
for the above reported assumptions and limitations. The 
administration must be based solely on patients’ response, 
safety profile of the drug, experience of the patient, and 
pharmacological and chemical properties such as duration 
of action and suppression of adrenals (55). Further, mul-
tiple well controlled trials have illustrated no significant 
difference with local anesthetic alone, or in combination 
with local anesthetic and steroids (58). 
Side effects of steroids are significant based on the 
complex pharmacokinetics and systemic absorption of 
epidurally administered steroids which has been explored 
in multiple reports. Friedly et al (1058) assessed systemic 
of epidural steroid injections for spinal stenosis in 200 pa-
tients receiving corticosteroids, with 32 patients (20.3%) 
experiencing cortisol reduction at 3 weeks of greater 
than 50% compared with 10 patients (6.7%) treated with 
lidocaine only. The effect on a 3-week cortisol changes did 
not differ by patient level characteristic. Further, those 
patients who were treated with methylprednisolone or 
triamcinolone had an average 3-week cortisol reduction 
of 41% and 41.6% from baseline respectively. In addition, 
patients treated with betamethasone or dexamethasone, 
found no significant changes with cortisol that they were 
similar to lidocaine alone. Hooten et al (1059) showed tri-
amcinolone concentrations almost 22 days. Multiple others 
have described HPA axis suppression (1075) and other side 
effects with increase in blood glucose levels along with 
adverse immune influence leading to influenza infections 
with specific concerns during COVID (1061-1064). In a dose 
dependant evaluation, Habib et al (1064) in 2013, exam-
ined the magnitude and duration of the suppression of a 
single epidural injection of methylprednisolone. Eighty-six 
percent of the patients who received 80 mg dose were 
reported to have laboratory confirmed HPA axis suppres-
sion one week post injection compared to 53% of those 
receiving 40 mg dose. Further, 20% of all participants had 
continued suppression at 4 weeks post injection. 
Thus, the frequency may be based on the type of 
injectate with no significant effect with local anesthetics 
with potential repeat of injection therapy if necessary 
after a 2 week waiting period, for dexamethasone and be-
tamethasone of 2 to 4 weeks and for methylprednisolone 
and triamcinolone 4 weeks and 4 to 6 weeks based on the 
dosage.
Manchikanti et al performed multiple randomized 
controlled trials with inclusion of over 12,000 patients 
with local anesthetic alone or with steroids utilizing a low 
dose betamethasone (i.e., 6 mg) has not reported any 
complications.
During COVID-19 pandemic it may be crucial to fol-
low these rules from the CDC, as well as guidance from 
multiple organizations including ASIPP (51,52,55,58). 
12.6.1 Lumbar Epidural Injections
Lumbar epidural injections include caudal, inter-
laminar, and transforaminal. Common indications are as 
follows: 
• Chronic low back and/or lower extremity pain of at 
least 3 months duration which has failed to respond 
or poorly responded to noninterventional and non-
surgical conservative management resulting from:
• Disc herniation/lumbar radiculitis: (evidence – 
Level I with strong recommendation for caudal, 
interlaminar, and transforaminal) 
• Lumbar spinal stenosis: (evidence – Level II for 
caudal with moderate to strong recommenda-
tion, Level II for lumbar interlaminar with moder-
ate to strong recommendation and Level IV to 
III with moderate recommendation for lumbar 
transforaminal)
• Post-lumbar surgery syndrome: (evidence – 
Level II for caudal with moderate to strong 
recommendation)
• Axial or discogenic low back pain without facet 
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joint or sacroiliac joint pain or disc herniation: (ev-
idence – Level II for caudal and lumbar interlami-
nar with moderate to strong recommendation) 
• Moderate to severe pain causing functional disability. 
• Lumbar interlaminar may be performed in post-sur-
gery syndrome only if the access to the epidural space 
is obtained outside the scar (caudal and transforami-
nal are preferred modalities). 
• Acute proven disc herniation with radiculitis with dis-
abling pain or to avoid surgical intervention, herpes 
zoster, post herpetic neuralgia, CRPS I and II, epidural 
injections may be performed at physician discretion 
without above requirements. 
12.6.2 Cervical Epidural 
While cervical epidural injections may be adminis-
tered either by the interlaminar or transforaminal ap-
proach, only the interlaminar approach has been studied 
with appropriate indications and effectiveness. Further, 
cervical transforaminal epidural injections are associated 
with high risk. Common indications for cervical interlami-
nar epidurals are as follows:|
• Chronic neck and/or upper extremity pain of at least 
3 months duration which has failed to respond or 
poorly responded to noninterventional and nonsurgi-
cal conservative management resulting from:
• Disc herniation/cervical radiculitis (evidence – 
Level I with strong recommendation)
• Cervical spinal stenosis (evidence – Level II with 
moderate to strong recommendation)
• Post cervical surgery syndrome (evidence – Level 
II to I with moderate to strong recommendation)
• Axial or discogenic pain without facet joint pa-
thology or disc herniation (evidence – Level II 
with moderate to strong recommendation)
• Intermittent or continuous pain causing functional 
disability.
• Acute proven disc herniation with radiculitis with dis-
abling pain or to avoid surgical intervention, herpes 
zoster, post herpetic neuralgia, CRPS I and II, epidural 
injections may be performed at physician discretion 
without above requirements. 
12.6.3 Thoracic Epidural 
Thoracic epidural injections may be performed either 
with an interlaminar approach or a transforaminal ap-
proach. The literature is scant in reference to thoracic epi-
dural injections, with Level II evidence. Consequently, only 
interlaminar epidural injections are described herewith. 
Common indications are as follows:
• Chronic mid back or upper back pain of at least 3 
months duration which has failed to respond or 
poorly responded to noninterventional and nonsurgi-
cal conservative management resulting from:
• Thoracic disc herniation/radiculitis 
• Thoracic spinal stenosis
• Thoracic post-surgery syndrome
• Axial or discogenic pain without facet joint pa-
thology or disc herniation
• Moderate to severe pain causing functional 
disability.
• Acute proven disc herniation with radiculitis with dis-
abling pain or to avoid surgical intervention, herpes 
zoster, post herpetic neuralgia, CRPS I and II, epidural 
injections may be performed at physician discretion 
without above requirements. 
12.7 Frequency of Epidural Procedures 
• Guidelines of frequency of interventions apply 
to epidural injections caudal, interlaminar, and 
transforaminal.
• In the diagnostic phase, a patient may receive 2 
procedures at intervals of no sooner than 2 weeks, 
preferably 4-6 weeks based on the type and dosage 
of steroid used.
• In the therapeutic phase (after the diagnostic phase 
is completed), the suggested frequency of interven-
tional techniques should be 2½ to 3 months or longer 
between each injection, provided that > 50% relief 
is obtained for 2½ to 3 months, not exceeding 4 per 
year, per region.
• If neural blockade is applied for different regions, 
they may be performed at intervals of no sooner than 
one week and preferably 2 weeks for most types of 
procedures. The therapeutic frequency may remain 
at intervals of at least 2 months for each region. It is 
further suggested that all regions be treated at the 
same time, provided all procedures can be performed 
safely.
• In the treatment or therapeutic phase, the epidural 
injections should be repeated only as necessary ac-
cording to medical necessity criteria, and it is sug-
gested that these be limited to a maximum of 4 times 
per year.
• Cervical and thoracic regions are considered as one 
region and lumbar and sacral are considered as one 
region.
12.8 Percutaneous Adhesiolysis 
At the present time, the evidence is available for 
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percutaneous adhesiolysis in the lumbar region only uti-
lizing a caudal approach. Evidence for the cervical and 
thoracic regions and transforaminal approach in the 
lumbar region is only emerging. Common indications 
for percutaneous adhesiolysis with a caudal approach in 
lumbar region are as follows: 
• Chronic low back and/or lower extremity pain of 
at least 6 months duration which failed to respond 
to or poorly responded to noninterventional and 
nonsurgical conservative management and fluoro-
scopically directed epidural injections secondary to:
• Post-surgery syndrome (evidence – Level I with 
strong recommendation).
• Central spinal stenosis (evidence – Level II with 
moderate to strong recommendation)
• Disc herniation/radiculitis/severe degenerative 
disc disease (evidence – Level II with moderate 
to strong recommendation)
• Intermittent or continuous pain causing functional 
disability.
12.8.1 Frequency of Interventions 
• The number of procedures is preferably limited to: 
• 2 interventions per year, with a 3-day 
protocol
• 4 interventions per year, with a one-day protocol.
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Appendix Table 1. Sources of  risk of  bias from Cochrane Review collaboration.
Bias 
Domain




(1) Was the method 
of randomization 
adequate?
A random (unpredictable) assignment sequence. Examples of adequate methods are coin 
toss (for studies with 2 groups), rolling a dice (for studies with 2 or more groups), drawing 
of balls of different colors, drawing of ballots with the study group labels from a dark bag, 
computer-generated random sequence, preordered sealed envelopes, sequentially-ordered 
vials, telephone call to a central office, and preordered list of treatment assignments. Yes/No/Unsure
Examples of inadequate methods are: alternation, birth date, social insurance/security 
number, date in which they are invited to participate in the study, and hospital registration 
number.
Selection (2) Was the treatment allocation concealed?
Assignment generated by an independent person not responsible for determining the 
eligibility of the patients. This person has no information about the persons included 
in the trial and has no influence on the assignment sequence or on the decision about 
eligibility of the patient.
Yes/No/Unsure
Performance
(3) Was the patient 
blinded to the 
intervention?
Index and control groups are indistinguishable for the patients or if the success of blinding 
was tested among the patients and it was successful. Yes/No/Unsure
Performance
(4) Was the care 
provider blinded to the 
intervention?
Index and control groups are indistinguishable for the care providers or if the success of 
blinding was tested among the care providers and it was successful. Yes/No/Unsure
Detection
(5) Was the outcome 
assessor blinded to the 
intervention?
Adequacy of blinding should be assessed for each primary outcome separately. This item 
should be scored ‘‘yes’’ if the success of blinding was tested among the outcome assessors 
and it was successful or:
Yes/No/Unsure
• for patient-reported outcomes in which the patient is the outcome assessor (e.g., 
pain, disability): the blinding procedure is adequate for outcome assessors if 
participant blinding is scored ‘‘yes’’
• for outcome criteria assessed during scheduled visit and that supposes a contact 
between participants and outcome assessors (e.g., clinical examination): the blinding 
procedure is adequate if patients are blinded, and the treatment or adverse effects of 
the treatment cannot be noticed during clinical examination
• for outcome criteria that do not suppose a contact with participants (e.g., 
radiography, magnetic resonance imaging): the blinding procedure is adequate if the 
treatment or adverse effects of the treatment cannot be noticed when assessing the 
main outcome
• for outcome criteria that are clinical or therapeutic events that will be determined 
by the interaction between patients and care providers (e.g., cointerventions, 
hospitalization length, treatment failure), in which the care provider is the outcome 
assessor: the blinding procedure is adequate for outcome assessors if item ‘‘4’’ 
(caregivers) is scored ‘‘yes’’
• for outcome criteria that are assessed from data of the medical forms: the blinding 
procedure is adequate if the treatment or adverse effects of the treatment cannot be 
noticed on the extracted data
Attrition
(6) Was the drop-out 
rate described and 
acceptable?
The number of participants who were included in the study but did not complete the 
observation period or were not included in the analysis must be described and reasons 
given. If the percentage of withdrawals and drop-outs does not exceed 20% for short-term 
follow-up and 30% for long-term follow-up and does not lead to substantial bias a ‘‘yes’’ is 
scored (N.B. these percentages are arbitrary, not supported by literature).
Yes/No/Unsure
Attrition
(7) Were all 
randomized 
participants analyzed in 
the group to which they 
were allocated?
All randomized patients are reported/analyzed in the group they were allocated to by 
randomization for the most important moments of effect measurement (minus missing 
values) irrespective of noncompliance and cointerventions.
Yes/No/Unsure
Reporting
(8) Are reports of the 
study free of suggestion 
of selective outcome 
reporting?
All the results from all prespecified outcomes have been adequately reported in the 
published report of the trial. This information is either obtained by comparing the 
protocol and the report, or in the absence of the protocol, assessing that the published 
report includes enough information to make this judgment.
Yes/No/Unsure
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(3) Was the patient 
blinded to the 
intervention?
Index and control groups are indistinguishable for the patients or if the success of blinding 
was tested among the patients and it was successful. Yes/No/Unsure
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(4) Was the care 
provider blinded to the 
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Index and control groups are indistinguishable for the care providers or if the success of 
blinding was tested among the care providers and it was successful. Yes/No/Unsure
Detection
(5) Was the outcome 
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Adequacy of blinding should be assessed for each primary outcome separately. This item 
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(6) Was the drop-out 
rate described and 
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The number of participants who were included in the study but did not complete the 
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given. If the percentage of withdrawals and drop-outs does not exceed 20% for short-term 
follow-up and 30% for long-term follow-up and does not lead to substantial bias a ‘‘yes’’ is 
scored (N.B. these percentages are arbitrary, not supported by literature).
Yes/No/Unsure
Attrition
(7) Were all 
randomized 
participants analyzed in 
the group to which they 
were allocated?
All randomized patients are reported/analyzed in the group they were allocated to by 
randomization for the most important moments of effect measurement (minus missing 
values) irrespective of noncompliance and cointerventions.
Yes/No/Unsure
Reporting
(8) Are reports of the 
study free of suggestion 
of selective outcome 
reporting?
All the results from all prespecified outcomes have been adequately reported in the 
published report of the trial. This information is either obtained by comparing the 
protocol and the report, or in the absence of the protocol, assessing that the published 
report includes enough information to make this judgment.
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Domain




(9) Were the groups 
similar at baseline 
regarding the most 
important prognostic 
indicators?
Groups have to be similar at baseline regarding demographic factors, duration and severity 







If there were no cointerventions or they were similar between the index and control 
groups. Yes/No/Unsure
Performance
(11) Was the 
compliance acceptable 
in all groups?
The reviewer determines if the compliance with the interventions is acceptable, based 
on the reported intensity, duration, number and frequency of sessions for both the 
index intervention and control intervention(s). For example, physiotherapy treatment 
is usually administered for several sessions; therefore it is necessary to assess how many 




(12) Was the timing of 
the outcome assessment 
similar in all groups?
Timing of outcome assessment should be identical for all intervention groups and for all 
primary outcome measures. Yes/No/Unsure
Other
(13) Are other sources 
of potential bias 
unlikely?
Other types of biases. For example:
Yes/No/Unsure
• When the outcome measures were not valid. There should be evidence from a 
previous or present scientific study that the primary outcome can be considered 
valid in the context of the present.
• Industry-sponsored trials. The conflict of interest (COI) statement should explicitly 
state that the researchers have had full possession of the trial process from planning 
to reporting without funders with potential COI having any possibility to interfere in 
the process. If, for example, the statistical analyses have been done by a funder with a 
potential COI, usually ‘‘unsure’’ is scored.
Appendix Table 1 (con’t). Sources of  risk of  bias from Cochrane Review collaboration.
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Appendix Table 2. Item checklist for assessment of  randomized controlled trials of  IPM techniques utilizing IPM – QRB.
Scoring
I. TRIAL DESIGN AND GUIDANCE REPORTING 
1. CONSORT or SPIRIT
Trial designed and reported without any guidance 0
Trial designed and reported utilizing minimum criteria other than CONSORT or SPIRIT criteria or trial was conducted 
prior to 2005 1
Trial implies it was based on CONSORT or SPIRIT without clear description with moderately significant criteria for 
randomized trials or the trial was conducted before 2005 2
Explicit use of CONSORT or SPIRIT with identification of criteria or trial conducted with high level reporting and criteria 
or conducted before 2005 3
II. DESIGN FACTORS
2. Type and Design of Trial
Poorly designed control group (quasi selection, convenient sampling) 0
Proper active-control or sham procedure with injection of active agent 2
Proper placebo control (no active solutions into active structures) 3
3. Setting/Physician
General setting with no specialty affiliation and general physician 0
Specialty of anesthesia/PMR/neurology/radiology/ortho, etc. 1







Less than 50 participants in the study without appropriate sample size determination 0
Sample size calculation with less than 25 patients in each group 1
Appropriate sample size calculation with at least 25 patients in each group 2
Appropriate sample size calculation with 50 patients in each group 3
6. Statistical Methodology
None or inappropriate 0
Appropriate 1
III. PATIENT FACTORS
7. Inclusiveness of Population
7a. For epidural procedures:
Poorly identified mixed population 0
Clearly identified mixed population 1
Disorders specific trials  (i.e. well defined spinal stenosis and disc herniation, disorder specific, disc herniation or spinal 
stenosis or post-surgery syndrome) 2
7b. For facet or sacroiliac joint interventions:
No diagnostic blocks 0
Selection with single diagnostic blocks 1
Selection with placebo or dual diagnostic blocks 2
8. Duration of Pain
Less than 3 months 0




> 6 months 2
9. Previous Treatments 
Conservative management including drug therapy, exercise therapy, physical therapy, etc. 
Were not utilized 0
Were utilized sporadically in some patients 1
Were utilized in all patients 2
10. Duration of Follow-up with Appropriate Interventions
Less than 3 months or 12 weeks for epidural or facet joint procedures, etc. and 6 months for intradiscal procedures and 
implantables 0
3 to 6 months for epidural or facet joint procedures, etc., or 1 year for intradiscal procedures or implantables 1
6 months to 17 months for epidurals or facet joint procedures, etc., and 2 years or longer for discal procedures and 
implantables 2
18 months or longer for epidurals and facet joint procedures, etc., or 5 years or longer for discal procedures and 
implantables 3
IV. OUTCOMES
11. Outcomes Assessment Criteria for Significant Improvement 
No descriptions of outcomes 
OR
 < 20% change in pain rating or functional status
0
Pain rating with a decrease of 2 or more points or more than 20% reduction 
OR
functional status improvement of more than 20% 
1
Pain rating with decrease of ≥ 2 points 
AND
≥ 20% change or functional status improvement of  20%
2
Pain rating with a decrease of  3 or more points or more than 50% reduction 
OR
functional status improvement with a 50% or 40% reduction in disability score 
2
Significant improvement with pain and function ≥ 50% or 3 points and 40% reduction in disability scores 4
12. Analysis of all Randomized Participants in the Groups
Not performed 0
Performed without intent-to-treat analysis without inclusion of all randomized participants 1
All participants included with or without intent-to-treat analysis 2
13. Description of Drop Out Rate 
No description of dropouts, despite reporting of incomplete data or ≥ 20% withdrawal 0
Less than 20% withdrawal in one year in any group 1
Less than 30% withdrawal at 2 years in any group 2
14. Similarity of Groups at Baseline for Important Prognostic Indicators
Groups dissimilar with significant influence on outcomes with or without appropriate randomization and allocation 0
Groups dissimilar without influence on outcomes despite appropriate randomization and allocation 1
Groups similar with appropriate randomization and allocation 2
15. Role of Co-Interventions
Co-interventions were provided but were not similar in the majority of participants 0
No co-interventions or similar co-interventions were provided in the majority of the participants 1
V. RANDOMIZATION
16. Method of Randomization
Quasi randomized or poorly randomized or not described 0
Appendix Table 2. Item checklist for assessment of  randomized controlled trials of  IPM techniques utilizing IPM – QRB. 
(continued)
Pain Physician: Epidural Guidelines 2021 24:S27-S208
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Scoring
I. TRIAL DESIGN AND GUIDANCE REPORTING 
1. CONSORT or SPIRIT
Trial designed and reported without any guidance 0
Trial designed and reported utilizing minimum criteria other than CONSORT or SPIRIT criteria or trial was conducted 
prior to 2005 1
Trial implies it was based on CONSORT or SPIRIT without clear description with moderately significant criteria for 
randomized trials or the trial was conducted before 2005 2
Explicit use of CONSORT or SPIRIT with identification of criteria or trial conducted with high level reporting and criteria 
or conducted before 2005 3
II. DESIGN FACTORS
2. Type and Design of Trial
Poorly designed control group (quasi selection, convenient sampling) 0
Proper active-control or sham procedure with injection of active agent 2
Proper placebo control (no active solutions into active structures) 3
3. Setting/Physician
General setting with no specialty affiliation and general physician 0
Specialty of anesthesia/PMR/neurology/radiology/ortho, etc. 1







Less than 50 participants in the study without appropriate sample size determination 0
Sample size calculation with less than 25 patients in each group 1
Appropriate sample size calculation with at least 25 patients in each group 2
Appropriate sample size calculation with 50 patients in each group 3
6. Statistical Methodology
None or inappropriate 0
Appropriate 1
III. PATIENT FACTORS
7. Inclusiveness of Population
7a. For epidural procedures:
Poorly identified mixed population 0
Clearly identified mixed population 1
Disorders specific trials  (i.e. well defined spinal stenosis and disc herniation, disorder specific, disc herniation or spinal 
stenosis or post-surgery syndrome) 2
7b. For facet or sacroiliac joint interventions:
No diagnostic blocks 0
Selection with single diagnostic blocks 1
Selection with placebo or dual diagnostic blocks 2
8. Duration of Pain
Less than 3 months 0
3 to 6 months 1
> 6 months 2




Appendix Table 3. Degree of  evidence as described by SIGN.
1++ - High-quality meta-analysis and systematic review conducted by randomized clinical trials- RCTs with a very low risk of bias
1+ - Well-designed meta-analysis and systematic review conducted by randomized or non-randomized clinical trials- Randomized or non-randomized clinical trials with a low risk of bias
1- - Meta analysis and systematic review conducted by randomized or non-randomized clinical trials- Randomized or non-randomized clinical trials with a high risk of bias
2++
High-quality systematic review conducted by a patient control study, cohort study, or diagnosis analytic study
- High-quality patient control study, cohort study, or diagnosis analytic study of very low risk of confounding, bias or contingency, or 
a high possibility of cause and effect relationship
2+ - High-quality patient control study, cohort study, or diagnosis analytic study of the low risk of a confounding, bias or contingency, or the normal possibility of a cause and effect relationship
2- - Patient control study, cohort study, or diagnosis analytic study of the high risk of a confounding bias or contingency, or the low possibility of a cause and effect relationship
3 - Non-analytic studies, e.g., before-and-after study, case series, case report
4 - Expert opinion
Source:  Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001; 323:334-336 (125).
Pain Physician: Epidural Guidelines 2021 24:S27-S208
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Appendix Table 4. IPM checklist for assessment of  nonrandomized or observational studies of  IPM techniques utilizing IPM-
QRBNR.
Scoring
I. STUDY DESIGN AND GUIDANCE REPORTING  
1. STROBE or TREND Guidance 
Case Report/Case Series 0
Study designed without any guidance 1
Study designed with minimal criteria and reporting with or without guidance 2
Study designed with moderately significant criteria or implies it was based on STROBE or TREND without clear 
description or the study was conducted before 2011 or similar criteria utilized with study conducted before 2011 3
Designed with high level criteria or explicitly uses STROBE or TREND with identification of criteria or conducted prior 
to 2011 4
II. DESIGN FACTORS
2. Study Design and Type
Case report or series (uncontrolled – longitudinal) 0
Retrospective cohort or cross-sectional study 1
Prospective cohort case-control study 2
Prospective case control study 3
Prospective, controlled, nonrandomized 4
3. Setting/Physician
General setting with no specialty affiliation and general physician 0
Specialty of anesthesia/PMR/neurology, etc. 1







Less than 100 participants without appropriate sample size determination 0
At least 100 participants in the study without appropriate sample size determination 1
Sample size calculation with less than 50 patients in each group 2
Appropriate sample size calculation with at least 50 patients in each group 3






7. Inclusiveness of Population
7a. For epidural procedures:
Poorly identified mixed population 1
Poorly identified mixed population with large sample (≥ 200) 2
Clearly identified mixed population 3
Disorders specific trials (i.e. well defined spinal stenosis and disc herniation, disorder specific, disc herniation or spinal 
stenosis or post-surgery syndrome) 4




No specific selection criteria 1
No diagnostic blocks based on clinical symptomatology 2
Selection with single diagnostic blocks 3
Selection with placebo or dual diagnostic blocks 4
8. Duration of Pain 
Less than 3 months 0
3 to 6 months 1
> 6 months 2
9. Previous Treatments 
Conservative management including drug therapy, exercise therapy, physical therapy, etc. 
Were not utilized 0
Were utilized sporadically in some patients 1
Were utilized in all patients 2
10. Duration of Follow-up with Appropriate Interventions
Less than 3 months or less for epidural or facet joint procedures, etc., and 6 months for intradiscal procedures and 
implantables 1
3-6 months for epidural or facet joint procedures, etc., or one year for intradiscal procedures or implantables 2
6-12 months for epidurals or facet joint procedures, etc., and 2 years or longer for discal procedures and implantables 3
18 months or longer for epidurals and facet joint procedures, etc., or 5 years or longer for discal procedures and 
implantables 4
IV. OUTCOMES 
11. Outcomes Assessment Criteria for Significant Improvement
No descriptions of outcomes 
OR
 < 20% change in pain rating or functional status
0
Pain rating with a decrease of 2 or more points or more than 20% reduction 
OR
functional status improvement of more than 20% 
1
Pain rating with decrease of ≥ 2 points 
AND
≥ 20% change or functional status improvement of  20%
2
Pain rating with a decrease of 3 or more points or more than 50% reduction 
OR
functional status improvement with a 50% or 40% reduction in disability score 
2
Significant improvement with pain and function ≥ 50% or 3 points and 40% reduction in disability scores 4
12. Description of Drop Out Rate
No description despite reporting of incomplete data or more than 30% withdrawal 0
Less than 30% withdrawal in one year in any group 1
Less than 40% withdrawal at 2 years in any group 2
13. Similarity of Groups at Baseline for Important Prognostic Indicators
No groups or groups dissimilar with significant influence on outcomes 0
Groups dissimilar without significant influence on outcomes 1
Groups similar 2
14. Role of Co-Interventions
Dissimilar co-interventions or similar co-interventions in some of the participants 1
No co-interventions or similar co-interventions in majority of the participants 2
Appendix Table 4. IPM checklist for assessment of  nonrandomized or observational studies of  IPM techniques utilizing IPM-
QRBNR. (continued)




15. Method of Assignment of Participants 
Case report/case series or selective assignment based on outcomes or retrospective evaluation based on clinical criteria 1
Prospective study with inclusion without specific criteria 2
Retrospective method with inclusion of all participants or random selection of retrospective data 3
Prospective, well-defined assignment of methodology and inclusion criteria (quasi randomization, matching, 
stratification, etc.) 4
VI. CONFLICTS OF INTEREST 
16. Funding and Sponsorship
Trial included industry employees with or without proper disclosure -3
Industry employees involved; high levels of funding with remunerations by industry or an organization funded with 
conflicts -3
Industry or organizational funding with reimbursement of expenses with some involvement or no information available 0
Industry or organization funding of expenses without involvement 1
Funding by internal resources only 2
Governmental funding without conflict such as NIH, NHS, AHRQ 3
TOTAL MAXIMUM 48
Appendix Table 4. IPM checklist for assessment of  nonrandomized or observational studies of  IPM techniques utilizing IPM-
QRBNR. (continued)
Source: Manchikanti L, et al. Development of an interventional pain management specific instrument for methodologic quality assessment of non-
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I. TRIAL DESIGN AND GUIDANCE REPORTING 
1. CONSORT or SPIRIT 0 2 2 3 3 3
II. DESIGN FACTORS
2. Type and Design of Trial 2 2 2 2 2 2
3. Setting/Physician 2 3 3 2 2 2
4. Imaging 3 3 3 3 3 3
5. Sample Size 1 1 3 3 3 3
6. Statistical Methodology 1 1 1 1 1 1
III. PATIENT FACTORS
7. Inclusiveness of Population 2 1 2 2 2 2
8. Duration of Pain 1 2 2 2 2 2
9. Previous Treatments 0 0 2 2 2 2
10. Duration of Follow-up with Appropriate Interventions 2 2 3 3 3 3
IV. OUTCOMES
11. Outcomes Assessment Criteria for Significant Improvement 1 2 2 4 4 4
12. Analysis of all Randomized Participants in the Groups 2 2 1 2 2 2
13. Description of Drop Out Rate 2 2 2 2 2 2
14.
Similarity of Groups at Baseline 
for Important Prognostic 
Indicators
1 2 2 0 1 1
15. Role of Co-Interventions 1 1 1 1 1 1
V. RANDOMIZATION
16. Method of Randomization 0 2 2 2 2 2
VI. ALLOCATION CONCEALMENT
17. Concealed Treatment Allocation 0 0 2 2 2 2
VII. BLINDING
18. Patient Blinding 0 0 1 1 1 1
19. Care Provider Blinding 0 0 1 1 1 1
20. Outcome Assessor Blinding 0 0 1 0 0 0
VIII. CONFLICTS OF INTEREST 
21. Funding and Sponsorship 1 0 0 2 2 2
22. Conflicts of Interest 3 2 0 3 3 3
TOTAL 25 30 38 43 44 44
Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interven-
tional pain management specific instrument. Pain Physician 2014; 17:E263-E290 (153). 
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Appendix Table 8 (cont.). Methodologic quality assessment of  randomized trials assessing fluoroscopic lumbar interlaminar epidural 
injections utilizing IPM-QRB.

















I. TRIAL DESIGN AND GUIDANCE REPORTING 
1. CONSORT or SPIRIT 3 3 3 2 2 0 0
II. DESIGN FACTORS
2. Type and Design of Trial 2 2 2 2 2 2 2
3. Setting/Physician 2 2 2 2 2 2 2
4. Imaging 3 3 3 3 3 2 2
5. Sample Size 3 2 2 2 3 1 2
6. Statistical Methodology 0 1 1 1 1 1 1
III. PATIENT FACTORS
7. Inclusiveness of Population 1 2 2 2 2 2 2
8. Duration of Pain 1 2 1 1 2 2 1
9. Previous Treatments 1 2 1 2 2 2 2
10. Duration of Follow-up with Appropriate Interventions 0 3 3 2 2 2 1
IV. OUTCOMES
11. Outcomes Assessment Criteria for Significant Improvement 0 4 4 2 2 2 2
12. Analysis of all Randomized Participants in the Groups 2 2 2 2 1 2 2
13. Description of Drop Out Rate 2 2 0 2 2 2 0
14. Similarity of Groups at Baseline for Important Prognostic Indicators 2 2 2 2 2 1 1
15. Role of Co-Interventions 0 1 1 1 1 1 1
V. RANDOMIZATION
16. Method of Randomization 2 2 2 2 2 0 2
VI. ALLOCATION CONCEALMENT
17. Concealed Treatment Allocation 2 2 2 2 2 0 2
VII. BLINDING
18. Patient Blinding 0 0 1 0 1 0 1
19. Care Provider Blinding 0 0 0 0 0 0 0
20. Outcome Assessor Blinding 0 0 0 0 1 0 1
VIII. CONFLICTS OF INTEREST 
21. Funding and Sponsorship 3 2 2 2 2 2 2
22. Conflicts of Interest 1 3 3 3 3 3 3
TOTAL 30 42 39 37 40 29 32
Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interven-
tional pain management specific instrument. Pain Physician 2014; 17:E263-E290 (153).




















































































































































































































































































































































































































































































































































































































































































































































































































Vad et al 
(879)
I. TRIAL DESIGN AND GUIDANCE REPORTING 
1. CONSORT or SPIRIT 0 2 2 2 1 2 1
II. DESIGN FACTORS
2. Type and Design of Trial 2 2 2 2 2 2 2
3. Setting/Physician 2 3 1 1 1 1 1
4. Imaging 3 3 3 3 3 3 2
5. Sample Size 1 1 3 3 2 1 1
6. Statistical Methodology 1 1 1 1 1 1 1
III. PATIENT FACTORS
7. Inclusiveness of Population 2 1 2 1 2 1 2
8. Duration of Pain 1 2 0 0 1 1 0
9. Previous Treatments 0 0 0 0 2 2 0




Criteria for Significant 
Improvement
1 2 2 2 1 2 2
12. Analysis of all Randomized Participants in the Groups 2 2 2 2 2 1 0
13. Description of Drop Out Rate 2 2 1 2 2 1 0
14.
Similarity of Groups at 
Baseline for Important 
Prognostic Indicators
1 2 2 2 2 1 0
15. Role of Co-Interventions 1 1 0 1 0 1 1
V. RANDOMIZATION
16. Method of Randomization 0 2 2 1 1 2 0
VI. ALLOCATION CONCEALMENT
17. Concealed Treatment Allocation 0 0 2 0 0 2 0
VII. BLINDING
18. Patient Blinding 0 0 1 1 1 1 0
19. Care Provider Blinding 0 0 1 0 1 1 0
20. Outcome Assessor Blinding 0 0 1 1 0 0 0
VIII. CONFLICTS OF INTEREST 
21. Funding and Sponsorship 1 0 2 2 2 2 0
22. Conflicts of Interest 3 2 3 2 3 3 2
TOTAL 25 30 34 31 32 32 16
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Friedly et al 
(278,818)








I. TRIAL DESIGN AND GUIDANCE REPORTING 
1. CONSORT or SPIRIT 3 3 3 3 0 0
II. DESIGN FACTORS
2. Type and Design of Trial 2 2 2 2 2 2
3. Setting/Physician 2 2 2 2 2 2
4. Imaging 3 3 3 3 2 2
5. Sample Size 3 3 2 2 1 2
6. Statistical Methodology 1 0 1 1 1 1
III. PATIENT FACTORS
7. Inclusiveness of Population 2 1 2 2 2 2
8. Duration of Pain 2 1 2 0 2 1
9. Previous Treatments 2 1 2 2 2 2




Criteria for Significant 
Improvement
4 0 4 2 2 2
12. Analysis of all Randomized Participants in the Groups 2 2 2 2 2 2
13. Description of Drop Out Rate 2 2 2 1 2 0
14.
Similarity of Groups at 
Baseline for Important 
Prognostic Indicators
1 2 2 2 1 1
15. Role of Co-Interventions 1 0 1 1 1 1
V. RANDOMIZATION
16. Method of Randomization 2 2 2 2 0 2
VI.
17. Concealed Treatment Allocation 2 2 2 2 0 2
VII. BLINDING
18. Patient Blinding 1 0 0 0 0 1
19. Care Provider Blinding 1 0 0 0 0 0
20. Outcome Assessor Blinding 0 0 0 0 0 1
VIII. CONFLICTS OF INTEREST 
21. Funding and Sponsorship 2 3 2 0 2 2
22. Conflicts of Interest 3 1 3 0 3 3
TOTAL 44 30 42 30 29 32
Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interven-





Friedly et al 
(278,818)








I. TRIAL DESIGN AND GUIDANCE REPORTING 
1. CONSORT or SPIRIT 3 3 3 3 0 0
II. DESIGN FACTORS
2. Type and Design of Trial 2 2 2 2 2 2
3. Setting/Physician 2 2 2 2 2 2
4. Imaging 3 3 3 3 2 2
5. Sample Size 3 3 2 2 1 2
6. Statistical Methodology 1 0 1 1 1 1
III. PATIENT FACTORS
7. Inclusiveness of Population 2 1 2 2 2 2
8. Duration of Pain 2 1 2 0 2 1
9. Previous Treatments 2 1 2 2 2 2




Criteria for Significant 
Improvement
4 0 4 2 2 2
12. Analysis of all Randomized Participants in the Groups 2 2 2 2 2 2
13. Description of Drop Out Rate 2 2 2 1 2 0
14.
Similarity of Groups at 
Baseline for Important 
Prognostic Indicators
1 2 2 2 1 1
15. Role of Co-Interventions 1 0 1 1 1 1
V. RANDOMIZATION
16. Method of Randomization 2 2 2 2 0 2
VI.
17. Concealed Treatment Allocation 2 2 2 2 0 2
VII. BLINDING
18. Patient Blinding 1 0 0 0 0 1
19. Care Provider Blinding 1 0 0 0 0 0
20. Outcome Assessor Blinding 0 0 0 0 0 1
VIII. CONFLICTS OF INTEREST 
21. Funding and Sponsorship 2 3 2 0 2 2
22. Conflicts of Interest 3 1 3 0 3 3
TOTAL 44 30 42 30 29 32
Appendix Table 11. Methodological quality assessment of  randomized trials of  percutaneous adhesiolysis procedures utilizing 
Cochrane review criteria.
Chun-






















adequate Y Y U Y Y Y Y Y Y
Concealed treatment 
allocation Y Y U Y Y Y Y Y Y
Patient blinded Y Y Y Y N Y Y N Y
Care provider 
blinded N N N N N Y N N N
Outcome assessor 
blinded Y U Y Y NA Y N Y N
Drop-out rate 




Y Y Y Y Y Y Y Y Y
Reports of the study 
free of suggestion of 
selective outcome 
reporting
Y Y Y Y Y Y Y Y Y




Y Y Y Y Y Y Y U Y
Co-interventions 
avoided or similar Y Y Y Y Y Y Y N Y
Compliance 
acceptable in all 
group
Y Y Y Y Y Y Y Y Y
Time of outcome 
assessment in all 
groups similar
Y Y Y Y Y Y Y Y Y
Are other sources 
of potential bias not 
likely
Y Y Y Y Y Y Y Y Y
SCORE 12/13 11/13 10/13 12/13 9/13 13/13 11/13 8/13 11/13
Y = Yes; N = No; U = Unclear
Source: Furlan AD, et al; Editorial Board of the Cochrane Back, Neck Group. 2015 updated method guideline for systematic reviews in the Cochrane 
Back and Neck Group. Spine (Phila Pa 1976) 2015; 40:1660-1673 (154).































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix Table 13. Assessment of  nonrandomized or observational studies of  
percutaneous adhesiolysis procedures in lumbar spinal stenosis  meeting inclusion criteria 
utilizing IPM-QRBNR.
Choi et al 
(908)
Choi et al 
(910)
I. STUDY DESIGN AND GUIDANCE REPORTING  
1. STROBE or TREND GUIDANCE 2 2
II. DESIGN FACTORS
2. Study Design and Type 3 2
3. Setting/Physician 2 2
4. Imaging 3 3
5. Sample Size 0 0
6. Statistical Methodology 2 2
III. PATIENT FACTORS
7. Inclusiveness of Population 2 0
8. Duration of Pain 2 2
9. Previous Treatments 2 2
10. Duration of Follow-up with Appropriate Interventions 2 1
IV. OUTCOMES 
11. Outcomes Assessment Criteria for Significant Improvement 2 2
12. Description of Drop Out Rate 0 1
13. Similarity of Groups at Baseline for Important Prognostic Indicators 0 0
14. Role of Co-Interventions 2 2
V. ASSIGNMENT
15. Method of Assignment of Participants 2 0
VI. CONFLICTS OF INTEREST 
16. Funding and Sponsorship 2 2
TOTAL 28 24
Source: Manchikanti L, et al. Development of an interventional pain management specific instru-
ment for methodologic quality assessment of nonrandomized studies of interventional techniques. 
Pain Physician 2014; 17:E291-E317 (157).
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Appendix Table 14. Methodological quality assessment of  randomized trials assessing fluoroscopic cervical/thoracic interlaminar 















Randomization adequate Y Y Y Y Y Y Y
Concealed treatment 
allocation Y Y Y Y Y N Y
Patient blinded Y Y Y Y Y N N
Care provider blinded Y Y Y Y Y N N
Outcome assessor blinded N N N N N N N
Drop-out rate described Y Y Y Y Y Y Y
All randomized participants 
analyzed in the group Y Y Y Y Y N Y
Reports of the study free 
of suggestion of selective 
outcome reporting
Y Y Y Y Y Y Y
Groups similar at baseline 
regarding most important 
prognostic indicators
Y N N N N Y Y
Co-interventions avoided or 
similar Y Y Y Y Y Y Y
Compliance acceptable in all 
group Y Y Y Y Y N Y
Time of outcome assessment 
in all groups similar Y Y Y Y Y Y Y
Are other sources of potential 
bias not likely Y Y Y Y Y N Y
SCORE 12/13 11/13 11/13 11/13 11/13 6/13 10/13
Y = Yes; N = No; U = Unclear
Source: Furlan AD, Malmivaara A, Chou R, et al; Editorial Board of the Cochrane Back, Neck Group. 2015 updated method guideline for systematic 
reviews in the Cochrane Back and Neck Group. Spine (Phila Pa 1976) 2015; 40:1660-1673 (154).
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Appendix Table 15. Methodologic quality assessment of  randomized trials assessing fluoroscopic cervical/thoracic interlaminar 















I. TRIAL DESIGN AND GUIDANCE REPORTING 
1. CONSORT or SPIRIT 3 3 3 3 3 3 3
II. DESIGN FACTORS
2. Type and Design of Trial 2 2 2 2 2 2 2
3. Setting/Physician 2 2 2 2 2 2 2
4. Imaging 3 3 3 3 3 3 3
5. Sample Size 3 3 2 2 3 2 3
6. Statistical Methodology 1 1 1 1 1 1 1
III. PATIENT FACTORS
7. Inclusiveness of Population 2 2 2 2 2 2 2
8. Duration of Pain 2 2 2 2 0 0 2
9. Previous Treatments 2 2 2 2 0 2 2
10.
Duration of Follow-
up with Appropriate 
Interventions




Criteria for Significant 
Improvement
4 4 4 4 0 2 4
12. Analysis of all Randomized Participants in the Groups 2 2 2 2 0 2 2
13. Description of Drop Out Rate 2 2 2 2 2 2 2
14.
Similarity of Groups at 
Baseline for Important 
Prognostic Indicators
0 1 1 1 1 2 0
15. Role of Co-Interventions 1 1 1 1 0 1 1
V. RANDOMIZATION
16. Method of Randomization 2 2 2 2 2 2 2
VI. ALLOCATION CONCEALMENT
17. Concealed Treatment Allocation 2 2 2 2 0 2 2
VII. BLINDING
18. Patient Blinding 1 1 1 1 0 1 1
19. Care Provider Blinding 1 1 1 1 0 0 1
20. Outcome Assessor Blinding 0 0 0 0 0 0 0
VIII. CONFLICTS OF INTEREST 
21. Funding and Sponsorship 2 2 2 2 1 2 2
22. Conflicts of Interest 3 3 3 3 1 3 3
TOTAL 43 44 42 42 24 37 43
Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interven-
tional pain management specific instrument. Pain Physician 2014; 17:E263-E290 (153).












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix Fig. 1. Percentage change in 12-months ending provisionala data on all fatal drug overdosesb, 50 states, the District of  
Columbia, and New York City: Overdose deaths from 12-months ending in June 2019 to 12-months ending in May 2020c.
a Provisional drug overdose death counts are based on death records received and processed by NCHS. Provisional drug overdose death 
data are often incomplete, and the degree of completeness varies by jurisdiction and 12-month ending period. Consequently, the numbers 
of drug overdose deaths are underestimated based on provisional data relative to final data and are subject to random variation. Provisional 
data are based on available records that meet certain data quality criteria at the time of analysis and may not include all deaths that occurred 
during a given time period. Therefore, they should not be considered comparable with final data and are subject to change. The counts used 
in this analysis are the “predicted” values. Predicted provisional counts represent estimates of the number of deaths adjusted for incomplete 
reporting.
b Deaths were classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths were identified 
using underlying cause-of-death codes X40–X44, X60–X64, X85, and Y10–Y14.
c Included time periods will have some amount of overlap. For example, the 12-months ending in June 2019 (i.e., July 2018 to June 2019) 
includes deaths occurring in June 2019, which is also included separately in 12-months ending in May 2020 (i.e., June 2019 to May 2020).
Pain Physician: Epidural Guidelines 2021 24:S27-S208
28  www.painphysicianjournal.com
Fig. 30. A suggested algorithm for therapeutic interventional techniques in the management of  chronic thoracic pain.
Reproduced with permission from authors and Pain Physician journal.
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